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Abstract:  
With the rise in plasmodial drug resistance throughout the world, a dwindling arsenal of anti-
malarials and a predilection for use of less than ideal murine models, the need for effective, 
applicable and established animal models through which to understand severe malarial disease and 
test potential treatments is becoming increasingly crucial.  Plasmodium coatneyi was discovered in 
the Philippines in the early 1960s in Rhesus macaque monkeys and has been evaluated sporadically as 
a potential platform for comparative studies of Plasmodium falciparum induced severe and cerebral 
malaria in humans. Using 30 years’ worth of archival samples at the Armed Forces Research Institute 
of Medical Sciences in Bangkok, Thailand, compounded with data and material from a series of 
prospective experimental studies, the work in this thesis sought to fully characterize and describe the 
pathology and pathobiology of the P. coatneyi/Rhesus macaque model. This included a thorough 
examination of the parasite host interaction, clinical symptomology, hematology and clinical 
pathology, gross pathology, histopathology, immunohistochemistry, cerebrospinal fluid cytokine 
profiles, transmission and scanning electron microscopy and atomic force microscopy of the disease 
in 45 adult rhesus macaques.  The study further compared P. coatneyi with existing P. falciparum 
infected human material maintained at the National University of Singapore’s Vivax laboratory and 
Oxford University’s Ultrastructural Morphology Group, Nuffield Division of Clinical Laboratory 
Sciences. The study culminated in a successful clinical drug trial which evaluated the efficacy of 
varying doses of methylene blue as a radical cure for malaria in this non-human primate model. In 
many ways, the model mirrors P. falciparum, however the benefit of this evaluation is that it 
highlights not only the similarities but also the divergences.  The successful completion of this 
description of the pathology and pathobiology of the P. coatneyi/Rhesus macaque model of severe 
and cerebral malaria adds a complex but effective animal model to the armamentarium in the 
ongoing war against malaria. 
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Chapter 1: Introduction and Literature Review 
1.1 Overall research aims of this thesis: 
The pathology and pathophysiology of fatal malaria remain areas of active research and 
controversy. The recent increase in the use of murine models has led to a dynamic and at times 
controversial discussion as to the relevance of these rodent models, due to differences in the basic 
pathology of experimental cerebral malaria in the mouse, the undoubted immunopathogenesis of 
disease in this setting, not reflected in adult human cerebral and severe malaria. Furthermore, the 
established recognition of ongoing and expanding plasmodial resistance to a range of the few anti-
malarial compounds which remain in the arsenal, as well as the ongoing but as yet unfulfilled pursuit 
of an effective malaria vaccine, underscores the critical need to establish reliable testing platforms for 
pharmacological and immunomodulatory anti-malarial compounds prior to establishing clinical trials 
in humans. The paramount importance of the arms race between the various plasmodiae and our 
dwindling anti-malarial options highlights that the use of murine models to test and propose adjuvant 
treatments, which then go straight to human trials, has become at best pernicious and at worst 
unethical.  
The Armed Forces Research Institute of Medical Sciences (AFRIMS), in collaboration with various 
academic institutions worldwide, had conducted studies over the span of 4 decades, using a severe 
malaria, non-human primate (NHP) model. This thesis began to investigate ways of utilizing NHP 
models of severe malaria with the following specific aims: 
1. To describe in detail, in a systemic and integrated fashion, the cerebral pathology of the 
Plasmodium coatneyi/Rhesus macaque (Macaca mulatta) model of severe malaria to 
determine its representation of the pathophysiology of cerebral malaria in the human, 
specifically 
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a. Does the clinical course of fatal malaria in the NHP model involve coma? 
b. Is this linked to cerebrovascular iRBC sequestration as is theorized to occur in human 
malaria cases? 
c. Use light and electron microcopy to examine the process of parasitized red blood cell 
(iRBC) sequestration in the cerebral microvasculature. 
2. Compare the non-human primate model with more recently described neuropathological 
features in human severe and fatal malaria 
a. Is the pathophysiology of cerebral malaria in the NHP model similar to adult or 
pediatric human cerebral malaria including more recently described secondary 
neuropathological features such as edema, blood brain barrier leakage (BBB), and 
axonal injury? 
b. To what extent do host leukocyte and platelet responses contribute to pathology in 
vital organs? 
c. Does malarial retinopathy occur in the NHP model and if so, what are the 
pathological correlates of the different patterns of retinal injury? 
d. Can these processes be detected using examination of BBB Leakage, neuroaxonal 
injury, and cytokine release in the Cerebrospinal Fluid? 
3. Recognizing that the select few studies of this model were widely heterogeneous in terms of 
the criteria of severity and animal protocols, to investigate the clinical, biochemical, 
parasitological and organ specific histopathology of the model, in order to understand 
heterogeneity within the model and allow establishment of effective criteria for drug, vaccine 
and adjuvant treatment trials.    
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4. Examine the interactions of the P. coatneyi parasite with host cells using ultrastructural/ 
electron microscopic and atomic force microscopic approaches both ex vivo and from tissues. 
5. Design prospective experimental approaches to re-invigorate the use of NHP models in 
understanding the pathophysiology of malaria, based around specific, hypothesis-driven 
research questions, namely:  
a. What is the incidence of other clinical complications of severe malaria in the NHP 
model and how do they correlate with those observed in humans, such as anemia, 
renal dysfunction and hepatic injury? 
b. Is the pathophysiology of severe malaria in this NHP model similar to adult or 
pediatric human falciparum malaria, primarily focusing on renal, pulmonary, hepatic 
and cardiac pathology?   
c. Are the clinical pathologic, macroscopic, histopathologic and ultrastructural findings 
consistent between the P. coatneyi/Rhesus macaque model and those observed in 
humans? 
6. Examine the use of the model in an anti-malarial treatment trial of methylene Blue in Severe  
Malaria. 
  
33 
 
1.2 Background and Literature Review: 
1.2.1 The Global Burden of Malaria 
Malaria remains one of the most critical public health problems in the world today, and the 
various responsible plasmodial species are prominent causes of morbidity and mortality in a range of 
developing nations.  Almost half of the world’s population is at risk of malaria infection, and 
vulnerable populations in endemic areas are most commonly children and pregnant women. The 
human malaria burden worldwide in 2012 was assessed by the World Health Organization to be in 
excess of 200 million cases, 90% of which were caused by Plasmodium falciparum. (WHO 2013) Of the 
estimated 627,000 fatalities, most occurred in sub-Saharan Africa and about 77% were in children 
under 5 years of age. (WHO 2013) Though these numbers are high, they represent a worldwide 
decrease in malaria morbidity and mortality since the start of the current century.  Between 2000 and 
2012 an estimated 3.3 million deaths due to malaria have been averted, with 90% of them among 
children younger than five years of age. (WHO 2013) Although phase 3 trials on the latest malaria 
vaccine RTS,S are promising (RTS,S Clinical Trials Partnership 2014), the current lack of an effective 
vaccine and increasing plasmodial drug resistance in Southeast Asia to the artemisinin-based anti-
malarial drugs (Ashley 2014) threatens to reverse these positive trends. (Aikawa 1992; Ashley 2014; 
Sá 2009)   
Of the Plasmodium spp. infecting man, P. falciparum is responsible for the vast majority of 
severe disease and significant morbidity. Plasmodium vivax has also been increasingly recognized as 
causing potentially severe clinical disease (Anstey 2012) to include renal and respiratory syndromes 
as well as severe anemia and variations of cerebral malaria. (Storm 2014) More recently, Plasmodium 
knowlesi has been shown to cause severe clinical disease including syndromes of anemia, respiratory 
and renal impairment (Cox-Singh 2015). However, the relative mortality and prevalence of severe 
disease in vivax and knowlesi malaria is less than falciparum (Barber 2013). Clinical syndromes of 
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severe falciparum disease vary between semi-immune children and immune naïve adults in non-
endemic areas. Severe disease is commonly manifested as cerebral malaria, anemia and metabolic 
disturbance, with additional complications such as renal and hepatic dysfunction frequent in adults. 
(WHO 2014)   
P. coatneyi has several biological features in common with P. falciparum as well as a variety 
of distinguishing phenotypic traits.  Both parasites show 48 hour cycles of intraerythrocytic 
development, followed by rupture (schizogony), and a resultant fever spike in the host and reinvasion 
of uninfected erythrocytes.  They also both demonstrate microvascular cytoadherence, form rosettes 
of infected red blood cells with uninfected erythrocytes and develop electron dense knobs on the cell 
surface which are theorized to play a role in cytoadhesion. (Aikawa 1983; Handunnetti 1989; Kawai 
1993; Kawai 1998; Kilejian 1977; Tegoshi 1993; Tongren 2000) Both parasites undergo deep vascular 
sequestration of trophozoite- and schizont-infected red blood cells and demonstrate a consistent 
predilection for specific tissues. (Aikawa 1983; Desowitz 1969; Desowitz 1967; Moreno 2013; Sein 
1993; Smith 1996)  
P. coatneyi was first identified in 1961 in an anophelene mosquito from Malaya.  It was 
experimentally inoculated into a Rhesus macaque monkey and its unique life cycle described. (Eyles 
1962) The species was subsequently found in the blood of a cynomolgus macaque (Macaca 
fascicularis) in the Philippines (Eyles 1963) and has since been used as a model for falciparum-like 
malaria in a variety of macaque species. (Aikawa 1983; Davis 1993; Davison 1998; Davison 2000; 
Desowitz 1967; Eyles 1963; Kawai 1993; Kawai 1998; Maeno 1993; Matsumoto 2000; Moreno 2013; 
Moreno 2007; Nakano 1996; Sein 1993; Semenya 2012; Smith 1996; Sullivan 2005; Tegoshi 1993; 
Tongren 2000; Udomsangpetch 1991; Yang 1999) Foundational work on the parasite and the 
pathophysiology of infection in macaques was, and continues to be, conducted at the Armed Forces 
Research institute of Medical Sciences (AFRIMS) in Thailand in collaboration with scientists and 
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research groups worldwide. (Aikawa 1983; Davis 1993; Desowitz 1969; Desowitz 1967; Desowitz 
2008; Maeno 1993; Sein 1993; Smith 1996; Tegoshi 1993; Udomsangpetch 1991)  
1.3 Primate malarias: 
Several animal models of human severe and cerebral malaria have been established over the 
past 50 years using various Plasmodium spp. in both rodent and non-human primate hosts. (Aikawa 
1992; Craig 2012; Collins 1988; Davison 1998; de Souza 2010; Kawai 1998; Langhorne 2011; Lou 2001; 
Maeno 1993; Moreno 2013; White 2010) The histologic and ultrastructural pathology as well as the 
clinical features and pathophysiology of severe disease have been assessed, in comparison to key 
features of the human disease, such as sequestration-dependent pathology or immune activation. 
These animal models are proven platforms for the testing of experimental anti-malarial drugs to 
determine safety and efficacy, as well as for the evaluation of potential adjuvant therapeutics. (Craig 
2012; Maeno 1993) There has however been significant controversy as to the quality and relevance of 
these various models. The concern has focused primarily on murine models of malaria as not 
representative of the human disease (Deschamps 2009; Hunt 2010; Langhorne 2011; Stevenson 2010; 
White 2010), leading to renewed interest in malaria models in non-human primates (NHP). 
There is a recent and significant shift in the understanding of falciparum malaria due to the 
application of molecular techniques, but these have not yet been evaluated in the NHP models.  With 
the increased parasite resistance to various established and newer anti-malarial compounds in our 
arsenal, therapeutics are required that can be tailored to modulate the immune response to 
effectively combat plasmodial infection. But in order to fully investigate novel compounds, the 
pathophysiology of malarial infection in the animal model used needs to be more clearly understood.   
Over 250 members of the genus Plasmodium have been described, and both new species and 
novel host-parasite interactions are reported with regularity. (Guimarães 2012; Levine 1988; Ramiro 
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2012) Unique plasmodium-vertebrate interactions continue to be discovered in reptiles and birds. 
(Garamszegi 2009; Howe 2012; Perkins 2009; Poharkar 2009; Woodworth 2005) 
The earliest genetic evidence of a malaria plasmodium, dated at approximately 30 million 
years ago, was obtained through the extraction of DNA from mosquitoes fossilized in amber from the 
Palaeogene period. (Poinar 2005) The old-world primate plasmodia themselves are polyphyletic and 
subdivide into 2 major groups.  The first of these consists of Plasmodium ovale, Plasmodium malariae 
and sublineages that infect old world monkeys.  Parasites of Cercopithecidae monkey species from 
Asia are more distantly related and comprise 10 species, including P. coatneyi.  This group also 
includes Plasmodium gonderi, infectious to Cercopithecidae from Africa, Plasmodium hylobati which 
parasitizes Hylobatidae monkeys from Asia, and P. vivax, the human plasmodium that is closely 
related to Plasmodium simium, a species of malaria affecting New World monkeys. (Hayakawa 2008) 
The closest relative P. coatneyi appears to be P. knowlesi, derived from a single ancestor species, 
based on evaluation of four different apicoplast genome-encoded genes in the 9 members of the 
Asian clade.  These include a small subunit rRNA, large subunit rRNA and caseinolytic protease C 
genes. (Mitsui 2010) P. falciparum is separate from all of these and is found within the second major 
group of old world malarias, paired with the chimpanzee parasite: Plasmodium reichenowi. (Bray 
1958; Hayakawa 2008) Potentially relevant to the debate over models, the rodent malarial parasites 
are located in a grouping distinct from primate and all other plasmodia. (Escalante 1995; Escalante 
1998; Leclerc 2004) 
While the various non-human primate species have far greater immunogenic homology to 
humans than do rodents, complications in both the macaque and murine models include potential 
variation of the disease progression associated with the route of infection.  In humans, the natural 
route of infection is via dermal injection subsequent to a mosquito bite, in comparison with the 
experimental murine models receiving predominantly intraperitoneal injections and NHPs inoculated 
intravenously.  Furthermore, the macaque models of severe P. coatneyi malaria hitherto reported 
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typically employ splenectomized animals, which are infected via an IV injection of parasitized blood 
and parasites which have been harvested from an animal with an intact spleen (hereafter referred to 
as spleen-intact) or a splenectomized donor animal, or infective stage sporozoites dissected out from 
infected mosquitoes.  Splenectomy results in much higher peripheral parasitemias, circulating mature 
parasitic stages, and may modulate cytoadhesion and host immune reactions.  Therefore, 
splenectomized experimental animals may be expected to suffer more severe clinical pathologic 
abnormalities and clinical course of disease.  Additionally, many of the studies to date have not had 
the luxury of using experimentally naïve animals, but instead employed adult animals that had been 
previously used for studies involving anti-malarial drugs or vaccine candidates in the relapsing malaria 
model (Plasmodium cynomolgi), or animals which have been previously infected with dengue virus, 
SIV or enteric bacteria, all of which will have had some modulatory effects on the immune status in 
an individual animal.  This presents a significant difference from the highly standardized murine 
experiments which use inbred mouse strains, but is more in line with the genetic and environmental 
heterogeneity in affected human populations. (Bruneel 2003; Craig 2012; Deschamps 2009; Dondorp 
2008; Hunt 2010; Langhorne 2011; Nagatake 1992; Smith 1982; Yacoub 2010)  
1.4 Ecology of non-human primate malarias: 
The fundamental lifecycle of malaria in non-human primates is quite similar to that of 
plasmodia infecting humans. This has been underscored with the recent recognition of the simian 
malaria parasite, P. knowlesi, as a previously unrecognized zoonosis and significant cause of malaria 
in humans. (Cox-Singh 2008) Early taxonomy, based on microscopy, was often complicated by 
morphological similarities between various species of Plasmodium and led to a degree of diagnostic 
confusion. (Eyles 1962; Ng 2008; Sabbatani 2010; Vythilingam 2010; Vythilingam 2008)  
The ecological and environmental requirements for the survival of any plasmodium depends 
on the parasite reaching a state of “balanced pathogenicity” with the host, whereby the majority of 
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infections are non-fatal and allow a mosquito to acquire gametocytes through a blood meal and 
thereby propagate the life cycle.  Experimentally, the non-human primate plasmodia of Southeast 
Asia can be transmitted by a wide range of mosquito species. However, the host-parasite 
combinations observed in the wild depend on the degree of pathogenicity within specific simian 
species.  This is evidenced by the incompatibility of P. knowlesi and the rhesus macaque to cohabitate 
the same range of forest, because P. knowlesi causes a rapidly fatal course of disease in this monkey 
making malaria persistence impossible. (Rogers 2002; Spangler 1978) This degree of pathogenicity 
may be the result of recent evolutionary collision between the host and pathogen in which the 
malaria parasite maintained a high level of virulence due to insufficient evolutionary time to adapt to 
the host.  This particular point is potentially important in selection and interpretation of a model, as 
differing species of macaques from diverse geographic origins may display differing susceptibility to 
various plasmodia.  At present, only limited comparative studies have been conducted with P. 
coatneyi, examining the pathology in small numbers of animals from different geographic “strains” of 
either cynomolgus or rhesus macaques. (Fooden 1994; Matsumoto 2000; Migot-Nabias 1999)  
Studies in Malaysia in the 1960s examined multiple features of the ecology of the vector 
mosquitoes, as well as describing and categorizing the malaria parasites found in the local 
populations of non-human primates.  It was established that Anophelene mosquitoes (specifically the 
Anopheles leucosphyrus group of mosquitoes), represented a common vector for Plasmodium 
cynomolgi, Plasmodium inui, Plasmodium fieldi, P. knowlesi and P. coatneyi. (Warren 1963) These 
Anopheles mosquitoes primarily, and apparently preferentially, blood feed on primates.  P. coatneyi 
was initially identified in Anopheles hackeri (Eyles 1962), a mosquito whose whole life cycle occurs 
within the forest, and which maintains a high level of endemic malaria within the non-human 
primates coexisting in the same forested areas.  This then translates to high rates of transmission to 
humans who enter these Southeast Asian rain forests for commerce, warfare or habitation. (Furst 
2009) 
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The epidemiology of transmission of disease within these border areas is especially critical in 
that the notable emergence of artemisinin-resistant falciparum malaria has come from such ecologic 
areas.  The resistant plasmodia now appear increasingly established within the forests of the 
Thailand-Cambodian and Thailand-Myanmar borders. (Bhumiratana 2013; Carrara 2013) The 
importance of this finding cannot be overstated since it holds the potential to reverse the worldwide 
trend of reduced P. falciparum induced morbidity and mortality. (Carrara 2013; Phyo 2012) The arms 
race between malarial drug resistance and the limited arsenal of effective treatment options, 
highlights the critical need for the development of a reproducible, reliable animal model which 
parallels the pathophysiology and tissue pathology of severe falciparum malaria in humans to act as a 
platform for future vaccine and drug development. 
P. coatneyi is considered to be one of the more pathogenic plasmodia in non-adapted hosts, a 
fact which parallels P. falciparum infection in humans. The course of disease in splenectomized 
macaques is variable, but typically culminates with severe anemia, renal dysfunction, metabolic 
acidosis, prostration and death. (Desowitz 1967) With P. falciparum, clinical presentation is highly 
heterogeneous, but the most frequently described complications, particularly in older, non-immune, 
patients, include dyspnea, respiratory distress and eventual coma, with a relatively high mortality rate 
occurring within hours or days of admission. The literature suggests that the most significant factors 
leading to death in severe falciparum malaria in both adults and children are metabolic acidosis and 
coma, as well as severely decreased renal function. (Dondorp 2008; Olliaro 2008; Yacoub 2010) 
There are marked differences in the clinical features of severe falciparum malaria in adult 
humans in comparison with children that bear description.  This is a significant field of study in the 
attempt to further understand the pathobiology of disease in the different age groups.  According to 
the WHO, clinical manifestations of impaired consciousness are more severe in children as is the case 
with repeated convulsions and dyspnea, while adults demonstrate a greater degree of jaundice in 
comparison with children.  Clinical chemistry and hematological values also differ, with children 
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having greater severity of anemia, hypoglycemia and metabolic acidosis, while adults typically display 
far more severe acute renal disease. (WHO 2014) 
P. coatneyi has been reported as causing both natural and experimentally-induced disease in 
a variety of non-human primate species. However, only cynomolgus macaques (M. fascicularis) (Eyles 
1962; Eyles 1962; Lee 2011; Migot-Nabias 1999), pig-tailed macaques (Macaca nemestrina) (Lee 
2011), stump-tailed macaques (Macaca arctoides) (Seethamchai 2008), and Bornean orangutans 
(Pongo pygmaeus) (Pacheco 2012) have been reported to be susceptible to infection in nature, with 
or without clinical evidence of disease.  In addition to use of those species that are naturally infected, 
animals in which experimental P. coatneyi infection has been studied to various extents include the 
rhesus macaque (M. mulatta) (Aikawa 1992; Arekul 1971; Arekul 1986; Davis 1993; Davison 1998; 
Davison 2000; Desowitz 1969; Eyles 1963; Maeno 1993; Matsumoto 2000; Migot-Nabias 1999; 
Moreno 2013; Moreno 2007; Nakano 1996; Semenya 2012; Smith 1996; Tegoshi 1993; Tongren 2000; 
Udomsangpetch 1989; Yang 1999), black-capped squirrel monkey (Saimiri boliviensis) (Sullivan 2005), 
Japanese macaque (Macaca fuscata) (Kawai 1993; Kawai 1998; Kawai 2003; Matsumoto 200), silvery 
lutung (Presbytis cristalus) (Coatney 1971) and white handed gibbon (Hylobates lar). (Coatney 1971) 
The cynomolgus macaque appears to be one of the natural hosts of P. coatneyi and is thought to have 
coevolved with the parasite.  Pathology elicited by P. coatneyi infection in this NHP species is variable 
and is likely dependent on the genetic heterogeneity of the infected population, since only a subset of 
animals appear to develop severe disease.  The rhesus macaque is far more susceptible to 
progression of disease than the cynomolgus, but the same heterogeneity appears to apply and may 
account for the spectrum of pathology and clinical syndromes observed experimentally.  The ability to 
elicit severe disease appears to be more consistent in the rhesus than in the cynomolgus macaques.  
While both species are used extensively in medical research, and their genomes have been fully 
sequenced (Yan 2011), it is the experimental reproducibility in the rhesus of the pathological 
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parameters of falciparum disease in humans, which make the P. coatneyi-rhesus macaque model of 
infection useful for the modeling of severe malaria in humans.  
1.5 Plasmodium coatneyi life cycle: 
The stage-specific morphology of P. coatneyi was beautifully illustrated in the original Eyles report 
(1962) and again by Mrs. Gertrude Nicholson in the Primate Malarias text (see Figure 1.1). (Coatney 
1971) 
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Figure 1.1: This plate is an illustration of the complex intraerythrocytic stages of Plasmodium coatneyi 
with clear demonstration of those diagnostic features which characterize the development of the 
trophozoites and schizonts. Illustration 1 represents a normal red blood cell, while 2, 3, 6, 7 are 
examples of young trophozoites demonstrating varying presentations such as rim or displaced types 
as illustrated in 6.  Images 4, 5, 8-11 are examples of growing trophozoites while in 12, 13 the 
trophozoites are considered to be mature.  14-17 are representative of early schizonts, and 18-21 are 
stages consistent with developing schizonts. Illustrations 22 and 23 are nearly mature and mature 
schizonts.  The reproductive stages are show in 24 which represents a mature macrogametocyte and 
in image 25 which is a mature microgametocyte.         
Reproduced with permission from Coatney GR, Collins WE, Warren M, Contacos PG. The primate 
malarias. Washington, D.C.: U.S. Government Printing Office; 1971. Pp. 289–299.   
 
The more immature stages of the species are indistinguishable from P. falciparum, and in fact 
share some diagnostic features with the human malarial parasite.  The trophozoite ring form of P. 
coatneyi is smaller than all other simian plasmodia with the exception of P. knowlsei. (Coatney 1971) 
There are frequently 1 to 2 chromatin bodies or nuclei noted within the organism, which are either in 
close proximity to each other or at polar opposite sides of the ring form (Figure 1.2).  Significant 
morphological variation was observed in the original description but all of the shapes mimicked those 
that had been described in P. falciparum. As with the human parasite, the location of P. coatneyi 
trophozoites within the host erythrocyte varied.  Common ring forms were observed as well as a high 
frequency of marginalized parasites along the periphery of the red blood cell.  These forms have been 
described in P. falciparum as “rim” or “displaced’ types (Figure 1.3). (Coatney 1971; Field 1956) The 
morphological description which was the staple of pathologists and parasitologists before the advent 
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of molecular technology remains crucial in malaria diagnostics.  The variability of location within the 
host erythrocyte holds true with P. falciparum as well, with the peripheralized forms having been 
called “accolé” or “appliqué”, and considered to be a diagnostic criterion for the human parasite.  In 
these rim forms, the plasmodium typically appears as a continuous thickening of the cell wall, while 
the displaced form extends beyond the margin of the cell, creating an extruded plaque or bleb which 
is most noticeable at the point of the trophozoite nuclei (Figure 1.4). (Coatney 1971) 
With maturation, both individual and global changes take place within the parasite.  As the 
trophozoites reach more advanced stages, their numbers in the peripheral circulation decrease 
dramatically, while morphologically, the plasmodia assume a more ovoid form.  As with P. falciparum, 
there is a single large food vacuole which decreases in size as time progresses.  It is at this stage in 
development that the highly visible and diagnostic malarial pigment begins to accumulate.  In 
contrast to the pigment of P. falciparum, P. coatneyi hemozoin crystals, formed as part of hemoglobin 
consumption by the parasite, do not coalesce until schizogony. Instead, they remain as distinct 
individual granules which increase in both size and number.  It is also at this point of growth that the 
parasitized erythrocyte begins to display the tinctorial stippling which has been coined Maurer’s 
spots.  These are posited to be secretory organelles, involved in cell signaling and other biochemical 
processes, which the plasmodium forms within the parasitized erythrocyte, but external to its 
parasitophorous vacuole. (Lanzer 2006) These require either Giemsa or a modified Leishmann’s 
staining to properly assess by light microscopy. (Mendiratta 2006) As with the hemozoin crystals, the 
Maurer’s clefts increase in density with maturation. (Bruce-Chwatt 1985; Eyles 1962) 
At a certain point in the development cycle, the trophozoite will transform into a schizont and 
begin the process of asexual division forming merozoites (Figure 4).  As with P. falciparum, at this 
stage the infected erythrocytes become infrequent in the peripheral circulation as they remain in the 
microvasculature, adhering to the endothelium in a process termed sequestration.  This process is felt 
to underlie the pathophysiology of severe forms of human disease such as cerebral malaria. The 
44 
 
Plasmodium parasite developing within the erythrocyte exports specific parasite-encoded adhesions 
(Rug 2006) to the surface of the RBC.  These proteins, such as PfEMP-1 in P. falciparum and its 
homologs in other plasmodium species, are organized at the electron dense knob protein structures.  
These mediate specific cytoadhesion to host receptor molecules such as intercellular adhesion 
molecule 1 (ICAM-1), CD36 and chondroitin sulfate A (CSA) (Almelli 2014).  This allows for adhesion 
not only to the vascular endothelium, but also to host leukocytes, platelets and uninfected 
erythrocytes (rosetting). 
Developing schizonts are round with condensed cytoplasm which contains up to 20 
merozoites.  Unlike other species of protozoa, the merozoites in P. coatneyi do not assume a specific 
orientation or pattern.  At this stage, the malaria pigment crystals begin to coalesce, forming larger 
irregular granules and the parasitized erythrocyte enlarges and is eventually obscured by the 
schizont. (Coatney 1971) During this stage, parasitized erythrocytes can still be identified in peripheral 
blood, but their numbers are significantly decreased in spleen-intact animals. Once the schizont is 
fully mature, it ruptures, releasing the merozoites into circulation (Figure 1.5).  This occurs with 
relative synchrony and results in the periodicity of parasitemia eliciting the pyrogenic response in the 
host.  In splenectomized monkeys, these late stages of the parasite are also found in peripheral 
blood, along with the ring forms. 
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Figure 1.2-5. Intraerythrocytic Plasmodium coatneyi trophozoites from peripheral blood smears of 
the rhesus macaque. (Giemsa staining).  Figure 1.2.  1.2% parasitemia: Erythrocytes infected with 
younger stages of the parasite often contain one or more parasites which have a ring shape and have 
chromatin bodies which are either in close proximity to each other or are at polar opposite ends of 
the plasmodium (arrowhead).  Figure 1.3.  18% parasitemia: As the parasites develop, they are 
marginalized in the erythrocyte (arrowheads). Figure 1.4. 1.2% parasitemia: Occasionally, these 
marginalized parasites expand the cytoplasm of the infected cell, generating a small bleb 
(arrowhead). At later stages in maturation, the erythrocyte is expanded by a schizont containing high 
numbers of merozoites (arrow).  Figure 1.5. 18% parasitemia: With maturation, the schizont ruptures, 
releasing the merozoites into the blood stream (arrow).  This photomicrograph contains another 
example of ring stage trophozoite with polar opposite chromatin bodies (arrowhead). 
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In their initial study, Eyles and colleagues (1962) infected six rhesus macaques (spleen-intact) 
with P. coatneyi.  The animals all became clinically ill, displaying marked anemia and severe lethargy.  
The parasitemia in all of the animals persisted for almost six months post–inoculation, with 
alternating peaks and troughs of parasite density that differed by 100- to 1000-fold. (Eyles 1962). A 
second study was conducted in which P. coatneyi-naïve animals were inoculated with blood passaged 
through the first experimental animals.  This cohort developed significant malaria-associated 
mortality causing the authors to question the possibility of multiple stains of P. coatneyi with varying 
levels of virulence. (Eyles 1963) 
There have been a variety of studies examining the suitability of P. coatneyi in macaques as a 
model for the cerebral or severe malaria caused in humans by P. falciparum, as well as for the 
evaluation of plasmodium-induced placental pathology. (Davison 1998; Davison 2000) Some of these 
experiments attempted to describe the pathophysiology of disease through histopathology, 
immunohistochemistry and transmission electron microscopy (Aikawa 1992; Desowitz 1967; Eyles 
1963; Eyles 1962; Kawai 1993; Kawai 2003; Kilejian 1977; Matsumoto 2000; Migot-Nabias 1999; 
Moreno 2013; Moreno 2007; Nakano 1996; Smith 1996; Tegoshi 1993; Tongren 2000; 
Udomsangpetch 1991), while others adopted the animal model as a route of drug assessment and 
testing. (Kyle 1994; Maeno 1993) 
 
1.6 Clinical course of P. coatneyi malaria in the Rhesus macaque model: 
Soon after the original identification of P. coatneyi, studies began at the US-Thai South East 
Asia Treaty Organization (SEATO) labs in Bangkok (now AFRIMS) to characterize the pathobiology of 
this infection in non-human primates. (Aikawa 1992; Aikawa 1983; Davis 1993; Desowitz 1967; 
Desowitz 1969; Desowitz 1967; Maeno 1993; Sein 1993; Smith 1996; Tegoshi 1993; Udomsangpetch 
1991) Though severe infections often led to death, coma and seizures were not typical of the clinical 
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picture in macaques, differing from the common pattern associated with severe cerebral malaria in 
humans.  Monkeys progressively lose appetite, develop malaise and lethargy leading to recumbency, 
and become dehydrated and tachypneic. (Moreno 2013; Smith 1996)  
The most consistent pathological effect described in the literature in a P. coatneyi infection of 
rhesus and cynomolgus macaques was anemia, which paralleled the rise in parasite density.  In many 
cases, this was followed by hemoconcentration and rapid deterioration secondary to a shock-like 
syndrome similar to that described in severe P. falciparum and the few reports of P. knowlesi malaria. 
(Cox-Singh 2008; Cox-Singh 2010) This exacerbation is theorized to result in part from a marked 
decrease in plasma volume concurrent with cytokine-associated increase in vascular permeability. 
(Arekul 1986; Davis 1993; Desowitz 1967; Desowitz 1967; Moreno 2013; Moreno 2007) These findings 
are in no way unique to malaria. The infection is more severe in splenectomized animals.  Anecdotal 
evidence from spleen intact donor animals suggests that the parasitemia may even be cleared in 
immunocompetent animals. 
 
1.7 Post mortem findings: 
There is only scant information in the literature regarding autopsy findings in P. coatneyi-
infected animals.  Macaques in one particular study consistently were dehydrated and either pale or 
icteric.  There was serous atrophy of fat in multiple organs, and a mild dilation of the ventricles of the 
heart was noted.  Petechiae and coalescing ecchymoses, were described in multiple tissues but most 
significantly within the epicardium.  Concentrated within the kidneys and the liver, much of the 
viscera was described as having a diffuse brown discoloration (Figure 6) as well as concurrent organ 
enlargement.  This was characterized by splenomegaly (2-3 times normal), hepatomegaly and 
enlarged lymph nodes. (Aikawa 1992; Davis 1993; Kawai 2006; Smith 1996) 
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Clinical records of upwards of 60 splenectomized rhesus macaques at AFRIMS provided the 
foundation of the previously reported pathological data. (Davison 2000; Desowitz 1967; Desowitz 
1969; Kawai 1993; Kawai 2006; Lawrence 1986; Moreno 2007; Smith 1996) and corroborated the 
clinical findings and the autopsy observations in this current study.  With parasitemias of 20% and 
higher, the animals’ clinical condition rapidly deteriorated around the 7th day post (intravenous) 
infection.  Clinical signs included hematuria, hemorrhage within the perineum and scrotum, severe 
depression, recumbency and eventual prostration, progressively worsening anorexia, occasional 
vomiting and severe dyspnea and tachypnea.  Once the animals began to display signs of decreased 
mentation, death followed rapidly and only rare animals survived beyond the 8th day post infection. 
Post mortem findings were consistent with the few descriptions in the literature.  Animals with higher 
parasitemias in and around the time of euthanasia or sudden death were observed to have brown 
discoloration of the liver, lungs, kidneys, heart and brain. (Davis 1993) The discoloration of the organs 
is due to both vascular congestion and the abundance of malaria hemozoin pigment in erythrocytes 
and monocytes, both circulating and sequestered.  The relationship between malaria infection and 
the brown discoloration of organs was established by Rudolph Virchow and Friedrich Theodor von 
Frerichs in the mid-1800s. (Hempelmann 2013) Additional macroscopic findings in this retrospective 
review conducted at AFRIMS included hepatomegaly with increased friability, heavy congested lungs, 
and petechiae in the epicardium.   
There is a single report in the literature in which a rhesus macaque experimentally infected 
with P. coatneyi developed progressive cutaneous necrosis of the extremities secondary to 
disseminated intravascular coagulopathy (DIC). This resulted in dermal infarction of the digits and the 
tail due to thrombosis of the superficial vasculature. (Moreno 2007) A similar unpublished case 
occurred in Thailand in a rhesus macaque also experimentally infected with P. coatneyi.  In that 
instance, the animal developed a necrotizing rhinitis and cheilitis which progressed to erosion and 
ulceration.   
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There are occasional reports of gangrenous necrosis in humans secondary to DIC associated with P. 
falciparum infection, but not with any other forms of human malaria. (Chittichai 1991; Liechti 2003; 
Sharma 2002) While reports of DIC vary in frequency in different human populations, progression to 
peripheral cutaneous gangrenous necrosis appears to be a rare complication. However, when it does 
occur, P. falciparum is implicated as the causative plasmodium in 95% of human cases and typically 
the presentation is of ischemia and subsequent necrosis within peripheral tissues. (Bruneel 2003; 
Ghafoor 2010; McGouran 1977; Mohanty 1985)  
 
1.8 Clinical pathology: 
Microscopy remains the gold standard of malaria diagnosis in humans and NHPs, both 
clinically and under experimental settings.  Examination is conducted using blood prepared as thin 
films, in which the sample is prepared with the same methodology as a routine blood smear, and 
thick films which involves a process of erythrocyte lysis.  The latter is more sensitive in plasmodium 
detection, especially earlier in infection when parasite density is lower; whereas, the former allows 
for speciation and parasite staging.  Although the World Health Organization (WHO) suggests that 
microscopic slide evaluation in cases of malaria is at best 75% effective based on a range of clinical, 
geographic and species-specific factors, microscopy has significant advantages over other diagnostic 
modalities that may be more accurate. (Wilson 2013) The benefits of microscopy for malaria diagnosis 
are linked to the geography and epidemiology of the various plasmodial diseases.  Falciparum malaria 
is endemic circumferentially along the equator and extends significant distances to the north and 
south, but still covers a large swath of the poorer and less developed portions of the planet.  As such, 
the most tangible benefits of microscopy are the low cost and the minimal need for infrastructure. 
However, the technique is also crucial in rapid speciation of parasites, identification of mixed 
infections, and monitoring treatment.  Microscopy has been the mainstay of NHP malaria research as 
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well, and the bulk of the publications evaluating models of malaria employ microscopic examination 
to quantitate parasitemias in experimental animals. By using skilled microscopists and associated 
clinical symptomology, hematologic and blood chemistry data, it is possible to closely map the course 
of disease.   
Up until recently, the clinical pathology of P. coatneyi infection in macaques had been poorly 
elucidated in the literature. A 2013 report by Moreno and colleagues provided more systematic data 
on the clinicopathological findings of P. coatneyi malaria in malaria-naïve, spleen-intact, rhesus 
macaques. (Moreno 2013) The animals were cured and re-infected at a later date to examine the role 
of specific acquired immunity in macaques.  The study noted that blood chemistry data from the 
primary infection showed marked azotemia, hypertriglyceridemia, hypoalbuminemia and increased 
levels of creatinine phosphokinase (CPK) in comparison to pre-infection levels.  There was a marked 
decrease in clinical signs in the second episode of infection which was reflected in the clinical 
pathology.  Triglyceride levels, while elevated, were not significantly different between the first and 
second P. coatneyi infections, suggesting that the release of triglycerides was not directly correlated 
to the severity of the malaria infection. (Moreno 2013) 
Furthermore, the authors observed thrombocytopenia and severe coagulopathy. This was associated 
with an increase in fibrin degradation product (FDP) levels and concurrent drops in protein C and 
protein S, suggesting increased consumption of inhibitors of coagulation. (Maeno 1993) 
There are several proposed reasons for severe thrombocytopenia occurring in animals during 
the acute phase of malaria infection.  As with the erythrocytic clearance, immune-mediated clearance 
of platelets may occur as a bystander effect of the presence of the parasitized erythrocytes, 
stimulating antibody-mediated clearance and upregulation of phagocytic activity in histiocytic cells. 
(Grau 2003; Jaff 1985) The thrombocytopenia may result from splenic sequestration, peroxidation of 
the platelet lipid membranes, or platelet consumption from formation of systemic microthrombi. 
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(Moreno 2007) Metabolic disturbances were evaluated in the rhesus macaque model. (Davis 1993) 
Animals infected with P. coatneyi demonstrated variably increased serum and CSF glucose levels, as 
well as elevated lactate which increased with parasitemia.  This was associated with progressive 
insulin resistance and a late tendency to lactate acidosis in infected animals, processes observed in 
human patients with P. falciparum infections. 
In an early study consisting of a small mixed population of cynomolgus macaques as well as 
Indian-origin and Thai-origin rhesus macaques, the renal and hepatic clinical pathology associated 
with severe P. coatneyi infection was followed through the course of disease and compared with 
spleen intact infected animals as well as with uninfected controls.  The authors noted concurrent 
increases in BUN and serum creatinine, both of which initially resolved, only to increase a second 
time with a concurrent rise in parasite density which continued until death.  Furthermore, a slight 
increase in hepatic alanine transaminase (ALT) was observed immediately following the initial 
parasitemia peak, but subsequently normalized.  Alkaline phosphatase (ALP) remained within 
reference ranges, though a minor decrease was observed in some of the animals.  The animal 
numbers in the study were insufficient for the purpose of drawing general conclusions as to clinical 
pathology. The study underscores the absence of adequate data within the literature as a whole. 
(Desowitz 1967) 
Noteworthy amongst these various studies is the significant variability in the level of 
parasitemia achieved and sustained. Often the degree of acquired immunity is either uncertain or is 
not reported.  This then translates to a degree of variation in the clinicopathological changes 
observed and reported.  There are also significant gaps in the P. coatneyi literature as to the impact of 
the parasite on separate organ systems within the rhesus, much less any of the other NHPs evaluated 
as models.  An example of this can be seen in the absence of adequate studies of the metabolic 
changes associated with the renal and the hepatic dysfunction.   
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1.9 Histopathology and immunohistochemistry: 
The literature contains scant systematic information on the histologic lesions resulting from 
P. coatneyi parasitism in any species. However, a few of the experiments did involve partial autopsies 
of the infected macaques and subsequent histopathological analysis, which is summarized herein.  
Chapter 4 of this thesis is dedicated to the histopathological examination of 45 Indian origin rhesus 
macaques infected with P. coatneyi as part of varying experimental protocols conducted at AFRIMS 
over the past several decades. The results of that study support, reinforce or contrast with the 
literature review of the histopathology described in the following.  
1.9.1 Central nervous system: 
Sequestration patterns in the infected animals have been the mainstay of the proposal that P. 
coatneyi be used as a model for cerebral malaria in humans. (Desowitz 1969; Nakano 1996; Sein 
1993) In P. falciparum infections in humans, the sequestration (adherence to endothelium) of 
parasitized erythrocytes in the microvasculature of the brain often results in partial or complete 
occlusion of the vessels as characterized by significant congestion with increased margination due to 
cytoadhesion of infected erythrocytes.  These microscopic lesions were correlated with hemorrhage 
and signs of tissue hypoxia and was theorized to be a significant contributing factor in the 
development of the symptomology associated with cerebral malaria in humans, namely coma and 
seizure activity. (Medana 2006) Histological degrees of vascular sequestration differ between 
different regions of the brain in both humans and non-human primates. (Nagatake 1992; Ponsford 
2012; Smith 1996) Reports based on microscopic examination of human brains with cerebral malaria 
noted a significantly higher degree of parasitized red blood cell sequestration in the cortical grey 
matter than in the white matter. (Nagatake 1992) 
As a result of the human data and building upon previous experiments which evaluated the 
sequestration patterns in the brains of P. coatneyi infected rhesus macaques (Desowitz 1967a; 
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Desowitz 1967b; Desowitz 1969; Sein 1993), a histopathological and electron microscopic study was 
conducted in Thailand to examine the distribution of sequestration within the brains of 
experimentally infected rhesus macaques. (Smith 1996) Animals (5 spleen-intact, 1 splenectomized 
after infection) were inoculated with a bolus of parasitized blood consisting of 77% trophozoites and 
23% schizonts.  Parasitemia was assessed daily and parasite staging was also conducted.  Between 
days 7 and 9 post infection, all animals were euthanized, necropsied and evaluated by a veterinary 
pathologist.  At the time of euthanasia, parasitemias ranged from in excess of 200,000 to almost 
900,000/mm3 and consisted primarily of trophozoites.  The highest parasitemia was observed in the 
animal which had been splenectomized at day 5 post inoculation.  The presence of sequestration was 
quantified in the microvasculature of the cortex, the midbrain and the cerebellum, based on 
histologic examination of 200 microvessels per section.  Sequestration was observed in 25% of 
microvessels in the cerebrum, 24% in the midbrain and 37% in the cerebellum.  While not specific to 
any of the three regions evaluated, the histopathological observations within the central nervous 
system consisted of congestion, functional obstruction, as characterized by evidence of perivascular 
edema, hemorrhage and cellular necrosis as well as increased cytoadhesion of parasitized cells 
(sequestration) of the microvasculature with parasitized and uninfected erythrocytes.  In addition, 
frequent intraerythrocytic and intramonocytic hemozoin pigment and occasional microhemorrhages 
within the neuropil were described. (Smith 1996) 
A window to events within the central nervous system, which has become of increasing 
clinical interest, and potential histopathological importance, are changes within the retina.  Based on 
recent descriptions of retinal findings in children in East African with severe malaria, retinal 
hemorrhages are being used as a diagnostic criterion for cerebral malaria in children. (Essuman 2010; 
Hidayat 1993; Lewallen 1999; Lewallen 2000) Preliminary unpublished histopathological evaluation of 
two cohorts of animals in prospective studies and the large body of retrospective tissues from various 
studies conducted at AFRIMS, have failed to show similar hemorrhaging within the retinas of P. 
54 
 
coatneyi infected animals.  However, based on the diagnostic significance in humans, malaria induced 
retinopathy should be evaluated in greater depth in animal models.  
1.9.2 Cardiovascular system:  
Two studies conducted in Thailand examined the histopathological sequestration patterns of 
P.  coatneyi in the viscera of rhesus macaques with microscopic examination of tissues from multiple 
organ systems by a veterinary pathologist. (Desowitz 1969; Smith 1996) Overall findings in multiple 
tissues consisted of congestion and occlusion of small vessels with both parasitized and uninfected 
erythrocytes.  There was also an abundance of phagocytic monocytes containing malaria pigment and 
varying degrees of lymphocytic inflammation.  Frequently, the erythrocytes formed rosettes of 
uninfected cells bound to a parasitized cell.  While this is typically an ultrastructural diagnosis, the 
authors of this study were able to microscopically identify the rosettes within larger vessels.  The 
study evaluated the degree of sequestration within different organ systems, and noted that the 
myocardium had the highest degree of histologic sequestration, with individual animals having 84-
95% of the myocardial microvasculature showing sequestered parasitized red blood cells. (Figure 7) 
This was particularly pronounced within the interventricular septum and the left ventricular free wall.  
Furthermore, the pericardial adipose tissue had a high degree of sequestration and congestion, as did 
the microvasculature of the pulmonary interstitium and the mesenteric adipose tissue, with an 
average microvascular sequestration of 85% in and 76% respectively. (Smith 1996) Other studies 
using macaques report sequestration of P. coatneyi-infected erythrocytes in the coronary 
vasculature, adipose tissue of the omentum, subcutaneous tissues and other sites of fat deposition, 
the intestinal tract and the skeletal musculature. (Kawai 1993; Levine 1988) This site partiality is 
consistent with those described in P. falciparum infections. (Maeno 1993) 
1.9.3 Hepatic system:  
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The liver of infected non-human primates occasionally has a diffuse centrilobular 
hepatocellular necrosis accompanied by mild increases in serum levels of transaminase. (Desowitz 
1967) In addition to the necrosis, mononuclear hepatitis was frequently noted, accompanied by a 
marked accumulation of birefringent malaria pigment observed within Küpffer cells. (Lawrence 1986; 
Moreno 2007) (Figure 8). 
It is significant that while increases in inducible liver enzymes are a common feature of severe malaria 
in adult humans, to the extent that a syndrome of ‘malaria hepatitis’ has been proposed in Indian 
adult patients, there are only rare reports of centrilobular hepatic necrosis. (Davison 2000; Desowitz 
1967) 
1.9.4 Urinary system: 
Kidneys from P. coatneyi-infected rhesus macaques in one study had varying degrees of acute tubular 
necrosis accompanied by hyaline droplet degeneration characterized by expansion of the cytoplasm 
of the tubular epithelium with eosinophilic globules which are interpreted as possible protein 
resorption. Furthermore, tubules contained both abundant hemoglobin and cellular casts, and the 
urinary space contained proteinaceous filtrate with a relative absence of inflammation. (Desowitz 
1967) With chronicity there was evidence of glomerular synechiae, interstitial fibrosis, tubular 
epithelial degeneration, necrosis and regeneration. (Figure 9).  Hemoglobinuria has been observed 
clinically but a formal correlation of clinicopathological and histopathologic findings of renal disease 
in this model remains to be done. 
1.9.5 Lymphatic system: 
An experimental infection of Japanese macaques observed splenomegaly in all P. coatneyi-
infected animals.  Microscopically, the spleens were characterized with lymphoid follicular 
hyperplasia, activated macrophages, and red pulp sequestration with parasitized erythrocytes 
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accompanied by hemozoin pigment (Figure 10). The splenic lesions were considered similar to those 
noted in humans infected with acute P. falciparum infections. (Kawai 2003) 
1.9.6 Reproductive system: 
Studies of placental pathology in the rhesus macaque model were conducted at Tulane 
University using primiparous and multiparous macaques.  The histopathological features of the 
disease in macaques mirrored that seen in humans infected with P. falciparum. The most severe 
placental lesions consisted of infarction, fibrinoid necrosis, deposition of fibrin and mononuclear and 
polymorphonuclear fibrinoid necrotizing placentitis.  A few of the experimental animals aborted, and 
fetal death was correlated with the presence of severe placental infarction. The endometrium was 
typically infiltrated with significant numbers of mixed inflammatory cells and the uterine 
microvasculature contained parasitized erythrocyte sequestration which increased with proximity to 
the placental tissues.  Furthermore, there was typically infarction of the basal plate with small 
numbers of neutrophils admixed with pigment laden macrophages. (Davison 2000) 
1.9.7 Other systems:  
Although other organ systems such as the respiratory and hematopoietic systems are involved in the 
pathophysiology of severe malaria in humans the histopathological examination of these systems in 
P. coatneyi infection in any species of NHP is significantly lacking.   
Only a few immunohistochemical studies of the pathophysiology of P. coatneyi in macaque 
models have been conducted. In 1993, Aikawa and colleagues examined rhesus macaques in which 
the cerebral microvasculature containing sequestered parasitized red blood cells was examined for 
immunohistochemical reactivity for the endothelial sequestration receptors: CD36, TSP 
(thrombospondin) and ICAM-1.  The cerebral microvasculature of infected animals demonstrated 
immunoreactivity to all three molecules while that of cerebral endothelial cells in the cerebral 
microvasculature of uninfected control macaques was negative. (Aikawa 1992)   This study mirrored 
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work that had been conducted in P. falciparum infected tissues. The positive immunoreactivity of P. 
coatneyi infected tissues suggests that there is a similar mechanism of cytoadherence in both humans 
and NHPs. (Oquendo 1989; Roberts 1985; Smith 2000) Subsequently, in 1996, non-cerebral macaque 
tissues were evaluated using the same molecular markers.  All of the experimentally infected animals 
displayed positive immunohistochemical staining in the heart, lungs, small intestine and the spleen in 
contrast to the control animals.  Additionally, deposition of immunoglobulin G and complement 
component 3 within the vascular wall (immune complexes) were evaluated using 
immunofluorescence in all harvested tissues.  All of the tissues examined in the Plasmodium coatneyi-
infected animals were positive for both markers. In contrast, in the uninfected animals, there was 
immunoreactivity in the spleens and faint immunofluorescence in the kidneys of 2 of the animals, but 
the brain, heart, lungs and small intestine were universally negative. This microvascular damage in 
the kidneys is consistent with studies that have been conducted in falciparum malaria infected tissue. 
(Maeno 1993)  
1.10 Electron Microscopic Findings: 
In contrast with the dearth of histopathological analysis described in the literature, the bulk 
of the early studies of P. coatneyi included transmission electron microscopic examination of the 
pathological changes in the rhesus macaque.  Concentrating on changes associated with the process 
of sequestration, which is best observed and confirmed using ultrastructural examination to identify 
specific cytoadhesion, a variety of pathological observations have been reported. 
Rosettes, consisting of a central infected erythrocyte, cytoadherent or bound to a variable 
number of surrounding uninfected erythrocytes, have been described as contributing to the 
pathogenesis of P. coatneyi (Udomsangpetch 1991), Plasmodium fragile, and P. falciparum infections. 
They have been observed with cultured P. falciparum and in occasional instances with fresh isolates 
of the human cerebral malaria agent. (Handunnetti 1989; Wahlgren 1992) Rosette formation has 
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been examined ultrastructurally, and the theorized mechanism of occurrence posits that the 
uninfected erythrocytes are bound by receptors to the electron-dense knobs found on the cell 
surface of a centrally located, parasitized red blood cell which contains either a trophozoite or a 
schizont. (Tegoshi 1993) Rosettes can subsequently begin to recruit and bind to other rosettes or 
uninfected erythrocytes, forming larger aggregates.  P. vivax, P. cynomolgi, P. knowlesi and the ring 
stage of P. falciparum (and P. coatneyi) lack the electron dense knobs which mediate cytoadherence 
and as such are not generally associated with high rates of rosetting.  Thus, erythrocyte 
sequestration, which is considered important for the pathogenesis and clinical outcome of cerebral 
malaria, is thought to result from a combination of rosette formation between parasitized and 
uninfected erythrocytes, interactions between distorted erythrocytes and induced pseudopodia of 
endothelial cells, and direct adhesion between erythrocytes and endothelial cells. (Handunnetti 1989; 
Howard 1989; Udomsangpetch 1989) 
Packed infected erythrocytes are characterized by distortion and prolongation of the 
cytoplasm, generating irregular forms.  These appear to intricate themselves into invaginations and 
pseudopod-like projections emanating from the adjacent endothelium.  Furthermore, the surface of 
the affected endothelium is crenated, with thickening of the endothelial basal lamina, especially in 
proximity to the parasitized red blood cells.  The infected erythrocytes themselves develop the 
conical, membrane delineated, electron dense, evenly spaced “knobs” which are involved in binding 
to unparasitized erythrocytes and potentially to the endothelium as well (Figure 11). (Aikawa 198; 
Kilejian 1977) Within the red blood cells, in addition to the malaria hemozoin crystals, the plasmodia 
were described at various stages of development ranging from trophozoites to schizonts, with 
schizonts predominant. (Sein 1993) Furthermore, infected erythrocytes were noted to be bound to 
uninfected cells at the point of the electron dense knobs and in doing so formed the described 
rosette patterns. (Tegoshi 1993)  
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Figure 1.6-11 Rhesus macaque, Plasmodium coatneyi infection. 
Figure 1.6. Liver. A macroscopic autopsy photograph showing the diffuse pale brown to grey 
discoloration of the liver from an animal that died of severe Plasmodium coatneyi malaria, normally 
attributed to malaria hemozoin pigmentation.   
Figure 1.7. Myocardium.  A photomicrograph of the Intravascular, intraerythrocytic trophozoites with 
microvascular sequestration of both infected and uninfected erythrocytes (inset), associated with 
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severe Plasmodium coatneyi infection. Hematoxylin and Eosin (HE) stain, magnification x 100, inset x 
200. 
Figure 1.8. Liver.  There is severe, focally extensive, centrilobular hepatocellular coagulative necrosis 
with sinusoidal sequestration, intrasinusoidal pigment and intraerythrocytic Plasmodium coatneyi 
trophozoites (inset), as is occasionally observed in animals with severe Plasmodium coatneyi malaria. 
HE stain. magnification x 100, inset x 200. 
Figure 1.9. Kidney.  There is severe, multifocal to coalescing tubular necrosis with epithelial 
degeneration, rare regeneration, cellular casts and proteinosis. HE magnification x 400.  
Figure 1.10. Spleen. Splenic histiocytosis is diffuse and marked with innumerable intraerythrocytic 
Plasmodium coatneyi trophozoites and hemozoin pigment. The white pulp is diffusely expanded by 
activated histiocytes and the red pulp is replete with abundant malaria pigment (inset).  HE. 
magnification x 100, inset x 200. 
Figure 1.11. Electron micrograph of cytoadherence (arrow) of parasitized red blood cell knobs (K) to 
endothelial cells (E) in a cerebral microvessel. P = Plasmodium coatneyi (magnification x 36,000). 
Inset:  Cytoadherence (arrow) of knobs to endothelial cells (magnification x 56,000). Transmission 
electron micrograph. Replicated with permission from Aikawa M et al.  A primate model for human 
cerebral malaria: Plasmodium coatneyi–infected rhesus monkeys.  Am J Trop Med Hyg: 46: 391-
397,1992 
 
The descriptions in the literature suggest that the observed endothelial pseudopodia occur 
with greater frequency within the microvasculature of the cerebellum than in other regions of the 
brain. (Sein 1993) Cerebral endothelial pseudopodia have only rarely been described in the literature 
in diseases other than malaria.  Chickens fed a diet high in linoleic acid and deficient in vitamin E were 
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reported with similar changes (Yu 1974) as were cats with induced endotoxic shock.  Rats 
experimentally manipulated to generate or decrease fluid shear in skeletal muscle microvessels 
induced formation of endothelial pseudopodia. (Hueck 2008) Furthermore, pigs with experimental 
Mycoplasma suis infections were assessed ultrastructurally and were noted to have similar changes in 
endothelium throughout multiple organ systems as is described with P. coatneyi. (Sokoli 2013) 
MacPherson et al. suggested that the endothelial pseudopodia within the cerebral 
microvasculature, which has also been described in human cases, is a possible pathological 
manifestation of cerebral vascular insult and a response to endothelial damage.  Since these were 
observed in regions with the slowest blood flow, it was proposed that there was a higher likelihood of 
trophozoite and schizont-infected erythrocyte deposition. (MacPherson 1985) Ultrastructural lesions 
in endothelial infections other than malaria have been described in detail including the cytokine-
mediated transendothelial migration of leukocytes as well as ligand-receptor connections, suggesting 
that electron microscopic findings seen in cerebral malaria are multifactorial and not necessarily 
specific to the plasmodium pathogens. (Gonçalves 2010; Schmidt 2011) 
 
1.11 Atomic Force Microscopy Studies of Malaria: 
Atomic force microscopy (AFM) or Scanning force microscopy (SFM) is a technology which has 
shown extraordinary diversity in its application and has been used to successfully map the 
ultrastructural topography of malaria infected erythrocytes for various different plasmodia, including 
the human parasites: P. falciparum (Aikawa 1996; Aikawa 1997; Akaki 2002; Garcia 1997; Li 2013; 
Nagao 2000; Olliaro 1997; Quadt 2012), P. malariae (Li 2010), P. vivax (Malleret 2015) and the rodent 
parasite: P. yoelli. (Claser 2014) The technology is used primarily in the assessment of the forces 
associated with or in imaging surface ultrastructure of polymer chemistry, semiconductor technology, 
solid state physics, as well as having applicability in a range of research investigations in medicine, 
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molecular and cell biology.  Our specific use of the technology in this study has been in descriptive 
imaging, as, through the interface of the probe with the forces generated by the sample, three 
dimensional images of the topography of the surface of a given sample can be generated. (Binnig 
1986; Giessibl 2003) One of the fundamental benefits of this technology is that, as AFM does not use 
lenses or beam irradiation for imaging, it is not limited by issues of diffraction limit and aberration 
which affect space resolution, nor does it require a vacuum or particular staining in sample 
preparation, which are required for either optical microscopy and electron microscopy. The image 
produced generates a surface map of individual cells and as such is an extraordinary tool in the 
description and measurement of the structural changes which occur following plasmodial infection of 
erythrocytes. As such, the final images generate data which provides cross-over and complementary 
information between both AFM and SEM. The descriptive results of the use of this modality are 
described in Chapter 6 which discusses the ultrastructural findings in depth. 
Transmission Electron Microscopy, Scanning Electron microscopy and Atomic Force 
Microscopy have all allowed for an in-depth examination of malaria infected erythrocytic surface 
ornamentation.  Knobs (or some variant thereof), caveolae, caveola-vesicle complexes, cytoplasmic 
clefts, and electron-dense material have all been described in plasmodium infected erythrocyte 
plasma membranes using various ultrastructural techniques. (Atkinson 1990) The two most important 
forms of surface ornamentation which are expressed on the plasma membrane of plasmodium spp. 
infected primate erythrocytes, vary in association with the specific species causing the infection, are 
Knobs and Caveolae. 
Knobs or knob like protuberances, have been well described in P. falciparum and P. malariae 
(Aikawa 1996; Aikawa 1997; Aikawa 2002; Li 2010) as well as in P. coatneyi (Aikawa 1992), while 
caveolae are seen on the surface of P. vivax, P. ovale, P. fragile, P. cynomolgi and one passing report 
of the structure observed in P. coatneyi. (Aikawa 1975; Aikawa 1977) There are sporadic reports 
which describe knobs on P. ovale (Matsumoto 1986) and portrayals of caveolae on the surface of P. 
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malariae infected erythrocytes. (Atkinson 1990; Mackenstedt 1989) Both of these characteristic 
morphological alterations have been primarily described through the use of transmission electron 
microscopy and scanning electron microscopy. 
P. coatneyi infected Rhesus macaques and Japanese macaques have been employed as 
animal models for severe and cerebral malaria associated by P. falciparum. (Aikawa 1992; Davison 
1998; Kawai 1993; Lombardini 2015; Moreno 2013) P. coatneyi shares a range of pathophysiological, 
pathological and ultrastructural features with P. falciparum, as well as several distinguishing 
phenotypic characteristics.  Both species of plasmodium have 48 hour intraerythrocytic development 
cycles, subsequent to which schizogony occurs. The newly released merozoites undergo reinvasion of 
uninfected erythrocytes and the host has a resultant febrile spike.  Both P. falciparum and P. coatneyi 
develop rosettes comprising one or multiple infected red blood cells which recruit uninfected 
erythrocytes (Doumbo 2009; Lombardini 2015; Moreno 2013), they both have well documented 
microvascular cytoadherence and both parasites appear to share some variation of knob-like 
structure on the cell surface hypothesized to be involved in the pathogenesis of cytoadhesion. The 
knobs on erythrocytes infected with mature asexual forms of P. falciparum are posited to allow the 
infected cells to cytoadhere to the vascular endothelium under shear ﬂow conditions and thus avoid 
splenic clearance. (Malleret 2015) 
 
1.12 The Pathophysiology of Severe Malaria in human and simian models: 
While there have been remarkable advances, the pathophysiology of both P. falciparum and 
P. coatneyi infections remain areas of significant scientific debate.  In particular, the pathogenesis of 
coma in severe malaria is a controversial topic of research. (Turner 1997; Turner 2006; Milner 2011) 
Previous investigations have tended to split into several camps, the first based around a ‘mechanical’ 
theory of coma, in which the pathophysiology of disease is directly linked to microvascular 
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obstruction by sequestered iRBC and its subsequent effects, whilst other authors view sequestration 
as an epiphenomenon. This has led to the proposal that the systemic effects of infection, such as 
soluble cytokine release, nitric oxide or immune dysfunction lead to CNS disease independently of the 
presence of parasitized erythrocytes in the brain (Clark 1994). This was in part fueled by the 
observation that murine and hamster models of the disease lacked significant cerebral sequestration. 
As such, various simian models have been used in pathophysiological studies of severe malaria in an 
attempt to study and elucidate some of these opposing theories. 
Erythrocytic sequestration and cytoadherence have been definitively shown to occur with 
both parasites through in-vitro studies and electron microscopy (Kawai 1993; Kawai 2003; Smith 
1996; Udomsangpetch 1991), and it is this pathological commonality which promoted the use of the 
P. coatneyi-rhesus macaque as a good model of sequestration dependent P. falciparum induced 
cerebral malaria in humans.  However, although sequestration is described in the brain, there are a 
wide range of secondary neuropathological features of the disease which have been recently 
described in the human disease.  Examples include cerebral edema, breakdown of the blood brain 
barrier, axonal injury, as well as leukocyte and fibrin/platelet thrombus formation.  All of these 
features have been more recently described in both adult and pediatric post mortem studies in 
human malaria (Turner and Milner 2014), but need to be examined in the macaque model to 
determine the conformance of the macaque model with the human disease. (Mendiratta 2006) 
The role of cytokines in the immunopathogenesis of plasmodium-induced disease has been 
extensively studied in murine models, however there have been few reports of similar work in non-
human primates.  One of these studies, undertaken at the U.S. Centers for Disease Control and 
Prevention, utilized the rhesus macaque-P. coatneyi model to evaluate the relationship between 
serum levels of inflammatory cytokines and prostaglandin with parasitemia levels.  Serum interferon-
γ levels rose earlier and mirrored the periodicity of the parasitemia, while interleukin-1β and tumor 
necrosis factor-α increased late in infection. The authors theorized that the change in interferon-γ 
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was associated with early activation of T-lymphocytes, while the elevated levels of the latter two 
cytokines correlated with monocyte activation paralleling increased parasitemia. Serum prostaglandin 
E2 (PGE-2) levels were also elevated.  Considering the microvascular insult associated with severe 
malaria in human disease, the report theorized that the progressive increase in PGE-2 observed in the 
rhesus was a corollary to the rise in inflammatory cytokines.  Finally, the study also evaluated ciliary 
neurotropic factor, a molecule which is involved in the maintenance of calcium homeostasis in glial 
cells and neurons, as a means of assessing neural injury in the rhesus.  By the later stages of disease, 
ciliary neurotropic factor had risen in all four of the experimental animals. (Yang 1999) 
A more recent study evaluated erythropoietin (EPO) levels in serum and compared the 
findings with microscopic evaluation of core bone marrow samples.  EPO levels in P. coatneyi-infected 
macaques reached a peak of 6 times that recorded in the uninfected control animals, and the EPO 
zenith coincided with the nadir in hemoglobin levels in the affected monkeys.  The increase in renal 
production of EPO strongly suggests a functional hyperplastic response in the bone marrow to the 
massive erythrocyte destruction. The bone marrow had a significant shift towards immaturity in both 
the myeloid and the erythroid lineages during the acute stage of infection.  Furthermore, concurrent 
dyserythropoiesis was morphologically observed, characterized by karyorrhexis and increased nuclear 
lobulation.  Within a week following cure, the nuclear changes in the bone marrow had normalized. 
(Moreno 2013) 
Erythrocyte longevity was also assessed in the infected macaques.  A severe anemia was 
observed approximately 10 days following infection and was correlated with parasitemia.  The 
highest degree of erythrocyte turnover occurred at relatively low parasitemias, suggesting that 
infected erythrocytes have a bystander effect resulting in concurrent destruction of uninfected red 
blood cells.  Greater than 90% of the cleared erythrocytes were uninfected. (Moreno 2013) Suggested 
mechanisms of this bystander effect relate to changes in erythrocyte morphology, decreased 
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longevity and immune-mediated clearance through up-regulated erythrophagocytosis. (Smith 1982; 
Sri-Hidajati 2005) 
 
1.13 Controversies surrounding existing animal models of Experimental Cerebral Malaria: 
Partly because of the basic histopathological differences between murine models of 
experimental CM (ECM) and both those observed in humans and in non-human primate models, the 
use of these models in an increasing number of adjuvant treatment trials, the status of the mouse 
model of ECM has been challenged. (White 2010)  
One major issue with mouse models is the lack of a basic pathological description of the 
model and relating this to pathophysiology both in terms of the clinical pattern of disease in the 
model and comparison of these to the natural host. Additionally, there have been a large number of 
host/parasite combinations used, characterized to varying degrees, the most popular being the P. 
berghei/ANKA mouse model. This has led to an explosion in the use of this model to represent 
‘experimental’ cerebral malaria. (de Souza 2010; Hunt 2010; Hvid 2010; Langhorne 2011)  
The utility of these rodent models tends to be both in their ease of experimental approach, 
the use of inbred strains and gene knockout strains to study particular pathways of pathogenesis. 
However, the explosion of research in murine models led to some papers drawing unsustainable 
conclusions, and the ethically questionable practice of clinical trials in humans being based on 
minimal data raised solely in animal studies (often underpowered) of unproven relevance. 
For instance, human trials of Erythropoietin as an adjuvant treatment in pediatric CM have 
been conducted (Picot 2009), based on data from murine model studies (Kaiser 2007) despite data in 
adult PM studies of human CM cases suggesting EPO receptor levels were not significantly different in 
brainstem tissue of patients with or without coma. (Medana 2009) The use of limited data from 
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animal models to justify clinical trials is not a minor issue, because results can be misleading since 
properly controlled large trials with appropriate ethical oversight and safety monitoring are difficult 
to organize in areas where severe malaria is common, on a par to the logistical challenges of vaccine 
trials. However, they may have a role in testing potential adjuvant treatments in CM. For instance, 
the use of Erythropoietin and hypothermia in the treatment of hypoxic-ischemic encephalopathy in 
Western settings shows some promise. (Rogers 2014) Many such adjuvant or neuroprotective 
treatments have been proposed in theory for malaria, and those attempted thus far have been in 
small and overwhelmingly unsuccessful human trials. (John 2010) Therefore, basing decisions for 
entry into human trials on data from animal models would seem unwise until the models themselves 
are better characterized.  
Other non-human primate models are also employed, with specific focus on vaccine trials.  P. 
falciparum itself will infect New World Aotus and Saimiri monkeys, however, neither cytoadherence 
in the brain nor cerebral malaria develop in those species.  Immunohistopathologic studies show no 
deposition of P. falciparum antigen, complement or IgG. (Aikawa 1990; Fujioka 1994) Additionally, the 
size and frailty of the New World species render them difficult to use for pharmacokinetic or 
toxicology studies.  Sequestration will develop at high parasitemia of P. fragile in rhesus, but electron-
dense knobs are not seen on parasitized erythrocytes. (Howard 1989) Furthermore, symptoms do not 
develop until just before death, rendering the P. fragile model particularly difficult for use in drug 
studies of acute malaria. (Miller 1969) 
Such controversies led to a period of heated exchanges in the literature and eventually a 
consensus conference in 2012 in Hinxton, Cambridge UK, which agreed amongst other 
recommendations that “Development and standardization of animal models, including renewed 
investment in non-human primate systems, is a priority.” (Craig 2012) 
1.13.1 What positive advantages do animal models of malaria offer? 
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The utility of animal models of malaria is unquestionable given the fact that most patients 
with severe malaria live in resource-poor settings with often limited medical infrastructure in which 
to base clinical and pathological studies. For instance, gene knockout studies allow close examination 
of the role of a single specific gene or pathway in the pathogenesis of disease, such as the 
investigation of gamma interferon related pathology in the mouse brain. (Hunt 2014) This, of course, 
depends on agreement that the clinical and pathophysiological nature of that disease pattern in the 
model accurately represents that which is observed in humans.  
A second major advantage of animal models is the ability to perform more invasive 
physiological monitoring or therapeutic studies in controlled circumstances, which would not be 
ethically acceptable as proof of concept studies in humans – e.g. ex vivo organ based studies such as 
splenic perfusion as a means to study hemofiltration as a treatment in malaria (Buffet 2011), isolated 
kidney experiments for examination of reno-protective drugs, or imaging studies of the brain. (Kawai 
2010)  
Thirdly, as and when basic in vitro research or studies from the murine model provide 
evidence for a promising treatment, a better developed and more relevant model to human 
physiology and immunology, such as the simian model, could be used as an intervening stage in 
safety and efficacy testing before moving on to human trials, thereby ensuring maximal and more 
efficient use of time and funding.  
As such, full characterization of animal models is potentially key to understanding the 
similarities and differences to the human disease which may influence interpretation for specific 
studies using the model.  
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1.14 Discussion: 
It has been over 50 years since the discovery of P. coatneyi in the forests of Malaysia, but 
there remains much to accomplish in describing this potentially valuable model of severe human 
malaria.  Considering the continuing debate as to the suitability of rodent models of experimental 
severe and cerebral malaria, there remains a significant need to more fully describe the rhesus 
macaque/P. coatneyi model. Animal models of severe and cerebral malaria are being used not only to 
study pathophysiology but also in drug, vaccine and adjuvant treatment trials, where detailed 
descriptions of their clinical and pathological characteristics are lacking.  
The pathology and pathophysiology of severe and cerebral malaria are still active areas of 
research and have stimulated significant debate. Conducting such studies in humans poses ethical 
and logistical difficulties that have resulted in an increasing reliance on murine ECM models, despite 
basic pathophysiology which differs markedly from that of malaria in humans.  Additionally, post 
mortem based studies of cerebral malaria in adult and pediatric severe malaria cases have led to 
proposals that these two different patient groups may show pathological differences and have 
differing pathophysiology in the genesis of similar clinical syndromes.  
One of the key areas of controversy has been the degree to which parasite sequestration 
within the brain can be linked to ante mortem coma. Evidence from Southeast Asian adults seems to 
clearly support a correlation as is demonstrated in pediatric cases of CM, even though the latter 
group, in Southeast Asia, has significant rates of coinfection with HIV which may alter secondary 
aspects of neuropathology. (Hochman 2015; Mbale 2016; Ponsford 2012) However once 
sequestration is present, which seems to be a process dependent both on parasite load and host 
immunological responses, it is not inevitable that a patient will develop coma. Patients demonstrating 
significant levels of cerebral sequestration will not necessarily fall within the clinical criteria of CM, as 
defined by WHO criteria, and some patients with significant sequestration will not exhibit coma. 
70 
 
Although quantitative recognition of a relationship between sequestration in the brain and coma has 
been established (by histology and ultrastructural studies) more recently the concept of parasite 
biomass has been used (Dondorp 2005; Hendriksen 2013) to relate severe disease to indirect 
measures of pathogen load using serum HRP-2 levels.  
A key drawback of murine ECM models is that this process of parasitized erythrocyte 
sequestration in the cerebral microvasculature does not occur, rather there is localization of host 
leukocytes mediating an autoimmune meningoencephalitis. Since sequestration is so characteristic of 
CM in humans, it seems important, when characterizing a putative animal model of severe malaria, 
that the degree of microvascular sequestration should be determined and the effects of this on 
clinical course and specific end organ dysfunction examined be in detail. 
The simian model of P. coatneyi/splenectomized Rhesus macaque had been previously 
proposed to represent a good model of sequestration dependent pathology and ‘cerebral malaria’. 
Yet we lack a detailed clinical and pathophysiological description of whether this model produces 
coma, seizure activity or other clinical evidence of the mechanisms of secondary neuropathological 
injury similar to those more recently described in the humans, such as has been described in 
associated with blood brain barrier breakdown, host leukocyte responses, cytokine release, astroglial 
activation, axonal injury, or platelet mediated endothelial cell dysfunction. (Combes 2006; Hora 2016; 
Medana 2002; Medana 2006; Medana 2007; Storm 2014; Turner 1997)  
 Fundamentally the question remains as to what represents a substantiated and scientifically 
valid model of severe or cerebral malaria in humans.  Is the macaque model able to replicate 
falciparum malaria in children as well as adults? In addition to the organ specific complications of 
severe malaria such as cardiac, renal or hepatic pathology which occur in simian models, can these be 
linked to sequestration or immune mediated pathology in this model, and are these pathological 
manifestations consistent with human disease? A clearer understanding of the basic pathology is 
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critical for understanding the utility of this particular model in both preventive and therapeutic 
studies.   
The macaque model has the potential advantage of a high degree of homology to the human 
immune system. This evolutionary proximity to human infection, as opposed to the murine models, is 
only further emphasized by the recent description of P. knowlesi infection as a zoonotic human 
malaria parasite. (Cox-Singh 2015; Vythilingam 2014; Vythilingam 2016) NHP models could address 
problems involving metabolic and physiologic changes (for instance, the pathogenesis of coma and 
neurological dysfunction) which are difficult to study in human patients. (Beignon 2013) Functional 
MRI imaging, intracranial pressure monitoring (Newton 1991) and laser video microscopy of flow and 
EEG under controlled settings (and in response to potential adjuvant therapies) are difficult to 
perform, and ethically justify, in human patients with malaria. In comparison with the non-
sequestration dependent, immune mediated encephalitis of experimental murine cerebral malaria, 
the similarities of the pathophysiological tapestry of P. coatneyi to human disease should make the 
simian results more medically relevant.   
Thus, using both retrospective pathological studies, and prospective clinical, histopathological 
and ultrastructural studies this thesis aims to provide data to help determine the validity of the P. 
coatneyi infected rhesus macaque as a model for severe and cerebral malaria in humans.  The arms 
race which is ongoing with this disease is all the more heightened by the parasite’s broadening drug 
resistance, and the search for a strong model of human disease therefore all the more crucial. 
 
1.15 Summary: 
While there is significant, complex and at times, controversial, ongoing debate as to the validity of 
murine versus simian models of cerebral and severe malaria, what is constant is the absolute need for 
effective, replicable, and scientifically confirmed animal models which will serve as a platform for 
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anti-malaria drug development and vaccine studies moving forward. In-depth examination of the 
current literature demonstrates extreme heterogeneity of animal based malaria research to date, 
which is underscored by the controversy as to the murine malaria model focus.  Additionally, based 
on the advent of Artemisinin and Artemisinin Combination Therapy (ACT) drug resistance, the relative 
absence of effective replacement compounds to combat drug resistance and the sheer 
epidemiological weight of falciparum malaria susceptible people world-wide, the results of this 
dissertation gain heightened importance and urgency.  Recognizing that the criteria for a model of P. 
falciparum severe or cerebral malaria must include features of cytoadherance, rosette formation, 
sequestration, similar clinical symptomology to human disease and equivalent immunopathology, this 
study consists of a thorough, in-depth examination of descriptive clinical, histopathological, 
ultrastructural and molecular pathology of the rhesus macaque/P. coatneyi as an appropriate and 
replicable animal model for cerebral and/or severe malaria syndromology of P. falciparum induced 
disease in man.  In doing so we have attempted to validate its use as a platform for drug and vaccine 
studies. 
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Chapter 2: Materials and Methods 
 
2.1 Introduction: 
 
2.1.1 Evolutionary basis for non-human primate modelling: 
Genomic comparison between humans and the various other great apes have noted that 
chimpanzees display the greatest homology to humans in total DNA sequence, with interspecies 
sequence differences limited to approximately 1-1.5%. (Page 2001; Stewart 1998) Orangutans and 
gorillas have similar homology as do chimpanzees, however the next group of animals which 
demonstrate the closest homologous alignment of whole DNA sequence are the Old World monkeys, 
to include rhesus macaques. Humans diverged evolutionarily from the great apes approximately 6-7 
million years ago.  Furthermore, the evolutionary separation of the great apes from Old World 
monkeys occurred 25 million years ago and the split with New World monkeys is posited to have 
occurred approximately 35-40 million years ago. (Stewart 1998) Of significant importance to the 
overall argument as to validity of different animal models, mankind is theorized to have split from 
rodents and mammals, other than primates, greater than 65-85 million years ago. (Eizirik 2001; 
Kumar 1998) Based on this relative evolutionary proximity, the rhesus macaque has been employed 
in a range of comparative biomedical research to include drug development protocols. (Bluemel 
2015) The belief that the rhesus macaque metabolism of medication derivatives more closely 
resembles that of humans in comparison with rodent models remains one of the most significant 
arguments in the debate as to relevancy of different animal models of severe and cerebral malaria. 
(Mestas 2004; Perlman 2016; Rhesus Macaque Genome Sequencing and Analysis Consortium 2007) 
Of significant historical consequence in model selection for drug discovery and applicability research 
is the failure associated with the Thalidomide safety studies conducted in Europe in the 1950s.  In 
that particular tragic instance, the potential teratogenic effects of the drug were not observed as the 
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toxicity studies had been limited to research in rodents, lagomorphs, cats and dogs, but excluded the 
use of non-human primates.  The subsequent, disastrous effect of the drug, which resulted in over 10 
thousand children being born with severe congenital abnormalities, is paramount to the care which 
must be given to model selection and the required due diligence in describing the applicability of any 
animal model. (Bluemel 2015) 
 
2.1.2 Non-Human primate models: 
The rhesus monkey is one of the hardiest of the established primate malaria models and 
therefore is considered to be optimal in its ability to tolerate the required procedures for drug 
evaluation protocols.  Although there are New World monkeys that can be infected with P. 
falciparum and P. fragile as models of severe malaria (Aikawa 1990; Fujioka 1994; Howard 1989; 
Miller 1969), the rhesus macaque remains a superior model to the New World Aotus monkey in 
particular, because sufficient blood volumes can be collected for adequate analysis without causing 
an adverse iatrogenic anemia.   
The model that appears to mimic human severe malaria most closely is the rhesus 
monkey/Plasmodium coatneyi model.  The animal protocol employed for this study focused on the 
methodology of the use of the rhesus monkey/P. coatneyi severe malaria model specifically in order 
to evaluate the use of Methylene Blue (MB) for the treatment of severe blood-stage malaria, the 
results of which will be described in the subsequent chapter. The experimental model is essentially 
the same as that which was used in both the retrospective and the prospective studies from which 
we have drawn data throughout this dissertation.  The prospective studies employed a far greater 
degree of scrutiny and refinement of the data collection to ensure uniformity between the study 
animals and to maximize the understanding of the pathogenesis of disease progression in this 
species.  The protocol was used primarily for the comparison of two dose levels of MB to 
intramuscular (IM) Quinine dihydrochloride (QD).  After an initial trial of the experiment which proved 
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to have too few data collection points to adequately monitor the development of severe parasitemia 
in the animals, the protocol was altered and significantly refined.  The original protocol had three 
primary endpoints: Firstly, to evaluate MB in terms of overall safety.  Secondly, to determine if IV MB 
will be non-inferior to IM QD in terms of efficacy.  And finally, to provide efficacy and limited safety 
data for the selection of an optimal dose of MB for use in planned phase II human clinical trials. 
As the animals included in both the retrospective and prospective data were from the 
AFRIMS closed colony, the degree of inbreeding is a potential confounding factor.  To counteract that 
concern, by Standard Operating Procedure, three generations of the pedigrees of both the male and 
female monkeys in the AFRIMS Department of Veterinary Medicine’s database are reviewed prior 
pairing or grouping of animals to avoid inbreeding.  Furthermore, on a periodic basis (approximately 
every 15 years), an influx of new, genetically distinct animals are introduced into the AFRIMS colony 
from suppliers in the United States. 
In 2012, the Department of Veterinary Medicine conducted an internal, unpublished study 
calculating the degree of inbreeding in the rhesus colony through the use of the phylogeny program 
"Pedigraph" in order to determine the inbreeding coefficient by using the pedigree data of each 
animal in the colony. 584 rhesus monkeys were examined, and of those, there were 43 monkeys that 
expressed an Inbreeding Coefficient greater than 0. Throughout the entire population, the Inbreeding 
Coefficient ranged from 0 to 1.  
Table 2.1: Inbreeding coefficient of the AFRIMS rhesus macaque colony 
 
Inbreeding coefficient Number of animals out of 584 total 
0.0078125 1 
0.03125 6 
0.0625 23 
0.125 6 
0.25 7 
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2.1.3 Ethics: 
As part of WRAIR’s and AFRIMS’s ongoing commitment to the reduction of the number of 
animals used in medical research, the AFRIMS IACUC put in place a Tissue Sharing Program. This 
program allows investigators to utilize tissue or other biological materials from ongoing approved 
research protocols without the need to euthanize additional animals. Furthermore, the AFRIMS 
comparative pathology division of the Department of Veterinary medicine maintains a 
comprehensive database of all pathologic samples collected in the 50+ years of medical research 
conducted in the Institute.  Formalin fixed, paraffin embedded tissue blocks from historical protocols 
dating back over 20 years were used for the application of novel techniques and for histopathological 
examination.  Additionally, medical records were available from the bulk of the retrospective animals, 
allowing for a consolidation and evaluation of the clinical, experimental and baseline data.  Control 
tissues were harvested post-mortem through the tissue sharing program in association with ongoing 
IACUC approved infectious disease protocols at AFRIMS, to include renal transplantation studies, 
Shigella sp. drug trials, Simian-Human Immunodeficiency Virus chimera pathogenesis studies, 
Plasmodium cynomologi drug trials and routine attrition within the macaque colony correlated with 
spontaneous neoplasms or other lesions not associated with experimental protocols. In particular, 
the animal use protocol for the prospective animals was approved by the AFRIMS IACUC, protocol 
number 12-08. In all cases, animals were maintained in strict accordance with established principles 
under the Guide for the Care and Use of Laboratory Animals. (National Research Council 2011) 
Furthermore, the AFRIMS macaque colony has undergone continuous Association for Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC) accreditation. Retrospective studies 
post 1985 were approved by the AFRIMS IACUC, protocol numbers: 90-12; 92-3; 93-6 and 01-05.  
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2.1.4   Spleen-intact Donor Monkeys: 
P. coatneyi was inoculated from one rhesus to another through a blood challenge of infected 
erythrocytes.  Inoculation began in an infected donor by intravenous inoculation of freshly thawed 
cryopreserved P. coatneyi strain infected blood.  The stabilate stock used was the Hackeri strain of P. 
coatneyi which originated from stocks maintained by cryopreservation at the Centers for Disease 
Control and Prevention, donated to and archived at AFRIMS (Collins 2001), has been tested and 
confirmed negative for Herpes B virus, SRV, SIV and STLV-1 to ensure no possibility of adventitious 
virus transmission into the monkey colony.  A 1cc aliquot of a thawed stabilate of P. coatneyi infected 
RBCs (approximately 1 mL equivalent to 5x106 infected RBCs) was administered intravenously into a 
peripheral vein of the donor monkey as described below.  Blood smears were prepared to detect 
malaria parasites starting on Day 0 before inoculation and continued daily. 
Once the blood smear was noted to be positive, either white blood cell (WBC) and/or red 
blood cell (RBC) counts were performed daily to determine a parasite density (parasitemia).  After the 
parasitemia had reached > 50,000 parasitized RBCs per µL, 10-20 mL of blood was drawn into a 
heparinized tube, diluted with sterile PBS solution to a concentration of 5x106 infected erythrocytes 
per 1 mL suspension, and divided into equal 1 mL aliquots.  The 1 mL aliquots were subsequently 
used to infect the study animals and to prepare additional cryopreserved stabilates for future use.  
The volume and number of times that parasitized blood could be drawn from the donor animals was 
determined by the attending veterinarian based on calculation of total blood volume in each animal 
and governed by the IACUC approved protocol, such that at no time would it exceed established 
guidelines for phlebotomy described below. 
After completion of the blood draws, curative treatment was given with CQ 10 mg/kg, PO 
daily for 7 days.  The donor monkeys were considered to be off-study once blood donation had been 
completed and animals were cleared of parasites.  If a blood smear result was positive on day 8 of the 
CQ treatment, 2-5 additional doses of CQ treatment were continued.  Blood smears were collected 
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daily and continued until the monkey demonstrated 5 consecutive days of negative blood smears.  
Subsequently, the monitoring schedule was reduced to two times weekly for 2 weeks, and then 
weekly for 2 more weeks.  The donor monkeys were considered to be off-study once they are cleared 
of parasite, and alternate therapy could have been prescribed as determined by the attending 
veterinarian.  A minimum of 8 weeks recovery period from the last positive smear was required 
before the donor monkey could be re-infected. 
Table 2.2:  Donor Inoculation and Treatment Schedule 
Day Procedures Samples to be collected 
-15 Ketamine restraint 15 mg/kg, weighing, 
venipuncture 4 ml 
Complete physical examination 
1 ml in EDTA tube for CBC 
3 ml in SST tube for ALT, 
creatinine and total protein 
-14 Start pole-collar training and continue for 2 
weeks 
none 
0 Inoculation, IV, cryopreserved P. coatneyi 
infected blood 
2 blood smears 
1-7 Daily blood collection* Blood samples for parasite 
determination 
Approximately 
7-10 
 
Daily blood collection* 
 
At parasitemia >50,000/cu.mm 
Ketamine restraint 5-10 mg/kg 
Venipuncture to collect 10-20 ml of blood for 
inoculum preparation and cryopreservation (if 
needed). 
Chloroquine HCl 10 mg/kg, PO after harvest 
Blood samples for parasite 
determination 
 
Inoculum preparations: 5 x 106 
infected RBCs in 1 ml in PBS 
Submit the rest of blood for 
cryopreservation 
For 6 days after 
blood harvesting 
Chloroquine HCl 10 mg/kg, PO Blood smears 
follow daily and continue until 5 consecutive 
negative smears. 
2 blood smears for parasite 
determination 
1st to 4th week Follow up blood smears twice weekly for 2 2 blood smears for parasite 
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after negative 
smear  
weeks and once weekly for 2 more weeks. 
 
determination 
* Blood collection for parasite monitoring and parasitemia determination: Approximately 0.3 ml 
whole blood were collected in EDTA tube each day (0800-1000 hours) from each monkey by sterile 
pediatric lancet puncture for WBC count and RBC to determine parasitemia level. Pole-collar 
restraining was used for this procedure. Hematocrit was occasionally needed. 
 
2.2   Experimental Monkeys:  
2.2.1   Splenectomized Experimental Monkeys:   
Splenectomized P. coatneyi-naïve rhesus monkeys were used for the severe malaria 
pathophysiology, pathology and MB studies in this thesis.  Splenectomy was necessary to develop and 
sustain high-grade parasitemia and initiate severe and cerebral malaria effects. 
2.2.1.1   Splenectomy procedure:   
Splenectomies were performed using aseptic technique.  The standard midline laparotomy (a 
surgical procedure involving an incision through the abdominal wall to gain access into the abdominal 
cavity) was used.  A midline incision was made 3 to 4 inches long just cranial to the animal’s 
umbilicus.  The spleen was identified and gently exteriorized, avoiding trauma to the pancreas and 
was held by a piece of damp gauze with sterile normal saline.  The surrounding area was examined 
for accessory splenic tissue.  Main blood vessels supplying the spleen were identified and the 
surrounding adipose tissue was removed by gentle blunt dissection.  Triple ligatures of plain catgut 
No. 3-0 were applied to the splenic blood vessels in close proximity at the hilus roughly 0.5 to 1 cm 
distal to the splenic capsule.  Mosquito forceps were used to clamp the blood vessel group adjacent 
to the splenic capsule and also to hold the tissue above the ligatures.  A scalpel blade or a pair of 
scissors were used to transect all vessels at the splenic hilus and to remove the entire spleen.  The 
ligatures of the pedicle were observed to ensure hemostasis was intact.  The pedicle was returned to 
the abdomen.  The pedicle was observed again for hemostasis and the omentum was re-positioned.  
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The peritoneum and muscle layer incisions were closed with catgut No. 2-0, with simple interrupted 
sutures.  If loose or excessive subcutaneous tissue was observed, the subcutaneous area was closed 
with an absorbable suture, Vicryl™ No. 3-0 by subcuticular pattern.  The skin was approximated and 
closed with horizontal mattress sutures of non-absorbable polyamide monofilament (Ethilon™) No. 3-
0. 
2.2.1.2   Peri-operative procedures:  
Pre- and Post-Operative Provision, Intra-operative Monitoring and Anesthetic Record for non-
human primates.  While anesthetized, thermal support was provided by means of an insulated 
circulating heated water blanket or forced air heating blanket (BAIR hugger).  Depth of anesthesia 
was monitored by testing the strength of response to toe pinch at ten-minute intervals and isoflurane 
was administered as deemed necessary.  Heart and respiratory rate were monitored via esophageal 
stethoscope and/or pulse oximeter constantly throughout the procedure.  Recordings were 
conducted every five minutes and logged onto the Form: Pre- and Post-Operative Provision, Intra-
operative Monitoring and Anesthesia Record for NHP. 
2.2.1.3   Post-operative Provisions:   
As part of post-operative care, splenectomized animals were allowed up to 4 weeks to 
recover before they were entered into the study.  Immediate post-surgical critical care was provided 
in the Recovery Room.  An antiseptic spray was applied to the incision wound.  Each individual animal 
was observed closely for recovery by an assigned technician.  Long-acting antibiotics, i.e., Shotapen 
LA™ (Benzathine penicillin G 100,000 IU, Benzathine penicillin 100,000 IU and Dihydrostreptomycin 
sulphate 200 mg per ml) at 20,000 IU/kg, IM or equivalent were prescribed.  The animals were 
returned to their home cages once they were fully conscious and limb movement occurred.  
Observation continued at the animal’s home cage until the animal regained consciousness.  Food was 
offered after the animals were fully recovered.  The animals and the incision site were observed daily 
by the staff veterinarian and sutures were removed at 7 to 10 days.  Buprenorphine 0.01 mg/kg was 
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given 1 hour prior to surgery and twice daily (every 12 hours) post surgically by intramuscular 
injection for the first 48 hours post-operatively, and every 12 hours thereafter as needed as 
determined by the veterinarian-on-duty. 
2.3      Experimental interventions: 
2.3.1   Parasite Inoculation:  
On their inoculation day, all monkeys were infected by peripheral vein inoculation with P. 
coatneyi-blood stage parasites (approximately 1 mL equivalent to 5x106 infected RBCs) drawn from 
the donor monkeys.  The blood stage inoculation procedure was conducted using a 22-24 Gauge 1-
inch needle. 
2.3.2   Inoculations/Phlebotomy guidelines: 
Monkeys were handled as little as possible.  Monkeys were trained in humane restraint with 
pole-collar devices for all injections or phlebotomy procedures.  Chemical restraint with ketamine (5-
20 mg/kg ketamine hydrochloride IM) was used for physical examinations and weight determinations 
and the initial inoculum injections.  The ketamine dosage and its use in injection and/or phlebotomy 
procedures was adjusted by the Attending Veterinarian as necessary to minimize discomfort to the 
monkey. 
An inoculum of P. coatneyi parasitized erythrocytes in a volume of 1.0 mL was injected into 
the saphenous or a peripheral vein of each monkey by 22-23 Gauge, ½-1-inch needle.  The monkeys 
were chemically restrained with ketamine HCl (5-10 mg/kg IM) for this procedure.  Injections of MB 
were administered into a peripheral vein by an intravenous catheter (size: 22 to 24 G).  The maximum 
volume of the IV injection did not exceed 3 ml/kg/day.  No chemical restraint was used for 
phlebotomy or drug administration in these pole-and-collar trained animals, unless deemed 
necessary by the Attending Veterinarian. 
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Injections of MB was administered via IV push into a peripheral vein by an intravenous catheter (size: 
22 to 24 G). IV injections for MB was drawn directly from 10 mg/mL solutions of 1% USP MB.  
The maximum volume of the IM injection did not exceed 1.0 ml/injection site.  Compounds given IM 
included: 
1. Ketamine HCl 5-20 mg/kg, IM by 21-23 G needles or smaller.  
2. Quinidine (QD), was injected into the thigh muscle. The loading dose was typically a split  
dose due to volume.     
3. The opioid analgesic, buprenorphine, for perisurgical use was prescribed by the 
veterinarian-on-duty at 0.01 mg/kg, IM, 1hour prior to surgery and every 12 hours post-
surgery for 5 to 7 days. 
2.3.3 Dose Formulations Stability and Storage Conditions:  
1. Methylene Blue:  Methylene blue was packaged as a USP 1% solution in water for injection 
at 10 mg/mL pH adjusted with sodium hydroxide and/or hydrochloric acid.  The injectable 
solution was stored in the dark at controlled room temperature (15° - 30°C). 
2. Quinine dichloride:  Pre-formulated quinine dichloride was sourced from ANB Laboratories, 
Thailand was stored at controlled room temperature (15° - 30°C) until use. 
2.3.4    Pole and Collar restraint: 
For pole, collar, and chair training, monkeys were trained for 2-3 weeks, such that the animals 
became familiar with the various procedures involved.  This allowed for short term restraint for brief, 
non-invasive procedures, i.e., venipuncture to obtain blood samples from peripheral veins; test 
compounds or vehicle administration orally or by IM or IV routes; routine data collection conducted 
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in conjunction with phlebotomy (i.e. Temperature assessment or electrocardiogram) and palpation or 
examination of the compound injection sites.  
 
2.4 Animal protocol Pilot study: 
Initially, the overall study design began with a pilot arm of the study in which a small group of 
animals were separated randomly into dose groups of 3 animals with a low, mid and high dose of MB 
at 20% parasitemia.  This would allow a characterization of drug efficacy as proof of concept at high 
parasitemia, and then the intent was to move forward with the rest of the study using the most 
effective dose.  The initial phase required a single donor spleen intact rhesus macaque.  The intended 
subsequent phase was to compare the most effective MB dose level to an established dose of IM QD.  
Pitfalls which occurred during the initial trial required a series of amendments to the protocol.  
Problems which arose were associated with an inadequate understanding of the parasitemia curves 
in the infected animals and the clinical symptomology in the affected animals using the previous 
retrospective protocols as a foundation.  The blood draws to assess parasitemia were too infrequent 
and did not adequately capture the spike in parasitemia which occurred in the model and as such, 
three animals died unexpectedly.  Those three animals were autopsied and provided the first data set 
for use in our histopathological, immunohistochemical and ultrastructural descriptions. 
The Pilot phase was intended to comprise of the first experimental cohort and was projected to 
compare the efficacy of three dose levels of IV MB once 15% parasitemia was reached. This would 
have been equivalent to a moderately severe case of malaria in a human, but was theorized to have 
been low enough that the rhesus subjects would not die from the disease prior to initiation of 
therapy.  The mid-level, 10 mg/kg IV bid MB, dose was based on prior pharmacokinetic data collected 
on MB administered in rhesus monkeys, which showed an area under the curve (AUC) ratio of 3.5:1 
for drug levels in rhesus monkeys when compared with human data (Barker et al, unpublished).  This 
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corresponded to an estimated human dose of 3 mg/kg IV bid.  The lower dose of MB was planned to 
be 6 mg/kg IV bid, estimated to be equivalent to just under 2 mg/kg IV bid dose in humans, and the 
higher 17 mg/kg IV bid dose was estimated to be a dose of 5 mg/kg IV bid in humans. The most 
effective dose would then have been utilized in Phase II of the protocol.   
Any animal which showed criteria of treatment failure at Treatment Day (TD)+72hrs was to be 
euthanized, and the remaining animals were to be euthanized upon treatment failure or on Day 6 
following initiation of treatment (see Criteria for Treatment Success and Treatment Failure below). 
A total of 15 monkeys in this portion of the study were randomly assigned to each of three 
experimental groups with three monkeys in Group 1 and six monkeys per Groups 2 and 3.  Group 1 
served as the untreated controls.  Two additional monkeys were used as donors for inoculum 
donation.  Experimental animals (not including donors) were to be euthanized upon treatment failure 
or on day six after initiation of treatment.  The ultimate goal of this study was to provide efficacy and 
safety data for the selection of an optimal dose of MB for use in planned phase II human clinical trials, 
and to support the U.S. Army anti-malarial research program. 
As the initial phase failed, the study was restructured and resubmitted to the AFRIMS’ IACUC so 
as to allow for a protocol refinement study and then a subsequent relaunch of the MB pilot, 
comparing drug dosage levels and parasite clearance in P. coatneyi infected rhesus.  As animal 
numbers were restricted by the original protocol, the refinement study and the MB dosing study 
were limited to an additional experimental 12 animals (three animals included in our prospective data 
collection were the three P. coatneyi infected and untreated animals that died unexpectedly during 
the initial attempt of the MB dosage study).  Of those 12, three were allocated to the refinement 
study and nine were assigned to the MB dosage study.  (Study schedules described in Table 2 and 
Table 3) The three animals from the failed initial study and the three animals dedicated to the 
refinement study represented untreated control animals for the subsequent MB dosage study.  No 
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uninfected, MB treated animals were included as drug controls in the study due to limited numbers 
of available animals. 
The MB dosage groups are described in Table 4 and the drug dosing schedule is described in 
Table 5.  Due to the labor intensity of blood sampling, parasitemia assessment, clinical monitoring 
and eventual autopsy, each of the three MB groups were staggered by a week, and an individual 
donor macaque was randomly assigned to each group.  Equally, a fourth donor animal was dedicated 
to the refinement study, and that experiment was conducted almost a year prior to initiation of the 
relaunch of the MB dosage study. 
As described above, the model refinement study required three splenectomized, chair trained, 
experimental animals and one donor macaque. The MB drug dosage study required nine 
splenectomized, chair trained, experimental animals and three donor macaques. The requirement for 
four total donors was due to the need to stagger the three separate cohorts of the MB drug dosage 
phase based on the lessons learned from the failed previous study as well as data derived from the 
model refinement study which was conducted a year prior to the MB drug dosage study, and which 
illustrated the significant labor requirements for clinical data collection, parasitemia assessment, drug 
administration and autopsy timing.  The nine experimental animals were splenectomized in 
accordance with AFRIMS surgical protocols, injected with a microchip temperature recording device 
(telemetry) in the subcutaneous tissues between the shoulder blades and recovered for one month 
prior to being infected by peripheral vein inoculation with P. coatneyi-blood stage parasites 
(approximately 1 mL of 5x106 infected RBCs) drawn from the donor monkeys.  
Throughout the study, blood draws were calculated using a reference point of a 6.8kg animal as 
the least common denominator.  However, with larger animals, under the purview of the attending 
veterinarian, blood draws were increased based on their body weight and permissible blood draws 
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per SOP.  All blood drawn was used in accordance with the testing described in the IACUC approved 
protocol amendments. 
Table 2.3: Refinement study schedule 
Study 
Days 
Procedures Specimens 
-70 Ketamine restraint 5-20 mg/kg, weighing, 
venipuncture 1.5 ml 
Complete physical examination 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
-62 Splenectomy and implant transponder  
-14 Withhold morning feed, Ketamine restraint 5-
20 mg/kg, weighing, venipuncture 1.5 ml 
Complete physical examination 
Place neck collar 
Start clinical observation with VET-GP-008-F5 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
Start pole-collar training and continue for 2 
weeks 
 
-1 Start Clinical observation three time daily using 
study specific form#1  
(Temperature measurement both rectally and 
via transponder 3 times) 
Pole-collar and chair restraint 
Venipuncture 2.5 ml 
EKG measurement 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
0.5 ml in EDTA for TNF-α3 
0.5 ml in heparin for nitric oxide4 
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0 
Blood smear collection 3 times at 0700 (prior 
malaria infection), 1100 and 1900 
Venipuncture 1.5 ml for CBC and chemistries 
one time at 1100  
Clinical observation 6 time daily using study 
specific form#1  
Temperature measurement from both 
transponder and rectal temp recorded 6 times 
at 0700, 1100, 1500, 1900, 2300 and 0300 
Ketamine restraint 5-20 mg/kg, weighing 
Blood inoculation 
Inoculation 1 ml, IV (5 x 106 infected 
erythrocytes) (not late than 0800-0830) 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
Thick and thin blood smears 
1 -2 
Blood smear collection 3 times at 0700, 1100 
and 1900 
Venipuncture 1.5 ml for CBC and chemistries at 
1100*  
Clinical observation 6 time daily using study 
specific form#1  
Temperature measurement from both 
transponder and rectal temp recorded 6 times 
at 0700, 1100, 1500, 1900, 2300 and 0300 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
Thick and thin blood smears 
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Study 
Days 
Procedures Specimens 
3-5 Blood smear collection 3 times at 0700, 1100 
and 1900 
 
Venipuncture 1.5 ml for CBC and chemistries 
twice at 1100 and 1900 
 
Clinical observation 6 time daily using study 
specific form#1  
 
Temperature measurement from both 
transponder and rectal temp recorded 6 times 
at 0700, 1100, 1500, 1900, 2300 and 0300 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
Thick and thin blood smears 
6 Blood smear collection 12 times at 0700, 0900, 
1100, 1300, 1500, 1700, 1900, 2100, 2300, 
0100, 0300 and 0500  
 
Venipuncture 1.5 ml for CBC and chemistries at 
0700, 1500 and 2300 
 
Clinical observation 12 times using study 
specific form#1 and temperature from both 
transponder and rectal temp recorded 6 times 
at 0700, 0900, 1100, 1300, 1500, 1700, 1900, 
2100, 2300, 0100, 0300 and 0500. 
 
EKG measurement 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
Thick and thin blood smears 
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7 Blood smears collected every hour when 
parasitemia reached 6% or on study day 7 at 
0700, 0800, 0900, 1000, 1100, 1200, 1300, 
1400, 1500, 1600,1700, 1800, 1900, 2000, 
2100, 2200, 2300, 2400, 0100, 0200, 0300, 
0400, 0500 and 0600 
 
Venipuncture 1.5 ml for CBC and chemistries at 
0700, 1500 and 2300 
 
Clinical observation 24 times daily on study 
specific form#1 and temperature from both 
transponder and rectal temp recorded 24 times 
at 0700, 0800, 0900, 1000, 1100, 1200, 1300, 
1400, 1500, 1600,1700, 1800, 1900, 2000, 
2100, 2200, 2300, 2400, 0100, 0200, 0300, 
0400, 0500 and 0600 
Thick and thin blood smears, and 0.3 
ml EDTA tube for CBC and parasitemia 
determination5 
8 
Blood smears collection every hour at 0700, 
0800, 0900, 1000, 1100, 1200, 1300, 1400, 
1500, 1600,1700, 1800, 1900, 2000, 2100, 
2200, 2300, 2400, 0100, 0200, 0300, 0400, 
0500 and 0600 
 
Venipuncture 1.5 ml for CBC and chemistries at 
0700, 1500 and 2300 
 
Clinical observation 24 times daily on study 
specific form#1 and temperature from both 
transponder and rectal temp recorded 24 times 
at 0700, 0800, 0900, 1000, 1100, 1200, 1300, 
1400, 1500, 1600,1700, 1800, 1900, 2000, 
2100, 2200, 2300, 2400, 0100, 0200, 0300, 
0400, 0500 and 0600 
Thick and thin blood smears, and 0.3 
ml EDTA tube for CBC and parasitemia 
determination5 
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Study 
Days 
Procedures Specimens 
 EKG measurements conducted before 
euthanasia 
The monkeys euthanized if parasitemia reached 
20-25% and/or a combination at least three of 
the following clinical signs**  
Collect 2.5 ml blood, blood smear, 3 ml CSF and 
perform full autopsy 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
0.5 ml in EDTA for TNF-α3 
0.5 ml in heparin for nitric oxide4 
 
 
Monkey ID.NO.: DA831, DA923 and R519 
 
1 0.5 ml EDTA blood for complete blood count, reticulocyte count and parasite determination at DVM.  
2 1.0 ml heparin blood for blood chemistries: BUN, CREA, BUN/CREA ratio, ALT, AST, ALP, GLUC, Total 
Protein, Na, K, Cl, Serum Lactate, blood pH and methemoglobin by automated hematology analyzer 
at Department of Veterinary Medicine (DVM). 
3 0.5 ml EDTA blood for TNF-α level, to DVM lab for centrifuging 20 minutes at 2000 x g. Plasma was 
either removed and assayed immediately or aliquoted and stored at -20° C. Subsequent use avoided 
repeated freeze-thaw cycles. 
4 0.5 ml heparin blood for nitric oxide levels was sent to DVM lab for centrifuging, 20 minutes at 2000 
x g. Plasma was either removed and assayed immediately or aliquoted and stored at -20° C. 
Subsequent use avoided repeated freeze-thaw cycles.  
50.3 ml EDTA blood was collected when parasitemia became positive. WBC count and RBC count were 
also performed for parasitemia determination. CBC was also determined according to clinical 
indication. A daily blood smear was collected after malaria infected blood inoculation, from day 0 to 
day 5; blood smears were collected 3 times prior to malaria infection at 0700, 1100 and 1900. On 
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study day 6, Blood smear collection was increased to 12 times at 2 hourly intervals. On study day 7 
and 8, Blood smears were collected every hour when parasitemia reached 6%. Thick and thin blood 
smears were prepared from capillary blood samples collected from each monkey by sterile pediatric 
lancet puncture of the lateral auricular vein. The monkeys were physically restrained in the squeeze-
cage restraint apparatus or pole-collar restraining for this short procedure.  
60.5 ml heparin blood for PK analysis, sent to DVM lab. Whole blood was kept in freezers until 
analysis.  
*In addition to CBC/Chemistry blood collection on day -1, blood was drawn to generate baseline TNF-
alpha and NO references.  Terminal blood collection allowed repeat sampling for these two assays.   
§ Chemistry and CBC measurement increased to 2x daily at day 2 if changes were noted on day 1 and 
on the day 2 blood draw.  In that instance, the total blood draw increased by 1.5mls to a total of 
31mls for the experiment. This volume was still within the 1% allowable volume per day for 
sequential sampling IAW SOP VET VC-301, Nonhuman Primate Phlebotomy. 
 **Criteria for euthanasia: Parasitemia of 20-25% and/or a combination at least three of the 
following clinical signs:  
- Evidence of severe acute tubular injury (evidenced as both hemoglobinuria/ hematuria combined 
with elevated creatinine and Blood Urea Nitrogen) 
- Hepatic failure (as evidenced by jaundice and significantly elevated ALT, AST, ALK Phos, GGT and 
decreased albumin) 
- Severe anemia as determined by a hematocrit of 15% or less or a precipitous drop as determined by 
the AV 
- Coagulopathy based on improper clotting as well as cutaneous petechiae, and ecchymoses 
- Anorexia lasting 3 meals 
- Continued recumbency combined with severe lethargy and depression 
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- Neurological signs such as papillary dilation, lack of a menace response, marked depression and 
severe weakness characterized by an inability to sit or perch 
- Persistent vomiting 
- Persistent diarrhea with either frank blood or melena 
- Persistent tachycardia or bradycardia 
- Marked and persistent dyspnea/tachypnea 
- Excessive vocalizing or other signs of significant distress 
- Persistent fever of 3 degrees C above baseline or 2 degrees C below baseline in the individual animal 
- Ataxia as a feature of neurologic disease (but not specifically due to weakness) as determined by the 
Attending Veterinarian (AV) 
- Progressive cutaneous necrosis 
 
Table 2.4: Procedure schedule  
Study Days Procedures Specimens 
 
Screening 
Ketamine restraint 5-20 mg/kg, weighing, 
venipuncture 1.5 ml 
Complete physical examination 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for ALT, AST, BUN, 
Creatinine, ALP, Glucose, NA, K, Cl and TP 
 Splenectomy  NA 
 
Ketamine restraint 5-20 mg/kg, weighing 
Implant transponder 
NA 
 
Withhold morning feed,  
Ketamine restraint 5-20 mg/kg, weighing, 
venipuncture 1.5 ml 
Complete physical examination 
Place neck collar 
Start clinical observation with VET-GP-008-F5 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
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Start pole-collar training and continue for 2 weeks  
-1 
Start Clinical observation** 3 times daily using 
study specific form#1  
Temperature measurement via both rectum and 
transponder 3 times at 0800, 1100 and 1900 
NA 
0 
Clinical observation** 3 times daily with study 
specific form#1 and measure temperature both via 
transponder and rectal temp at 0800, 1100 and 
1900 
 
Pole-collar restraint 
Blood smear collection 3 times prior to malaria 
infected at 0800, 1100 and 1900 
Venipuncture 2.5 ml for CBC, chemistries, blood 
gas, nitric oxide and TNF-α at 0800 
 
Ketamine restraint 5-20 mg/kg, weighing, blood 
smear collection 
Inoculation 1 ml, IV (5 x 106 infected erythrocytes) 
(not later than 0800) 
 
Pole-collar and chair restraint 
Venipuncture 1.5 ml for CBC, chemistries and blood 
gas at 1900 
 
Baseline at 0800 before blood 
inoculation: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
0.5 ml in EDTA for TNF-α3 
0.5 ml in heparin for nitric oxide4  
Thick and thin blood smears 
 
At 1900: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
Thick and thin blood smears 
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Study Days Procedures Specimens 
1 – 4 
Clinical observation** 3 times daily with study 
specific form#1 and measure temperature both via 
transponder and rectal temp at 0800, 1100 and 
1900 
  
Pole-collar restraint 
Blood smear collection 3 times at 0800, 1100 and 
1900 
 
Pole-collar and chair restraint 
Venipuncture 1.5 ml for CBC, chemistries and blood 
gas at 1900 
At 0800 and 1100: 
Thick and thin blood smears 
 
At 1900: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
Thick and thin blood smears 
5 
Clinical observation** 3 times daily with study 
specific form#1 and measure temperature both via 
transponder and rectal temp at 0800, 1100 and 
1900  
 
Pole-collar restraint 
Blood smear collection 3 times at 0800, 1100 and 
1900 
 
Pole-collar restraint at 1500 
Venipuncture 4 ml for nanostructural analysis 
 
Pole-collar and chair restraint 
Venipuncture 1.5 ml for CBC, chemistries and blood 
gas at 0700 and 1900 
At 0800, 1100 and 1900: 
Thick and thin blood smears 
 
At 0700 and 1900: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
 
At 1500 
4 ml heparin for nanostructural analysis 
and atomic force microscopy5 
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6 
Weighing by transfer box 
 
Clinical observations 8 times/daily on study specific 
form#1 and temperature measurements both via 
transponder and rectal temp 8 times at 0700, 1000, 
1300, 1600, 1900, 2100, 2400 and 0300 
 
Pole-collar restraint 
Blood smear collection 8 times at 0700, 1000, 1300, 
1600, 1900, 2100, 2400 and 0300  
 
Pole-collar and chair restraint at 0700, 1500 and 
2300 
Venipuncture 1.5 ml for CBC and chemistries  
EKG measurement at 0700, 1500 and 2300 
 
Send animal’s weight to DVM Lab 
 
At 0700, 1000, 1300, 1600, 1900, 2100, 
2400 and 0300: 
Thick and thin blood smears 
 
At 0700, 1500 and 2300: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
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Study Days Procedures Specimens 
7 
Clinical observation 8 times on study specific form#1 and 
measure temperature both via transponder and rectal 
temp 8 times at 0700, 1000, 1300, 1600, 1900, 2100, 2400 
and 0300 
 
Pole-collar restraint 
Blood smear collection 8 times at 0700, 1000, 1300, 1600, 
1900, 2100, 2400 and 0300  
 
Pole-collar and chair restraint at 0700, 1500 and 2300 
Venipuncture 1.5 ml for CBC and chemistries  
EKG measurement 
 
At 1500 pole-collar and chair restraint  
Venipuncture 5.5 ml for nanostructural analysis 
 
 
At 0700, 1000, 1300, 1600, 1900, 
2100, 2400 and 0300: 
Thick and thin blood smears 
 
At 0700, 1500 and 2300: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for 
chemistries2 
 
At 1500 or before treatment  
5.5 ml heparin for nanostructural 
analysis and atomic force 
microscopy5 
 
8 
Clinical observation 8 times on study specific form#1 and 
measure temperature both via transponder and rectal 
temp 8 times at 0700, 1000, 1300, 1600, 1900, 2100, 2400 
and 0300 
 
Pole-collar restraint 
Blood smear collection 8 times at 0700, 1000, 1300, 1600, 
1900, 2100, 2400 and 0300  
 
Pole-collar and chair restraint at 0700, 1500 and 2300 
Venipuncture 1.5 ml for CBC and chemistries  
EKG measurement 
 
At 0700, 1000, 1300, 1600, 1900, 
2100, 2400 and 0300: 
Thick and thin blood smears 
 
At 0700, 1500 and 2300: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for 
chemistries2 
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9 
 
Clinical observation 8 times on study specific form#1 and 
measure temperature both via transponder and rectal 
temp 8 times at 0700, 1000, 1300, 1600, 1900, 2100, 2400 
and 0300 
 
Pole-collar restraint 
Blood smear collection 8 times at 0700, 1000, 1300, 1600, 
1900, 2100, 2400 and 0300  
 
Pole-collar and chair restraint at 0700, 1500 and 2300 
Venipuncture 1.5 ml for CBC and chemistries  
EKG measurement 
Day TX 1: 
1st Tx around 2000: 
Pole-collar and chair restraint  
 
Place IV catheter, and infuse methylene blue as a slow IV 
push (3-4 mL/minute) per drug into an IV extension line of 
D5W Twice daily 
 
At 0700, 1000, 1300, 1600, 1900, 
2100, 2400 and 0300: 
Thick and thin blood smears 
 
At 0700, 1500 and 2300: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for 
chemistries2 
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Study Days Procedures Specimens 
10 
 
Clinical observation 8 times on study specific form#1 
and measure temperature both via transponder and 
rectal temp 8 times at 0800, 1100, 1300, 1600, 1900, 
2100, 2400 and 0300 
 
Pole-collar restraint 
Blood smear collection 8 times at 0800, 1100, 1300, 
1600, 1900, 2100, 2400 and 0300  
 
EKG measurement at 1100, 1500 and 2300 
 
Day TX 2: 
2nd and 3rd Tx (at 0800 and 2000): 
 
Pole-collar and chair restraint  
 
Place IV catheter 
Venipuncture 1.5 ml for CBC and chemistries before 
providing treatment and infuse methylene blue as a 
slow IV push (3-4 mL/minute) per drug into an IV 
extension line of D5W Twice daily 
 
At 0800, 1100, 1300, 1600, 1900, 2100, 
2400 and 0300: 
Thick and thin blood smears 
 
At 0700 and before providing treatment: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
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11 
Clinical observation 8 times on study specific form#1 
and measure temperature both via transponder and 
rectal temp 8 times at 0700, 1000, 1300, 1600, 1900, 
2100, 2400 and 0300 
Pole-collar restraint 
Blood smear collection 8 times at 0700, 1000, 1300, 
1600, 1900, 2100, 2400 and 0300  
EKG measurement at 0700, 1500 and 2300 
 
Day TX 3: 
4th and 5th Tx (at 0800 and 2000): 
Pole-collar and chair restraint  
Place IV catheter 
Venipuncture 1.5 ml for CBC and chemistries before 
providing treatment and infuse methylene blue as a 
slow IV push (3-4 mL/minute) per drug into an IV 
extension line of D5W Twice daily 
At 0700, 1000, 1300, 1600, 1900, 2100, 
2400 and 0300: 
Thick and thin blood smears 
 
Before providing treatment and 1900: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
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Study Days Procedures Specimens 
12 
Clinical observation 8 times on study specific form#1 
and measure temperature both via transponder and 
rectal temp 8 times at 0700, 1000, 1300, 1600, 1900, 
2100, 2400 and 0300 
Pole-collar restraint 
Blood smear collection 8 times at 0700, 1000, 1300, 
1600, 1900, 2100, 2400 and 0300 
  
Day TX 4: 
6th   Tx (at 0800): 
Pole-collar and chair restraint  
 
Place IV catheter 
Venipuncture 1.5 ml for CBC and chemistries before 
providing treatment and infuse Methylene blue as a 
slow IV push (3-4 mL/minute) per drug into an IV 
extension line of D5W Twice daily 
 
At 1900: Venipuncture 1.5 ml for CBC and chemistries   
At 0700, 1100 and 1900: 
Thick and thin blood smears 
 
At before providing treatment and 1900: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
 
 
 
 
  
13 
Clinical observation** 3 times daily using study 
specific form#1 and measure temperature both via 
transponder and rectal temp at 0800, 1100 and 1900 
  
Pole-collar restraint 
Blood smear collection 3 times at 0800, 1100 and 1900 
 
Pole-collar and chair restraint 
Venipuncture 1.5 ml for CBC and chemistries at 1900 
At 0800, 1100 and 1900: 
Thick and thin blood smears 
 
At 1900: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
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14 
Clinical observation** 3 times daily using study 
specific form#1 and measure temperature both via 
transponder and rectal temp at 0800, 1100 and 1900 
  
Pole-collar restraint 
Blood smear collection 3 times at 0800, 1100 and 1900 
 
Pole-collar and chair restraint 
 
Venipuncture 1.5 ml for CBC and chemistries at 1900 
At 0800, 1100 and 1900: 
Thick and thin blood smears 
 
At 1900: 
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
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Study Days Procedures Specimens 
15 
6 Days post initiation of treatment, the animals where 
to be euthanized 
 
Ketamine restraint 5-20 mg/kg, weighing, blood 
collection 2.5 ml 
 
Euthanized all experimental animals, collected 
exsanguination blood, blood smear, 3 ml CSF and 
perform full autopsy 
 
Before scheduled euthanasia  
0.5 ml in EDTA tube1 
1.0 ml heparin tube for chemistries2 
0.5 ml in heparin for nitric oxide4  
Thick and thin blood smears 
 
Exsanguination 
50 ml in EDTA tube 
50 ml clot tube 
100 ml heparin tube  
 
1 0.5 ml EDTA blood for complete blood count, reticulocyte count and parasite determination at DVM.  
2 1.0 ml heparin blood for blood chemistries: BUN, CREA, BUN/CREA ratio, ALT, AST, ALP, GLUC, Total 
Protein, Na, K, Cl, Serum Lactate, blood pH and methemoglobin by automated hematology analyzer 
at DVM. 
3 0.5 ml EDTA blood for TNF-α level, send to DVM lab for centrifuging 20 minutes at 2000 x g. Plasma 
was either removed and assayed immediately or aliquoted and stored at -20° C. Subsequent use 
avoided repeated freeze-thaw cycles. 
4 0.5 ml heparin blood for nitric oxide levels was sent to DVM lab for centrifuging, 20 minutes at 2000 
x g. Plasma was either removed and assayed immediately or aliquoted and stored at -20° C. 
Subsequent use avoided repeated freeze-thaw cycles. 
5 0.5-2 ml heparin blood for nanostructural analysis and atomic force microscopy. 
 
2.4.1 Study endpoints:   
Treatment failure was determined by the attending/supervising veterinarian in association with 
the Principal Investigator and the infected monkeys were considered as having reached study 
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endpoints if/when the level of parasitemia reached between 20-25% PLUS any THREE of the following 
clinical criteria post treatment. 
1. Activity score of 3 for 2 consecutive clinical sign assessment periods 
2. Non-responsive mentation score 
3. Anorexia for 3 consecutive feeding periods. 
4. Jaundice (by appearance-scleral icterus)  
5. Hematuria with frank blood 
6. Severe anemia (Hgb <8 mg/dl) 
7. Acute renal failure (Persistent rise in BUN and Creatinine as interpreted by the supervising 
veterinarian and the PI) 
8. Marked to severe dyspnea 
9. Vomiting 
10. Petechiae/ecchymoses on skin or mucous membranes 
11. Persistent elevated temperature of 104oF or higher for 3 consecutive assessment periods 
 
Table 2.5:  Methylene Blue dosage study – 9 experimental monkeys 
Agent Group designation 
MB 6 mg/kg IV bid Group 1 n=3 
MB 10 mg/kg IV bid Group 2 n=3 
MB 17 mg/kg IV bid Group 3 n=3 
 
Table 2.6:  Drug Dosing Schedule 
Cohort/Group Monkeys* Drug/Route Dose (mg/kg) Frequency 
Donor A, B  2 monkeys CQ PO 10 mg/kg Daily for 7 days 
Group 1-Pilot 3 monkeys MB IV 6 mg/kg  Twice Daily for 3 
days 
Group 2-Pilot 3 monkeys MB IV 10 mg/kg** Twice Daily for 3 
days 
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Group 3-Pilot 3 monkeys MB IV 17 mg/kg Twice Daily for 3 
days 
*    All available monkeys may have had prior exposure and infections with one or more of the 
following monkey malaria infections (P. knowlesi or P. cynomolgi).   
** MB dose levels based on data collected from prior pharmacokinetic studies in rhesus monkeys, 
humans and rats. AUC for rhesus monkey is 3.5 times smaller than in humans. Human doses in clinical 
trials have ranged from 2-12 mg/kg orally. Single doses up to 20 mg/kg have been tolerated in rhesus 
monkeys. 
 
2.4.2 Clinical Observations:  
Observations for signs of clinical toxicity, disease symptomology and evaluation of having 
reached the treatment window were made at varying timepoints as laid out in the study schedules 
(Table 2/Table 3).  These consisted of a minimum of three times daily and peaked at every other hour 
over a 24-hour period based on parasitemia. These evaluations included an assessment of appetite, 
posture, activity, breathing, level of arousal, color of urine and feces, blood pressure, temperature, 
and signs of painful urination, and were recorded on the Animal Care record as well as in the study 
specific forms.  Electrocardiograms were obtained from chaired, pole and collared animals without 
sedation. 
Each monkey’s injection/phlebotomy sites were closely observed for irritation/swelling or 
other adverse reactions.  All unusual observations were recorded.  Exact observation times were 
recorded for each monkey. Any signs of major organ toxicity based on clinical criteria combined 
clinical chemistry and hematology results were recorded and appropriate actions determined by the 
Attending Veterinarian in consultation with the PI and co-PIs. 
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2.5   Clinical Sign recording: 
Monitoring of the experimental animals in both the refinement study and the MB drug dosing 
study included Giemsa-stained blood films (thick and thin), clinical and repeated daily hematology 
and serum chemistry evaluations.  On treatment days for the MB drug dosing study, all clinical 
observations and weights measurements were conducted prior to the scheduled treatment and all 
phlebotomies were performed prior to treatment as well. 
Throughout the study, at each blood draw, clinical signs were assessed and recorded in Study Specific 
Form #1 (SSF #1) to include neurological signs, activity level, respiratory changes, pulse, level of 
consciousness, urine characteristics, vomiting/diarrhea, jaundice, dermal petechiae/coagulative 
abnormalities, anorexia and dehydration.  Study Specific Form #2 (not shown) consisted of a 
spreadsheet which outlined the specific times for blood collection, identified the volumes and the 
type of collection vial and number of blood smears performed.  As temperatures were measured both 
rectally and via subcutaneous transponder at each blood collection, this data was also recorded on 
the study specific form.  This form followed the individual animal throughout the study, from study 
day -1 through euthanasia. 
Study Specific form #1 assigned values to the clinical signs observed.  The additive score was 
used by the technical staff as a guideline with which to decide when to notify the attending 
veterinarian and for the veterinary staff as a mechanism in which to determine the need for initiation 
of fluid therapy.  The clinical signs evaluated included activity level, menace response (spontaneous 
blink and withdrawal reaction to sudden movement near the eyes), mentation, breathing 
characteristics (bradypnea, tachypnea, dyspnea), presence or absence of vomitus, skin discoloration 
(to include erythema and petechiation) and turgor, urination facility, volume and color, and appetite.  
Furthermore, additional features would be annotated such as diarrhea, melena, ataxia, seizure 
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activity, tremoring, epistaxis, opisthotonus, piloerection, salivation, hemiplegia and inappropriate 
vocalization.  
Study Specific Form #1 
 
 
2.5.1   Clinical Parasitology (Blood Smears and Developmental Stage Assessment): 
Blood smears were conducted beginning on ID-0 before the parasite inoculation and 
continued three times daily until positive parasitemias exceeding 5000 per mm3 were reached, 
typically on day five to six.  Beginning on day six, parasitemia assessments increased to eight times 
daily until the treatment criteria were reached and for several subsequent days (typically day six 
through day 10).  Once a smear was positive, WBC and/or RBC counts were performed on an 
increasing schedule both to determine parasite density and percent parasitemias (calculations per 
AFRIMS Standard Operating Procedures: Malarial Parasite Count for Quantifying Parasitemia in 
Protocol #: Study Specific Form #1
Animal ID: Group ID: Study Date (Day 0):
Date: Time: Study Activity Menace Animal Animal Vomit Skin Skin Urine Urination Appetite Animal Initial Temp Animal VT Other Observations
Day: Level Mentation Breathing color Turgor color food score (F) weight (kg) int Treatments
Activity: 0 = Active and responsive, 1 = reduced/subdued, 2 = immobile and sit on the cage floor occasionally lie down  3= recumbent and lethargy 
Mentation/eye 
response 0 =Alert/watch and follow (penlight),1 =inattentive/ watch and follow when stimulation, 2 =non-responsive/fail to watch or follow Score 0-4:  Normal
Menace 0 =blinking of the eyelids, 1 = non-responsive Score 5-9:  Monitor carefully Inform veterinarian, may provide electrolyte in drinking water.
Breathing 0 = normal breathing  1 = panting/rapid and shallow breathing  2 = Dyspnea slow and deep breathing   3 = gasping Score 10-14:  Inform Veterinarian Provide electrolytes or IV fluid, 
Vomiting 0 = none present    1 = retching or dry heaves.  2 = vomiting or vomitus present consider analgesic, monitor Q15minutes or as veterinarian advises, 
Skin color 0 = normal skin color, 1 = pallor skin, 2= jaundice
Skin turgor 0 = normal (<2sec)    1 = return 2-4sec   2 = return 5-9sec   3 = >10sec skin return
uirne color 0 = clear yellow normal urine color 1 = mild red urine 2 = moderate red urine 3 = bloody urine Score ≥ 15 INFORM VET - Start Fluid Therapy
urination 0= normal urination, 1 = painful when urination, 2 = dysuria, none = no urine E = electrolytes in water bottle IVL5S = Lc. Ringers 5%Dex IV
Appetite -bisc. {# eaten / # given}    0 =  ≥80% normal appetite   1 = ≥60% slightly reduced appetite  OE = oral electrolyte IVLR =Lactated Ringers IV
2 = ≥40% moderate reduced appetite  3 = < 40% anorexia OS = Oral supplement, Bc = Vitamin B complex given IV
Other Signs Codes: A=ataxia, D=diarrhea, E=epistaxis, M=melena, O=opisthotonus, P=piloerection, S=salivation, T=tremor or twitching of finger or corner of mouth, H=hemiplegia, V= Inappropriate vocalization
Clinical Observation Record for Sever Malaria Study
the initial treatment may be provided if parasitemia level reaches 25 % or hemoglobin
 is lower than 8 g/dl
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Experimental Animal’s Infected Blood), as well as for clinical chemistry evaluation and complete blood 
count (CBC). 
Blood smear samples on glass slides were fixed in methanol and stained with Giemsa.  They 
were examined for the presence or absence of parasites under the oil-immersion objective as well as 
parasite staging.  If no parasites are found in 50 microscopic oil-immersion thick fields or per 1000 
white blood cells (WBCs), the smears were considered negative.  The parasitemia level was reported 
as number of parasites per 1µl or mm3 of whole blood.  Parasites were counted per number of WBCs 
or red blood cells (RBCs), i.e., per 100 –300 WBCs or 500 – 10,000 RBCs.  Parasitemia levels were 
calculated by the appropriate total blood cell count (white or red) per mm3. 
2.5.2     Parasitemia assessment: 
Using a non-anticoagulant capillary pipette, the blood was drawn from a well-mixed EDTA blood vial 
and filled the capillary at least two-thirds with blood. The end of the capillary was touched onto the 
first clean glass slide. The first drop (for thick smears) was placed about 1 cm from the frosted end 
and another one drop (for thin smears) about 1 cm apart from the first drop. 
2.5.2.1   Thick smear. Using a second clean slide (as a spreader slide) the first drop of blood was 
smoothed in a circular motion to cover an area 1-1.5 cm in diameter. Excess blood on the spreader 
was wiped off with clean dry gauze. 
2.5.2.2   Thin smear. One end of the spreader slide was placed in front of the second drop of blood at 
a 35 -45° angle and then pulled back into the drop of blood. The blood film was allowed to spread and 
fill the angle between the two slides. The spreader slide was then pushed forward until all of the 
blood had been spread into a moderately thin film. 
Note: The blood smear should not cover the entire surface of the slide. In a good thin smear, there 
was a thick portion and a thin portion and a gradual transition from one to the other. A quality blood 
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film was determined to have a smooth, even appearance, free from ridges waves, or holes. The 
feathered edge (an end of smear) was smooth and even. (Figure 1) It was crucial that the edge of the 
"spreader" slide was absolutely smooth. If it was rough, the blood film had ragged tails containing 
many leukocytes.  
Figure 2.1.  
Photograph of a glass slide demonstrating the differences between thick and thin blood smears for 
malaria parasitemia counts. 
The spreader was then alternately used for making the second smear slide with the same animal's 
blood sample. The first completed slide was used as a spreader slide and prior to making the blood 
smear on the second slide, the spreader slide was wiped off of excess blood remaining on the edge of 
slide with a clean gauze. 
2.5.2.3   Parasite staging: 
Parasite stage evaluations were conducted by experienced technicians at AFRIMS.  These 
were performed using the blood smears generated during the study for the purpose of parasitemia 
assessment, but were evaluated typically weeks following the close of the experiment due to the time 
requirements for accurate assessments.  For the sake of this study, the parasite stages were limited 
to categories of trophozoites, gametocytes and schizonts. 
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Figure 2.2.1-4.  Giemsa stained rhesus macaque blood smears infected with P. coatneyi examined 
under oil immersion at 1000x. Parasite stage examples. 
1.  Trophozoites, ring stage, multiple infection (arrow) 
2.  Schizont (arrowheads) 
3. Gametocyte (arrow); trophozoites, ring stage (arrowheads) 
4. Gametocyte (arrow) 
 
2.5.3 Blood chemistry and hematology: 
2.5.3.1 Clinical Chemistry: 
1. Alanine transaminase (ALT)    
2. Aspartate aminotransferase (AST) 
3. Alkaline phosphatase (ALP)  
4. Gamma-glutamyl transferase (GGT) 
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5. Glucose 
6. Blood Urea Nitrogen (BUN) 
7. Creatinine (CRE)  
8. Albumin 
9. Total Protein 
10. Bilirubin 
11. Lactate   
12. Total Cholesterol 
13. C-reactive Protein 
14. Creatine phosphokinase 
15. Sodium (Na+)  
16. Potassium (K+) 
17. Chloride (CL-) 
 
2.5.3.2 Hematology: 
1. Total leukocyte count (WBC)  
2. Erythrocyte count (RBC)  
3. Hemoglobin (HGB)  
4. Hematocrit (HCT)  
5. Mean corpuscular volume (MCV)  
6. Mean corpuscular hemoglobin (MCH) 
7. Mean corpuscular hemoglobin concentration (MCHC)  
8. Reticulocyte counts (RETIC) by flow cytometry  
9. Platelet count (PLT)  
10. Differential leukocyte count 
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2.6 Blood volume calculations: 
Blood volumes were calculated in adherence with SOP requirements for maximum blood volume 
draw per week based on each individual animal’s weight. 
The guidelines for the total volume of blood drawn followed published guidance in the guide for the 
care and use of laboratory animals (NRC 2011), “Removal of blood from laboratory mammals and 
birds” (Joint Working Group on Refinement).  Accordingly, up to 10% of the circulating blood volume 
could be safely taken every 3 to 4 weeks without the need for hematologic monitoring.  The 
circulating blood volume was estimated as 54-70 mL/kg (cc/Kg) of body weight.  
For a rhesus monkey, circulating blood volume is estimated conservatively to be 54 cc/kg.  Thus, using 
the lowest weight in kg of a monkey eligible for enrollment (6 kg = 324 cc total blood volume), at least 
33 cc could be safely drawn every 4 weeks from each monkey.  
The recommended 32 cc in a four-week window was at no point exceeded, prior to euthanasia.  See 
Table 6 for listing of blood draws. 
Table 2.7:  Daily Blood Volumes:  
 Parasitemia CBC Chemistry Temperature Clin. 
signs 
Blood volume 
Day 0 3x daily 2x 
daily 
2x daily 3x daily 3x daily 3cc 
Day 1 3x daily 1x 
daily 
1x daily 3x daily 3x daily 1.5cc 
Day 2 3x daily 1x 
daily 
1x daily 3x daily 3x daily 1.5cc 
Day 3 3x daily 1x 
daily 
1x daily 3x daily 3x daily 1.5cc 
Day 4 3x daily 1x 
daily 
1x daily 3x daily 3x daily 1.5cc 
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*Anticipated treatment initiation would be Day 6 and continue through Day 11. 
 
2.7 Retinoscopy: 
Immediately prior to euthanasia, four animals from the MB study were anesthetized using 
intramuscular ketamine hydrochloride injection (5-20mg/kg) and underwent ophthalmoscopy to 
assess retinal changes. Immediately upon sedation, both pupils were dilated using 0.5%/1% 
tropicamide. Once mydriasis was achieved, digital fundus photography was performed using a 
portable handheld retinal camera (Kowa Genesis D, Kowa, Japan). A minimum of nine overlapping 
photographs were captured from each retina to cover the macula, optic disc and peripheral retina. 
Two masked expert investigators examined the composite photographs for retinal abnormalities. 
Inter-observer variations were resolved through consensus.  
2.8    Study endpoints:   
2.8.1   Treatment Outcome Definitions: 
Day 5 3x daily 2x 
daily 
2x daily 3x daily 3x daily 7.5cc 
Day 
6* 
8x daily 3x 
daily 
3x daily 8x daily 8x daily 4.5cc 
Day 
7* 
8x daily 3x 
daily 
3x daily 8x daily 8x daily 10cc 
Day 
8* 
8x daily 3x 
daily 
3x daily 8x daily 8x daily 4.5cc 
Day 
9* 
8x daily 3x 
daily 
3x daily 8x daily 8x daily 4.5cc 
Day 
10* 
3x daily 2x 
daily 
2x daily 3x daily 3x daily 4cc 
Day 
11* 
3x daily 1x 
daily 
1x daily 3x daily 3x daily 2.5cc 
     Total 45.5cc/2 weeks 
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Success: 
• Parasitemia decline by  75% at 48 hours with clinical improvement, and 
• Parasitemia clearance >99% at the third day after treatment initiation, and 
• Absence of moribund behavior, stable respiratory status, and stable blood pressure. 
Failure: 
• Parasitemia decline by < 75% at 48 hours with clinical deterioration, or 
• Failure to clear parasitemia by 99% by day 3 after treatment initiation, or 
• Moribund behavior, unstable respiratory status, or unstable blood pressure at the end of three 
days of therapy. 
Further treatment failure was determined by the attending/supervising veterinarian in association 
with the Principal Investigator and the infected monkeys were considered as having met study 
endpoints if/when the level parasitemia reached between 20-25% PLUS any THREE of the following 
clinical criteria are reached post treatment. 
1. Activity score of 3 for 2 consecutive clinical sign assessment periods 
2. Non-responsive mentation score 
3. Anorexia for 3 consecutive feeding periods. 
4. Jaundice (by appearance-scleral icterus)  
5. Hematuria with frank blood 
6. Severe anemia (Hgb <8 mg/dl) 
7. Acute renal failure (Persistent rise in BUN and Creatinine as interpreted by the supervising 
veterinarian and the PI) 
8. Marked to severe dyspnea 
9. Continued vomiting 
10. Petechiae/ecchymoses on skin or mucous membranes 
11. Persistent elevated temperature of 104 or higher for 3 consecutive assessment periods 
 
If monkeys were deemed to be in significant pain or distress in the opinion of the Attending 
Veterinarian, analgesics and/or supportive treatment as required were to be administered using IV 
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fluids and buprenorphine (0.01 mg/kg IM q12 hours). If the monkeys became moribund or otherwise 
experienced severe pain or distress that could not be alleviated, they would have been humanely 
euthanized. Other examples, as described below, of criteria for euthanasia included: unresponsive 
shock, severe respiratory distress or respiratory failure, severe anemia causing shock symptoms, 
recurrent or persistent seizures, evidence of stroke, or continued clinical deterioration after 48 hours 
of therapy.   
It was expected, in this severe malaria model, that the animals would display signs of severe 
malaria at the initiation of therapy, and that they would continue to show these signs during the first 
24 hours of therapy regardless of the medication used. Anticipated clinical signs included 
combinations of the above listed clinical criteria, however these were expected to be transient and 
reversible once treatment was initiated.  Additionally, clinical chemistry and hematological findings 
were expected to demonstrate organ pathology.  These included:   
1. Hypoglycemia 
2. Metabolic acidosis 
3. Severe anemia 
4. Hyperparasitemia 
5. High blood lactate 
6. Renal impairment (elevated BUN and Creatinine) 
 
2.9 Euthanasia:   
These were terminal experiments, and the intent was for all experimental animals to be humanely 
euthanized upon reaching euthanasia criteria or their timed study endpoint.  Due to the rapid spike in 
parasitemia in some animals in the first stages of the pilot study, animals died without the benefit of 
euthanasia.  This problem was subsequently managed through increasing the parasitemia 
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assessments to every other hour.  Euthanasia was performed in accordance with AFRIMS Vet Med 
SOP: Euthanasia of Nonhuman Primates and Other Small Mammals.   
Briefly:  
1. The person performing euthanasia was required to be technically proficient, use humane 
handling methods, to understand the reasons for euthanasia, and be trained in the method 
of euthanasia being employed.  
2. Euthanasia was performed in an appropriate area, such as autopsy room or procedure room, 
that did not contain other animals. 
3. Gentle restraint minimizes animal distress, including fear and anxiety. As prescribed by a 
veterinarian, appropriate chemical restraint was required prior to euthanasia, especially 
when humane restraint could not be achieved manually or might have posed a risk of injury 
to the animal or to the person restraining it.  As such, the monkeys were chemically 
restrained with intramuscular ketamine hydrochloride injection (5-20mg/kg).  
4. Once sedated, injectable commercial euthanasia agent (Fatal-plus or its equivalent) was 
given intravenously to induce euthanasia.   
5. The euthanizing dose of Fatal-plus use was 100mg/kg.  The first half of the dose was given 
rapidly, with the second half being given more slowly.   
6. The animals were observed by the attending veterinarian for a few minutes or until 
breathing stopped.  The complete absence of heartbeats was confirmed by stethoscope 
before the needle was removed. 
7. An additional ¼ dose of euthanasia or anesthetic agent was given if the heartbeat remained.   
2.9.1     Terminal sample collection: 
1. Terminal blood smears were made in order to quantify the parasitemia and for subsequent 
parasite staging. 
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2. Sterile urine was collected at autopsy via cystocentesis and a urinalysis was conducted.  The 
remaining volume was spun down and frozen.  
3. Cerebral Spinal Fluid was collected immediately post mortem and just prior to autopsy and a 
drop was placed on a slide for a cellularity assessment.  Remaining volume was spun down 
and frozen.  CSF was collected from the cisterna magna at the juncture of the point where the 
cranial wings of the atlas and the external occipital protruberance bisect. The subarachnoid 
space was entered using a 22-gauge spinal needle.  In rare cases where there was difficulty in 
collecting CSF in this manner, at autopsy, a cut down was performed and the pathologist 
collected a CSF sample prior to initiating the autopsy.  
2.9.2 Autopsy guidelines: 
1. Multiple representative tissues were collected from every organ system and photographed.  
2. The liver with the gallbladder emptied; brain (cerebrum, cerebellum, brain stem); lungs 
(without trachea) were weighed. 
3. CSF was sampled at euthanasia.  As previously described, a drop was placed on a slide for 
cellularity evaluation and the rest was spun down, aliquoted and frozen at -80°. 
4. Terminal blood was taken from the vena cava and the heart.  Samples were separated into 
whole blood and serum.  Excess not allocated for use in various tests was aliquoted and 
frozen at -80°. 
5. Both eyes were taken to include a section of optic nerve.  Retinal samples were removed 
from one of the eyes and small sections preserved in Glutaraldehyde and in RNA later.  The 
remaining ocular tissue was preserved in Davidson’s solution and in the intact eye, Davidson’s 
was injected at the lateral canthus into the anterior chamber until the globe was firm.  
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6. Sections of the entire gastrointestinal tract were sampled, 2-3 cm sections were tied off at 
both end and injected with formalin. 
7. The entire spinal cord was removed and preserved whole, a suture was placed in the cervical 
cord as an identifier. 
8. Representative lymph nodes (Mesenteric, popliteal, axillary, inguinal, submandibular and 
ileocecal), pituitary gland and adrenal glands were identified and labeled. 
9. Bone marrow was fixed in-situ in sections of the sternum. 
10. Cortical cerebrum samples were made into smears and stained with Giemsa following 30 
second fixation in 50% ethanol/methanol mix and air dried. 
11. Sterile urine was collected during autopsy directly from the urinary bladder.  A urinalysis was 
conducted, and the remaining volume spun down, aliquoted and frozen at -80°. 
12. Tissues for TEM were collected and sectioned into 1 cm cubes and preserved at a volume of 1 
mm/1 ml of solution in individual tubes.  Tissues for molecular analysis were sectioned at ½ 
cm and placed in a 1.8 ml Eppendorf tube filled to 1.5ml with RNA later medium.  All tubes 
were clearly labeled as to organ, RNA vs EM and animal accession number.  Collection of 
these tissues were prioritized and ideally were collected within the first 5-10 minutes of the 
autopsy. 
• The following tissues were preserved in RNA later as multiple (3-5) squares: Central 
Nervous System (thalamus; hippocampus; fore brain; cerebellum; brain stem; spinal 
cord), kidney, heart, liver, lung, retina 
• The following tissues were preserved in buffered Glutaraldehyde as multiple (3-5) 
squares: Central Nervous System (thalamus; hippocampus; fore brain; cerebellum; brain 
stem; spinal cord), kidney, heart, liver, lung, retina 
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13. Ante-mortem retinal photographs were taken as possible, immediately prior to euthanasia. 
Atropine drops were applied during pre-euthanasia blood draw 10 minutes prior to imaging 
to ensure adequate iridial dilation. 
2.9.3    Fixation, processing and staining: 
1. All tissues collected for histopathology were trimmed into small sections (approximately 2-5 
cm), placed into 10% buffered formalin at a tissue:formalin ratio of at least 1:10 within 
minutes of euthanasia. Formalin was refreshed after 24 hours of fixation to help avoid 
formation of formalin pigment within tissue sections. 
2. For adequate fixation, it was important that tissue sections were no more than 1 cm thick, 
with the exception of lung and brain.  If larger sections were collected, the samples were 
“bread-loafed” to ensure adequate penetration by the formalin and were preserved with a 
higher formalin to tissue ratio (up to 1:20) to ensure rapid fixation. 
3. In general, sampled lesions involved taking a sample at the margin of any observed lesion 
that includes adjacent normal tissue as well as one from the center of the lesion.  Normal 
tissue from the affected organ was also sampled for comparison. 
4. The fixed tissues were trimmed into 5 mm dice and processed using an automated tissue 
processor (SLEE medical, Mainz, Germany) as follows: dehydration (70% Isopropanol for 1 h, 
95% Isopropanol for 1 h x 3 times, and 100% Isopropanol for 1 h x 3 times), clearing (Xylene 
substitute (Sigma, St. Louis, MO, USA) for 1 h x 3 times) and paraffin infiltration (molten 
paraffin for 30 min x 2 times).   
2.9.4 Histological staining:  
Formalin fixed tissue samples were prepared for histopathological evaluation as H&E Sections 
as described by Prophet et al.  Simply, sections were cut at 4µm using a semi-automated rotary 
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microtome (RM2245, Leica, Buffalo Grove, IL, USA). The tissue sections were mounted onto poly L-
lysine coated microscope slides and baked at 60 °C for 14-18 h. Sections were stained with H&E using 
described techniques. (Harris hematoxylin for 6 min, running tap water for 1 min, eosin Y for 10 min, 
70% ethanol for 1 min, 95% ethanol for 1 min, 100% ethanol for 1 min, two rinses in 100% xylene for 
1 min each). 
2.9.5   Histopathological analysis and scoring system: 
 The H&E stained tissue slides were examined by both a board certified veterinary pathologist 
(EL) and by a board certified medical pathologist (GT) using Olympus BX43F bright field microscopes 
(Olympus, Tokyo, Japan). This study reviewed the histopathology from animals within the AFRIMS 
tissue archives as well as through tissue sharing from an ongoing drug trial protocol using the 
splenectomized rhesus macaque/P. coatneyi model of severe malaria. The selected autopsy cases, 
which numbered a total of 45, comprised of 30 retrospective and 15 prospective cases where chosen 
primarily based on experimental history (excluding those cases in which animals had prior clinical 
infections with either P. falciparum or P. coatneyi).  These were then compared to several spleen-
intact animals and 15 malaria naive control animals.  Tissues were evaluated qualitatively for 
histopathologic changes in comparison with control animals and excluding any background lesions 
observed in the AFRIMS macaque colony through experience or described in the literature. (McInnes 
2012)  
The spectrum of tissues available for review was constrained in animals from the 
retrospective cohort by which tissues were collected at the time of those particular studies.  In all 
animals, cerebrum, cerebellum, brain stem, liver, kidneys, heart and lungs were available, while in 
only some animals were specimens of adrenal and pituitary glands, pancreas, gastrointestinal system, 
skeletal muscle, eyes, lymph nodes, urinary bladder and reproductive tract obtained and available for 
review. In contrast, full autopsies were conducted in the prospective study, which included sampling 
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from multiple areas of the brain and spinal cord.  Spinal cord samples were not available from any 
retrospective study. In 3 animals, splenunculi were identified and evaluated. Once each pathologist 
had read out the material, consensus relating to any lesion description or scoring discrepancies, was 
reached through working jointly on a multi-head microscope. Histopathological lesion scoring 
conducted by both pathologists as follows: 0 = Within Normal Limits, 1= Minimal, 2 = Mild, 3 = 
Moderate, 4 = Marked, 5 = Severe. Results are discussed in detail in Chapter 4: Cytology and 
Histopathology. 
 
2.10 Immunohistochemistry staining: 
2.10.1 Sample preparation:  
Rhesus tissue samples were fixed in 10% phosphate buffered formalin for at least 48 h. The 
ratio of tissue: formalin was 1 part tissues to 10 parts formalin. The fixed tissues were trimmed into 5 
mm dice and processed using an automated tissue processor (SLEE medical, Mainz, Germany) as 
follows: dehydration (70% Isopropanol for 1 h, 95% Isopropanol for 1 h x 3 times, and 100% 
Isopropanol for 1 h x 3 times), clearing (Xylene substitute (Sigma, St. Louis, MO, USA) for 1 h x 3 
times) and paraffin infiltration (molten paraffin for 30 min x 2 times). The processed tissues were 
then embedded into paraffin blocks and sectioned at 5 μm using a semi-automated rotary microtome 
(RM2245, Leica, Buffalo Grove, IL, USA). The tissue sections were mounted onto poly L-lysine coated 
microscope slides and baked at 60 °C for 14-18 h.  
2.10.2 Deparaffinization, rehydration, and antigen retrieval:  
To retrieve the epitope in formalin-fixed tissue sections for immune reaction, the heat-
induced epitope retrieval (HIER) was used in this study. For CD3, CD20, CD68, Fibrinogen, and Glial 
Fibrillary Acidic Protein (GFAP) staining, the formalin-fixed paraffin embedded tissues were 
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deparaffinized, rehydrated, and antigen-retrieved using Pre-treatment module 3-in-1 procedure (PT-
link, Dako, Glostrup, Denmark), with Tris/EDTA buffer pH 9 (3-in-1 Target Retrieval solution, Dako, 
Glostrup, Denmark) at 95 °C for 20 min and then left to cool down to 65 °C. The tissue slides were 
transferred to incubate in PT-link tank with wash buffer (EnVision™ FLEX Wash Buffer, Dako, Glostrup, 
Denmark) for 20 min at room temperature.   
For CD61 staining, paraffin embedded tissue sections were deparaffinized with Xylene substitute 
(Sigma, St. Louis, MO, USA) for 5 min 3 times, 100% Ethanol for 2 min twice, 95% ethanol for 2 min 
twice and an 80% Ethanol for 2 min, and deparaffinized tissue sections were then placed in pressure 
cooker (Decloaking chamber™ NxGen, Biocare Medical, Concord, CA, USA) and heated at 110ºC for 10 
min with citrate buffer, pH6 (Dako, Glostrup, Denmark). The tissue section slices were then removed 
from the pressure cooker when the chamber temperature decreased to 80 °C and let cool down at 
room temperature for 20 min. 
Before immunostaining, the slides were washed for 3 min in wash buffer bath for 3 times. From this 
point onwards, tissue sections were always kept moist to avoid non-specific binding and therefore 
artefactual high background staining. 
2.10.3 Immunohistochemical staining:  
To determine the immunohistopathology of P. coatneyi infection in rhesus macaque model, 
the tissue sections from P. coatneyi infected (6 monkeys) and control monkeys (6 monkeys) were 
immunostained with CD3, CD20, CD61, CD68, Fibrinogen, and GFAP antibodies as primary antibodies. 
After antigen retrieval, the tissue sections were circled with a hydrophobic barrier pen (Dako, 
Glostrup, Denmark) to create a barrier for liquids and minimize the amount of reagents required. The 
optimal dilution of primary antibodies, secondary antibodies, and substrates are shown in Table 1. 
Primary antibodies and secondary antibodies were diluted with antibody diluent (Dako, Glostrup, 
Denmark). The diluted primary antibody was added to cover the entire tissue section and incubated 
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at room temperature in a humidified chamber. Negative control slides included tissue sections 
incubated with antibody diluent without primary antibody, or omission of the secondary antibody 
step. The slides were then washed 3 times for 3 min each in a wash buffer bath and incubated with 
secondary antibodies for 30 min at room temperature in a humidified chamber.  After 3 washes in the 
wash buffer bath, the slides were incubated with prepared substrates for 5 min and washed 3 times 
in a distilled water bath. The slides were then counterstained for 5 min using hematoxylin solution, 
Mayer’s (Sigma, St. Louis, MO, USA) and washed 3 times in a distilled water bath. The stained slides 
were dehydrated (95% Ethanol twice, 100% Ethanol three times) and cleared (Xylene twice) before 
mounting with Toluene based mounting medium (Thermo Fisher Scientific, Drive Kalamazoo, MI, 
USA). 
2.10.4 Quantitative analysis and scoring system:  
The stained tissue slides were observed under Olympus BX43F bright field microscope 
(Olympus, Tokyo, Japan). The immunostaining of CD3-, CD20-, CD61-, and CD68-positive cells was 
quantified as immunoreactive cells per 20 high-power field (HPF) at 400x magnification. Fibrinogen 
and GFAP immunostaining was quantified using a five point range scoring system; 0 = Within Normal 
Limits to 5 = Severe.  β-APP and Cleaved caspase-3 staining characteristics were assessed 
qualitatively.  
Statistical significance was determined for the following immunohistochemical stains: CD3, 
CD20, CD68, GFAP and Fibrinogen.  Significance was determined based on a comparison between 
brain stem controls and experimental samples, cerebrum controls and experimental samples as well 
as in comparing experimental cases of brain stem and cerebrum.  Individual slides were evaluated as 
described above and mean values were calculated so as to regularize the sample size.  This was 
necessary as there were two cerebral slides and a single section of brain stem harvested from each 
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animal for the purpose of this study. P values were determined using a Mann-Whitney test 
(GraphPad, La Jolla, CA, USA). 
Table 2.8: Immunohistochemistry of paraffin-embedded formalin fixed macaque tissues. 
Primary 
antibody 
Primary antibody 
clone and source  
Primary 
antibody 
dilution 
Primary 
antibody 
incubation 
time 
Secondary antibody Substrate 
CD3 Polyclonal rabbit 
anti-human CD3 
(Dako, Glostrup, 
Denmark) 
1:50  30 min AP labelled polymer 
conjugated to goat anti-
mouse and goat anti–rabbit 
(Nichirei biosciences inc, 
Chuo-ku, Tokyo, Japan) 
Liquid 
Permanent 
Red solution 
(Dako, 
Glostrup, 
Denmark) 
CD20 Monoclonal 
mouse anti-
human CD20 
clone L26 (Oxford 
University, 
Oxford, UK)  
1:5  30 min AP labelled polymer 
conjugated to goat anti-
mouse and goat anti–rabbit 
(Nichirei biosciences inc, 
Chuo-ku, Tokyo, Japan) 
Liquid 
Permanent 
Red solution 
(Dako, 
Glostrup, 
Denmark) 
CD61 Monoclonal 
mouse anti-
human CD61 
clone Y2/51 
(Dako, Glostrup, 
Denmark) 
1:50 60 min HRP labelled polymer 
conjugated to goat anti-
mouse and goat anti-rabbit 
(Dako, Carpinteria, California, 
USA) 
3,3’-
diaminoben
zidine 
chromogen 
solution; 
DAB (Dako, 
Carpinteria, 
California, 
USA) 
CD68 Monoclonal 
mouse anti-
human CD68 
clone KP1 (Oxford 
University, 
Oxford, UK) 
1:3  30 min AP labelled polymer 
conjugated to goat anti-
mouse and goat anti–rabbit 
(Nichirei biosciences inc, 
Chuo-ku, Tokyo, Japan) 
Liquid 
Permanent 
Red solution 
(Dako, 
Glostrup, 
Denmark) 
Fibrinogen Polyclonal rabbit 
anti-human 
fibrinogen (Dako, 
Glostrup, 
Denmark) 
1:200  30 min AP labelled polymer 
conjugated to goat anti-
mouse and goat anti–rabbit 
(Nichirei biosciences inc, 
Chuo-ku, Tokyo, Japan) 
Liquid 
Permanent 
Red solution 
(Dako, 
Glostrup, 
Denmark) 
Glial Fibrillary 
Acidic Protein 
(GFAP) 
Polyclonal rabbit 
anti-GFAP, Ready-
to-Use (Dako, 
Glostrup, 
Denmark) 
1:1 30 min AP labelled polymer 
conjugated to goat anti-
mouse and goat anti–rabbit 
(Nichirei biosciences inc, 
Chuo-ku, Tokyo, Japan) 
Liquid 
Permanent 
Red solution 
(Dako, 
Glostrup, 
Denmark) 
 
124 
 
AP; Alkaline phosphatase (N-Histofine® Simple Stain alkaline phosphatase (MULTI), Nichirei biosciences inc, 
Chuo-ku, Tokyo, Japan) 
HRP; Horseradish peroxidase (Envision® + Dual Link System-HRP, Dako, Carpinteria, California, USA 
 
2.10.5 Quantitative enzyme-linked immunosorbent assay for albumin index and brain injury 
markers:  
Cerebrospinal fluid (CSF) samples were collected from macaques at euthanasia and 
centrifuged at 10,000 x g for 10 min. CSF supernatant was collected and used for ELISA and multiplex 
cytokine immunoassay. Plasma samples were also collected on the same day for albumin ratio 
determination. There were 3 sample groups, uninfected (2 monkeys), 12-week SHIV infected (12 
monkeys), and P. coatneyi infected (6 monkeys) monkeys. The SHIV group formed a control group of 
known CNS infected monkeys where it was hoped that any characteristic cytokine signature or BBB 
injury leading to leakage would differ in pattern to CNS effects on the experimental severe malaria 
animals. This part of the thesis was conducted in collaboration with Dr. Sandy Vasan and the SHIV 
model development group at AFRIMS.  
2.10.6 Albumin ELISA:  
To determine albumin index (AI), the plasma samples were diluted at 1:400,000 and the CSF 
samples were diluted at 1:2,000 using Albumin Monkey Diluent (Abcam, Cambridge, UK). The albumin 
present in diluted samples was measured using the albumin monkey ELISA kit (Abcam, Cambridge, 
UK) according to the manufacturer’s instructions. Optical density 450 nm values were measured with 
SPECTRAmax® 340 PC microplate reader (Molecular Devices, Sunnyvale, CA, USA), and the albumin 
concentration was interpolated from the standard curve using SOFTmaxPRO 4.3.1(Molecular Devices, 
Sunnyvale, CA, USA) and multiplies by the dilution factor. The AI was calculated using the formula: AI 
= (CSF albumin/plasma albumin) × 103. The statistical analysis among groups was compared using 
Kruskal-Wallis test (GraphPad, La Jolla, CA, USA). 
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2.10.7 Tau (total) protein ELISA:  
Tau (Total) protein is a biomarker of neuraxonal degeneration in CSF. (Dittrich 2015) To 
evaluate neuronal injury as a factor of brain pathology, the CSF Tau (total) protein was determined 
using Human Tau (Total) ELISA kits (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. Optical density 450 nm values were determined with SPECTRAmax® 340 PC microplate 
reader (Molecular Devices, Sunnyvale, CA, USA). Background absorbance was subtracted from all data 
points, including standards, samples, and controls prior to plotting.  The concentration of Tau (Total) 
in samples was calculated from standard curves using a four parameter algorithm by SOFTmaxPRO 
4.3.1(Molecular Devices, Sunnyvale, CA, USA) and multiplied by two (dilution factor). The statistical 
analysis among groups was compared using Kruskal-Wallis test (GraphPad, La Jolla, CA, USA). 
2.10.8 Multiplex cytokine immunoassay:  
Multiplex cytokine immunoassay was conducted as an adjunct to and in collaboration with 
the ongoing project by the AFRIMS’ Simian-Human Immunodeficiency Virus model development 
project. Through the generosity of the SHIV group, we were able to submit samples for multiplex 
analysis which were then run in conjunction with the SHIV infected macaque samples and control 
samples.  This was conducted only once and while not a primary feature of the descriptive study, did 
allow for some fascinating data for both this severe malaria study, but also as a disease comparison 
for the SHIV group.  
To determine specific cytokine involved in P. coatneyi infection in rhesus macaques CSF, 23 
cytokines, including G-CSF, GM-CSF, IFN-γ, IL-1ra, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23 (p40), 
IL-13, IL-15, IL-17, IL-18, MCP-1, MIP-1α, MIP-1β, sCD40L, TGF-α, TNF-α, and VEGF, were screened 
using MILLIPLEX® MAP Non-Human Primate Cytokine Magnetic Bead Panel (PRCYTOMAG-40K, 
Millipore, Darmstadt, Germany) according to the manufacturer’s instructions. Briefly, 200 microliters 
of Assay buffer were added into each well of the plate. The plate was sealed and mixed on a plate 
126 
 
shaker for 10 min at room temperature. Assay Buffer was removed from all wells by inverting the 
plate and tapping it on paper towels. Twenty-five microliters of standard or control were added into 
appropriate wells, and 25 µl of Assay Buffer was added into sample wells. Then, 25 µl of CSF matrix 
solution was added into standard and control wells while samples were added into appropriate wells. 
Mixed beads were then added into all wells. Subsequently, the plate was sealed and wrapped with 
foil and incubated at 4°C with gentle shaking for 16-18 hr. The following day, the plate was washed 
twice with 200 µl wash buffer. Detection antibody was added and incubated at room temperature for 
1 hr. Streptavidin-Phycoerythrin was added and incubated at room temperature for 30 min. After 
incubation, plate was washed 2 times, and Sheath Fluid was added into all wells. The plate was run on 
a Luminex 200™ (Luminex, Austin, USA). The Median Fluorescent Intensity (MFI) data using a 5-
parameter logistic method was analyzed. GraphPad software was used for graphing and statistical 
analysis (GraphPad, La Jolla, CA, USA). 
 
2.11 Ultrastructural Evaluation of Tissue sections using Transmission and Scanning Electron 
Microscopy:  
2.11.1 Transmission Electron Microscopy (TEM) Methodology: 
2.11.1.1 Transmission electronmicroscopy (Spurr resin) Tissue fixation and processing: 
Examination of the ultrastructural changes in tissues from infected monkeys was performed to 
determine both the relationship between iRBCs and host cells (such as sequestration within the 
microvasculature of different organs) and specifically to examine the type of adhesive contacts made 
by P. coatneyi in comparison to that characterized in human tissues in P. falciparum infections. 
(Pongponratn 2003, Promano 2005, Nguangsangiam 2007) This part of the thesis was done in 
collaboration with Professor David Ferguson, Department of Ultrastructural Morphology, Radcliffe 
Department of Medicine, Oxford University. EM sections were prepared from tissues as follows: 
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1. Tissue samples were cut into 6-8 small squares ~ 0.5-1 mm at autopsy, immediately following 
euthanasia 
2. Tissue preservation was in 2.5 % phosphate buffered glutaraldehyde at 4oC until use 
3. Prior to processing, tissue samples were washed in 0.1 M phosphate buffer for 20 min; 3-4 times 
4. Post fixation: The samples were submerged in 1% osmium tetroxide mixed with 0.1 M phosphate 
buffer and put on the shaker for 1 hour. 
5. 0.1 M phosphate buffer for washing the tissue sample for 20 min; 1 time 
6. Normal saline for washing 20 min; 1 time 
7. Tissue processing: Dehydration 
• 35% alcohol 15-20 min 
• 50% alcohol 15-20 min 
• 70% alcohol 15-20 min 
• 95% alcohol 15-20 min 
• 100% alcohol 15-20 min; 3 times 
• propylene oxide 15-20 min; 3 times 
• infiltrate with Spurr resin with propylene oxide (ratio 1:3) for 3 hours- over night 
• infiltrate with Spurr resin with propylene oxide (ratio 1:1) for 3 hours- over night 
• infiltrate with Spurr resin with propylene oxide (ratio 3:1) for 3 hours- over night 
• infiltrate with Spurr resin for 3 hours- over night; 3 times 
8. Embedding with Spurr resin 
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9. Curling in oven 70o C for 8 hours 
10. Section with an ultramicrotome; 70 nm thick 
11. Staining with uranyl acetate and lead citrate 
12. Grids were examined using JEM-2100 and JEM-1400 Transmission Electron Microscopes; Japan 
2.11.2 Scanning Electron Microscopy (SEM) methodology: 
This part of the thesis was conducted in conjunction and collaboration with Dr. Bruce Russell 
and Dr. Benoit Malleret at the Vivax Laboratory, National University of Singapore.   
In order to further examine the structure of the Knob adhesion proteins on the surface of P. coatneyi 
infected red cells, SEM was performed after magnetic enrichment on ex-vivo infected red blood cell 
samples from the three splenectomized P. coatneyi infected rhesus macaques associated with the 
model refinement phase of the prospective study.  Standard protocols were used as in described in 
Malleret et al (2013) and outlined in the following section. 
2.11.2.1 SEM tissue fixation and processing: 
1. Sorted cells were coated on a poly-lysine (Sigma) pretreated glass coverslip for 15 mins at room 
temperature (RT) and were fixed in glutaraldehyde and post-fixed in osmium tetroxide.   
2. Cells were washed in deionized water, dehydrated with a graded series of ethanol immersions 
starting at 25% to 100% and critical point dried (CPD 030, Bal-Tec) 
3. Fixed in 2.5% glutaraldehyde 0.1 M phosphate buffer for 1 hours (pH 7.4) at RT 
4. The samples were washed twice in PBS and subsequently underwent post-fixation with 1% osmium 
tetroxide (Ted Pella Inc.) at RT for 1 hour.   
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5. The glass coverslip surfaces were coated with 5 nm of gold by sputter coating in a high-vacuum 
sputtering device (SCD005 sputter coater, Bal-Tec) 
6. The coated samples were examined with a field emission scanning electron microscope (JSM-
6701F, JEOL) at an acceleration voltage of 8 kV using the in-lens secondary electron detector at a 
working distance of 8 µm. 
2.11.3 Atomic Force Microscopy (AFM) Methodology: 
Atomic Force Microscopy was conducted in collaboration with Dr. Bruce Russell, Dr. Benoit Malleret 
and Dr. Rosemary Zhao at the Vivax Laboratory, National University of Singapore.  Atomic force 
microscopy was pursued as a mechanism to further describe the comparative nanostructural surface 
morphology in P. coatneyi infected erythrocytes in comparison with both normal cells and P. 
falciparum infections in humans. Results are described in detail in Chapter 6: Ultrastructure. 
2.11.3.1 AFM Slide preparation: 
1. Peripheral venous blood was drawn from the three splenectomized P. coatneyi infected rhesus 
macaques, when their peripheral parasitemia as judged by smear preparation was more than 
10% (from the model refinement phase of the prospective study). These were harvested by 
venipuncture, centrifuged at 5000g for 5 minutes, then resuspended in 1×PBS with 1% BSA 
medium at 50% to 75% hematocrit. 
2. This suspension was then used to make a thin blood smear on microscope slides.  
3. The blood smear was air-dried.  
4. Dimension FastScan AFM was used to scan the slides. Approximately 100-200 cells were scanned 
per slide by Bruker AFM probes (FASTSCAN–B). The height images were captured with the 
samples per line of 512, and scan rate of 3 to 4 Hz. The images were analyzed using NanoScope 
Analysis (version 1.40), and the details of the nanostructures were measured. 
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Chapter 3: Clinical, Parasitemic and Macroscopic Autopsy Pathology 
in the Rhesus Macaque/P. coatneyi Severe Malaria Model 
 
3.1 Introduction to clinical trials: 
The fundamental intent of this dissertation was a complete and coherent description of the 
Rhesus macaque/P. coatneyi model in order to facilitate its use as a legitimate and effective platform 
on which to conduct anti-malarial drug, adjuvant treatment or vaccine trials.  The Armed Forces 
Research Institute of Medical Sciences (AFRIMS) has long been interested in this model for severe and 
cerebral malaria, and in collaboration with academics globally, has remained at the forefront of those 
few experimental studies which have been conducted world-wide.  As described in the introduction, 
there is significant variation in the application of the model and even the definition of severity.  In 
order to study the regenerative impact on the bone marrow as well as the metabolic disturbances, 
Moreno et al. have used a relapsing version of the model in non-splenectomized monkeys, 
characterized by a much lower parasitemia as well as having the experimental animals undergo sub-
curative treatment with artemether between episodes. (Moreno 2013) Davison et al. examined the 
placental and fetal pathology secondary to P. coatneyi infection and their model involved spleen 
intact animals whose parasitemias, while significant, did not exceed 150,000 parasites/mm3 red blood 
cells. (Davison 1998; Davison 2000; Davison 2005) Other groups have described the model in very 
limited numbers and have used either Japanese macaques (Kawai 1993; Kawai 1998; Matsumoto 
2000) or combined populations of crab-eater macaques and rhesus macaques. (Desowitz 1967)   
All of this diversity in the use of P. coatneyi as a model for disease in humans highlights not 
just the heterogeneity of data and reporting in the experimental scientific literature, but to some 
extent mirrors the heterogeneity of human falciparum infection. In contrast the murine model usually 
utilizes genetically inbred strains such as the ANKA or CBA mouse, where groups defined as having 
different disease states such as ‘experimental cerebral malaria’ or ‘severe anemia’ are compared.  As 
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such, our intent in this chapter, is to provide a relatively cohesive description of the clinical and gross 
findings of P. coatneyi infections in a uniform population of adult, Indian origin, splenectomized 
rhesus macaques from the closed colony at AFRIMS.   
This chapter focuses specifically on the disease progression in the 15 prospective animals 
which were used in the model refinement study and in the methylene blue drug trial.  For the 
purpose of description of the findings associated with temperature and parasitemia, the study 
concentrates on representative data associated with the refinement protocol as opposed to those 
that underwent radical cure drug treatment.  The primary intent of the refinement study was to 
establish repeatable and predictable disease progression details.  In contrast with other studies, this 
was done specifically with the resolve of establishing criteria of disease severity similar to those used 
to define severe malarial disease in humans, as detailed in the WHO criteria. (WHO 2014) This was 
intended to study the clinical similarities between the model at high levels of parasitemia (maximum 
52%), and synchronous severe clinical symptomology.  All data was tabulated, graphed, 
photographed and compared so as to determine the practicality and applicability of the P. 
coatneyi/rhesus macaque model as being adequately representative of cerebral and/or severe 
malaria in humans.   
 
3.2 Clinical and gross pathology methodology overview: 
‘Signalment’ in veterinary medicine refers to systematic identifying criteria that are the foundation of 
each individual.  In this case, the factors considered included species, genetic origin, gender, age, 
weight and prior clinical/experimental history.  Subsequent to intravenous inoculation with 
approximately 1 mL equivalent to 5x106 infected RBCs of P. coatneyi infected blood derived from a 
parasitemic, spleen intact donor animal, all animals were closely monitored. The animals used in this 
arm of the study had not been exposed to P. falciparum or P. coatneyi in any previous studies in the 
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colony, in order to ensure that infection was on a ‘naïve’ immunological background. Parasitemia was 
monitored throughout the experiment either through blood smears generated from an ear nick or 
concurrent with the larger venous blood draws. The larger volume phlebotomy events evaluated the 
hematological parameters and a panel of clinical chemistry.  Temperatures and clinical signs were 
monitored throughout the study with frequency increasing in synchrony with the rising parasitemia 
to a peak of every other hour over 24 hour cycles.  Temperatures were recorded via rectum as well as 
by using a subcutaneous transponder that was injected under the skin between the shoulder blades 
in all animals. Electrocardiograms were conducted concurrent with blood draws.  Immediately prior 
to death, a subsection of animals had their irises dilated for retinal photography, and all animals had 
terminal blood, cerebrospinal fluid and urine collected.  Complete autopsy was performed in all 
animals with weighing of select organs (brain, lungs, heart, liver), collection of all tissues in 10% 
buffered formalin, selected tissues in Glutaraldehyde and RNA-later, as well as photography of all 
significant lesions.  
 
3.3 Typical clinical progression: 
Clinical Symptomatology Criteria 
Assessment of activity level as determined by moving around the cage and the response to 
the presence of a veterinarian or a technician; mentation which was evaluated as a response to 
stimuli outside the cage; menace response in which an animal will blink or withdraw when a sudden 
movement occurs close to the eyes; breathing, to include both the quantitative number of breaths as 
well as the quality: labored, shallow, gasping…etc; skin color to include any signs of hemorrhage, 
jaundice or cyanosis; presence of vomitus; skin turgor as a sign of hydration status; urination 
characteristics (anuria, dysuria, stranguria), urine color and both quantitative and qualitative 
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assessment of the urine captured in the pans under the cage; and appetite.  All signs were graded, 
with a maximum score of 24.  A normal animal would score 0. (See Study Specific Form #1, Chapter 2) 
Additional signs were coded but not scored, included: ataxia; inappropriate vocalization; 
diarrhea; melena; epistaxis; opisthotonus (abnormal posturing); piloerection; salivation; tremor or 
twitching of mouth or fingers and/or hemiplegia. 
Experimental animals typically began to develop clinical symptomology around day 7 post 
inoculation, although decreased appetite or anorexia was often noted around day 4 to 5.  Initial signs 
were often found to be associated with activity level and mentation.  Parasitemia at this stage would 
typically be in the range of 105 – 106/mm3. These were closely aligned with the first significant 
increases in temperature.  At this stage, an animal would typically have a total score of around 7, 
consisting of anorexia (3), some degree of hematuria (1-3), moderate to marked reduction in activity 
(1-2) and decreased mentation (1).  When the hematuria became more significant, changes in skin 
turgor would typically follow.  Immediately prior to death or euthanasia, animals had severely 
decreased mentation with loss of the menace response.  Animals were recumbent in their cages and 
non-responsive to external stimuli without reaching human criteria of true coma. (Figure 3.1) Animals 
would typically have been anorexic for 2 days, and at some point, have vomited.  Occasionally, there 
were episodes of dysuria in which animals strained to urinate or were observed to lack sphincter 
control, and in all animals varying degrees of hematuria was observed.  By day 7, most animals were 
showing signs of dehydration, and in about 30% of animals, prior to death there was evidence of 
dyspnea.  40% of the animals began to have erythema of the skin concentrated around the perineum, 
scrotum and the inner thighs.  (Figure 3.2) 
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Figure 3.1: Photograph of a recumbent P. coatneyi infected rhesus macaque demonstrating lethargy. 
While decreased mentation cannot be captured as a static image, these animals were typically poorly 
or non-responsive to stimuli. 
Figure 3.2: Photograph of a P. coatneyi infected rhesus macaque demonstrating severe erythema and 
occasional petechiae on the perineum, scrotum, thighs and legs. 
 
3.4 Temperature: 
In normal adult animals from the AFRIMS colony, baseline temperatures measured rectally 
fluctuate between 99.5° F to 102° F (37.5° C to 38.9° C) depending on a range of physiological factors 
to include gender, feeding schedule, stress, handling time and concurrent procedures. 
Experimentally, following the initial temperature spike at day 7, which would often be around 104° 
Fahrenheit (F) or 40° Celsius (C), the temperature would remain higher than baseline, with peak 
temperatures reaching up to 107° F or 41.7° C, but fluctuating until death or euthanasia.  
 
3.5 Parasitemia: 
Parasitemia curves were plotted in all animals in the prospective study.  These graphs 
examined the progression of total parasitemia over time as well as by identifying the life cycle stage 
of the parasite over the course of the experiment.  This allowed for a prediction of specific windows 
in which there was an anticipated spike in overall parasitemia as well as life cycle stages that were 
consistent with overlapping clinical symptomology.  Previous attempts over the past 30 years to use 
the model for both pathophysiological studies or drug trials had produced somewhat haphazard 
results.  This was largely due to the fact that the parasitemia spike with P. coatneyi is very rapid and 
subject animal devitalization, collapse and death occurred within a short time frame, frequently 
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occurring late at night.  Specifically, the steep increase in parasitemia observed on day 7, resulted in 
peak parasitemias of up to 52%.  As is described in the demonstrated temperature, clinical chemistry 
and hematology sections which follow, this spike was associated with severe clinical signs which were 
likely irreversible after a certain point.  Clinical symptomology and the spikes in temperature occurred 
with a slight lag to the parasitemia increase, however, once established and the animals reached high 
parasitemias in excess of 15-20%, there was typically significant evidence of multiorgan injury. 
Without the development of these graphs and an understanding of the rapidity of 
development of parasitemia, the model becomes too cumbersome for the use in drug trials.  
However, by mapping disease progression and overlapping symptomology, parasitemia and 
temperature data, the model become both manageable as well as relatively predictable.   
Beginning on day 1 post inoculation, there was an observable parasitemia which 
subsequently decreased and by the beginning of day 3 was no longer significant.  By the 3rd sampling 
on day 3, the parasitemia had undergone an initial spike in the range of 10,000 to 30,000 
parasites/mm3 red blood cells corresponding to the first phase of post schizogony in the infected 
macaque.  The cycle then continued and the parasitemia again decreased, implying sequestration, 
rising again by the end of day 5 at which point the values ranged from 200,000 to 350,000 
parasites/mm3 red blood cells.  The next round of intraerythroctytic development, followed by 
sequestration and a subsequent decrease in peripheral parasitemia occurred over day 6 and was 
followed by the expected spike by the end of day 7 with calculated parasitemia in excess of 1 million 
parasites/mm3 red blood cells.  The parasitemia remains sustained at that threshold until death or 
euthanasia which never exceeded day 8 without some form of medical intervention, due to the 
severity of clinical symptoms by this stage. 
Parasite life cycle stage was a crucial feature in terms of understanding the disease 
progression as well. The parasitemia spike on day 5 represented a peak of ring stages followed by a 
predictable spike and peak in trophozoites on day 6 leading to a small spike in schizonts.  This was 
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closely followed by the day 6 (evening) spike in ring forms, a smaller increase in trophozoites and 
then a schizont increase on day 7. This is followed closely by a dramatic increase in ring forms, which 
as it began to taper off, yields to the spike in trophozoites at the beginning of day 8.  The animals in 
the refinement protocol typically did not survive beyond this peak, and were euthanized or died 
naturally. Animals in the methylene blue drug trials showed similar initial parasitemia curves, but 
once the treatment window was achieved, the parasitemias were significantly controlled, decreased 
and eventually cleared in the drug study animals. 
These results imply a degree of homogeneity both in control of parasitemia in the 
splenectomized animal, and the development of clinical symptoms in response to infection between 
different animals. 
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    Daily Parasitemia Levels 
Study 
Day Date Time DA831 DA923 R519 
0 22-May-14 
0800 0 0 0 
1100 0 0 0 
1900 0 0 0 
1 23-May-14 
0800 0 0 0 
1100 0 0 0 
1900 233 348 295 
2 24-May-14 
0800 83 73 35 
1100 17 22 12 
1900 8 7 23 
3 25-May-14 
0800 0 0 0 
1100 7 648 64 
1900 10,634 24,936 17,332 
4 26-May-14 
0800 1,169 2,377 1,676 
1100 511 606 718 
1900 1,932 4,218 1,916 
5 27-May-14 
0800 386 239 203 
1100 6,443 20,905 8,302 
1900 217,200 276,480 304,440 
6 28-May-14 
0700 144,500 47,300 71,925 
0900 73,984 36,850 86,100 
1100 48,552 51,700 78,225 
1300 36,992 26,950 50,400 
1500 45,645 34,140 37,157 
1700 42,423 36,985 42,756 
1900 27,387 38,123 47,337 
2100 32,220 45,520 37,666 
2300 38,570 31,428 41,715 
7 29-May-14 
0100 34,713 29,100 35,630 
0300 28,652 26,190 27,405 
0500 22,591 15,132 21,378 
0700 23,562 16,095 15,068 
0800 21,879 38,295 26,130 
0900 29,733 56,610 33,462 
1000 69,564 131,535 61,854 
1100 291,720 549,450 375,180 
1200 1,009,800 1,110,000 922,740 
1300 992,970 1,298,700 1,541,280 
1400 1,391,280 1,737,150 1,647,750 
1500 1,532,580 1,676,080 1,433,440 
1600 1,623,360 1,778,280 1,616,960 
1700 1,826,280 1,737,400 1,612,000 
1800 1,623,360 1,747,620 1,507,840 
1900 1,543,260 1,793,610 1,612,000 
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Table 3.5.1 Parasitemias (p./mm3 RBCs) over the course of the refinement study.  Peak parasitemia 
typically occurs during day 7 post infection, and high parasitemia was maintained through the end of 
the study.   
 
Graph 3.5.1: Representative parasitemia graph demonstrating the spike in parasitemia over time.  It is 
notable that the animals tabulated in this graph demonstrate both a strong correlation in parasitemia 
0
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0 1 2 3 4 5 6 7 8 9
p
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m
m
3
Time (d)
Parasitemia (p./mm3)  of DA831, DA923, and R519
DA831 DA923 R519
2000 1,701,360 1,823,320 2,140,600 
2100 1,751,400 1,823,320 2,079,440 
2200 1,590,160 1,979,110 2,123,920 
2300 1,536,800 1,950,480 1,936,480 
2400 1,813,650 1,939,140 1,827,800 
8 30-May-14 
0100 1,808,000 1,791,720 1,758,640 
0200 1,649,800 1,871,100 1,798,160 
0300 1,389,900 1,587,600 1,600,560 
0400 1,356,000 1,598,940 1,541,280 
0500 1,440,750 1,542,240 1,791,880 
0600 1,175,200 1,496,880 1,501,760 
0700 1,607,040 1,557,300 1,445,520 
0800 1,353,600 1,487,490 1,413,600 
0900 1,192,320 1,315,650 1,409,040 
1000 1,042,560 1,428,420 884,640 
1100 1,013,540 1,514,340 1,249,440 
1200 END 1,547,340 1,345,200 
1300 
 
1,401,570 1,190,160 
    
END END 
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and in terms of disease progression.  This trend held true for all 15 prospective animals in the 
refinement and the drug ranging studies.   
 
 
Graph 3.5.2: This parasitemia graph is the same data represented in 3.1, however is represented as 
percentages of erythrocytes infected. 
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Graph 3.5.3. Percentage of ring forms of P. coatneyi staged over the course of the experiment. 
The parasitemia for each time point assessed was staged to describe the linear life cycle of 
the parasite within infected cells over the course of the experiment. (Graph 3.5.3) As with the overall 
parasitemia, there was extremely close correlation as to parasite developmental stage between 
infected animals, allowing for a significant degree of prediction as to the anticipated schizogony, spike 
in febrile disease and resultant clinical symptomology.  The ring stage (early trophozoite) of P. 
coatneyi are phenotypically very similar to those of P. falciparum. (Figure 3.1.1 arrow) These usually 
have either a single or double chromatin body, and can present either centrally within the infected 
erythrocytes or in a marginalized “accolé” or “pliqué” form which are peripheralized but closely 
associated with the plasma membrane of the erythrocyte and having little impact on the silhouette of 
the cell. (Figure 3.1.2 arrow) Another form which is described is the vesicular form, in which the 
peripheralized ring creates a blister elevated from the plasma membrane. (Figure 3.1.5 arrowhead) 
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With significant infections, there can be multiple young trophozoites or rings infecting individual 
erythrocytes.  (Figure 3.1.3 arrow) 
As the trophozoites mature, their cytoplasm intensifies in color and often appears to have a 
cytoplasmic vacuole.  Additionally, the trophozoites being to demonstrate the characteristic 
hemozoin crystals which stain a golden brown. (Figure 3.1.4 arrow) The younger schizonts are 
typically round and begin to obscure the host cell.  This stage will begin to demonstrate the formation 
of the merozoites which are comingled with the granular hemozoin pigment.  The visible cytoplasm 
stains a light blue on Giemsa and with maturity the hemozoin granules begin to coalesce.  At later 
stages, the schizont completely fills the erythrocyte making it difficult to distinguish any of the 
preexisting host cell.  Nearing rupture, the schizont is filled with approximately 20 merozoites. (Figure 
3.1.5 arrow) The macrogametocytes are highly visible with blue cytoplasm and a red, often 
peripheralized nucleus.  The cytoplasm contains scattered small granules of hemozoin crystals.  
(Figure 3.1.6 arrow) Microgametocytes are reddish-purple when stained with Giemsa, and often have 
a large dappled nucleus. 
During the course of both the refinement study as well as the methylene blue drug dosage 
study, each sampling to assess for parasitemia was also analyzed for parasite staging.  This provided 
additional data allowing for a more complete understanding of the projected parasitemia curves.  The 
various stages of maturation of the trophozoites were by far the predominant forms, while for a brief 
period highlighting the malignant tertian nature of P. coatneyi malaria, trophozoites predominate at 
two points in the course of the disease in this experiment with a separation of 48 hours.   
Additionally, there is a peak of schizonts on day 7 and it would be anticipated that should the animals 
not succumb to the severity of the disease, that another larger spike of schizonts would be expected 
at day 9, however in those animals which participated in the refinement portion of the study, no 
animal was maintained beyond day 8. 
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Figure 3.5.1-6 Blood smears from P. coatneyi infected rhesus macaques.  Each figure within the plate 
demonstrates progressive developmental stages of the plasmodium within the infected erythrocytes.  
3.5.1 illustrates an infected red blood cell containing a single ring stage or young trophozoite (arrow), 
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while another cell contains 3 or more parasites which appear to be later stage rings.  3.5.2 shows 
variants of the “accolé” or “pliqué” forms in which the ring stage plasmodium is peripheralized and is 
essentially confluent with the plasma membrane of the infected cell.  These forms are evident in that 
their cytoplasm is clearer than that of the host cell, and the chromatin body stains brightly and is 
highly visible (arrow). 3.5.3 demonstrates a single cell infected with 4 parasites all of which are more 
mature ring forms (arrow) while another cell contains a single accolé ring form (arrowhead). 3.5.4 
illustrates a single mature trophozoite which is centralized within the infected erythrocyte (arrow).  
3.5.5 has a highly visible mature schizont containing upwards of 20 merozoites (arrow).  Additionally, 
there is an excellent example of the vesicular form of the early trophozoite or ring stage (arrowhead).  
Finally, in 3.5.6 a macrogametocyte is evident with its blue cytoplasm and speckling of hemozoin 
granules (arrow).  Additionally, within the photomicrograph are two mature trophozoites 
(arrowheads). 
 
Graph 3.5.4 
The mature trophozoites dominate in the blood immediately and predictably following the drop in 
earlier ring stages.   
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Graph 3.5.5 
 
Graph 3.5.6 
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Graph 3.5.7 
The preceding 3 graphs, each representing the parasitemia percentage broken out over time as to the 
specific stage of the erythrocytic life cycle are essentially identical between individual animals.  These 
findings, combined with the parasitemia curves allowed for highly reliable disease progression and 
subsequently a predictable if brief window in which the animals reached treatment criteria. 
 
3.6 Temperature versus parasitemia curves:  
Mapping the temperatures against the parasitemia curves across all experimental animals, 
there was a slight progressive increase in temperatures immediately preceding the initial parasitemia 
spikes, followed by a predictable, significant and pathological febrile event synchronous with the leap 
in parasitemia over the course of day 7 and day 8.  The initial temperature increases, while notable 
and allowing for prediction of the critical spike, were not significant due to the range of physiological 
temperatures noted in pre-experiment data collection and in control animals. 
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Graph 3.6.1 
 
 
Graph 3.6.2 
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Graph 3.6.3 
Graphs 3.6.1-3.6.3 represent the temperature graphed over time further overlain with the percent 
parasitemia in 3 of the animals from the refinement study.  These data were repeatable and 
predictable over the drug ranging study.   
 
As temperature measurements are far less labor intensive and do not require the specific skill 
set of microscopic malaria parasite life cycle staging, the use of temperature may represent adequate 
data collection to map out disease progression in this model, if staggered with parasitemia 
assessments.  If so, the requirement of collecting blood samples every other hour as was done in this 
study may be excessive.  Modern technology and telemetry allows for remote and constant 
temperature data collection and as such, subsequent studies could employ said technology in order 
to predict the parasitemia spike.  It is important to note that in this study we collected temperature 
readings both via manual rectal measurement as well as using a subcutaneous microchip.  The rectal 
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temperatures were far more reliable than the microchip readings, and therefore any future studies 
which choose to employ remote telemetry should first establish their core temperature algorithms 
and error margin if employing only the superficial temperature rather than a core reading.   
3.7 Hematological Parameters: 
 
Graph 3.7.1 Mean % Hematocrit and % Reticulocytosis versus % parasitemia from DA831, DA923 and 
R519.  While the mean hematocrit of animals in the acute refinement study remained relatively 
constant, the reticulocyte count resultant from the regenerative anemia and the upregulation of the 
bone marrow erythrocyte release demonstrated a steep increase which lagged slightly behind the 
spike in parasitemia after day 6.  
Early studies examining the pathophysiology of P. coatneyi in non-human primates noted that 
the parasite preferentially infects reticulocytes, a trait it shares with P. vivax.  (Coatney 1971) 
Additionally, comprehensive evaluation of the bone marrow regenerative response has been 
described by Moreno et al. (Moreno 2013).  In their study, which examined animals over a 30-day 
period during which they were treated with sub-curative anti-malarial artemether and allowed to 
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relapse.  Bone marrow dyseryrthropoeisis, characterized by nuclear lobulation and nuclear 
fragmentation (karyorrhexis) with concurrent erythroid hyperplasia was described using microscopic 
evaluation of core bone marrow biopsies sampled at various time points in the study.  Their results 
suggest that P. coatneyi-infected rhesus macaques develop severe anemia with concurrent 
coagulopathy, acute renal disease, as well as systemic metabolic dysfunction.  These findings are 
consistent with observations reported in humans with falciparum malaria. (Chang 2004; Dörmer 
1983; Planche 2005; von Siedlein 2012) Animals in the refinement study did not demonstrate 
significant anemia, however this is theorized to be due to the short duration of the study (8 days).  In 
the methylene blue drug dosing study, animals survived up to a maximum of 15 days post infection, 
and in spite of highly successful radical cure and clearance of the parasites using the drug, there was a 
progressive anemia observed in all animals with hematocrits dropping to a low of 12%. 
 
Graph 3.7.2 Mean White Blood Cell count versus % parasitemia from DA831, DA923 and R519.  A 
leukocytosis was observed in the experimental animals which essentially paralleled the spike in 
parasitemia. 
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The total white blood cell count shows an increase around day 6 to 7 which parallels the spike 
in parasitemia.  A large, unpublished study of normal blood values of Indian origin rhesus macaques 
within the AFRIMS colony demonstrated a range in resting total WBC count from 5000-10000 per 
microliter depending on a variety of physiological factors to include gender, age, experimental 
history, hierarchical status as well as concurrent disease and environmental stress.  Additionally, 
there are reports of normal blood value ranges in Chinese origin rhesus available. (Chen 2009) Within 
our study, the white blood cell count was observed to fluctuate over the course of the study, but to 
reliably decrease at the same point as the parasitemia began to spike, and then with approximately a 
12-hour lag, would increase from 2 to 3-fold and the resultant leukocytosis would remain through the 
end of the study.  In the methylene Blue drug ranging study, once the parasitemia began to drop, so 
too would the WBC count.  
 
Graph 3.7.3 Mean WBC differentiation over the course of the experiment from DA831, DA923 and 
R519.   
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During the peak leukocytosis, there was a concurrent increase in neutrophils while 
lymphocytes dropped. This circulating leukocytosis does not translate to an infiltration of affected 
tissues, with the exception of moderate numbers of neutrophils being observed within the 
sequestered microvasculature of the glomerular tufts. This leukogram mirrors that observed in 
malignant falciparum malaria with the exception of the monocytosis which is observed in a small 
percentage of severely affected human victims. (Clark 2003; Fransichetti 2008; Gupta 2015; McKenzie 
2005; Tobón-Castaño 2015) The most frequent finding in humans is actually a normal leukogram, 
with less than 20% of human patients having a leukopenia predominated by lymphopenia.  
Interestingly, in one study conducted in Colombia by Tobón-Castaño et al, the presence of a 
leukocytosis, predominated by neutrophils was associated with clinical complications.  (Tobón-
Castaño 2015) 
 
 
Graph 3.7.3 Mean platelets/microliter versus percent parasitemia from DA831, DA923 and R519. 
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While still having adequate numbers of thrombocytes, an initial decrease in the total number 
was observed in all animals. Thrombocytopenia is commonly described in human malaria infection in 
adults. (Hanson 2015) This finding likely would continue to increase and to accelerate, however 
euthanasia predates a significant thrombocytopenia in all experimental animals.  It is noteworthy to 
mention that in the histopathology review of both retrospective and prospective cohorts of 
experimental animals, that fibrin thrombi were not a significant finding except in a few exceptions. 
Furthermore, special staining using Masson’s trichrome did not highlight a primary thrombotic 
process.  
 
3.8 Renal and hepatic clinical chemistry: 
Clinical chemistry data supported the clinical symptomology of acute renal disease which was 
evident in the findings of oliguria, hematuria and dehydration, with hematuria being a common and 
early clinical sign of disease. The sporadic vomiting observed in some of the animals could be the 
result of a uremic syndrome, however as it is a relatively non-specific finding, it is not possible to 
draw a direct correlation and this is unlikely as blood urea nitrogen and the creatinine both increased 
subsequent to the parasitemia spike on day 7.  The increase in blood chemistry abnormalities lagged 
approximately 12 hours behind the increase in parasitemia.   Liver enzymes demonstrated a similar 
pattern of injury, with elevation of values occurring in a lagged pattern behind the parasitemia.  In the 
case of the hepatic enzymes, Aspartate aminotransferase (AST) showed an initial small increase which 
was essentially parallel to the parasitemia and temperature increases, while both Alkaline 
Phosphatase (ALP), and Alanine aminotransferase (ALT) increased approximately 18 hours behind the 
spike in parasitemia.  At that point, AST had a second and significant increase corresponding with the 
other two enzymes. 
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Graph 3.8.1. Mean BUN and CRE versus percent parasitemia from DA831, DA923 and R519. 
Date 
Taken 
Parasitemia % 
BUN mean mg/dl CRE mean mg/dl 
0 0.00 14.03 0.85 
0 0.00 12.97 0.88 
1 0.00 12.30 0.95 
1 0.00 10.43 0.84 
2 0.00 7.97 0.88 
2 0.00 8.53 0.87 
3 0.00 5.77 0.86 
3 0.18 7.73 0.82 
4 0.02 8.27 0.85 
4 0.03 8.03 0.83 
5 0.03 9.43 0.85 
5 4.00 7.67 0.89 
6 2.50 6.03 0.88 
6 0.84 6.60 0.90 
6 0.51 5.17 0.87 
7 0.52 6.33 1.01 
7 7.40 9.10 1.05 
7 32.50 10.40 1.03 
7 38.20 13.50 1.15 
8 21.20 24.90 8.76 
8 26.10 32.63 12.29 
 
Table 3.8.1. Mean BUN and CRE values versus percent parasitemia from DA831, DA923 and R519. 
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Graph 3.8.2. Median renal values (Blood Urea Nitrogen and Creatinine) from the 3 pilot animals 
measured over the course of infection. 
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Graph 3.8.3. Median Blood Urea Nitrogen values at peak infection from 3 experimental animals 
compared with pre-infection median baseline values. 
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Graph 3.8.4. Median creatinine values at peak infection from 3 experimental animals compared with 
pre-infection median baseline values. 
 
Median values of both creatinine and blood urea nitrogen were assessed at peak infection in the 3 
experimental animals from the pilot study.  These values were compared with median baseline values 
drawn from the same three animals prior to infection.  The Mann Whitney test was applied to assess 
non-parametric significance between baseline and peak values.  In both instances, the results were 
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observed to not be significant.  It is important to recognize the small sample size, and the fact that 
empirically, renal blood chemistry values, as well as the hepatic values described subsequently all 
demonstrate an observable and marked increase in value lagging behind the spike in parasitemia.  
Since these values demonstrate acute injury to the renal system (in the case of blood urea nitrogen 
and creatinine) and to the hepatic system (in the case of ALT, AST and ALP), the empirical increases 
observed as both median and mean values when compared with internal control baseline values 
demonstrates that there is a corollary pathological effect of P. coatneyi hyperparasitemia on the 
rhesus. 
 
 
Graph 3.8.5. Mean hepatic enzymes versus percent parasitemia from DA831, DA923 and R519. 
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Graph 3.8.6. Median hepatic values (ALT, AST, ALP) from the 3 pilot animals measured over the 
course of infection. 
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Graph 3.8.7. Median ALT values at peak infection from 3 experimental animals compared with (2) 
pre-infection median baseline values. 
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Graph 3.8.8. Median AST values at peak infection from 3 experimental animals compared with pre-
infection median baseline values. 
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Graph 3.8.9. Median ALP values at peak infection from 3 experimental animals compared with pre-
infection median baseline values. 
 
3.9 Electrolytes and Glucose:  
Sodium, potassium and chloride remained within normal limits throughout the study in all 
animals, with no demonstrably significant increases in the values. This argues against significant early 
acute tubular injury, as this is usually associated with hyperkalemia, although several animals in the 
terminal phase demonstrated marked abnormalities in renal chemistry just before euthanasia and 
death.  
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Graph 3.9.1. Mean electrolytes versus percent parasitemia from DA831, DA923 and R519. 
Date 
Taken 
 K 
mEq/l  
 Na 
mEq/l  
 Cl 
mEq/l  
0 3.21 141.4 103.7 
0 3.19 143.9 105.4 
1 3.61 132.2 105.1 
1 3.20 143.2 110.6 
2 4.34 143.0 111.2 
2 3.60 142.5 105.8 
3 3.81 143.0 107.3 
3 3.58 139.7 105.2 
4 3.69 146.5 110.1 
4 4.38 144.3 109.8 
5 3.07 144.8 108.9 
5 4.09 144.2 109.4 
6 3.83 143.3 108.7 
6 4.10 149.4 113.7 
6 4.12 142.9 108.7 
7 4.04 144.8 108.9 
7 3.98 143.1 109.3 
7 4.09 143.3 106.1 
7 3.93 141.1 106.4 
8 4.03 140.3 103.4 
8 16.50 138.0 98.4 
 
Table 3.9.1. Mean electrolyte values from DA831, DA923 and R519. 
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Hypoglycemia, which is a feature of severe malaria in humans, was not a significant finding in 
this P. coatneyi/Rhesus macaque model.  In four of the six animals assigned to the model refinement 
study, there was a marked decrease in glucose levels the day of either euthanasia or death, however 
the nine animals in the methylene blue study did not demonstrate any significant change in glucose 
levels throughout the course of the study.  The majority of the animals were both well-muscled and 
had significant adipose reserves to the point of being overweight in several cases.  This may account 
for their ability to resist the periods of anorexia and the severity of disease by being able to mobilize 
their fat reserves and maintain normoglycemic levels. 
3.10 Lactate: 
 
Graph 3.10.1. Mean lactate versus percent parasitemia from P. coatneyi infected pilot animals. 
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Graph 3.10.2. Median lactate values at peak infection from 3 experimental animals compared with 
pre-infection median baseline values. 
A spike in lactate measurements lagged behind the rise in parasitemia, however with relative 
consistency, increased just prior to death or euthanasia.  These findings were most significant in the 
prospective, untreated, experimental animals which were used in the model refinement portion of 
the study.  Interestingly, this finding did not occur in the methylene blue study.  In those nine animals, 
the blood lactate remained within normal limits in all animals throughout the course of the study.  
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Lactic acidosis is a recognized complication of severe malaria, and is one of the primary contributing 
strong acids in the acidosis observed in severe malaria. (Day 2000) The increased lactate to pyruvate 
ratio observed demonstrates that anaerobic glycolysis occurs as a result of microcirculatory 
hypoperfusion in tissues systemically in the patient.  In humans, as in the P. coatneyi/rhesus macaque 
model, sequestration of infected erythrocytes by means of cytoadherence, as well as the resultant 
margination of cells bound to the endothelium, rosette formation, autoagglutination, and endothelial 
cell injury likely further exacerbates the microcirculatory flow and likely induces regional hypoxia and 
with additional compromise, anoxia and ischemia. In severe malaria in humans, hyperlactatemia is 
often correlated with a poor prognosis, especially in children. (Agbenyega 2000; Casals-Pascual 2006; 
Ishioka 2016) As with analysis of renal and hepatic blood chemistry values, the median lactate at peak 
parasitemia in the pilot animals was not deemed to be statistically significant in comparison with 
baseline controls when assessed using the non-parametric Mann-Whitney test, however, empirical 
assessment of the lactate spike which is slightly delayed behind the marked increase in parasitemia is 
supportive of lactic acidosis in 2 of the 3 pilot animals. 
 
3.11 Retinal photography:  
Retinal photography was conducted in a select few animals and the resulting images were evaluated 
by a human ophthalmologist as well as a specialist in ocular toxicology in rhesus macaques.  While no 
definitive hypotheses can be drawn from the resulting interpretation, the findings do correlate with 
the absence of retinal hemorrhages noted on microscopic examination of the retinas taken from all of 
the prospective experimental animals.  Furthermore, the retinal edema which is described in one of 
the three animals appears to correlate with the edema observed histopathologically within the 
ganglion layer of the retina in multiple of the affected animals. 
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Number Fundus Features 
DA977 Left Normal disc. Marked NFL light reaction. Difficult to see beyond the reflection 
especially near vessels however no obvious changes 
Right Normal disc. Again, marked NFL light reflection.  No obvious lesions except 3 
pale focal lesions just temporal to the disc. 
R130 Left Optic disc enlarged and swollen. Papilloedema and some burying of vessels 
just superior to the disc.  Relatively discrete areas of perifoveal whitening. 
Thinning of the retina temporal to the fovea.  Temporal to fovea multiple 
small discrete pale lesions 
Right Optic disc appears swollen.  Irregular right foveal border. Multiple temporal 
discrete pale lesions. 
R338 Left Normal disc, Some generalised whitening along temporal arcade vessels.  
Single pale focal lesion at inferior temporal arcade 
Right Normal disc and retina, no additional comments 
R761 Left Normal disc and retina, no additional comments 
Right Mottled pigmentation of fovea and perifovea with discrete drusen like lesions. 
 
Table 3.11.1 Retinal photography findings. All samples were from P. coatneyi infected animals. 
Comparison was conducted between animals with normal findings versus those with evidence of 
injury. 
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Figure 3.10.1. 1,2: R761 Left eye, Normal; 3,4 R130 Right eye; 5,6 R130 Left eye. In comparison with 
the normal images at the top of the plate (1,2), in both the right and left eyes of R130 there is 
evidence of papilloedema which consists of a blurring of the disc margins.  This is typically seen as a 
passive swelling of the optic disc which is predominantly non-inflammatory in nature, rather is often 
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seen secondary to increased intracranial pressure (3,5).  Additionally, the images are illustrative of 
discrete areas of perifoveal whitening and thinning of the retina temporal to the fovea. (4,6)  
 
The retina can be a ‘window’ into pathology within the central nervous system, and detailed 
studies over the past 20 years have led to controversy surrounding how specific retinal changes are in 
reflecting malaria induced neuropathology. Indirect imaging studies of the brain in CM have proved 
useful in detailing the variable extent of cerebral edema, which in adults is not a uniform event in 
coma (Looaresuwan 1983; Looaresuwan 1995; Ponsford 2012), whilst in children the edema has been 
strongly linked to death in CM. (Seydal 2015) 
A spectrum of retinal findings has been reported in malaria, including vascular changes, 
hemorrhages, white patches related to ischemia, and cloudy exudates. (White 2001; Beare 2003; 
Beare 2006) While some reports have stated that retinal changes are so strongly linked to malaria 
that they are being used as a clinical diagnostic criterion for CM in some centers (Beare 2006; Milner 
2010), others have reported more variable findings in adult cases. (Abu-Sayeed 2011) Whether retinal 
changes happen in patients without coma, where neuropathology is less severe, is unclear, and the 
study of retinopathy in the simian model has not been reported prior to this preliminary examination.   
3.12 Gross findings: 
Autopsy findings described are combined post mortem descriptions from all 45 animals in the 
study, however these were segregated in terms of those animals who survived the initial insult and 
were thereby categorized as chronic in comparison with animals whose disease progression was 
deemed to be acute and in which animals either died spontaneously or were euthanized as a direct 
result of the P. coatneyi infection. 
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  Acute     Chronic   
  Findings Figures   Findings Figures 
Brain: Cerebrum 
Rare, multifocal parenchymal 
hemorrhages and congestion √   NSL   
Brain: Cerebellum 
Rare, multifocal parenchymal 
hemorrhages     NSL   
Brain: Brain stem 
Rare, multifocal parenchymal 
hemorrhages and congestion √   NSL   
Spinal cord 
Rare, multifocal parenchymal 
hemorrhages and congestion     NSL   
Meninges 
Congestion and edema and 
rare petechiae     NSL   
Eyes NSL     NSL   
Integument 
Erythema with multifocal 
petechiae and ecchymoses √   
Dermatitis, necroulcerative, 
multifocal to coalescing, severe   
Lungs 
Mild to marked brown 
discoloration √   NSL   
Heart 
Mild to marked brown 
discoloration with multifocal 
white myocardial streaks and 
rare petechiae and 
ecchymoses.  Cardiac 
dilatation. √   NSL   
Liver 
Friable hepatomegaly with 
moderate to severe brown 
discoloration with sinusoidal 
congestion √   
Diffuse lobular, zonal pallor and 
necrosis and hepatomegaly √ 
Gallbladder Choleostasis √   NSL   
Spleen 
Splenomegaly with severe 
brown discoloration     Brown discoloration   
Kidneys 
Moderate to severe brown 
discoloration with congestion √   
Mild capsular nodularity and 
diffusely shrunken and severely 
pale √ 
Pancreas Congestion and edema     NSL   
Adrenal glands Moderate congestion     NSL   
UB 
Moderate to severe hematuria 
with mucosal hemorrhage √   NSL   
Reproductive tract 
Scrotal and testicular infarction 
with hemorrhage     NSL   
Gastrointestinal  
Multifocal to coalescing, 
serosal erythema and mucosal 
hemorrhagic erosive and 
ulcerative enteritis √   NSL   
Muscle NSL     NSL   
Lymph nodes Draining hemorrhage     NSL   
Thorax Mediastinal edema     NSL   
Abdominal cavity 
Hemoperitoneum and 
mesenteric edema √   
Peritoneal adhesions and serous 
atrophy of mesenteric adipose   
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Table 3.12.1: Consolidated macroscopic findings from all experimental animals. 
The main overall findings in all acute cases are associated with hemozoin deposition in 
tissues.  This presents as a dark brown discoloration of the parenchymal organs.  Liver, heart, lungs, 
kidneys and spleen, when available, all were severely darkened by the presence of the malaria 
pigment.  Additionally, there was enlargement of multiple organs with the liver being the primary 
organ demonstrating megaly. 
Organ specific changes included congestion, rare hemorrhage and edema within multiple 
sections of the central nervous system, both parenchymal and within the meninges.  Integumentary 
pathology included varying degrees of hemorrhage, as evidenced either by erythema or progressing 
to petechiae and ecchymoses.  The lungs were frequently dark brown and congested.  In rare cases, 
there was consolidation of the interstitum and alveolar collapse, however it was difficult to separate 
post mortem changes from true malaria induced macroscopic pathology.  The heart often 
demonstrated a spectrum of brown discoloration with multifocal white myocardial streaks and rare 
epicardial petechiae and ecchymoses.  In many cases a flaccid cardiac dilatation was observed within 
the ventricles. The liver was often noted to be markedly enlarged with rounded edges 
(hepatomegaly) and was observed to be friable.  Furthermore, there was moderate to severe brown 
discoloration and marked sinusoidal congestion.  In cases in which the animal survived beyond the 
initial acute phase of infection, the liver eventually became very pale, while remaining enlarged.  In 
those instances, the pallor was likely the result of a combination of lipidosis, glycogenosis and zonal 
coagulative necrosis, patterns of which were subsequently confirmed on histopathology. The 
gallbladder was often markedly expanded and congested, consistent with cholestasis.  Additionally, 
when the spleen was available, either in spleen intact animals or thanks to the presence of a daughter 
spleen or splenunculum, the organ was markedly enlarged with bulging edges on cut section and was 
noted to be very dark.  The kidneys were slightly enlarged and dark in the early stages of infection, 
consistent with severe congestion, resulting in a loss of differentiation between the cortex and the 
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medulla.  Rarely there was superficial cortical pitting.  With a degree of chronicity, the kidneys 
became pale and either remained swollen or became shrunken and nodular with a loss of the smooth 
superficial surface observed in normal kidneys. The urinary bladder was frequently full of 
hemorrhagic urine, while the urinary bladder mucosa was often markedly hemorrhagic and 
edematous.  The endocrine organs observed, primarily the adrenal glands and pancreas were noted 
to be congested and occasionally edematous.  In two animals, notably those with scrotal ecchymoses, 
the testicles often had large areas of acute infarction and had regions which were markedly 
hemorrhagic. No changes were noted within the uterus or ovaries of the select few female animals 
included in the study.  
All levels of the gastrointestinal tract serosa frequently contained petechiae and ecchymoses 
while the mucosa was often hemorrhagic and either eroded or ulcerated. The lymph nodes were 
expanded and dark, resultant from severe draining hemorrhage from multiple organ systems. This 
was most notable within the mesenteric lymph nodes. Finally, multiple animals were observed to 
have a combination of pericardial, thoracic and peritoneal accumulation of serosanguinous fluid. 
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Figures 3.12.1-3. Fig 1. Rhesus macaque, brain. This photograph demonstrates the mildly discolored 
brain with significant congestion of the superficial vasculature.  Note the lack of appreciable cerebral 
edema. Figure 2. Rhesus macaque, brain. This photograph shows marked hemorrhage within the 
brain stem and the covering meninges. Figure 3.  Rhesus macaque, lungs.  The lungs in this images are 
severely congested and overall the parenchyma of the lungs is markedly darkened. 
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Figures 3.12.4-6. Figure 4. Rhesus macaque, heart. Multifocally within the epicardium of the atrium 
and the ventricle there is evidence of petechiae and coalescing ecchymoses. Figure 5. Rhesus 
macaque, heart.  Multifocally the epicardium contains streams of white which extend beyond the 
pericardial adipose and into the myocardium. These are interpreted as early signs of necrosis. Figure 
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6. Rhesus macaque, thorax and abdomen. The lungs and liver in this photograph are severely 
discolored, congested and enlarged. 
 
Figures 3.12.7-9. Figure 7. Rhesus macaque, liver. This photograph is representative of the lobular 
accentuation within the discolored liver secondary to the hepatocellular damage and to the hemozoin 
pigment accumulation. Additionally, the gallbladder is markedly enlarged, suggestive of cholestasis.  
Figure 8. Rhesus macaque, liver. This photograph contrasts the acute presentation with that observed 
with chronicity.  In this image, the severely enlarged liver is swollen and pale, suggestive of hepatic 
lipidosis or zonal necrosis.  Additionally, the liver has foci of hemorrhage.  When correlated with 
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microscopy, these macroscopic findings are consistent with a diffuse hepatocellular glycogenosis, 
regional lipidosis and centrilobular coagulative necrosis. Figure 9. Rhesus macaque, thorax and 
abdomen.  The liver is enlarged and has a brown discoloration. The abdomen contains abundant 
serosanguinous fluid. Furthermore, the image is demonstrative of the consolidation and pigment 
accumulation which is observed in the lungs.   
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Figures 3.12.10-13. Figure 10. Rhesus macaque, stomach. Multifocally to coalescing, the gastric serosa 
has streaks of ecchymotic hemorrhage.  Figure 11. Rhesus macaque, stomach. The hemorrhage is 
frequently observed within the mucosa of affected animals, and overlies areas of erosion and rarely, 
ulceration. Figure 12. Rhesus macaque, stomach.  This section of stomach contains multifocal to 
coalescing necroerosive lesions within the gastric mucosa, overlain with hemorrhage. Inset: Increased 
magnification of a focus of erosion and hemorrhage within the mucosa. Figure 13. Rhesus macaque, 
small intestine.  Diffusely, the intestinal mucosa is overlain by a layer of mucoid hemorrhage. The 
mucosa itself is severely erythematous and hemorrhagic. 
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Figures 3.12.14-16. Figure 14. Rhesus macaque, kidney.  This photograph is demonstrative of the 
severe discoloration observed secondary to hemozoin pigment accumulation within the kidneys.  This 
figure shows a severe highlighting of the medulla by the dark pigment.  Figure 15. Rhesus macaque, 
kidney.  This image shows a diffuse discoloration which makes distinction of the cortex and the 
medulla difficult.  Figure 16. Rhesus macaque, urinary bladder. This photograph shows the severe 
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mucosal hemorrhage frequently noted within the urinary bladder.  The small amount of urine found 
within the bladder in this image is blood tinged. 
 
Figure 3.12.17-18. Figure 17 and Figure 18. Rhesus macaque, kidney. These photographs are from 
animals which survived the initial phase of infection, and are considered to have a chronic form of 
disease within the kidneys.  This manifests grossly as marked pallor of the cortex which is 
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representative of the loss of parenchyma, interstitial fibrosis and other microscopic aspects of chronic 
renal injury. 
 
Figure 3.12.19-20.  Figure 19. Rhesus macaque.  Frequently those animals euthanized during the 
acute stage of injury with fulminant and high parasitemias demonstrated cutaneous petechiae and 
ecchymosis.  Figure 20. Rhesus macaque.  In one case, consistent with another published in the 
literature (Moreno 2007), the animal developed gangrenous necrosis of the distal digits as well as the 
upper lip and nasal meatus.  The necrosis is theorized to be secondary to the sequestration of the 
superficial vasculature by infected erythrocytes, causing anoxia, ischemia and necrosis. 
 
3.13 Discussion: 
While the model proved to be labor intensive, the effort associated with the increased 
sampling and the close observation of the animals allowed for significant reproducibility both within 
the experimental animals used in the refinement phase of the study as with the eventual application 
of the model as a platform for the evaluation of methylene blue as an anti-malarial compound in 
cases of severe malaria.  In all cases, parasitemia, temperatures, clinical symptomology were 
consistent and reproducible, suggesting that there was a high degree of homogeneity in the model, in 
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spite of variation in the signalment of the monkeys.  Parasitemias were observed to reach extremely 
high levels of up to 50%.  In human disease reports of hyperparasitemia of >20-30% are frequently 
associated with very severe disease and even death.  The parasitemia and temperature curves when 
combined with the clinical pathology, hematology and clinical symptomology allow for a significant 
degree of predictability.  As such, the potential future application of the model would include a 
window for therapeutic intervention at an earlier stage in the parasitemia spike noted on day 7, 
however it is important to note that the sampling frequency is crucial in order to capture the parasite 
increase and to be able to intervene.   
The clinical pathology and hematology described in these experiments both demonstrate 
certain important similarities to severe human disease.  This is particularly notable in regards to the 
acute hepatic and renal injury as well as some of the hematological changes such as the 
thrombocytopenia, metabolic disturbances and associated hyperlactatemia.  (Carvalho 2014; 
Barsoum 2000; Taylor 2006; Trampuz 2003; WHO 2014) In humans, the primary complications 
associated with severe malaria include variations of cerebral malaria, acute renal failure, pulmonary 
edema, severe anemia, hepatic dysfunction and coagulopathies or bleeding disorders. The most 
common metabolic abnormalities include acidosis (hyperlactatemia) and hypoglycemia. (Trampuz 
2003; WHO 2014) 
With particular focus on thrombocytopenia, and as described in chapter 1, frank DIC is rare in 
adult severe malaria but does occur, and is generally a poor prognostic sign. This appears to either be 
an area of diversion from falciparum induced disease in pediatric cases, where coagulopathies are 
relatively well described (Ghosh 2008; Grau 2003; Milner 2014) and disturbances in hemostatic 
mechanisms have been linked to tissue pathogenesis (O’Sullivan 2016), such as the collection of 
platelets in cerebral microvessels, although this appears to be increased in HIV-coinfected pediatric 
cases in Africa. (Hochman 2015) It is possible in this splenectomized model that any coagulopathy 
driven pathogenesis would occur at a lower parasitemia with increased longevity of the experimental 
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animals, however without conducting coagulopathy studies, our ability to discuss the role of the 
coagulation pathway in the pathology of this model is limited.  
This hypothesis bears consideration in that the animals which did have evidence of 
microthrombotic disease or even histopathological and gross evidence suggestive of Disseminated 
Intravascular Coagulopathy (DIC) appeared to have lower parasitemia counts and to survive the initial 
insult. In humans, DIC leading to peripheral gangrenous necrosis, while infrequent, is a well reported 
phenomenon. (Francischetti 2008; Ghosh 2008; Grau 2003; Helbok 2008; Kataki 2004; Lerolle 2007; 
Liechti 2003; Musoke 2014; Tessier-Marteau 2009; Thanachartwet 2006) As described in Chapter 1, in 
experimental cases of P. coatneyi infection in Rhesus macaques, DIC with gangrene has also been 
reported (Moreno 2007) and is subsequently illustrated from unpublished data from this study 
(Figure 3.11.20) in which one of the retrospective animals was treated and survived beyond the first 
week of infection.  In that particular animal, although the peak parasitemia was very high, it was 
treated with a combination of Artesunate and Quinine and survived almost a month from the initial 
infection date. In general, the experimental animals decompensate rapidly due to the elevated 
parasitemia and without radical cure, typically did not survive long enough to demonstrate platelet 
associated pathology.  In the methylene blue drug dosing study, the animals did become moderately 
thrombocytopenic (±150,000 platelets/µl) by day 9-10, however those animals that were maintained 
beyond that low point were noted to undergo a significant rebound by the end of the study. 
Similarly, while only occurring in a segment of the affected human population, the acute 
tubular necrosis, interstitial nephritis and glomerulonephrosis described from histopathology of 
kidney samples from humans suffering from severe malaria are consistent with our findings in 
macaques. (Das 2008)  
The renal malaria syndrome observed primarily in African children consists of the chronic and 
progressive glomerulopathy which is a crucial factor in therapy and recovery.  Acute renal failure 
observed with P. falciparum in Southeast and South Asia as well as in sub-Saharan Africa is associated 
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with less than 5 percent of the victims of malaria in endemic areas while up to 30% of naïve travelers 
who become infected present with acute renal failure. (Barsoum 2000; WHO 2014) 
Critical differences between human disease and severe P. coatneyi infection in 
splenectomized rhesus macaques include the absence of clinical coma, glucose levels and the lack of 
severe pulmonary symptoms.  Reports of traditional coma in macaques, consistent with the WHO 
criteria in humans, are vanishingly rare in the literature.  A single case report of coma is described in 
association with experimental pancreatectomy and subsequent diabetic acidosis. (Mirsky 1941) 
Macaques in this study became so severely lethargic and displayed such a degree of decreased 
mentation as to come relatively close to the clinical diagnosis, however in keeping with a strict 
diagnosis, the animals did not meet the WHO criteria of malaria induced unarousable coma.  A 
corollary negative finding included the fact that the macaques did not become hypoglycemic during 
the course of the infection in spite of severe clinical symptoms.  Potentially the stress of severe acute 
infection in animals with adequate energy reserves compensates for the traditional hypoglycemia 
observed in humans. (Dungan 2009; Marik 2013)   Furthermore, case reports describing abnormal 
presentations of malaria abound in the literature, to include instances of hyperglycemia. (Chianura 
2012; Singh 2014; Trombe 1993; Zaki 2011) In fact, a large retrospective study of children in Kenya 
noted that almost 50% of children diagnosed with hyperglycemia had concurrent malaria infections. 
(Osier 2003)  
Pulmonary edema is described as a significant factor in severe malaria in humans infected 
with P. falciparum, while in no case was it an important finding in any of the infected macaques 
participant in this study.  Pulmonary edema in humans can occur at any point of the acute stages of 
infection, however it is reported to happen with much greater frequency later in infection and 
secondary to other manifestation of disease. The pathogenesis of pulmonary manifestations of 
falciparum induced disease includes increased pulmonary venous pressure secondary to venous and 
lymphatic obstruction by sequestration of infected RBCs, increased alveolar capillary permeability 
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followed by intravascular fluid loss, and associated hypoalbuminemia, resulting in alveolar effusion. 
(Sirivichayakul 2000; Taylor 2006; WHO 2014) It is possible that the progression of illness in the 
macaques in this study was too acute to permit pulmonary edema to develop, or that there may be 
an anatomo-physiological difference in the susceptibility of the pulmonary endothelium between 
humans and macaques in response to malaria. 
The retinoscopic images described in this chapter are purely illustrative and as control images 
were not taken prior to infection with P. coatneyi in these animals, there is no mechanism to infer a 
correlation of lesions observed with the pathogenesis of P. coatneyi induced disease.  However, this 
highlights the fact that the technology employed in human diagnostics can be used effectively in this 
model, to describe the potential ocular pathology in the P. coatneyi/rhesus macaque model. The 
incidence and clinical significance of retinopathy varies between adult and pediatric cerebral malaria 
(Maude 2009), and some groups now require retinopathy to a clinical diagnosis of cerebral malaria in 
pediatric African cases. (Beare 2011) The findings of some changes without marked clinical 
symptomatology of coma imply that retinopathy in severe malaria infection is not restricted to severe 
cerebral disease, so interpretation of retinal changes as a ‘mirror’ onto underlying CNS pathology 
should be further investigated.  
A fundamental question raised by this section and of significant comparative importance is in 
understanding what the ultimate cause of death was in the experimental animals in this study.  
Putting aside the fact that the majority of the animals in the study were euthanized, the severe 
morbidity in all cases combined with the clinical pathology and hematology findings suggests that 
metabolic acidosis and resultant shock were the main contributing factors leading towards death.  
Metabolic acidosis is described as a primary feature in the pathogenesis of severe malaria induced 
disease and is felt to be the most reliable indicator of mortality in humans. (Maitland 2004; Maitland 
2005) The pathophysiology of metabolic acidosis is multifaceted in any disease and equally so in 
severe malaria. Most likely, the absence of pulmonary compromise in these animals does not exclude 
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the microscopic hypoxic and anoxic damage caused by the microvascular circulatory disruption by the 
profound cytoadherence of infected erythrocytes, auto agglutination and rosette formation. 
Subsequently, the hypoxia induced shift within the injured cells toward anaerobic metabolism, with 
resultant oxidation and lactic acid production may result in the observed metabolic acidosis and 
progression towards multi-organ failure and death. (English 1997; Maitland 2004; Planche 2005; 
Planche 2006; Sasi 2007) While at this stage, specific determinants of death in the animals evaluated 
in both the retrospective and prospective cohorts of this thesis remain unknown, we theorize that the 
complex interaction with the physical modifications of the infected erythrocytes, the extraordinarily 
high parasitism, the interactions between parasitized RBCs and both normal RBCs and the 
microvascular endothelium, resultant vascular damage and leakage, evidence of microscopic cerebral 
edema, renal, hepatic and cardiac cellular damage, multi-organ hemorrhage, metabolic disturbances, 
severe pyrexia and inflammatory mediators combine and contribute to fatal outcome. 
 
3.14 Summary: 
Evaluation of both those ante-mortem findings in retrospective studies which employed the P. 
coatneyi/rhesus macaque model as well as close monitoring and data collection in the 15 prospective 
animals allowed for a strong comparison and contrasting of the clinical pathology, parasitemia 
dynamics and macroscopic autopsy findings with those described in falciparum induced disease in 
humans.  Our findings demonstrated a consistently reproducible hyperparasitemia spiking on day 7, 
correlating with a consistent 48-hour parasite maturation cycle.  Additionally, we have established 
that splenectomized animals infected with P. coatneyi undergo a significant febrile spike (up to >106° 
F) concordant with the observed hyperparasitemia.  Affected animals develop respiratory signs of 
dyspnea as well as urological pathology as observed with unfailing hematuria combined with anuria 
or stranguria. All animals became severely anorexic, occasionally with evidence of vomiting and 
diarrhea.  The effects on the cardiovascular system suggest development of coagulopathy and 
multifocal hemorrhage.  Neurologically, all infected animals develop severely depressed mentation, 
186 
 
with markedly suppressed menace response and withdrawl.  However, and crucially, there was no 
evidence of either fitting or coma which are deemed to be defining characteristics of human disease.  
Clinical pathologic findings included reticulocytosis with no statistically significant anemia (within the 
experimental timeframe), a leukocytosis consisting of a primary mononuclear cell increase.  Renal 
insult was a consistent finding in this model, with BUN and creatinine increases lagging the 
parasitemia spike.  Similar findings occurred within the liver, with hepatic insult resulting in ALT, AST, 
and Alk Phos increases which lagged behind the parasitemia spike.  Of note, hyperlactatemia also 
occurred consistently, but also appeared to lag after the parasitemia spike.  No significant electrolyte 
abnormalities were observed in any of the infected animals.  Similarly, and discordant with human 
disease, there was a notable absence of hypoglycemia and only mild thrombocytopenia observed 
(within the experimental timeframe).  Finally, in all cases, onset of fatal multiorgan failure occurred 
by day 8, resulting in either natural death or animals reaching euthanasia criteria.  On autopsy, 
severely affected animal developed cutaneous erythema; petechiae and ecchymoses, multiorgan 
hyperpigmentation (interpreted to be deposition of malaria pigment). Hepatomegaly and 
renomegaly, multi-organ hemorrhaging with rare thrombosis and rare gangrenous necrosis were 
noted.  These ante-mortem and autopsy findings in the rhesus macaque display areas which strongly 
correlate with human syndromology, such as those observed in terms of metabolic acidosis, as well as 
the hepatic and renal pathology.  Severe anemia and thrombocytopenia have both been 
demonstrated in other studies using this animal-parasite combination and the fact that these were 
not significant factors in the pathology observed in this series of experiments is likely related to the 
curtailed experimental timeframe rather than a real absence. Finally, while the neurologic disease in 
the rhesus is profound, the lack of fitting and coma development is a crucial divergence as are the 
absences of pulmonary injury, hypoglycemia and retinal changes.   
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Chapter 4: Cytological and Histopathology 
4.1 Introduction: 
Since the seminal work of Marchiafava and Bignami in the 1880s, numerous significant 
studies have been conducted using histopathological evaluation of autopsy specimens from fatal 
human cases of P. falciparum induced malaria. (Carlson 1993; Burel 2008; Brown HC 2000; Deaderick 
1909; Dorovini-Zis 2011; Dudgeon 1917; Dudgeon 1919; Harnagel 1954; Kean 1944; Kirchgatter 2005; 
Medana 2002; Menezes 2012; Milner 2013; Milner 2014; Nagatake 1992; Olsson 1969; Patel 2003; 
Saya 2012; Spitz 1946; Taylor 2004; Taylor 2012; Toro 1978; White 2001; Wilairatawa 2000) These 
have allowed for generalizations to be made as to the spectrum of pathology within various organ 
systems in patients dying of falciparum malaria.  There are obvious difficulties with such grouped 
categorization as a wide range of complicating factors must be taken into account.  Among these are 
variability in the immune status and demographics of the subjects, to include the genetic profile of 
the infected individual, geographic location, pathogenicity and density of the infecting parasite, stage 
of disease at onset of any therapy, treatment modalities, time to death and co-morbidities to name a 
few.  In essence, the heterogeneity of the parasite and host populations, treatment effects and the 
varying clinical syndromes of severe and fatal disease all translate to a range of histopathological 
presentations at autopsy.   
 Human falciparum malaria presents in a variety of syndromes which have been classified by 
World Health Organization (WHO 2014) and include cerebral malaria (CM) and associated 
retinopathy, severe malaria anemia, metabolic derangement with acidosis, shock, acute kidney injury, 
lung involvement progressing to acute respiratory distress syndrome, disseminated intravascular 
coagulopathy (DIC) as well as cardiac and hepatic disease. In order to better understand the 
pathophysiology of these complications, a number of murine and simian models of severe malaria 
have been developed.   
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P. coatneyi is one of the parasites that is considered to be an effective correlate to P. 
falciparum and, when infected into the rhesus macaque and similar non-human primates, presents 
with a parasite periodicity and clinical presentation similar to that observed in human falciparum 
malaria. The model is not perfect in that there are important features of human falciparum malaria 
which are absent. For instance, while affected animals may have severely depressed mentation, 
lethargy and decreased menace response, there is no antemortem neurological syndrome analogous 
to the coma of human cerebral malaria.  In spite of this, the model has been used for 
pathophysiological investigation of CM (Aikawa 1992; Kawai 1993; Lombardini 2015), renal pathology 
(Lombardini 2014) and anemia (Moreno 2013). Despite this, to date there has been no 
comprehensive and systematic survey of the histopathological changes in macaques infected with P. 
coatneyi, beyond small studies with limited numbers of animals from heterogeneous backgrounds 
and which only evaluated specific target tissues such as the brain, heart or placenta. (Davison 2000; 
Desowitz 1967; Desowitz 1969; Desowitz & Pavanand 1967; Nagatake 1992; Nakano 1996; Sein 1993; 
Smith 1996) 
 As described, this study reviewed the histopathological findings in a large group (n=45, 30 
retrospective and 15 prospective) of autopsy cases of P. coatneyi infection causing severe malaria in 
Rhesus macaques (predominantly splenectomized) compared to several spleen-intact animals and 15 
non malaria-infected control animals. The histopathological and ultrastructural morphological 
features of severe and fatal infection were examined and correlated with the clinical features.   
 
4.2 Clinical and clinicopathology findings: 
Following blood-stage infection the typical course of disease typically presented with a blood 
stage parasitemia appearing within 2 days, reaching peak of a maximum of 54.6% with severe disease 
typically at 6-10 days and death/euthanasia generally around 7-12 days post infection depending on 
the severity of the parasitemia. In synchrony with the periodicity of the parasites’ development and 
with associated schizogony, animals within the prospective cohorts had increasing temperatures 
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which peaked on average by day 7 at 105-106° Fahrenheit, assessed both by peripheral subcutaneous 
microchip telemetry as well as rectally.   
As described in Chapter 3, animals became anorexic and lethargic with markedly decreased 
mentation without achieving the criteria of complete non-responsiveness seen in those human 
patients who develop the coma of cerebral malaria. (Brewster 1990; Clark 2009; Idro 2005; Taylor 
2004; WHO 2014) Between days 5 and 7 post infection, all animals developed hematuria and in cases 
with significant parasitemia, defined as prolonged parasitemias greater than 15%, periods of anuria 
developed.  A smaller percentage of animals had episodes of vomiting or diarrhea.  Animals with a 
significant level of parasitemia displayed mild progressive anemia with reticulocytosis, mild 
leukocytosis and thrombocytopenia, biochemical evidence of acute renal failure, and hepatic injury 
which lagged behind clinical signs of hematuria by 24-48 hours. Metabolic acidosis was also seen in 
the majority of the cases with high parasitemias. 
 
4.3 Macroscopic findings at autopsy: 
In general terms, the most significant findings at autopsy included vascular congestion in all 
organs, hepatomegaly with brown discoloration, renomegaly with brown discoloration, brown 
discoloration of the lungs, a small amount of multifocal white streaking within the epicardium and 
myocardium interpreted as necrosis, adrenal gland congestion, cerebellar brown discoloration and 
vascular congestion, and rare hemorrhages within the brain stem and spinal cord.  There was rare 
thrombosis and necrosis within multiple organ system, and soft tissue necrosis most notably within 
the scrotum and testes in several animals.  In one animal from a retrospective study which survived 
the initial insult and progressed into a chronic infection phase, disseminated intravascular 
coagulopathy (DIC) developed and led to severe peripheral gangrenous necrosis occurring in the 
digits, nasal planum and upper lip. 
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4.4 Histopathological findings: 
The spectrum of tissues available for review was constrained by which tissues were collected 
in retrospective studies.  In all animals, cerebrum, cerebellum, brain stem, liver, kidneys, heart and 
lungs were available, while in only some animals were specimens of adrenal and pituitary glands, 
pancreas, gastrointestinal system, skeletal muscle, eyes, lymph nodes, urinary bladder and 
reproductive tract available.  In contrast, all tissues were collected and evaluated in the prospective 
study, including multiple areas of the brain and spinal cord samples which were not available from 
any retrospective study. In three animals splenunculi were identified and evaluated. In all cases, the 
tissue pathology was evaluated in comparison to archival tissue from normal control rhesus 
macaques, with attention paid to changes which may represent normal aging or background 
variation. (Chamanza 2012) A qualitative and for some features a semi-quantitative assessment of 
histopathological changes was conducted in all available tissues and the results from select key 
tissues are summarised in Table 1.      
Throughout all tissues, there was significant microvascular sludging with parasitized 
erythrocytes and hemozoin pigment, which appeared to be causing microvascular obstruction, due to 
an increased congested appearance to many vessels (represented by increased microvascular caliber 
within a section) and increased numbers of vessels seen in a section, implying opening of collateral 
vessels.  Sequestration is typically interpreted via ultrastructural analysis and is the result of 
cytoadherance of infected erythrocytes (iRBC) to other infected red cells, uninfected erythrocytes 
(rosette formation) or to the vascular endothelium (margination), all of which were observed using 
transmission electron microscopy. This binding, mediated by specific molecular adhesion through 
parasite encoded adhesins expressed at electron dense membrane knobs on the iRBC surface, results 
in the formation of rosettes (with uninfected RBC) or autoagglutinates (with other iRBC and platelets) 
which can contribute to occlusion of small caliber vessels (Figure 4.1.1-4.1.4).  
In addition to this apparent disruption of vascular flow, there was light microscopic evidence 
of infected erythrocytes containing either late ring stage, trophozoites and schizonts stage parasites.  
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In the case of later stage parasites, food vacuoles containing brown - gold crystalline hemozoin 
pigment were clearly seen even at low magnification. 
 
 
Accession #
Acute/ 
Chronic
Peak 
parasitemia 
recorded
Spleen/ 
Splenunculum 
Y/N
General 
sequestration 
severity
CNS hemorrhage 
severity and 
location
CNS 
edema 
severity
Cerebellum 
Purkinje 
damage 
severity
Axonal/ 
neuronal injury 
severity and 
location
Renal 
Injury 
severity
Renal histopath 
findings
Cellular/ 
Hemoglobin 
casts
Hepatic 
injury 
severity 
Hepatic histopath 
findings
Cardiac 
injury 
severity
Cardiac histopath 
findings
Fibrin 
thrombi 
Y/N
Mural 
vascular 
necrosis 
Y/N
13-106 A 13.60% N 5 3; spinal cord 3 1
3/2; cerebrum/ 
spinal cord 2
H GN; epithelial 
D/N Y/Y 2
Hepatocellular 
individualization; 
vacuolar 
degeneration 2
Cardiomyocyte 
vacuolar D/N Y N
13-107 A 10.50% N 5 3; spinal cord 3 3 3; spinal cord 2
H GN; epithelial 
D/N Y/Y 2
Hepatocellular 
individualization; 
LP/N portal 
hepatitis 2
Cardiomyocyte 
vacuolar D/N Y Y
13-108 A 7.50% N 5 3; spinal cord 3 1
2; cerebrum, 
spinal cord 2
LP GN; 
synechiae; 
epithelial D/N Y/Y 3
Hepatocellular 
individualization; 
vacuolar 
degeneration 2
Cardiomyocyte 
vacuolar D/N Y N
14-198 A 34.80% N 5
2; brain stem/ 
cerebrum 3 3
2/1; cerebrum/ 
spinal cord, 
brain stem 3
Synechiae; 
epithelial D/N Y/Y 3
Hepatocellular 
individualization; 
vacuolar D/N 2 Cardiomyocyte D/N N N
14-199 A 39.20% N 5
1; spinal cord, 
cerebrum 3 3
2/1; cerebrum/ 
spinal cord, 
brain stem 3
Synechiae; 
epithelial D/N Y/Y 3
Hepatocellular 
individualization; 
vacuolar D/N 2 Cardiomyocyte D/N N N
14-200 A 34.20% Y (DS) 5 2; spinal cord 3 2
2/1; cerebrum/ 
spinal cord, 
brain stem 2
LP GN; 
synechiae; 
epithelial D/N Y/Y 3
Hepatocellular 
individualization; 
vacuolar D/N 2 Cardiomyocyte D/N Y N
15-264 A 16.90% N 0
3/2; brain stem/ 
spinal cord 2 3
3/2; cerebrum/ 
spinal cord 2
LP IN; 
synechiae; 
epithelial D/N Y/Y 3
Coag. N; 
hepatocellular 
individualization 1 Cardiomyocyte D/N N N
15-265 A 24.50% N 0 0 3 3
3/2; cerebrum, 
brain stem/ 
spinal cord 4
N/H and LP 
tubulitis/ IN; 
synechiae; 
epithelial D/N Y/Y 4
Sinusoidal H; 
hepatocellular 
D/N 3 Cardiomyocyte D/N N N
15-266 A 25.40% N 0 0 1 1
1; cerebrum; 
brain stem 3
LP IN; 
synechiae; 
epithelial D/R Y/Y 2
Focal N; 
hepatocellular 
D/N 1 Cardiomyocyte D/N N N
15-271 A 42.50% N 0
3/2; spinal cord/ 
brain stem 1 1 3; spinal cord 5
N/LP tubulitis/ 
nephritis; 
epithelial D/N Y/N 2
Sinusoidal H; 
hepatocellular 
D/N 1 Cardiomyocyte D/N Y Y
15-272 A 40.80% N 0 1; spinal cord 2 1
1; cerebrum; 
brain stem 5
N/LP tubulitis/ 
nephritis; 
epithelial D/N Y/N 2
Sinusoidal H; 
hepatocellular 
D/N; vasculitis 1 Cardiomyocyte D/N Y Y
15-273 A 38.30% N 0 0 2 0 2; cerebrum 5
N/LP tubulitis/ 
nephritis; 
epithelial D/N Y/N 2
Hepatocellular 
vacuolar D/N 3 Cardiomyocyte D/N N N
15-274 A 42.80% N 0 0 3 3
3/2; cerebrum/ 
spinal cord 4
N tubulitis; 
H/LP IN; 
synchiae; 
epithelial D/N Y/Y 4
Hepatocellular 
individualization; 
vacuolar D/N; 
LP/N portal 
hepatitis 3 Cardiomyocyte D/N N N
15-275 A 45.20% N 0 0 2 1
2/1; spinal cord/ 
cerebrum 3
LP IN; epithelial 
D/N Y/Y 2
Coag. N; 
hepatocellular 
individualization; 
H/LP hepatitis 3 Cardiomyocyte D/N Y Y
15-276 A 42.60% Y (DS) 0 1; spinal cord 2 1
1; cerebrum, 
brain stem 5
N/LP tubulitis/ 
nephritis; 
epithelial D/N Y/Y 3
Coag. N; 
hepatocellular; 
H/LP hepatitis 2 Cardiomyocyte D/N Y N
90-239 A
257,000/ 
cumm Y 3 0 0 0 2; cerebrum 1 LP IN Y/N NA
Coag. N; (prior 
pathology report, 
no tissue 
available for 
eval.) NA NA N N
90-261 A
465,120/ 
cumm Y 2 (spleen 4) 0 0 0 2; cerebrum 1 LP IN Y/N 2
Hepatocellular 
vacuolar D/N; LP 
hepatitis 0 NA N N
92-523 A 10.50% Unknown 3 0 3 0 0 0 NA N/N 0 NA 0 NA N N
92-525 A 30.01% N 5 0 2 NA 1; cerebrum 4 Epithelial D/N Y/N 4
Coag. N; 
hepatocellular 
individualization 0 NA N N
92-526 Unk 9.10% Y 3 1; cerebrum 2 NA 0 NA NA NA 1
Hepatocellular 
individualization; 
vacuolar 
degeneration 0 NA N N
92-527 Unk 5.20% Unknown 3 1; cerebrum 1 NA 0 1 Epithelial D/N Y/N 1 LP hepatitis 0 NA N N
92-530 Unk 35.20% Y 3 (spleen 5) 0 2 NA 1; cerebrum 3
Synechiae; 
epithelial D/N Y/Y 3
Hepatocellular 
individualization; 
vacuolar D/N 1 Cardiomyocyte D/N N N
92-548 C 22.60% Y 2 (spleen 4) 0 2 3 2; cerebrum 3
Synechiae; 
epithelial D/N Y/N NA NA 0 NA N N
94-380 A 51.30% N 5 NA NA NA NA 4 Epithelial D/N Y/Y 2
Hepatocellular 
individualization; 
LP portal hepatitis 2 Cardiomyocyte D/N N N
94-381 A 49.50% N 5 NA NA NA NA 2 Epithelial D/N Y/N 2
Hepatocellular 
individualization; 
LH perivascular 
hepatitis 0 NA N N
94-382 A 46.20% N 5 NA NA NA NA 2
Synechiae; 
epithelial D/N Y/N 2
Hepatocellular 
individualization 1 Cardiomyocyte D/N N N
94-383 A 41.70% N 5 NA NA NA NA 2
LP nephritis; 
epithelial D/N Y/N 3
Hepatocellular 
individualization; 
LH perivascular 
hepatitis 2 Cardiomyocyte D/N N N
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Key: 
A: Acute 
C: Chronic 
Coag. N: Coagulative Necrosis 
D/N: Degeneration/Necrosis 
D/N/R: Degeneration/Necrosis/Regeneration  
GN: Glomerulonephritis 
H: histiocytic 
IN: Interstitial Nephritis 
LH: Lymphohistiocytic 
LP: Lymphoplasmacytic 
N: Neutrophilic 
NA: Not available or Not applicable 
 
Table 4.4.1. Summary of selected major histopathological features.  Severity score is represented as 
a mean of those semi-quantitative data generated during the reading of the histopathology from all 
from n=45 Rhesus macaque monkeys infected with P. coatneyi. Severity scores consist of a range 
from 0 to 5. 0=Within normal limits; 1= Minimal; 2= Mild; 3= Moderate; 4= Marked; 5=Severe.  
Accession #
Acute/ 
Chronic
Peak 
parasitemia 
recorded
Spleen/ 
Splenunculum 
Y/N
General 
sequestration 
severity
CNS hemorrhage 
severity and 
location
CNS 
edema 
severity
Cerebellum 
Purkinje 
damage 
severity
Axonal/ 
neuronal injury 
severity and 
location
Renal 
Injury 
severity
Renal histopath 
findings
Cellular/ 
Hemoglobin 
casts
Hepatic 
injury 
severity 
Hepatic histopath 
findings
Cardiac 
injury 
severity
Cardiac histopath 
findings
Fibrin 
thrombi 
Y/N
Mural 
vascular 
necrosis 
Y/N
02-023 A 35.10% N 4 2; cerebellum 2 2 2; cerebrum 3
Synechiae; 
epithelial D/N Y/Y 2
Hepatocellular 
vacuolar D/N 2 Cardiomyocyte D/N N N
02-042 A 51.01% N 4 0 2 2 2; cerebrum 4 Epithelial D/N Y/Y 2
Hepatocellular 
individualization 2 Cardiomyocyte D/N N N
02-043 A 50.01% N 4 2; cerebellum 2 1 1; cerebrum 4 Epithelial D/N Y/Y 3
Hepatocellular 
individualization 1 Cardiomyocyte D/N N N
02-044 A 38.50% N 5 0 2 2 2; cerebrum 5 Epithelial D/N Y/Y 2
Hepatocellular 
individualization 2 Cardiomyocyte D/N N N
02-045 A 40.01% N 4 0 2 2 2; cerebrum 4 Epithelial D/N Y/Y 2
Hepatocellular 
individualization 1 Cardiomyocyte D/N N N
02-046 A 49.50% N 4
3; cerebrum, 
spinal cord 2 1 0 5
Epithelial D/N; 
hemorrhage Y/Y 5
Coag. N; 
hepatocellular 
individualization; 
H/LP hepatitis 2 Cardiomyocyte D/N N N
02-058 C 51.50% Y (DS) 4 0 0 2
1; cerebrum, 
spinal cord 5
Cortical infarct; 
fibrosis; LP IN; 
epithelial D/R Y/Y 2
Hepatocellular 
individualization 0 NA N N
02-059 A 39.20% N 5 2; brain stem 2 0 2; cerebrum 5
Epithelial D/N; 
hemorrhage Y/Y 2
Hepatocellular 
individualization 0 NA N N
02-060 A 49.20% Y (DS) 5
3/2; spinal cord/ 
cerebrum 3 2 3; spinal cord 4
Epithelial D/N; 
hemorrhage Y/Y 3
Coag. N; 
hepatocellular 
vacuolar 
degeneration 2
Cardiomyocyte D/N; 
interstitial 
edema/fibrin Y N
02-061 A 48.01% N 5
4/3/2; spinal 
cord/ brain stem/ 
cerebrum 3 2 0 4
Epithelial D/N; 
hemorrhage Y/Y 5
Coag. N; 
hepatocellular 
vacuolar 
degeneration 1
Cardiomyocyte D/N; 
interstitial 
edema/fibrin Y Y
02-062 C 50.80% Y (DS) 0 0 0 2 0 3
Epithelial 
D/N/R; LH IN Y/N 0 NA 0 NA N N
02-067 A 47.40% N 5 2; spinal cord 2 2 2; cerebrum 5
Epithelial D/N; 
hemorrhage Y/Y 3
Hepatocellular 
individualization; 
vacuolar 
degeneration NA NA N N
02-068 A 54.60% N 5
2; cerebellum, 
spinal cord 2 1 1; cerebrum 5
Epithelial D/N; 
hemorrhage Y/Y 5
Coag. N; 
hepatocellular 
vacuolar 
degeneration 2
Cardiomyocyte D/N; 
interstitial 
edema/fibrin Y N
02-069 A 41.20% N 5 2; cerebrum 3 2 0 5
Epithelial D/N; 
hemorrhage Y/Y 5
Coag. N; 
hepatocellular 
vacuolar 
degeneration 1
Cardiomyocyte D/N; 
interstitial 
edema/fibrin N N
02-070 A 49.60% N 5 4; cerebrum 4 2 2; cerebrum 5
Epithelial D/N; 
hemorrhage Y/Y 3
Coag. N; 
hepatocellular 
vacuolar 
degeneration 1
Cardiomyocyte D/N; 
interstitial LH 
Myocarditis; 
edema/fibrosis Y Y
02-071 A 41.01% N 5 0 2 1 1; cerebrum 5
Epithelial D/N; 
hemorrhage Y/Y 3
Coag. N; 
hepatocellular 
vacuolar 
degeneration 1
Cardiomyocyte D/N; 
interstitial LH 
Myocarditis; 
edema/fibrosis N N
02-089 A 20.20% N 5
3/2; spinal cord/ 
cerebrum 2 2 1; cerebrum 2 Epithelial D/N Y/Y 3
Hepatocellular 
D/N (prior 
pathology report, 
no tissue 
available for 
eval.) 2
Cardiomyocyte D/N; 
interstitial LH 
Myocarditis; 
edema/fibrosis N N
02-090 A NA N 4
2/1; cerebrum/ 
cerebellum 1 1 0 2 Epithelial D/N Y/Y 3
Hepatocellular 
D/N 1 Cardiomyocyte D/N N N
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Primary target tissues include the central nervous system, kidneys, liver and heart as well as 
descriptive evaluation of vascular injury, presence or absence of fibrin thrombi and qualitative 
evaluation of vascular sequestration.  
 
Figure 4.4.1-4: This plate consists of ultrastructural patterns of parasite adhesion in P. coatneyi 
infected rhesus macaque tissues. 4.4.1: Cerebrum with demonstration of microvascular margination 
of infected erythrocytes to the endothelium within a focal vessel. Additionally, there is mild evidence 
of perivascular edema. Transmission Electron Microscopy (TEM) 2500x. 4.4.2: Kidney. Similar to 4.4.1, 
this electron micrograph shows evidence of multiple erythrocytes infected with 1 to 2 plasmodial 
trophozoites marginated to the vascular wall. TEM 5000x. 4.4.3 Kidney. Within the lumen of this renal 
vessel are 3 infected erythrocytes forming a rosette with a series of peripheral uninfected 
erythrocytes. TEM 2500x. 4.4.4 Higher magnification of the binding between iRBC and RBC within a 
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renal vessel.  In this electron micrograph, there is evidence of the surface ornamentation and the 
cleft-like structures within the cell cytoplasm surrounding the intracellular trophozoite. TEM 12000x. 
 
4.4.1 Central Nervous System: 
a. Cerebrum:  Areas of the cerebrum that were evaluated consisted of the cortex, taken from  
the frontal lobe and allowing for an evaluation of grey and white matter, thalamus, mid-brain and 
hippocampus.  Microvasculature within both the grey and white matter, but more significantly within 
the former, was occluded by high numbers of late trophozoite stage infected erythrocytes containing 
abundant pigment. Levels of sequestration were high and in some cases approached 100% of all 
vessels seen. The sequestered iRBC appeared to contain predominantly mature trophozoite stages. 
No significant qualitative difference was observed in sequestration patterns within the different 
regions of the cerebrum. Frequently surrounding affected vessels, there was an area of clearing or 
rarefaction within Virchow-Robin space with strands of neuropil connecting to the vessel wall, 
interpreted as perivascular edema (Figure 4.4.1.1-4.4.1.2).   
 
Figure 4.4.1.1-2: Cerebrum. Photomicrograph 4.4.1.1 demonstrates the perivascular edema observed 
throughout the central nervous system. 400x Hematoxylin and Eosin (HE). This was not observed in 
control animals and is further supported by the myriad ultrastructural photomicrographs (as in 
4.4.1.2) which illustrate the proteinaceous material filling the artificial space surrounding the 
capillaries. TEM 4000x. 
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Occasionally, the perivascular space and neuropil contained extravasated erythrocytes or a 
focal punctate microhemorrhage (Figure 4.4.1.3-4). However, this was a relatively rare finding and no 
classical ring hemorrhages or reactive astroglial nodules, similar to the Dürck’s granulomas described 
in humans, were observed.   
 
Figure 4.4.1.3-4. 4.4.1.3: Cerebrum. Multifocally the neuropil is expanded by extravasated 
erythrocytes (hemorrhage), frequently adjacent to or surrounding microvessels with evidence of 
fibrinoid necrosis to the vascular wall. 200x HE.  4.4.1.4: Cerebrum. Higher magnification of fibrinoid 
necrosis to the microvascular wall and extravasated erythrocytes expanding and replacing the 
perivascular neuropil. 400x HE. 
 
Either frank hemorrhage or accumulation of perivascular hemosiderin was noted in the 
cerebrum in 27% of the animals, but only in 1 case was the hemorrhage a histopathological feature 
which warranted a severity score of ‘marked’.  Typically, the score was minimal to moderate.  In the 
spinal cord and brain stem, hemorrhage was noted in 44% of the animals, and in these cases the 
severity was typically mild or moderate. Occasional neurons were condensed, angular and showed 
hypereosinophilic cytoplasm which was occasionally microvaculated; distorted nuclei contained 
consolidated and clumped chromatin (varying stages of degeneration or necrosis). (Figure 4.4.1.5) 
Affected cells were often bounded by reactive microglial cells (satellitosis). Focal areas of edematous 
swollen white matter tracts showed features suggestive of acute axonal injury. In addition, there 
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were some collections of monocytes/macrophages both within vessels and in the perivascular space, 
although in the large majority of cases little host inflammation (lymphocyte localisation) was seen. 
Rarely fibrin-platelet thrombi were identified, but typically these were in association with those few 
cases in which mural vascular necrosis was identified in the brain. 
 
Figure 4.4.1.5a-5b: Figure 4.4.1.5a is representative of degenerative changes within the cerebrum. 
Multifocally, within this photomicrograph there are examples of neuronal degeneration 
(neuroplasmic vacuolization) (arrows). Additionally, there is satellitosis of affected neurons and both 
perivascular/perineuronal edema. 400x HE. Figure 4.4.1.5b illustrates neuronal necrosis characterized 
by neuronal angulation, nuclear condensation (arrow) and fragmentation. 400x HE.  
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b. Cerebellum: High levels of microvascular sequestration were seen, consistent with previous 
reports in this model showing the higher levels in cerebellum than cerebrum. (Sein 1993) In 71% of 
the cases, there was some degree of Pürkinje cell degeneration, necrosis and loss (Figure 4.4.1.6).  
Degeneration was characterized by swollen microvacuolated cells with retracted plump dendrites and 
peripheral edema, while necrosis was comprised of fragmented and angulated cells with 
hypereosinophilic cytoplasm and disrupted nuclei.  Lost cells were in evidence by clear spaces (‘empty 
baskets’), with residual fragments and occasional microgliosis.  Foci of microhemorrhage were 
observed in only 4 cases and the extravasated erythrocytes were typically seen in the perivascular 
space which is interpreted as a breach of the vessel wall. 
 
Figure 4.4.1.6: Cerebellum. This photomicrograph illustrates Pürkinje cell degeneration, and necrosis.   
400x HE. 
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c. Brain stem:  Microvessels within the brain stem contained moderate to high numbers of 
sequestered iRBC containing abundant hemozoin pigment.  No marked increase in intravascular 
lymphocytes was seen although monocyte-macrophage numbers did appear increased in both intra- 
and peri-vascular spaces in individual cases. This was not accompanied by formation of fibrin-platelet 
thrombi, nor ring hemorrhage formation. Frequently there was perivascular edema, and occasionally 
small foci of punctate hemorrhage were observed.  Furthermore, within the white matter, 
longitudinal sections of myelin sheaths showed axonal fragmentation and rare digestion chambers. 
(Figure 4.4.1.7) 
 
Figure 4.4.1.7: Brain stem.  Multifocally throughout this section, the neuropil is replaced by edema, 
characterized by vacuoles both surrounding degenerate neurons and throughout the neuropil.  The 
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neurons themselves are frequently angulated, shrunken and hypereosinophilic (arrow) suggestive of 
degenerative and necrotic changes. 400x HE. 
 
d. Spinal cord: In 60% of the prospective cases, hemorrhage was observed to be multifocally 
infiltrating the spinal cord parenchyma surrounding obstructed (due to sequestration) 
microvasculature.  This finding was noted to be more significant within the grey than white matter.  
Additionally, there were frequent swollen axons (spheroids), rare digestion chambers and dilated 
myelin sheaths.  (Figure 4.4.1.8-9) 
 
Figure 4.4.1.8-9: Spinal cord.  Figure 4.4.1.8 demonstrates the punctate hemorrhages which were 
frequently observed in sections of the spinal cord. 400x HE. The longitudinal section in 4.4.1.9 
demonstrates digestion chambers and dilated myelin sheaths suggestive of axonal injury, necrosis 
and loss. 400x HE. 
 
4.4.2 Eyes: 
Microscopic changes were most significant within the ganglion layer of the retina.  In that layer, there 
was increased sequestration of microvasculature, accompanying perivascular edema and multifocally, 
there was degeneration and loss of ganglion cells (Figure 4.8.1).  All other layers of the retina were 
200 
 
unaffected.  The remainder of the globe displayed similar changes to those seen universally in all 
tissues. 
 
Figure 4.4.2.1: Eye: This photomicrograph of the retina of a P. coatneyi infected rhesus macaque 
shows subtle changes within the outermost layer.  Within the ganglion layer there is perivascular 
edema and ganglion cell loss. 400x HE. 
 
4.4.3 Sequestration in Brain Microvessels and Calculation of Sequestration Index: 
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Brain smears were prepared from cortical grey matter in three prospective animals. (Figure 4.4.3.1-2) 
In all animals the proportion of vessels showing sequestered iRBC was 100%. The vast majority of 
iRBC were late trophozoite stage with only occasional schizonts forms. Calculation of sequestration 
index was performed to compare the number of parasites within vessels (iRBC/100RBC) with those in 
the peripheral circulation, (as per the method used in human tissues by Silamut et al 1999) which 
indicated an excess compared to that expected by free mixing with a median of 2.5 times expected 
parasite levels. 
Animal # 
Total 
RBCs 
Counted iRBC 
Individual  
parasites Schizonts 
Terminal 
peripheral 
parasitemia 
Terminal  
parasitemia 
% 
R519 300 119 133 0 1190160 26.1 
DA923 300 181 283 0 1547340 24.6 
DA831 300 146 283 1 1013540 18.7 
Table 4.2: Summary of the calculated results of brain sequestration in three P. coatneyi infected 
animals. 
 
Figure 4.4.3.1-2: Brain: Photomicrograph 4.4.3.1 is an example of the histopathological evidence of 
vascular sequestration in a medium sized cerebral vessel.  200x HE. Photomicrograph 4.4.3.2 is a 
brain smear with a central longitudinal section of the cerebral capillary.  The malaria pigment and 
parasites are highly evident in both sections.  400x Giemsa. 
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4.4.4 Gastrointestinal tract: 
All sections of the gastrointestinal tract were examined.  Gastric mucosa occasionally had multifocal, 
mild erosion and ulceration with an underlying neutrophilic and lymphoplasmacytic gastritis.  
Occasionally in the submucosa of the stomach, duodenum and colon, there was formation of 
lymphoid follicles, but these were interpreted to pre-existing background changes associated with 
chronic immune stimulation of the gastrointestinal tract.  The sequestration and obstruction pattern 
of vessels within all sections of the tract demonstrated a marked predilection for the mucosa in 
comparison with the underlying connective tissue of the submucosal layer, muscularis or serosa. 
(Figure 4.4.4.1) 
 
Figure 4.4.4.1: Jejunum: This image highlights the extent of sequestration observed in the 
gastrointestinal mucosal lamina proprial vasculature.  Within this single vessel are myriad P. coatneyi 
trophozoites. (1000x HE) 
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4.4.5 Liver:   
Diffusely the hepatic sinusoids were markedly expanded and congested with high numbers of iRBCs 
and abundant intraerythrocytic and intramonocytic hemozoin pigment.  Within centrilobular tissue, 
there was frequent piecemeal degeneration and necrosis of individual hepatocytes.  Küpffer cells 
were noted to be reactive and increased in number, and these often contained phagocytosed 
hemozoin pigment.  In those few cases which were either treated or, through supportive care, 
survived beyond the initial insult and lived days or even weeks beyond the peak parasitemia, severe 
chronic lesions were observed histopathologically.  These changes were comprised of marked to 
severe centrilobular mixed coagulative and lytic necrosis. (Figure 4.4.5.1-4) Multifocally, lost 
hepatocytes were replaced by loose fibrosis and, while no parasites were observed, there was often 
abundant residual pigment. 
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Figure 4.4.5.1-4: Liver: This plate of photomicrographs of the liver illustrates evidence of centrilobular 
coagulative necrosis, sinusoidal sequestration, piecemeal necrosis and disruption of the hepatic 
plates.  4.4.5.1 shows a low magnification of the hypereosinophilic zone surrounding a central vein.  
In this case there is loss of nuclear staining while retaining evidence of the prior architecture 
(coagulative necrosis). 200x HE. 4.4.5.2 is a higher magnification of the same centrilobular coagulative 
necrosis. There is a strong line of demarcation between the viable and necrotic tissue (arrowheads). 
400x HE. 4.4.5.3 is a high magnification demonstrating piecemeal necrosis (arrow) and sinusoidal 
sequestration and congestion with infected erythrocytes. 1000x HE. 4.4.5.4 is consistent with lytic 
necrosis, comprised of fragmentation and loss of cells, eosinophilic cytoplasmic and nuclear debris 
and loss of architecture. 1000x HE. 
 
4.4.6 Kidney: 
The kidneys were among those organs most severely affected in all cases.  All animals were found to 
have microscopic evidence of acute tubular necrosis.  This was characterized by mild to severe 
degeneration, loss of the proximal tubular epithelial cell brush border on PAS staining, individual 
tubular epithelial cell necrosis and shedding, and formation of intratubular cellular casts, hemoglobin 
casts and proteinosis. (Figure 4.4.6.1). Tubular debris and red cell casts were seen within collecting 
tubules. These changes were in excess to post-mortem artefacts seen in control animals. Within the 
interstitial capillaries were high numbers of sequestered iRBC and hemozoin pigment.   
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Figure 4.4.6.1-4: Kidney.  This plate accentuates the various changes which were observed in the 
histopathological and ultrastructural evaluation of the renal tissue in severe P. coatneyi infection.  
4.4.6.1 This photomicrograph illustrates early, subtle changes.  Within the renal interstitium, vessels 
are markedly expanded and congested with infected erythrocytes.  Frequently within the lumen of 
renal tubules there are sloughed, necrotic epithelial cells. (arrow) 400x HE. 4.4.6.2 A similar 
magnification of damage associated with a more chronic stage of the disease.  In this image, there is 
fibrosis of the interstitium, degeneration, necrosis, regeneration and loss of the tubular epithelium, 
protein, cellular and hemoglobin casts (arrow) within the tubules and rare foci of inflammatory cells.  
400x HE.  4.4.6.3 This photomicrograph also shows significant necrosis and loss of the renal 
architecture, tubular cellular and hemoglobin casts, as well as marked microvascular congestion and 
sequestration both within the interstitium as well as within the glomerular tuft. 400x HE. 4.4.6.4 
Ultrastructural micrograph illustrates a single tubular epithelial cell undergoing necrosis (arrows) 
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bounded by two viable cells.  There is fragmentation and rupture of the cytoplasm, swelling and 
vacuolization of the organelles and nuclear pyknosis. TEM 4000x. 
 
The glomeruli were occasionally hyperlobulated and, in animals with higher parasitemias, 
there were focal adhesions of the glomerular tuft to the Bowman’s membrane (synechiae or tip 
lesions) as well as abundant congestion with both iRBCs, uninfected erythrocytes and hemozoin 
pigment. (Figure 4.4.6.5-8) Both within the interstitial capillaries as well as within the glomerular tuft 
there were increased numbers of intravascular monocytes and neutrophils. However, these rarely 
transmigrated into the adjacent tissue and no features of a tubulointerstitial nephritis were seen to 
explain the clinical picture of acute tubular injury.  The glomerular expansion, endocapillary 
leukocytes and hyperlobulation gave the appearance of a proliferative endocapillary 
glomerulonephritis, although no active vasculitis, destructive lesions or crescent formation was seen 
in any case, and no mesangiolysis. Silver and PAS staining indicated no membrane complexity, spike 
formation or immune complex deposition. The lack of immune complex deposition was confirmed 
ultrastructurally, although focal podocyte foot process effacement and proliferation was observed 
indicative of proteinuria.   
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Figure 4.4.6.5-8: Kidney. This plate of histological and ultrastructural photomicrographs highlights 
glomerular changes within the renal tissue of P. coatneyi infected rhesus macaques. 4.4.6.5 
demonstrates early changes in which there are only subtle changes.  Aside from the changes 
described in the tubules in 4.4.6.1, the glomerulus in this image is beginning to adhere to the reactive 
parietal epithelium of the Bowman’s capsule, forming synechiae (arrows). 400x HE. 4.4.6.6 is a higher 
magnification showing periglomerular fibrosis, more pronounced synechiae as well as dilation of the 
microcapillaries and low levels of interstitial mononuclear inflammatory cells. 1000x HE. 4.4.6.7 This 
silver stain of the glomerulus demonstrates that while there is evidence of a proliferative response in 
the glomerulus, that we do not observe the membranous expansion of the basement membrane as 
can be seen in immune mediated glomerulopathy in rare cases of P. falciparum and P. malariae 
induced malaria.  1000x von Kossa. 4.4.6.8 Further reinforcing the findings described in 4.4.6.7, the 
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glomerulus in this ultrastructural photomicrograph is essentially normal, with the exception of 
infected erythrocytes lodged in the microcapillaries of the glomerular tuft. TEM 2000x. 
As with the liver, those animals which survived beyond the peak of infection, developed 
chronic lesions including severe tubular necrosis with interstitial fibrosis and glomerular sclerosis.  
Rarely in these animals, the microvasculature was obscured by fibrin thrombi.  
 
4.4.7 Heart:  
The myocardium was the tissue that displayed the greatest degree of vascular congestion, 
obstruction or sequestration.  The interstitial capillaries were almost universally expanded by iRBC, 
cytoadhered uninfected erythrocytes and intraerythrocytic and intramonocytic hemozoin pigment.  
Both light microscopic and ultrastructural examination of the myocardium noted that there was only 
scant haemorrhage, and that the vast majority of the infected erythrocytes were intravascular. 
Commonly the perivascular connective tissue was expanded by edema.  One feature not previously 
reported, but consistently observed within this study, was an increased degree of microscopic 
pathology within the cardiomyocytes of the myocardium. Overall 71% of the experimental animals 
were noted to have some degree of damage to the cardiomyocytes, although rarely did the severity 
exceed a ranking of mild.  That was increasingly evident when comparing the population of 
retrospective animals, many of which had lower peak parasitemias, with the prospective cases. 
Affected cardiomyocytes were either swollen with microvacuoles (degenerative) or shrunken, 
hypereosinophilic and angular, with contraction bands and nuclear fragmentation or loss (necrosis).  
(Figure 4.4.7.1-4).  This was typically noted to occur in a piecemeal fashion, and coalescing areas of 
necrotic tissue or neutrophil/monocyte reactive infiltrates were not observed.  The rest of the 
cardiovascular system was less affected. However, at high magnification changes to the endothelium 
are observed in vasculature throughout the body.  Frequently the endothelium of obscured and 
sequestered microvasculature was swollen and vacuolated (degenerative) or occasionally fragmented 
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(necrotic).  Ultrastructurally, the endothelium occasionally formed membrane bound pseudopodia 
which interdigitated with the cytoadhered iRBC. 
 
Figure 4.4.7.1-4: Heart. This plate illustrates the severe sequestration observed microscopically in the 
cardiac interstitial microvasculature and the cardiomyocytic piecemeal necrosis, degeneration and 
loss noted in most of the infected animals.  These findings were relatively subtle and rarely did the 
changes coalesce, however they were consistent and contrasted with the cardiac tissue of the control 
animals.  4.4.7.1 High magnification of markedly expanded interstitial capillaries, congested with 
innumerable P. coatneyi infected erythrocytes.  Furthermore, the perivascular space is expanded by 
proteinaceous material or clear space interpreted to be edema. 1000x HE. 4.4.7.2 This 
photomicrograph illustrates a field in which the majority of the cardiomyocytes are either swollen, 
pale and vacuolated (degenerate) or hypereosinophilic, angular and fragmented with condensed 
nuclei and loss of structural integrity (necrotic) (arrow). 1000x HE. 4.4.7.3 This ultrastructural 
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photomicrograph demonstrates a necrotic cardiomyocyte adjacent to a vessel containing iRBCs. TEM 
1500x. 4.4.7.4 In this instance the image shows a couple of cardiac microvessels in which there is 
margination of iRBCs with cytoadhereance to the endothelium and a degree of autoagglutination. 
TEM 2000x. 
 
4.4.8 Lung: 
The model exhibited plentiful infected erythrocyte sequestration within pulmonary 
microvessels, but a minimal degree of histopathological signs of resultant pulmonary injury. The lungs 
were typically affected by expansion of the alveolar septae by sequestered iRBC and uninfected 
erythrocytes, with variable increases in host leukocyte numbers, some of which contained 
phagocytosed hemozoin pigment (Figure 4.4.8.1-4). Occasional animals had an interstitial histiocytic 
pneumonitis, but there was no significant pulmonary edema in any animal, nor was there marked 
inflammatory destruction of the parenchyma and no development of hyaline membranes to suggest 
diffuse alveolar damage or incipient ARDS.  Of note however, was that in larger pulmonary vessels, 
histocytes and other leukocytes were often noted to be pavementing along the endothelium.  
Potentially, this finding might represent a precursor to a greater degree of pulmonary disease should 
the animals have survived into a chronic stage. 
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Figure 4.4.8.1-4: Lung. This plate illustrates subtle early changes within the pulmonary interstitium, as 
well as the complete absence of alveolar edema in this model.  4.4.8.1 is a low magnification 
photomicrograph with margination of mononuclear leukocytes. 400x HE. 4.4.8.2 illustrates a higher 
magnification of the same phenomenon. 1000x HE. 4.4.8.3 serves to describe the sequestration of 
the alveolar wall capillaries with high numbers of infected erythrocytes. Additionally, there are rare 
alveolar macrophages within the alveolar space, however these are not noted to be in excess of 
normal background numbers. 400x HE. 4.4.8.4 Similarly, this high magnification photomicrograph 
shows the fact that all vessels are packed with plasmodium infected erythrocytes. 1000x HE.  
 
4.4.9 Spleen:  
In the select few cases in which splenectomized animals were found at autopsy to have a 
daughter spleen (splenunculum), these were examined.  In all cases, the red pulp was markedly 
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expanded by high numbers of iRBC and monocytes, both of which contained abundant hemosiderin 
or hemozoin pigment (Figure 4.4.9.1-2).  Additionally, there was a significant amount of 
erythrophagocytosis observed throughout the sections, and rarely splenic vasculature contained 
fibrin thrombi. 
 
Figure 4.4.9.1-2: Spleen. In the rare cases in which there was splenic material available for 
examination, the degree of concentration of infected erythrocytes, hemozoin and hemosiderin within 
the sinusoids was significant as is demonstrated in 4.4.9.1. 400x HE.  Furthermore, when rare fibrin 
thrombi were noted, they were most often observed within the splenic tissue as in 4.4.9.2. 400x HE. 
 
4.4.10 Endocrine system: 
 a. Pituitary gland: Within the pars anterior there was a high degree of vascular sequestration with 
intravascular abundance of hemozoin pigment.  Rare mononuclear macrophages were observed 
phagocytozing the hemozoin-laden food vacuoles.  No significant changes were observed in the 
parenchymal tissue of the pituitary. However, the sequestration density was more pronounced in the 
pars anterior than in the pars intermedia (pars nervosa). 
b. Adrenal gland: The only significant changes observed in the adrenal glands consisted of a high 
degree of cortical congestion with medullary vessels being packed with iRBC and hemozoin. 
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c. Pancreas: Sequestration was seen with greater density within the endocrine pancreas versus the 
exocrine tissue. However, no other tissue changes were noted. (Figure 4.4.10.1) 
d. Thyroid and parathyroid glands: No tissue-specific histopathologic findings were noted in any of 
the affected animals.  
 
Figure 4.4.10.1: Pancreas. Throughout the endocrine tissue, potentially associated with the increased 
vascularity, the microvasculature was markedly expanded, congested and sequestered with infected 
erythrocytes and hemozoin pigment.  This photomicrograph shows two central islets of Langerhans 
(endocrine pancreas) in contrast with the surrounding exocrine pancreatic tissue.  No significant 
tissue specific pathology was noted in any of the endocrine tissues. 200x HE. 
 
4.4.11 Bone marrow: 
The changes in the bone marrow in response to the regenerative anemia which occurs 
secondary to the intense destruction of both infected and uninfected erythrocytes has been well 
described by Moreno and colleagues in their studies in the P. coatneyi/rhesus model, albeit under 
different experimental conditions.  (Moreno 2013) Bone marrow was only available in 10 of the 
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prospective animals.  Evaluation consisted primarily of establishing a Myeloid to Erythroid ratio within 
sections of sternal marrow.  Additionally, the average number of megakaryocytes were assessed in 10 
high powered fields.  Other than those two quantitative criteria, qualitative examination included the 
maturity of the megakaryocytes, the condition of the stroma, degree of mitotic activity and features 
associated with the destruction of iRBC or systemic damage.  The average ME ratio of those animals 
was approximately 5.4:1. Megakaryocyte numbers ranged from 1.5 to 10 per high powered field, and 
frequently these were noted to be immature.  In about 30% of the cases there was an increase in 
mitotic activity in the hematopoietic elements.  No significant change was noted in the stroma, but in 
almost all of the animals, pigment accumulation was observed. This was interpreted to be a 
combination of both hemozoin pigment and hemosiderin, as there was also frequent evidence of 
erythrophagocytosis. Additionally, in 2 cases fibrin thrombi were observed in the marrow samples. 
(Figure 4.4.11.1) 
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Figure 4.4.11.1: Bone marrow.  As with the splenic tissue, the bone marrow fibrin thrombi were rarely 
observed within sections of bone marrow hematopoietic tissue. Phagocytes within the marrow were 
often replete with ingested erythrocytes and both hemosiderin and malaria pigment. 1000x HE. 
 
4.4.12 Other tissues: 
Other tissues were variably available from retrospective and control animals, but collected 
comprehensively in prospective cases. Sections were examined from skin, mesenteric and 
subcutaneous adipose, lymph nodes (including mesenteric, inguinal, axillary, submandibular and 
visceral), abdominal aorta, skeletal muscle (diaphragm and thigh), trachea, larynx, thymus, salivary 
glands, gallbladder, ears, urinary bladder, testes, epididymides, uterus, ovaries, fallopian tubes and 
cervix. 
In all of these tissues, the capillaries contained varying amounts of sequestered erythrocytes 
(infected and uninfected) as well as hemozoin malaria pigment, some of which appeared free and 
some phagocytosed by host leukocytes.  No specific pathology was noted in the majority of examined 
samples, apart from a select few animals (n=4) which developed a form of severe, neutrophilic, 
necrotizing dermatitis and inflammation of the testes. This appeared associated with a coagulopathy, 
and may represent a leukocytoclastic vasculitis related to DIC as evidenced by thrombosis most 
notably within the haired skin, testes and scrotum.  In one animal which survived into the chronic 
phase, the superficial necrosis progressed to the point of loss of the nasal planum and several digits.   
 
4.5 Discussion: 
Prior to this study, which incorporated a significant number of animals within relatively 
controlled parameters, there has not been a comprehensive description of pathology in this animal 
model.  Histopathological examinations of autopsy samples from P. coatneyi-infected rhesus 
macaques are reported in the literature. However, with the exception of recent work examining the 
dyserythropoeisis in the bone marrow (Moreno 2013) and several elegant studies of placental 
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pathology (Davison 1998; Davison 2000), these descriptions were typically limited. They were 
conducted in only a select few animals and targeted to specific organs, such as the brain and the 
heart, in order to confirm particular aspects of the pathophysiology such as rosette formation 
(Aikawa 1992; Tegoshi 1993; Udomsangpetch 1991), deep vascular sequestration (Desowitz 1969) or 
knob formation. (Aikawa 1992; Kawai 1993; Kawai 1998; Tegoshi 1993; Udomsangpetch 1991) 
Furthermore, interpretation of these reports is complicated by the heterogeneous populations of 
experimental animals, variable levels of parasitemia, splenic status and whether curative treatment 
had been given.    
As such, the scale and relative uniformity of this study represents a unique attempt at 
characterizing the microscopic tissue changes in the splenectomized rhesus macaque/P. coatneyi 
model of severe malaria.  Additionally, this study includes many organs and tissues, such as the spinal 
cord, in which the pathology of P. coatneyi infection had not been previously evaluated, and yet may 
be critically important in the pathophysiology of the disease. The results from this research 
demonstrate the pathology of P. coatneyi in the rhesus macaque and allow more comprehensive 
comparison with the reported lesions in human patients afflicted with P. falciparum-induced disease.  
The relative heterogeneity of the monkeys in these studies performed over more than two decades, 
mirrors the diversity of human populations suffering from malaria and appears to underscore the 
importance of the host response. 
P. falciparum infection in humans has been associated with a range of severe life-threatening 
complications to include cerebral malaria (CM), severe anemia, metabolic acidosis, hepatic insult with 
accompanying jaundice, acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), 
disseminated intravascular coagulopathy (DIC), malaria retinopathy and cardiac disease. (WHO 2014)   
These syndromes are almost universally seen as part of a spectrum of lesions that are interconnected 
rather than independently responsible for disease.   Using the kidneys as an example, falciparum 
induced disease has been reported to present with various histopathologic appearances to include 
acute tubular injury, mild endocapillary but non-immune complex mediated glomerulonephritis and 
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inflammatory interstitial host leukocyte infiltrates, although without classical tubulointerstitial 
nephritis. (Barsoum 2000; Elsheikha 2007; Ngaungsangiam 2007; Thanachartwet 2013; Trang 1992) 
The histopathological features of renal disease are found to be closely recapitulated in this model, 
with resultant AKI in some cases.  In this review of the histologic lesions in the rhesus, we have 
described acute tubular injury with a proliferative glomerulopathy, but lacking in a significant 
inflammatory response.  This raises the question as to variability in disease presentation, and 
underscores the fact that no perfect model exists.   
While the P. coatneyi/rhesus macaque model appears to be very appropriate for the study of 
multi-organ involvement, there is still significant variability in comparison with human disease in that 
the pathology was not replicated equally in every organ system.  This is particularly underscored by 
the lack of pneumonitis and pulmonary edema in the lungs, or with the rarity of significant cerebral 
hemorrhage.  Just as some of the histopathologic features of human disease are absent in the animal 
model, there are findings in the rhesus which are not typical of human disease.  Examples of this 
include the cardiac findings which are relatively novel and may be similar to human cases with algid 
malaria. However, in those cases, the myocytic damage noted in the rhesus is predominantly absent.  
Hepatic injury in these animals is likewise more pronounced than in human cases, and the zonal 
necrosis described here is only rarely reported to occur in humans.  
One of the main pathophysiological questions arising from clinico-pathological investigations 
of severe falciparum malaria in humans is the relative role of parasitized erythrocyte sequestration in 
causing end organ damage. Some investigators believe this to be an epiphenomenon, and that severe 
disease is a consequence of host immune response (Hu 2014; Ladhani 2002; Storm 2014), while 
others support concepts of alternative mechanisms such as an apoptosis-driven pathogenesis. 
(Lackner 2007; Pino 2003; Toure 2008) Much of this data arises from the murine experimental models 
of cerebral or severe malaria (Craig 2012; Schmidt 2011; Sun 2003; Xu 2001; White 2010) although 
the relevance of this model to human CM has been questioned due to the lack of iRBC sequestration 
in the brain in murine models. In addition, neurological signs following P. berghei, P. yoellii and P. 
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chabaudi infection in a variety of host murine strains are clearly related to an inflammatory and 
immune-mediated encephalitis which does not recapitulate the pathological features of human 
disease.  
The Rhesus-P. coatneyi model has been used to study the chronic effects of repeated 
infection on bone marrow function (and subsequent anemia). (Moreno 2013) The splenectomized 
model allows higher parasitemias (up to 50%) which is associated with multi-organ severe disease. 
(Aikawa 1992; Lombardini 2015) Whilst earlier studies used this model to study the effects of 
cytoadhesion-dependent sequestration in the brain as a model of CM (Aikawa 1992), the degree of 
secondary neuropathological changes observed here are limited. There were practically no 
microhemorrhages, some perivascular but limited gross edema, limited cellular inflammatory 
responses or platelet deposition within microvessels, but definite astroglial activation, and mild 
axonal injury which is most apparent in the brainstem and spinal cord, rather than the cortical white 
matter. 
There was evidence for sequestration of iRBC in all organs. In the brain this caused 
microvascular obstruction which was mediated both by cytoadhesion to endothelial cells (as shown 
on EM) but also by the marker degree of autoagglutination and rosetting in this parasite species. The 
degree of sequestration is in excess of that expected in a free mixing model. Calculation of the 
sequestration index (SI) confirmed this although the peripheral parasitemia was higher than might be 
expected in natural infection of these animals, due to splenectomy, so the SI is probably an 
underestimate of the preferential sequestered parasite burden leading to tissue disease. In human 
studies SI in the brain can approach 20 (Silamut 1999) due to lower relative circulating parasitemia, 
and in kidney may be in the range of 1.5-2. Using adjuvant markers of parasite biomass to investigate 
the relationship between tissue burden and disease is indicated, although P. coatneyi does not 
produce HRP-2 which is commonly used in P. falciparum. (Ly 2010; Parra 1991) However, use of 18S 
DNA within serum may offer another useful adjuvant marker. (Imwong 2014) 
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The neuropathological feature of the model which is notably different to the human 
pathology is the relative lack of cerebral ring hemorrhages which are reported to be a common 
diagnostic feature in advanced cases of cerebral malaria. (Milner 2014; Turner 1997) While only 12 
cases of cerebral hemorrhage were observed in our experimental animals, and of those, only one 
case was severe, brain stem and spinal cord hemorrhage was found with a relatively high incidence 
(44% of the animals).  Additionally, morphological evidence of axonal injury was more common in the 
brain stem and the spinal cord than in the rest of the central nervous system. The retinas were 
examined in all of the prospective animals and in those sporadic retrospective cases in which the eyes 
had been collected.  In no case were retinal hemorrhages noted although these lesions are a field of 
significant interest in children with cerebral malaria. (Beare 2006; Maude 2009) Histopathological 
features of severe or cerebral malaria have not been reported in the spinal cord. 
Cardiac changes represented one of the more consistent findings in infected animals and, 
while the histopathological changes were subtle, their significance cannot be overlooked.  The 
question which needs to be addressed is what the role of sequestration is in causing myocyte 
necrosis, especially in the absence of a significant inflammatory myocarditis.  Although the 
histopathologic lesions are piecemeal or in multifocal clusters with few infiltrating inflammatory cells, 
the interstitial microvasculature is severely congested with iRBC. Does sequestration directly 
contribute to primary cardiogeneic shock? There is certainly information available on cardiac 
complications of severe malaria. However, in those instances in which humans succumb to disease 
and are autopsied, it is infrequent that the microscopic examination of the heart demonstrates any 
direct evidence of ischemic injury to the cardiomyocytes. (Costanero 2011; Dudgeon 1917; Mohsen 
2001; Sprague 1946; Wichmann 2003)   
Comparative analysis of this model is of most use to understand changes which may be age 
related and normal. (Chamanza 2012; Lowenstine 2003) While the model shows strong correlations 
with human pathology in many organs (such as the kidneys and to a lesser extent, the heart), there 
are also areas in which the P. coatneyi/rhesus macaque model differs from human disease.  The 
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degree of liver damage varied, however in 47% of the animals the histopathological lesions consisted 
of either centrilobular coagulative necrosis or a degree of hepatocellular degeneration and necrosis 
warranting a severity score of moderate, marked or severe.  This is interpreted to be much more than 
is typically observed in human disease, which is characterised by liver function abnormalities and a 
mild inflammatory “hepatitis’ (Saya 2012) but rarely presents with frank zonal necrosis.  
The relative absence of any severe lung pathology, such as alveolar edema, fulminant 
pneumonitis or diffuse alveolar damage/hyaline membrane formation, is discordant with the 
observations in humans with severe malaria. (Taylor 2012; Ampawong 2015) This is despite the 
presence in the monkeys of host leukocyte collections, pigment-laden macrophages and iRBC as have 
been described in the human lung. The causal link between these pathological features and specific 
clinical syndromes such as ARDS is therefore likely to be dependant both on the species-parasite 
combination and the individual infected.  
Finally, whilst increased numbers of circulating monocytes and polymorphonuclear 
leukocytes were observed in infected animals, there was a relative absence of inflammation in 
affected tissues. In particular, there was almost no evidence for collections of platelets, fibrin-platelet 
thrombi and related microvascular injury in the brain, which has been described in pediatric cases of 
CM. (Dorovini-Zis 2011; White VA 2001) 
The utility of any animal model depends on both the similarities and differences to the 
disease in humans which is being modelled. But for optimal use and interpretation, it is essential for 
investigators to be aware of the differences from, as well as the similarities to, human disease as they 
apply a specific model to the investigation of therapies, vaccines or pathophysiology.  
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4.6 Summary:   
The in-depth evaluation of the histopathology in this model is unparalleled in the simian and the 
human literature of malaria.  While this may seem to be a highly presumptuous assertion, the fact is 
that the scope of this study outstrips the majority of autopsy examinations in terms of the systemic 
investigation and the relative uniformity of the study population in terms of age, body condition, 
disease history, lack of co-morbidities and criteria of infection.  Furthermore, this dissertation 
represents the only review of malaria induced spinal cord, endocrine, retinal and respiratory 
pathology in any species, as well as providing significant details on features of disease in all body 
systems and in quantifying the pathology therein.  In doing so, this study describes the effect of P. 
coatneyi in those tissues which parallel falciparum induced disease in humans, as well as highlighting 
those areas in which the two diseases deviate from one another.  An example of the former is seen in 
the kidneys which show synchrony of acute tubular injury without glomerulonephritis, while the 
latter is most evident in the lungs, which in the P. coatneyi/rhesus macaque model lacks the 
significant pulmonary edema observed in humans.  The primary benefit of this study is in having 
enough conformity of experimental disease, and an adequate animal population so as to be able to 
demonstrate consistent changes which directly relate to the clinical syndromology, as well as to the 
hematology, clinical chemistry and autopsy findings.           
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Chapter 5: Studying Secondary Neuropathological Changes in the 
Brain of the Rhesus Macaque/P. coatneyi Severe Malaria Model 
 
5.1 Introduction:  
Cerebral malaria (CM) is one of the most crucial manifestations of severe falciparum malaria 
resulting not only in significant numbers of deaths in victims of infection, but also often resulting in a 
spectrum of neuropathology in surviving patients. The greatest challenge for care providers for CM 
patients is in the treatment and management of both the symptomology of active disease as well as 
in the survival and recovery phases due to the severity of damage to the central nervous system. It is 
important to underscore the fact that the clinical presentation of disease in P. coatneyi-infected 
rhesus macaques does not mimic that observed in humans as there is the absence of coma. However, 
early ultrastructural studies of the model proposed that it may represent a good model for 
sequestration-dependent cerebral pathology. (Aikawa 1992; Maeno 1993) The histopathological 
findings described in the previous chapter provided some concordance of pathology between that 
described in humans and that in the rhesus macaque model (eg. the high levels of sequestration, 
widespread astroglial responses but a relative lack of host leukocyte responses) whereas other 
features showed some differences (such as the relative lack of cerebral hemorrhages, significant brain 
edema or morphological evidence of axonal injury).  
In the last 20 years more comprehensive immunohistochemical studies of human brain tissue 
from fatal CM cases (Brown 1999a; 1999b; Dorovini-Zis 2011; Medana 2002; Medana 2011; Ponsford 
2012; Turner 1994), and CSF studies in living patients on BBB function, cytokine and neurological 
injury markers (Brown 2000; Brown 2001; Dittrich 2015; Medana 2005) have expanded our 
understanding of processes such as astroglial activation, BBB breakdown and edema in mediating 
secondary neuropathological injury in CM. Cellular inflammatory infiltrates, which are widely 
223 
 
described in murine models of CM are much less marked in human studies, although some authors 
have proposed both leukocyte (Patnaik 1994) and platelet adhesion (Grau 2003) as mediators of 
endothelial injury in CM.  Another recent article describing the inflammatory response in children 
with fatal HIV and malaria coinfections does confirm a monocyte/macrophage predominant 
inflammatory response. The study examined ionized calcium binding adapter molecule 1 (Iba1) which 
is an immunohistochemical marker specific for the monocyte lineage that includes macrophages, 
monocytes and microglia.  Additionally, that particular study examined Cluster of Differentiation 61 
(CD61), a platelet glycoprotein, and neutrophil elastase (NE), a serine protease found specifically in 
the granules of neutrophils. (Hochman 2015) Other case reports of cerebral malaria in humans 
describe a macrophage- and monocyte-driven inflammation, but those instances relied on 
histopathology without the adjunct diagnostic of IHC. (Boonpucknavig 1988; Porta 1993) In general 
there have been emerging differences proposed for the microvascular pathology of CM in pediatric 
African cases and adult Southeast Asian patients, not all of which have been based on detailed 
histopathological studies (summarized in Turner & Millner 2014). 
Previous studies have used a range of animal models to attempt to elucidate the 
pathophysiology of cerebral and severe malaria, with specific focus on the impact of disease on the 
BBB.  (Gitau 2005; Hunt 1992; Migasena 1968; Neill 1992; Rénia, 2012; Thumwood 1988) Early studies 
in rhesus examined the integrity of the BBB in P. knowlsei infections by determining the degree of 
albumin passage from the cerebral microvasculature. (Migasena 1968) That study utilized P. knowlsei 
which does not have a predilection for the central nervous system in non-human primates. Rather, 
sequestration concentrates in the liver and gastrointestinal tract in contrast to P. falciparum. (Gitau 
2005) 
As corollary to these human studies, and the histopathological evaluation of the experimental 
animals in both the retrospective and prospective populations in this study, as reported in Chapter 3, 
further studies were performed using immunohistochemistry and studies of peri-mortem CSF 
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samples, focusing specifically on the secondary neuropathology of the central nervous system in the 
prospective animals, compared with a range of control animals.  
These studies were designed to examine the following potential pathways of CNS damage previously 
identified in human CM, namely: 
1. Blood-brain barrier leakage: Immunohistochemical analysis of fibrinogen leakage and 
astrocyte foot process GFAP expression, measurement of the Blood/CSF Albumin index as 
a marker of BBB breakdown and histological observation of hemorrhages and edema. 
2. Host Leukocyte and Platelet Localization: Immunohistochemical quantitation of host 
leukocytes including CD3+ T-cells, CD20+ B-cells, CD68+ monocyte/macrophages and 
CD61+ platelets in and around cerebral microvessels. 
3. Axonal Injury: Morphology and immunohistochemistry for β-amyloid precursor protein 
(β-APP) accumulation in axon 
4. Apoptosis:  Morphology and immunohistochemistry for Cleaved caspase-3 
5.   CSF Measurement of β-APP and Tau protein, as marker for neuroaxonal injury 
 
6.   Multiplex ELISA measurement of CSF cytokine signatures. These were conducted in a 
limited number of P. coatneyi-infected animals to generate a preliminary description of the 
immune response in the brain. 
 
5.2 Immunohistochemical Markers background: 
A range of immunohistochemical markers were employed and assessed in sections of the cerebrum 
and brain stem of the prospective animals.  These included amyloid precursor protein Beta (β-APP), 
fibrinogen, glial fibrillary acidic protein (GFAP), CD3 for T-cells, CD20 for B-cells, CD61 for 
thrombocytes, CD68 for monocyte/macrophages, Amyloid Precursor Protein (β-APP) for axonal injury 
and Cleaved caspase 3 as a marker of early apoptosis.  The markers were selected in an attempt i) to 
identify and, to a certain extent, quantify the predominant inflammatory cells involved in the 
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pathology observed in the brain, ii) to determine if there was compromise of the blood brain barrier, 
and if so to characterize and compare the immunohistochemical features of the insult, and iii) to 
identify and describe the degree of neuronal and astrocytic damage associated with severe CNS 
disease associated with P. coatneyi in the rhesus model.    
 
5.2.1 GFAP: GFAP is an intermediate filament protein expressed by a range of different cell types 
within the central nervous system to include ependymal cells and astrocytes, where it is upregulated 
on astrocyte foot processes following damage to the BBB, or leakage of serum proteins into the 
perivascular (Virchow-Robin) space.  The protein plays a significant role in a variety of different CNS 
processes including cellular mitosis through the adjustment of the filament network, as well as being 
crucial in blood brain barrier function and cell to cell communication. Examination of the importance 
of GFAP in CNS function has been studied in a murine knockout model in which the affected animals 
succumb to a range of neurodegenerative disorders associated with atypical myelination, deficiencies 
in the function of the blood brain barrier and white matter degradation. (Liedtke 1996) GFAP is 
theorized to play a significant part in the molecular pathways associated with astrocytic 
communication and interaction with neurons.  (Weinstein 1991) 
Of critical importance to this study is the role of GFAP in exhibiting both astroglial activation 
and repair mechanisms in the CNS following injury.  The protein has been shown to make up a 
significant portion of glial scars observed in the brain following insult. (Paetau 1985) In the P. berghei 
murine model of cerebral malaria, GFAP expression in perivascular spaces in the CNS has been 
evaluated to demonstrate the adaptive response of astrocytes to malaria-induced injury.  The marker 
was also used to highlight increased numbers of clustering astrocytes observed microscopically in the 
affected animals in comparison with controls. (Ampawong 2014; Ma 1997) 
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5.2.2 Fibrinogen: This is a serum protein which, at 340Kda is normally barred from passing into the 
brain through the function of the intact blood-brain barrier.  In cerebral malaria in humans, 
impairment of the blood-brain barrier is implicated in the pathophysiology of the disease, with 
increased permeability described as a feature following parasitized erythrocyte binding to cerebral 
endothelial cells. (Brown 1999) Histopathological and ultrastructural evidence of cerebral edema in 
victims of cerebral malaria was often associated with different fibrinogen staining patterns associated 
with vascular endothelial injury and/or fibrin thrombi. Additionally, in some cases the fibrinogen 
leakage was observed without overt signs of damage to the microvasculature. (Dorovini-Zis 2011; 
Medana 2011) 
 
5.2.3 CD3: ‘CD’ stands for cluster of differentiation, which defines a collection of antibodies which 
taken together define a specific antigen. CD3 corresponds to the pan-T-cell co-receptor which is 
integral to the activation of cytotoxic T-cells. It is a protein complex which is comprised of four 
distinct chains and is initially expressed in the cytoplasm of pro-thymocytes, the stem cells from 
which T-cells arise in the thymus. At later stages of development, once the pro-thymocytes have 
differentiated into medullary thymocytes, the CD3 antigen is localized in the cell membrane and is 
relatively unique to mature T-cells. As such, the immunohistochemical marker is highly useful and 
specific to the identification of T-cells in tissue. (Leong 2003) In the case of falciparum malaria 
infection, the cell-mediated immune response hinges upon Natural Killer cell-, γδT cell- or Th1-
derived interferon γ (IFN-γ) driven activation of macrophages resulting in enhanced phagocytosis and 
destruction of infected erythrocytes, as well as the inhibition by CD8+ cytotoxic and IFN-γ-producing T 
cells of intrahepatocyte parasitic growth and development. (Artavanis-Tsakonas 2003) 
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5.2.4 CD20: This is a B-lymphocyte antigen which is expressed on the surface of all B cells, and 
increases in concentration through maturation. Studies in murine malaria models have demonstrated 
that malaria infections can suppress the upregulation response of B cells, thereby stunting the 
patient’s ability to mount immunological memory to the parasite. (Liu 2012) P. falciparum infections 
in endemic areas elicit antibody-mediated immunity, however its development is very slow.  While 
the reasons behind this delayed acquisition of immunity remains poorly understood, theories include 
the significant genetic diversity of P. falciparum antigens as well as the clonality of the parasites 
reorganizing the genetic makeup of the antigens expressed on the surface of infected erythrocytes. 
(Portugal 2014) 
 
5.2.5 CD61: CD61 is the Integrin beta-3 (β3) which are associated primarily with platelets/ 
thrombocytes as well as being expressed by a wide range of other cells, including leukocytes, 
endothelial and smooth muscle cells as well as having been noted to be useful as a marker for certain 
malignancies. (Meehan 2003; Merono 2002) In human cerebral malaria, the pathogenesis of disease 
has been theorized to be associated with microthrombi composed of plasmodium infected 
erythrocytes adhered to thrombocytes causing occlusion of the microvasculature as well as 
cytoadhesion to and activation of the endothelium. (Cox 2010) In renal transplantation studies, 
microscopic CD61 immunoreactivity detection was observed in cases of capillary platelet activation 
without evidence of light microscopic thrombi. (Meehan 2003) CD61 has been used in the study of 
cerebral malaria in humans and in murine models of cerebral malaria (Grau 2003; Hochman 2015; Oo 
1987; Patnaik 1994; Porta 1993; Sun 2003; Wassmer 2003; White 2009) but as yet, we were not able 
to find any relevant non-human primate studies. 
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5.2.6 CD68: CD68 represents a glycoprotein widely expressed on monocytes/macrophages (and more 
weakly in some activated lymphocytes) is found in cytoplasmic granules within a range of 
hematopoetic cells. The immunohistochemical marker for the glycoprotein is used extensively to 
identify cells within the macrophage lineage. Macrophages play a crucial role in the control and 
elimination of malaria infections. However, in humans the disease has been demonstrated to inhibit 
macrophage function.  One theory involves an inhibitory role of malaria pigment or hemozoin. 
(Nielsen 1986) Researchers have observed that phagocytosis by macrophages of low numbers of 
infected erythrocytes (iRBCs) containing hemozoin inhibits additional phagocytosis of both iRBCs or 
other associated material.  Additionally, studies have noted that the actual process of intracellular 
destruction of the pathogens was also interrupted in those macrophages consuming hemozoin in 
comparison with monocytes which phagocytozed erythrocytes in earlier stages of infection. 
(Schwartzer 1996) 
 
5.2.7 Cleaved caspase-3: Cleaved caspase-3 is a caspase protein that interacts with caspase-8 and 
caspase-9. The caspases are a family of endoproteases involved in cell regulatory networks which are 
in turn associated with inflammation, apoptosis and cell death.  Sequential activation of caspases 
cascades to initiate cellular apoptosis. In Alzheimer's disease, the predominant caspase involved in 
the cleavage of amyloid-beta 4A precursor protein is Cleaved caspase 3. Amyloid-beta 4A is then 
associated with neuronal cell death. (McIlwain 2013) In malaria, studies have shown that Cleaved 
caspase 3 (and a variety of other apoptosis-associated molecules) are upregulated.  In the brain, this 
appears to be driven by TNF activation and subsequent platelet binding to the endothelium.  The 
apoptosis of vascular endothelial cells during malaria infection contributes to the compromise of the 
blood-brain barrier and the resulting cerebral edema. (Baton 2008) 
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5.2.8 Beta - Amyloid precursor protein (β-APP): β-APP is expressed in the synapses of neurons. While 
the primary purpose remains unknown, the integral membrane protein is theorized to play a 
regulatory role in neural plasticity (Turner 2003), synapse formation (Priller 2006), and iron export. 
(Duce 2010) The protein has been studied extensively due to its posited activity as the precursor 
molecule through which proteolysis forms beta amyloid (Aβ) whose amyloid fibrillar form is the 
primary component of the amyloid plaques observed in the cerebrum of patients with Alzheimer's 
disease.   β-APP is observed extensively in synaptic repair and formation, and its expression has been 
observed to be upregulated both during neuronal development and response to injury.  β-APP is an 
immunohistochemical marker of axonal injury, the expression of which was originally thought to be 
limited to trauma such as diffuse axonal injury, but has subsequently been shown to increase as a 
marker or axonal injury in infectious diseases as well. Inhibition of fast axonal transport causes beads 
of the protein to localize in damaged axons, allowing their demonstration in tissue sections, and was 
first described in CM by Medana et al (2002) and subsequently in pediatric fatal malaria cases. 
(Dorovini-Zis 2011) 
In this part of the study, as well as using negative control tissues (taken from animals dying of 
noninfectious causes from the same colony), there was an opportunity to study a limited number of 
animals infected with a chimeric Human Immunodeficiency Virus Envelope-expressing Simian 
Immunodeficiency Virus (SHIV). (Shedlock 2009) This particular model is being employed at AFRIMS in 
the examination of early CNS infection in HIV.  It was hoped that the SHIV infected animals would 
provide a good positive control for subtle neuropathological changes compared to P. coatneyi malaria 
infection, as it is generally represented by an early viral parenchymal CNS infection without marked 
neuropathology and without centralization of the pathological process in the vascular and 
perivascular compartment.   
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5.3 Immunohistochemical Results: 
Control staining of brain sections was performed on animals either sacrificed for normal 
colony control or dying of non-CNS disease including malignancy, or of trauma due to inter-animal 
fighting. These controls showed basal amounts of CD68+ monocyte staining, particularly on CD68+ 
subsets of pericytes which are a normal functional part of the Virchow-Robin space. Basal levels of T 
and B-cells were minimal, and no CD61+ platelet staining was seen in controls. Likewise, β-APP 
showed minimal staining in normal brain sections and Cleaved caspase 3 was predominantly non-
diagnostic and as such only permits speculation without substantiation. In all cases, the 
immunohistochemical substrate was chosen based on red staining so as to allow for differentiation 
with the brown color of both the hemozoin malaria pigment as well as instances of hemosiderin 
accumulation within phagocytes. (Ramos-Vara 2014) 
In general, immunostaining for the cellular immune subsets showed low numbers of CD3 
positive T-cells, but focally increased, and in some cases appreciable numbers of both intravascular 
and perivascular CD68 positive monocyte/macrophages. GFAP staining and Fibrinogen staining, 
indicating perivascular leakage, was also increased in malaria animals. Some of the CD68+ 
intravascular monocytes showed intracytoplasmic granules of phagocytosed malaria hemozoin 
pigment, were a response to vascular sequestration. (Figure 5.3.1-4) 
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Figure 5.3.1-4. This plate of immunohistochemical photomicrographs includes examples of the 
different antibodies evaluated in the present study.  5.3.1. This image is a representative negative 
control image from the cerebellum.  There is a small caliber blood vessel bounded by endothelium on 
the periphery of the granular layer (asterix). CD68 400x.  5.3.2.  This photomicrograph demonstrates a 
single CD3 positive T cell (arrow) within a cerebral microvessel in which hemozoin pigment is 
observable. CD3 1000x. 5.3.3. is an image in the brain stem in which there are myriad CD68 
immunoreactive cells scattered throughout the neuropil. CD68 1000x. 5.3.4. A blood vessel 
containing innumerable infected erythrocytes with scant CD61 positive platelets and no evidence of 
fibrin thrombus formation or thrombocyte adherence to the endothelium (vessel outlined by arrows).  
While there is no immunoreactivity noted within the photomicrograph, strong positive 
immunostaining was observed in control slides. CD61 1000x. 
 
232 
 
Immunohistochemical 
Marker  BS CTRL C CTRL BS Exp C Exp C Exp 2 
Mean C 
Exp 1&2 
CD3 8 2 NA 19 5   
  0 0 NA 25 10   
  6 4 NA 10 5   
  5 1 15 2 2   
  NA NA 16 6 0   
  NA NA 8 2 1   
  NA NA 21 4 NA   
  NA NA 16 9 NA   
  NA NA 28 4 NA   
Mean 4.75 1.75 17.33 9 3.83 6.93 
              
CD20 0 0 NA 0 0   
  NA 2 NA 1 NA   
  0 2 NA 1 NA   
  0 0 2 0 0   
  NA NA 0 0 0   
  NA NA 1 0 0   
  NA NA 1 0 NA   
  NA NA 0 0 NA   
  NA NA 0 0 NA   
Mean  0 1 0.67 0.22 0 0.15 
              
CD68 22 5 NA 30 1   
  23 5 NA 2 2   
  0 0 NA 21 NA   
  NA NA NA 1 NA   
  NA NA 102 7 0   
  NA NA 91 25 39   
  NA NA 137 47 NA   
  NA NA 190 22 NA   
  NA NA 120 5 NA   
  NA NA 146 35 NA    
Mean 15 3.33 131 19.5 10.5 16.93 
              
Fibrinogen* 0 0 NA 1 1   
  NA 0 NA 2 3   
  0 0 NA 3 2   
  0 0 4 3 1   
  NA 0 4 2 1   
  NA NA 4 2 2   
  NA NA 5 2 NA   
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  NA NA 4 1 NA   
  NA NA 4 1 NA   
Mean 0 0 4.17 1.89 1.67 1.8 
              
GFAP** 0 0 NA 3 4   
  NA 0 NA 2 1   
  0 0 NA 2 2   
  0 0 2 2 3   
  NA 0 2 3 2   
  NA NA 2 3 2   
  NA NA 2 2 NA   
  NA NA 2 2 NA   
  NA NA 3 1 NA   
Mean 0 0 2.17 2.22 2.33 2.27 
 
 
 
 
Table 5.3.1 Quantitative and semi-quantitative analysis of multiple immunohistochemical stains of 
central nervous system tissues from P. coatneyi infected rhesus macaques. 
This table contains the data from the evaluation of the CD3, CD20, CD68, GFAP and 
Fibrinogen immunohistochemical studies.  CD61 has been omitted as the results were negative across 
all experimental animals.  In the case of the various cluster of differentiation stains, the numbers 
represent absolute counts of immunoreactive cells over 20 high powered fields (defined as 400x).  
The GFAP and Fibrinogen severity scores are primarily qualitative and through assessment of a range 
of microscopic changes in comparison with control samples, a semi-quantitative score was assessed 
to each sample.  The five-point scoring system consisted of gradation in severity of changes to the 
neurons, axons and dendrites within a given section in contrast with normal controls as described in 
Chapter 2.  In all cases, stains were conducted in both the brain stem and the cerebrum, however 
each evaluated animal had two samples stained from the midbrain and as such, mean scores were 
* Fibrinogen: Overall impression is that microcapillaries are more susceptible to leakage than larger vessels.  
Additionally, there is uptake of fibrin by perivascular and parenchymal monocytes. 
** GFAP: Qualitative/ Loss of fine architecture, swelling, process blunting and increased staining. 
Key: BS = Brain Stem; C = Cerebrum; CTRL = Control; Exp = Experimental; NA = Not Available 
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analyzed in order to regularize the data.  From these, P values were then calculated using the Mann-
Whitney test in order to determine statistical significance of both brain stem and cerebral scores in 
comparison with control and between experimental brain stem samples and experimental cerebral 
samples.   
5.4 Immunohistohemical Results Interpretation: 
5.4.1 GFAP: The immunostaining of GFAP was characterized in tissue from experimental animals in 
comparison with similar sections of the cerebrum and brain stem in the control animals.  The 
evaluation was primarily qualitative and assessed the fine architecture of the astrocytes and the 
neuronal processes.  Neuronal/axonal injury was characterized based on swelling of the 
cytoplasm/neuroplasm, dendrites and axons with blunting of the processes and increased uptake of 
stain. (Figure 5.4.1.1-4)  
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Figure 5.4.1.1-4: GFAP immunostaining patterns.  5.4.1.1 This immunohistochemical 
photomicrograph of the cerebrum of a P. coatneyi infected rhesus macaque illustrates the loss of the 
axonal and dendritic fine architecture (arrow), the globular swelling of the soma, blebbing of the 
cytoplasm and pericellular edema. GFAP 1000x; 5.4.1.2. This is contrasted with the fine fibrillary 
architecture of a cerebral sample from a control macaque. GFAP 400x. 5.4.1.3. Similarly, in the brain 
stem, experimental samples stained with GFAP also displayed similar pathological changes to the 
neurons (arrow). GFAP 1000x; 5.4.1.4. Juxtaposed with control samples of brain stem in which the 
soma of neurons contains a small amount of uniform cytoplasm (arrow) and thin, interconnecting 
dendrites (arrowheads). GFAP 1000x. 
In all experimental samples, the qualitative observations demonstrated a highly significant 
change in the fine structure, with loss of detail in the experimental animals suggestive of 
degenerative, apoptotic or even early necrotic changes.  In the case of degeneration, the neurons 
became swollen with loss of fine processes.  There was frequent evidence of peri-cellular neuropil 
clearing interpreted to be edema. Although apoptosis is primarily an ultrastructural diagnosis, GFAP-
stained cells were interpreted to be apoptotic when there was nuclear condensation combined with 
cytoplasmic blebbing and increased GFAP staining. (Saraste 1999) Finally, those cells characterized as 
necrotic were typically fragmented, shrunken and angulated with loss of processes.  These findings 
were observed consistently among the experimental animals and a semi-quantitative assessment of 
the examined sections revealed a significant degree of damage in the infected animals in comparison 
with the normal control rhesus which represented a baseline. (Figure 5.4.2) 
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Table Analyzed GFAP  Table Analyzed GFAP  Table Analyzed GFAP 
Column B BS Exp  Column D C Exp  Column D C Exp 
vs. vs.  vs. vs.  vs. vs. 
Column A BS CTRL  Column C C CTRL  Column B BS Exp 
        
Mann Whitney test   Mann Whitney test   Mann Whitney test  
P value 0.0119  P value 0.0005  P value 0.8785 
Exact or approximate P value? Exact  Exact or approximate P 
value? 
Exact  Exact or approximate P value? Exact 
P value summary *  P value summary ***  P value summary ns 
Significantly different (P < 
0.05)? 
Yes  Significantly different (P < 
0.05)? 
Yes  Significantly different (P < 0.05)? No 
One- or two-tailed P value? Two-tailed  One- or two-tailed P value? Two-
tailed 
 One- or two-tailed P value? Two-tailed 
Sum of ranks in column A, B 6, 39  Sum of ranks in column C, D 15, 90  Sum of ranks in column B, D 46.5, 73.5 
Mann-Whitney U 0  Mann-Whitney U 0  Mann-Whitney U 25.5 
Difference between medians   Difference between medians   Difference between medians  
Median of column A 0, n=3  Median of column C 0, n=5  Median of column B 2, n=6 
Median of column B 2, n=6  Median of column D 2, n=9  Median of column D 2, n=9 
Difference: Actual 2  Difference: Actual 2  Difference: Actual 0 
Difference: Hodges-Lehmann 2  Difference: Hodges-Lehmann 2  Difference: Hodges-Lehmann 0 
Figure 5.4.2 GFAP staining. Semi-quantitative assessment of the presence of suspected neuronal 
damage ranked on a severity scale of 0-5 based on a mean calculation of all sections evaluated 
qualitatively and semi-quantitatively.  The criteria involved in the scoring included loss of fine 
architecture, neuroplasmic swelling, blebbing or fragmentation, process blunting, loss and increased 
GFAP staining intensity.  There was equivalent severity of changes observed in the cerebrum and the 
brainstem.  
 
0
0.5
1
1.5
2
2.5
0 0
2.17
2.27
BS CTRL          Cerebum CTRL            BS Exp          Cerebrum Exp
GFAP
237 
 
Statistical investigation was conducted for each of the immunohistochemical stains using the Mann-
Witney U test, 2 tailed, nn parametric, with significance scored as p<0.05.  In the case of the GFAP, 
analysis revealed a significant increase in the degree of GFAP expression in experimental animals in 
both the brain stem (p<0.001) and cerebrum (P<0.012) in comparison with control samples, however 
no difference was seen between GFAP expression in the brain stem and the cerebrum within the 
experimental cohort (p= 0.878).  
 
5.4.2 Fibrinogen: Fibrinogen staining revealed a similar pattern and was assessed in comparison with 
the normal controls both qualitatively and semi-quantitatively.  Normal control animals had 
fibrinogen staining uniquely restricted to the lumen of the microvasculature and in no instance 
extending into the adjacent perivascular space or the neuropil.  Conversely, in the experimental SM 
animals there was consistent and significant fibrinogen staining of cells around the affected vessels, 
as well as free fibrinogen in the perivascular space and dissecting the neuropil.  The staining pattern 
of fibrinogen in the experimental animals indicated definitive blood-brain barrier leakage when 
compared with the normal controls. (Figure 5.4.3.)  The findings were more significant in the brain 
stem than in the cerebrum which is consistent with the histopathological findings that severity of 
pathological features was also greater in the brain stem and the spinal cord than in the cerebrum or 
cerebellum. (Figure 5.4.4.) 
238 
 
 
Figure 5.4.3.1-4: Fibrinogen immunostaining patterns. 5.4.3.1. This photomicrograph demonstrates 
the fibrinogen leakage in a cerebral section from an experimental animal.  There is increased 
generalized neuropil staining as well as immunoreactivity within the endothelium and cells 
interpreted to be phagocytic cells within the periphery of the leaking vessel. Fibrinogen 1000x. 
5.4.3.2. In this sample from the brain stem, there is similar increased immunoreactivity in a 
generalized, background fashion as well as highlighting the perivascular area and within neighboring 
cells interpreted to be monocytes/macrophages. Fibrinogen 400x. These two experimental samples 
are contrasted with controls, 5.4.3.3. in the cerebrum and 5.4.3.4 in the brain stem. Fibrinogen 400x. 
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Table Analyzed Fibrinogen  Table Analyzed Fibrinogen  Table Analyzed Fibrinogen 
Column B 
BS Exp  Column D C exp  Column D C exp 
vs. vs.  vs. vs.  vs. vs. 
Column A BS ctrl  Column C C ctrl  Column B BS Exp 
Mann Whitney test 
  Mann Whitney test   Mann Whitney test  
P value 0.0119  P value 0.0010  P value 0.0002 
Exact or approximate P value? 
Exact  Exact or approximate P 
value? 
Exact  Exact or approximate P value? Exact 
P value summary *  P value summary ***  P value summary *** 
Significantly different (P < 
0.05)? 
Yes  Significantly different (P < 
0.05)? 
Yes  Significantly different (P < 
0.05)? 
Yes 
One- or two-tailed P value? Two-tailed  One- or two-tailed P value? Two-tailed  One- or two-tailed P value? Two-tailed 
Sum of ranks in column A, B 6, 39  Sum of ranks in column C, D 15, 90  Sum of ranks in column B, D 75, 45 
Mann-Whitney U 0  Mann-Whitney U 0  Mann-Whitney U 0 
Difference between medians 
  Difference between medians   Difference between medians  
Median of column A 0, n=3  Median of column C 0, n=5  Median of column B 4, n=6 
Median of column B 4, n=6  Median of column D 2, n=9  Median of column D 2, n=9 
Difference: Actual 4  Difference: Actual 2  Difference: Actual -2 
Difference: Hodges-Lehmann 4  Difference: Hodges-Lehmann 2  Difference: Hodges-Lehmann -2.5 
 
Figure 5.4.4 Fibrinogen staining. Semi-quantitative assessment of the integrity of the blood brain 
barrier, ranked on a scale of 0-5, within the cerebrum and the brain stem when compared with 
normal control sections.  There was increased leakage (and theorized associated injury) noted in the 
brainstem in comparison with the cerebrum. Calculations of P values demonstrated statistical 
significance between brain stem and controls, cerebrum and controls as well as demonstrating 
increased fibrinogen leakage in the brain stem in comparison with the cerebrum. 
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5.4.3 CD3: CD3 staining demonstrated a predilection for T-cell localization in the brain stem in 
comparison with the cerebrum.  However, the mean number of CD3-positive cells in the evaluated 
experimental sections was significantly higher in both the cerebrum and the brain stem when 
contrasted with the normal background levels in the central nervous system of the rhesus macaque 
control animals.  The highest count was 28 cells (per 20 HPF) observed to be immunoreactive in one 
of the brain stems of the experimental animals. 
 
Table Analyzed CD3  Table Analyzed CD3  Table Analyzed CD3 
Column B BS Exp 
 Column D C exp  Column D C exp 
vs. vs.  vs. vs.  vs. vs. 
Column A BS ctrl  Column C C ctrl  Column B BS Exp 
Mann Whitney test  
 Mann Whitney test   Mann Whitney test  
P value 0.0143  P value 0.0573  P value 0.0108 
Exact or approximate P value? Exact 
 Exact or approximate P 
value? 
Exact  Exact or approximate P value? Exact 
P value summary *  P value summary ns  P value summary * 
Significantly different (P < 
0.05)? Yes 
 Significantly different (P < 
0.05)? 
No  Significantly different (P < 0.05)? Yes 
One- or two-tailed P value? Two-tailed 
 One- or two-tailed P value? Two-
tailed 
 One- or two-tailed P value? Two-
tailed 
Sum of ranks in column A, B 10.5, 44.5  Sum of ranks in column C, D 15.5, 75.5  Sum of ranks in column B, D 69, 51 
Mann-Whitney U 0.5  Mann-Whitney U 5.5  Mann-Whitney U 6 
Difference between medians  
 Difference between medians   Difference between medians  
Median of column A 5.5, n=4  Median of column C 1.5, n=4  Median of column B 16, n=6 
Median of column B 16, n=6  Median of column D 4, n=9  Median of column D 4, n=9 
Difference: Actual 10.5  Difference: Actual 2.5  Difference: Actual -12 
Difference: Hodges-Lehmann 11  Difference: Hodges-Lehmann 3.25  Difference: Hodges-Lehmann -12 
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Figure 5.4.5 CD3 staining. Quantitative assessment of the number of CD3-positive cells counted in 
experimental and control sections of the brain stem and the cerebrum over 20 high powered fields 
(400x). There was statistical significance in the increased infiltration of CD3 immunoreactive cells 
within the P. coatneyi-infected animals in the brain stem but not in the cerebrum. Furthermore, there 
was an almost 3-fold higher number in the brain stem in comparison to the cerebrum in experimental 
animals. 
 
 
Figure 5.4.6 CD3 immunostaining patterns. CD3 immunohistochemical photomicrograph 
demonstrating a strongly immunoreactive cell adjacent to a cerebral capillary with notable infected 
erythrocyte sequestration.  CD3 1000x. 
 
5.4.4 CD20: Quantitative assessment of the number of CD20-positive cells counted in experimental 
and control sections of the brain stem and the cerebrum over 20 high powered fields (400x). There 
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was no significant difference in the frequency of CD20 immunoreactive cells between tissues of 
control and experimental animals.  In both cases, the maximum number of CD20 immunoreactive 
cells observed over 20 high powered fields was 2, and in most instances no cells were positive for the 
marker. No statistically significant difference was calculated between experimental or control animals 
in either the brain stem or the cerebrum. CD20 staining demonstrated that B cells do not show any 
increase within brain microvessels, which is a common feature with both human and murine disease. 
In the macaque model, there were only rare cells observed to be immunoreactive, and in those cases 
there was no significant difference between experimental and control animals nor between the brain 
stem and the cerebrum. 
 
 
Table Analyzed CD20  Table Analyzed CD20  Table Analyzed CD20 
Column B 
BS Exp  Column D C Exp  Column D C Exp 
vs. vs.  vs. vs.  vs. vs. 
Column A BS CTRL  Column C C CTRL  Column B BS Exp 
Mann Whitney test 
  Mann Whitney test   Mann Whitney test  
P value 0.3929  P value 0.2783  P value 0.2328 
Exact or approximate P value? 
Exact  Exact or approximate P 
value? 
Exact  Exact or approximate P value? Exact 
P value summary ns  P value summary ns  P value summary ns 
Significantly different (P < 
0.05)? 
No  Significantly different (P < 
0.05)? 
No  Significantly different (P < 0.05)? No 
One- or two-tailed P value? Two-tailed  One- or two-tailed P value? Two-  One- or two-tailed P value? Two-
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tailed tailed 
Sum of ranks in column A, B 
10.5, 34.5  Sum of ranks in column C, D 35, 56  Sum of ranks in column B, D 56.5, 
63.5 
Mann-Whitney U 4.5  Mann-Whitney U 11  Mann-Whitney U 18.5 
Difference between medians 
  Difference between medians   Difference between medians  
Median of column A 0, n=3  Median of column C 1, n=4  Median of column B 0.5, n=6 
Median of column B 0.5, n=6  Median of column D 0, n=9  Median of column D 0, n=9 
Difference: Actual 0.5  Difference: Actual -1  Difference: Actual -0.5 
Difference: Hodges-Lehmann 0.5  Difference: Hodges-Lehmann -0.5  Difference: Hodges-Lehmann 0 
Figure 5.4.7 CD20 staining. Quantitative assessment of the number of CD20-positive cells counted in 
experimental and control sections of the brain stem and the cerebrum over 20 high powered fields 
(400x). There was no statistical significance as to increased infiltration of CD20 immunoreactive cells 
within the P. coatneyi-infected animals in the brain stem or the cerebrum in the samples evaluated.  
 
5.4.5 CD61: CD61 immunoreactivity, within the microvasculature of the cerebrum, cerebellum, brain 
stem and spinal cord, was negative in both control and experimental animals in all cases examined.  
This was consistent with the preponderance of cases in which there were no observable aggregates 
of thrombocytes or fibrin thrombi in the central nervous system.  Those cases in which thrombi were 
noted in the brain during histopathological examination, they were observed as correlating with 
mural fibrinoid vasculitis.  Considering the low numbers of total cases examined with 
immunohistochemistry, the few cases with such pathology were excluded from 
immunohistochemical analysis to avoid skewing the results.  
 
5.4.6 CD68: CD68 immunohistochemistry demonstrated a notable increase of CD68 positive cells 
observed within the central nervous system of experimental animals in comparison with control 
animals.  As with CD3, immunoreactivity of CD68-positive cells in infected monkeys appeared to have 
a proclivity for the brain stem, with one animal having a count of 190 immunoreactive cells in 20 high 
powered fields (400x). This resulted in a 10-fold increase in immunoreactive cells in the brain stem of 
P. coatneyi infected animals in contrast with controls.  The calculated P value demonstrated statistical 
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significance. While the cerebrum had significantly fewer cells which were positive for the marker in 
comparison with the brain stem, there was still a 5-fold difference between the control and 
experimental animals, however calculation of the p value demonstrated that there was no statistical 
significance in the cerebrum.  These findings suggest strong evidence that within the brain stem, 
CD68 positive monocytes/macrophages play an important role in the neuropathology of P. coatneyi 
induced disease in rhesus macaques. 
 
 
Table Analyzed CD68  Table Analyzed CD68  Table Analyzed CD68 
Column B BS Exp  Column D C Exp  Column D C Exp 
vs. vs.  vs. vs.  vs. vs. 
Column A BS CTRL  Column C C CTRL  Column B BS Exp 
Mann Whitney test   Mann Whitney test   Mann Whitney test  
P value 0.0238  P value 0.2203  P value 0.0002 
Exact or approximate P value? 
Exact  Exact or approximate P 
value? 
Exact  Exact or approximate P value? Exact 
P value summary *  P value summary ns  P value summary *** 
Significantly different (P < 
0.05)? 
Yes  Significantly different (P < 
0.05)? 
No  Significantly different (P < 0.05)? Yes 
One- or two-tailed P value? 
Two-tailed  One- or two-tailed P value? Two-
tailed 
 One- or two-tailed P value? Two-
tailed 
Sum of ranks in column A, B 6, 39  Sum of ranks in column C, D 13, 78  Sum of ranks in column B, D 81, 55 
Mann-Whitney U 0  Mann-Whitney U 7  Mann-Whitney U 0 
Difference between medians 
  Difference between medians   Difference between medians  
Median of column A 
22, n=3  Median of column C 5, n=3  Median of column B 128.5, 
n=6 
Median of column B 
128.5, n=6  Median of column D 18.25, 
n=10 
 Median of column D 18.25, 
n=10 
Difference: Actual 106.5  Difference: Actual 13.25  Difference: Actual -110.3 
Difference: Hodges-Lehmann 114.5  Difference: Hodges-Lehmann 15.75  Difference: Hodges-Lehmann -108 
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Figure 5.4.8 CD68 staining. Quantitative assessment of the number of CD68-positive cells counted in 
experimental and control sections of the brain stem and the cerebrum over 20 high powered fields 
(400x). There was statistical significance in the increased infiltration of CD68 immunoreactive cells 
within the P. coatneyi-infected animals in the brain stem but not in the cerebrum. Furthermore, there 
was an approximately 8-fold increase of immunoreactive cells in the brain stem in comparison to the 
cerebrum in experimental animals. 
 
 
Figure 5.4.9.1-2: CD68 immunostaining patterns.  These CD68 immunohistochemical 
photomicrographs demonstrate aggregates of immunoreactive cells in the brain stem adjacent to a 
small focus of hemozoin pigment (left) and a high number of strongly immunoreactive cells adjacent 
to a cerebral capillary with notable infected erythrocyte sequestration (right).  CD68 1000x. 
 
5.4.7 Β-APP: Only a select few samples stained with βAPP and Cleaed caspase 3 were considered to 
be diagnostic. In those instances, there was observable evidence of cellular staining with both 
antigens. However due to the small sample size it is not possible to infer statistical significance.  As 
such, for the purpose of this dissertation, the valuation of both antigens must be limited to a 
qualitative assessment.   
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βAPP staining was far more intense and frequent in those sections evaluated from experimental 
animals in comparison with controls.  Staining was most frequently cytoplasmic and the most 
powerful immunoreactivity was noted in the neurons and the Purkinje cells, which correlates well to 
the histopathological observations which noted a significant increase in damage in these cells in 
comparison with the control animals. (Figure 5.4.10.1-4) 
 
 
Figure 5.4.10.1-4: βAPP immunostaining patterns: This immunohistochemical photomicrographic 
plate illustrates βAPP staining in multiple locations within the central nervous system.  5.4.10.1. 
Cerebrum, control. Background staining was typically very faint as can be noted in the cerebral 
control sample. βAPP 200x; 5.4.10.2. In this image from the cerebrum of an infected animal, multiple 
neurons are strongly immunoreactive, suggestive of injury. βAPP 400x. 5.4.10.3. This 
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photomicrograph demonstrates immunoreactivity in the brain stem of an experimental sample. βAPP 
400x. 5.4.10.4. In contrast with the control animal, the immunoreactivity of the Purkinje cells and 
astrocytes from the cerebellum of an experimental animal is extremely pronounced. This 
photomicrograph, combined with those from other segments of the central nervous system in 
contrast with the control demonstrate βAPP staining consistent with significant neuronal and Purkinje 
cell injury and the histopathological observations.  βAPP 1000x.    
 
5.4.8 Cleaved caspase 3: Cleaved caspase 3 staining was only successful in a select few animals and as 
such it is even less significant that the βAPP immunohistochemistry.  In the few cases in which 
staining was successful, scattered cells, often adjacent to microvasculature with iRBC sequestration, 
demonstrated the intense immunoreactivity.  (Figure 5.4.11) 
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Figure 5.4.11: Cleaved caspase 3 immunostaining patterns. In this photomicrograph, several cells 
conforming to the periphery of brain stem capillaries are immunoreactive to Cleaved caspase 3.  The 
limited number of successful immunoreactive slides precludes definitive statements as to the value of 
these findings, or even to the qualitative significance.  Cleaved caspase 3 is intended on highlighting 
those cells undergoing apoptotic change due to its role in DNA fragmentation and in chromatin 
condensation, and as such it may be posited that the illustrated cells which appear to be vascular 
endothelium are injured cells undergoing apoptosis, however the nuclei appear to be within normal 
limits and as such do not conform to the typical microscopic findings that are correlated with 
apoptosis.  As such, this is purely speculation due to the low numbers of cases in which Cleaved 
caspase 3 was considered to be diagnostic. The image is included purely to illustrate the need for 
further evaluation and elucidation of this immunohistochemical marker and of the role of apoptosis 
in P. coatneyi pathogenesis in general.  Cleaved caspase 3 1000x. 
 
5.5 CSF Measurement of Blood-Brain Barrier integrity and Tau protein release: 
As an adjunct to the immunohistochemical analyses, we examined the ratio of albumin in 
cerebrospinal fluid (CSF) to serum, thereby establishing an albumin index (AI) which served as a 
measure of BBB permeability in the P. coatneyi infected macaques.  The use of AI to measure BBB 
permeability is well established in a number of different CNS diseases, and has been used to study 
BBB function in both adult and pediatric CM cases. (Brown 2000; Brown 2001) CSF (and serum) taken 
from P. coatneyi infected macaques at post mortem was compared with control animals and a cohort 
of Simian Human Immunodeficiency Virus (SHIV)-infected animals from a collaborator’s study.   
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5.5.1 Blood-brain barrier integrity and brain injury in P. coatneyi-infected monkeys: 
The ratio of albumin in cerebrospinal fluid to serum served as an albumin index determining 
BBB permeability in infected monkeys. The CSF and serum albumin levels were evaluated using an 
albumin ELISA kit. As described above, we employed three cohorts of macaques: control group (n=2), 
12-week post SHIV-infection Indian origin rhesus macaques from the same AFRIMS colony (n=12), 
and P. coatneyi-infected monkeys (n=12). The control animals were normal rhesus macaques who 
were euthanized due to non-infectious disease or trauma. The SHIV-infected monkeys were 
euthanized at 12 weeks post-inoculation, and immediately post-euthanasia serum and CSF samples 
were collected. For P. coatneyi-infected monkeys, nine out of 12 monkeys were derived from the 
methylene blue clinical trial study described in Chapter 7, in which the animals were euthanized once 
15% parasitemia and pre-determined clinical symptomology and clinical pathologic criteria were 
reached.  As with the SHIV and control animals, serum and CSF samples were collected immediately 
after euthanasia. The AI and albumin concentrations in CSF and serum are shown in Table 5.5.1. The 
normal range of AI is < 5 x 10-3. All monkeys in control and SHIV groups (median 1.115 x 10-3, 
interquartile range 1.65-3.49 x 10-3) were in the control range (median 0.975 x 10-3, interquartile range 
0.74-1.21 x 10-3). Only one P. coatneyi-infected monkey had an abnormal albumin ratio calculated at 
10.99 x 10-3. However, the AI of P. coatneyi-infected monkeys (median 2.45 x 10-3, interquartile range 
1.65-3.49 x 10-3) was significantly higher in comparison with that in SHIV-infected monkeys using 
Kruskal-Wallis test, one-way ANOVA multiple comparison as shown in Figure 5.5.2.1.  While the 
majority of the P. coatneyi infected animals had CSF albumin index levels that were empirically higher 
than those observed in the two control animals, these findings were not statistically significant using 
the Kruskal-Wallis test.  While, this would appear to fail to support the immunohistochemical 
fibrinogen analyses which demonstrated visual evidence of BBB leakage and suggested potential 
injury to the microvascular endothelium, the statistically significant variance between the SHIV 
animals and the P. coatneyi animals appears to lend support, especially in light of having only two 
control animals. If nothing else, the AI study bears repeating with greater numbers of samples.  
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Monkey 
group 
Monkey 
ID 
Methylene blue 
treatment (mg/kg 
of monkey weight) 
Serum 
albumin 
(µg/ml) 
CSF albumin 
(µg/ml) 
AI (10-3) Tau (total) 
(pg/ml) 
Control R541 none 39600 48 1.212 298 
 R626 none 37600 28 0.745 139 
P. 
coatneyi DA831 
none 
42400 96 2.264 622 
 DA923 none 36800 138 3.750 410 
 R519 none 38000 82 2.158 730 
 R130 6  29200 80 2.740 286 
 R453 6  40800 28 0.686 168 
 R761 6  28000 74 2.643 198 
 DA977 10  30800 84 2.727 348 
 R420 10  32400 124 3.827 520 
 R711* 10  30400 334 10.987 294 
 R121 16  36800 80 2.174 462 
 R338 16  28400 42 1.479 1435 
 R745 16  31200 34 1.090 242 
SHIV R323  40000 34 0.850 174 
 R333  43600 32 0.734 ND 
 R441  32800 36 1.098 171 
 R450  44400 50 1.126 242 
 R514  44400 26 0.586 ND 
 R522  45600 40 0.877 268 
 R546  31600 102 3.228 ND 
 R607  39200 50 1.276 197 
 R629  44000 26 0.591 185 
 R708  35200 40 1.136 209 
 R731  36000 88 2.444 168 
 R759  45200 58 1.283 196 
AI =Albumin index; ND = not determined due to inadequate sample volume. *AI of this monkey 
(R711) was abnormal. 
 
Table 5.5.1 Albumin index and CSF Tau levels in monkeys by disease or control groups.  
 
 
5.5.2 CSF Tau (total) protein measurement as a biomarker for neuro-axonal degeneration:  
Tau proteins stabilize microtubules, with a specific function relating to axonal microtubules.  The 
proteins are abundant in neurons of the central nervous system, while being expressed at much 
lower levels in oligodendrocytes and astrocytes. Certain neuropathologies of humans such as 
Alzheimer's disease have been reported to cause Tau proteins to undergo transformative pathologies 
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resulting in an inability to properly stabilize microtubules. Due to the relative specificity of Tau to the 
neurons within the CNS, the protein is an excellent marker for neuronal damage.  
Nine CSF samples of SHIV-infected monkeys were available as a comparative diseased cohort for the 
Tau assay. The CSF Tau concentration in P. coatneyi-infected monkeys (median 379 pg/ml, 
interquartile range 253-597 pg/ml) was significantly increased in comparison to the SHIV groups 
(median 196 pg/ml, interquartile range 172-226 pg/ml), but interestingly were not significantly 
different when compared with the control cohort (median 219 pg/ml, interquartile range 139-298 
pg/ml) as described in Figure 5.5.2. 
                                                                                                                                                                     
 
 
Figure 5.5.2.1 Albumin index (AI) as a measure of blood-brain barrier function in different groups of 
monkeys. Middle lines indicate median; error bars represent interquartile range (IQR). Each dot 
represents an individual monkey. Shaded area shows normal values of AI. Asterisk (*) indicates 
significant difference at p ≤ 0.05 by Kruskal-Wallis test. 
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Figure 5.5.2.2 Tau (total) protein in different groups of monkeys. Middle lines indicate median; error 
bars represent interquartile range (IQR). Each dot represents an individual monkey. (*) indicates 
significant difference at p ≤ 0.05 by Kruskal-Wallis test. 
 
5.5.3 Pro-inflammatory cytokine response in the central nervous system of P. coatneyi-infected 
rhesus macaques:   
As a preliminary study to identify the spectrum of cytokine release into the CSF during 
experimental severe malaria, a panel of cytokine levels was measured using multiplex ELISA on 
cerebrospinal fluid from (n=3) P. coatneyi-infected monkeys and compared with the same controls 
and SHIV-infected animals used in the determination of an albumin index.   
Tau (total) ELISA
control SHIV P. coatneyi
0
200
400
600
800
1400
1600
Monkey group
T
a
u
 (
to
ta
l)
(p
g
/m
l)
*
253 
 
In order to evaluate the pro-inflammatory response in the central nervous system in P. coatneyi-
infected rhesus, 23 cytokines were evaluated using multiplex assays. Six cytokines, including G-CSF, IL-
6, IL-8, IL-15, MCP-1, TGF-α, were found to be expressed in greater amounts in comparison with both 
control and SHIV-infected macaque specimens which were run concurrently (Figure 5.5.3.1; Table 
5.5.3.1). The levels of G-CSF, IL-8, MCP-1 and TGF-α in P. coatneyi-infected rhesus were markedly 
increased in comparison to both control and SHIV-infected monkey groups, as well as there being a 
very large increase in IL-6 and IL-15 noted between P. coatneyi and SHIV groups. Statistical 
significance was assessed between the different groups when possible using the Kruskal-Wallis test, 
however based on the number of samples for both the controls and SHIV groups that were out of 
range (OOR) as well as the very small sample size for the P. coatneyi cohort, the significance needs to 
be taken with a high degree of caution.   
This preliminary cytokine profile demonstrated a range of interesting findings suggestive of activation 
of angiogenic pathways (TGF-alpha, IL-8) suggestive of endothelial injury, proinflammatory and 
specific inflammatory cell proliferation pathways (IL-6, IL-15 and MCP-1) and bone marrow 
stimulation (G-CSF).  Of note is that several of the cytokine which demonstrated increased profiles are 
either produced by macrophages and/or T-cells (IL-6, IL-8, TGF-alpha), are chemoattractants for 
macrophages (MCP-1) or are involved in proliferation of cells observed to be involved in the 
pathogenesis of P. coatneyi induced disease (IL-15: Induces NK cell and T-cell proliferation).  These 
findings support the data elucidated in the earlier portion of this chapter relating to the 
Immunohistochemical profiles which noted increases in CD68 and CD3 positive cells. 
This data provides an initial foundation and while these preliminary findings are of interest, 
significantly more intensive study is required prior to contributing to the comparative description of 
P. coatneyi and its correlation to severe and cerebral malaria in humans.   
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Figure 5.5.3.1. Pro-inflammatory cytokine responses in the CSF of different disease groups. Bar graphs 
represent median; error bars represent interquartile range (IQR). (*) indicates significant difference at 
p ≤ 0.05 by Kruskal-Wallis test. 
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Monkey 
group 
Monkey 
ID 
G-CSF 
(pg/ml) 
IL-6 
(pg/ml) 
IL-8 
(pg/ml) 
IL-15 
(pg/ml) 
MCP-1 
(pg/ml) 
TGF-α 
(pg/ml) 
Control R541 OOR 2.47 13.22 12.20 274.91 13.88 
 
R616 OOR OOR 5.61 18.54 223.84 12.35 
 
R626 OOR OOR 7.06 16.61 379.01 31.02 
Median 
(IQR) 
 
0  
(0-0) 
18  
(16-24) 
7.06 
(5.61-
13.22) 
16.61  
(12.2-
18.54) 
274.9 
(223.8-
379) 
12.35 
(12.35-
31.02) 
P. coatneyi DA831 13.19 107.985 141.50 23.75 742.51 74.10 
 
DA923 72.43 98.655 247.99 37.29 1427.98 94.65 
 
R519 176.57 500.765 359.96 38.05 1302.24 106.40 
Median 
(IQR) 
 
72.43 
(13.19-
176.6) 
795  
(688-
4354) 
248  
(141.5-
360) 
37.29 
(23.75-
38.05) 
1302 
(742.5-
1428) 
94.65 
(74.1-
106.4) 
SHIV R323 OOR OOR 13.68 14.63 428.48 13.33 
 
R333 OOR OOR 18.53 29.17 523.89 22.91 
 
R441 OOR OOR 7.61 14.13 305.32 11.59 
 
R450 OOR 2.47 18.41 12.97 603.61 11.87 
 
R514 OOR 2.59 12.56 20.02 397.37 26.74 
 
R522 OOR OOR 8.70 17.33 294.00 14.15 
 
R546 OOR OOR 11.30 21.18 299.38 10.51 
 
R607 OOR OOR 18.97 18.81 360.33 15.43 
 
R629 OOR 2.24 17.67 15.73 482.84 11.33 
 
R708 OOR 2.24 12.64 14.80 331.90 15.93 
 
R731 OOR OOR 9.76 12.47 364.17 9.48 
 
R759 OOR 3.26 16.61 15.29 283.64 12.82 
Median 
(IQR) 
 
0  
(0-0) 
2.47  
(2.24-
2.925) 
13.16 
(10.15-
18.23) 
15.51 
(14.26-
19.72) 
362.3 
(300.9-
469.3) 
13.08 
(11.4-
15.81) 
OOR = Out of range; G-CSF = Granulocyte-colony stimulating factor; IL-6 = Interleukin-6; IL-8 = 
Interleukin-8; IL-15 = Interleukin-15; MCP-1 = Monocyte chemoattractant protein-1; TGF-α = 
Transforming growth factor alpha. 
 
Table 5.5.3.1.  CSF cytokine levels in monkeys by disease groups. Comparison of 6 cytokines in the 
SHIV animal cohort, compared with 3 animals from the P. coatneyi study and contrasting those with 
samples from normal controls.  
 
5.6 Discussion: 
The histopathological findings described in the previous chapter, and those which will be 
subsequently illustrated in the chapter on ultrastructure, set the stage regarding the hypothesis of 
multifactorial nervous system injury in the P. coatneyi-Rhesus macaque model. The subtle changes 
associated with perivascular edema, neuronal degeneration, necrosis, rare hemorrhage and slight 
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leukocytic infiltrates required confirmation.  The overall analysis of Blood Brain Barrier integrity 
through the immunohistochemical study of fibrinogen and GFAP, combined with the preliminary 
work conducted into the molecular mechanisms of confirmation of the hypothesis of neuronal injury 
as well as the immunohistochemical assessment of different populations of leukocytes in the central 
nervous system have shed light on the pathogenesis of the disease, and reinforced the findings from 
the other modalities we employed.   
CD3, CD20, CD61 and CD68 immunostaining allowed for characterization of the 
immunological profile of those leukocytes which are involved in acute P. coatneyi severe malaria.  The 
analysis identified an increase in CD3 positive T-cells as well as a marked increase in the CD68 positive 
monocyte/macrophage response.  T-cells have been reported to drive pathogenesis in murine 
cerebral malaria as have monocytes (Finley 1982; Grau 1986), however with the exception of the 
occasional finding of Dürck’s granulomas in the white matter of the brain, inflammation is not a 
significant part of the histopathology in humans. (Boonpucknavig 1990; Hunt 2006; Medana 2001; 
Turner 1997)  
Furthermore, CD20 positive B-cells and CD61 positive platelets were minimal and were 
consistent with background findings in control animals.  As such, the immunological profile of P. 
coatneyi appears to deviate somewhat from that observed in humans.  Additionally, while 
microvascular fibrin thrombi have been described in histopathological studies of cerebral malaria in 
humans (Boonpucknavig 1990; Krishnan 2004; MacPherson 1985), other studies have posited that the 
immune system’s response to malarial infection may include a suppression of plasminogen activation 
and therefore, a decrease of thrombotic activity. (Pongponratn 1985; Thuma 2011) The absence of a 
significant platelet driven response in macaques may correlate to this hypothesized pathogenesis in 
humans. 
Difficulties with β-APP restricted the degree with which we can interpret the findings in the 
few cases that were diagnostic, however in those instances, there was a notable and marked increase 
in immunoreactivity in neurons, astrocytes and Purkinje cells in comparison with control animals.  
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Further investigation of the degree of axonal injury and neuronal damage is warranted based on 
these preliminary findings.  Furthermore, the retina is a tissue which was not examined in this study, 
but which, due to the histopathological findings of ganglion cell loss, merits additional evaluation with 
β-APP immunohistochemistry. The problems associated with refining the protocol for use of β-APP in 
the macaque limited the number of samples which could be examined and as such no retinal samples 
were evaluated. 
GFAP and fibrinogen immunostaining showed marked increases based on qualitative 
assessment of the fine architecture in the former and presence of fibrinogen immunoreactivity 
outside of the vessels and within phagocytic cells in the latter, both of which imply damage to the 
blood brain barrier and a degree of vascular leakage. This finding is theoretically supported by the 
ELIZA Albumin Index study in which there was an understated increase in the severe malaria cohort in 
comparison with the SHIV group and empirically in comparison with the two control animals.  The 
increase, while subtle, demonstrated significance when contrasted with the other disease cohort.  
This is similar to what has been reported in humans, where the BBB changes as judged by AI were 
increased in malaria patients compared to controls, but much less than other infectious diseases 
characterized by massive inflammatory destruction to the BBB, such as tuberculosis, Cryptococcosis 
and acute bacterial meningitis. (Brown 2000; Gitau 2005; Mturi 2008)  
There has been significant research examining the cytokine responses associated with the 
immunopathology of Plasmodial infections. (Aubouy 2002; Baptista 1997; Brown 1999; Day 1999; de 
Kossodo 1993; el Nashar 2002; Kern 1989; Peyron 1994; Prakash 2006; Newton 1998; Rodrigues-da-
Silva 2014) Unfortunately there remains a substantial amount of debate as to the specific correlation 
of the cytokine levels and their association with the pathophysiology of observed disease in humans. 
Severe malaria resulting from P. falciparum infection has been proposed to be modulated by the 
increases in circulating TNF-α, IL-1 and IL-6 and IL-8. (Akanmori 2000; Brown 1999) TNF-α levels in P. 
falciparum infections have been demonstrated to be higher in cases of fatal cerebral malaria than in 
those cases that are not fatal. (Grau 1989; Kwiatkowski 1990) Interferon-gamma responses are felt to 
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be key to development of cerebral symptoms in murine experimental CM (Hunt 2014), but the 
relevance of this to human disease is not established. The attempted reversal of circulating cytokine 
levels in both murine models and humans, using specific anti-TNF antibodies, has not been successful 
in a limited clinical setting. Additionally, high plasma levels of TNF-α, IL-1 and IL-6 have been 
described in human patients with uncomplicated malaria, which underscores the remaining need to 
understand the specific role of these cytokines in the pathogenesis of disease. (Baptista 1997)  
Chemokines have not been as intensely examined as cytokines in severe malaria, but there is 
still abundant work that has been conducted examining the association between increased 
chemokine production and severe malaria. In particular, these have examined T cell expressed and 
secreted RANTES, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-
1α, MIP-1β, and IL-8 among others. These are theorized to play important roles in the pathogenesis 
of malaria induced disease as they are powerful chemoattractants for monocytes which in turn 
generate increased production and secretion of TNF-α and IL-6. (Armah 2007) 
While the sample size was quite small, it is notable that the CSF samples from P. coatneyi-
infected rhesus yielded no difference in concentration in the majority of the cytokines assessed in the 
Multiplex assay.  Specifically, TNF-α, VEGF, IL-1b, IL-2, IL-4, IL-5, IL-12, IL-13, IL-17a, IL-18, MIP-1a and 
MIP-b did not show any differentiation of expression between control, SHIV and P. coatneyi 
cohorts.  Interferon-gamma, IL-1a and IL-15 demonstrated very slight increases but lacked statistical 
significance, while a single P. coatneyi-infected animal was noted to have an elevation of IL-
10.  Overall, these findings are surprising due to the fact that TNF-α has been implicated in the 
neuropathology of a range of diseases to include severe and cerebral malaria. Interpretation is 
difficult since the cytokine appears to have both physiological roles in the normal brain and 
pathological roles in the diseased central nervous system. (Montgomery 2012; Olmos 2014) Under 
pathological conditions, large amounts of TNF-α can be secreted from microglia and astrocytes which 
significantly contribute to the neuroinflammatory response that is associated with several 
neurological disorders. (Montgomery 2012; Wyss-Coray 2002) Two different mechanisms have been 
259 
 
elucidated in which TNF-α potentiates glutamate-mediated cytotoxicity.  This can occur either 
indirectly through the inhibition of glutamate transport on astrocytes, or directly through the 
increase of glutamate receptor localization to synapses. (Olmos 2014) In malaria, TNF-α is theorized 
to be formed and secreted by host cells subsequent to exposure to a range of plasmodial antigens. 
This increase in the secretion of TNF-α is felt to be associated with overexpression of adhesion 
molecules, potentiating the sequestration phenomenon and augmenting the severity of disease. 
(Gimenez 2003; Shaffer 1991)   
There is little literature examining the CSF cytokine profiles of severe malaria; rather, most 
studies have evaluated the serum profiles. In one of the few studies that included CSF, Ghanaian 
children were sampled and wide range of cytokines were evaluated.  The results found that IL-1ra, IL-
8, IP-10, PDGFbb, MIP-1beta, Fas-L, sTNF-R1, and sTNF-R2 were significantly increased in the cohort 
of children that had died of cerebral malaria in comparison with both those who died of severe 
malaria and a control group who died of causes unrelated to malaria. (Armah 2007) As such, the 
current findings in CSF of the experimental rhesus model may represent an alternate profile for 
severe malaria disease presentation, although the correlation with human disease appears to be 
piecemeal with MCP-1, IL-6 and IL-8 being the most consistent parallels to human falciparum 
disease.  Increases in IL-1ra and INF-γ, while not statistically significant, are worth noting and 
considered for further study. 
 
 
5.7 Summary: 
 
The synopsis of immunohistochemical findings in the dissertation consisted of the following:  
There was significantly greater evidence of pathology observed in the brain stem than comparable 
studies in the cerebrum, a finding which was consistent with the observations noted in the 
histopathology chapter.  Furthermore, in comparison with control animals, P. coatneyi infected 
animals had increased numbers of CD-68 positive monocyte/macrophages/glial cells within the 
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central nervous system.  This was also observed to be the case in the increased numbers of CD-3 
positive T cells.  However, and of interest, was the fact that there were no significant increases in CD-
20 B cells or CD-61 platelets observed in the CNS.   
Brain blood barrier injury was demonstrated through both the increased fibrinogen leakage, 
with perivascular uptake and astrocyte end feet absorption.  The strong GFAP immunoreactivity and 
highlighting of marked structural changes also argues for a degree of BBB injury, which parallels that 
which has been demonstrated in autopsy samples from humans having succumbed to P. falciparum 
induced cerebral malaria. The remaining two immunohistochemical assays proved difficult to manage 
and as such, the limited data only permits speculation rather than assertion.  Beta APP 
immunoreactivity demonstrated initial evidence of focal axonal injury within brainstem and spinal 
cord, while cleaved Caspase 3 suggested in those rare instances in which the staining worked that 
there was evidence of apoptotic endothelium in CNS samples. 
Additional examination of the blood brain barrier integrity was performed through the 
CSF/Plasma Albumin index in which the P. coatneyi infected animals were compared with both 
normal controls and SHIV chimera infected rhesus.  There was a statistically significant increase over 
SHIV chimera cohort, and empirical evidence of an increased in comparison with control animals, 
further supporting the hypothesis of BBB injury in P. coatneyi infection.   
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Chapter 6: Ultrastructural Studies 
6.1 Introduction: 
From the initial description of the parasite as part of a survey of blood parasites in 
cynomolgus macaques (Macaca fascicularis) in the Philippines (Eyles 1962), there has been significant 
interest in the use of the plasmodium as a comparative model for severe P. falciparum induced 
malaria, and those varied studies have described the morphological and ultrastructural features of 
the parasite and the infected erythrocyte. (Aikawa 1992; Aikawa 1992; Coatney 1971; Eyles 1963; 
Kawai 1993; Maeno 1993, Moreno 2013; Tegoshi 1993) While these reports have described the 
ultrastructure of the P. coatneyi parasite, they were typically conducted in a very limited number of 
animals, and the focus remained on the phenotypic alterations of the infected erythrocyte without 
describing the parasite host interaction or the tissue specific pathology of the disease.  As such, there 
is a dearth of comparative information relating the pathogenesis of P. coatneyi with the tissue 
pathology observed and described in P. falciparum.  
Ultrastructural pathology studies in human patients dying of P. falciparum were the first to 
detail the close interaction of parasitized erythrocytes with vascular endothelial cells via electron 
dense knob protein structures on the infected erythrocyte surface. (Luse 1971) Subsequently EM 
studies were used to quantitate sequestration within different organs, in order to link post mortem 
patterns of organ specific sequestration with pre-mortem clinical symptoms, such as coma, renal 
failure, liver and lung dysfunction. (Aikawa 1988; MacPerson 1985; Pongponratn 2003; Nakazawa 
1995; Nguangsangiam 2007; Sein 1993)   
P. coatneyi has a range of biological features that it shares with P. falciparum as well as 
several important distinguishing phenotypic traits. There is evidence of microvascular cytoadherence, 
with the formation of rosettes between infected erythrocytes and uninfected red blood cells and 
several early reports have described the development of electron dense knobs on the cell surface of 
infected erythrocytes which have been purported to be involved in cytoadhesion and have been 
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described ultrastructurally. (Aikawa 1992; Kilejian 1977; Lombardini 2015) Both P. falciparum and P. 
coatneyi undergo deep vascular sequestration of red blood cells infected with trophozoites and 
schizonts. (Desowitz 1969; MacPherson 1985; Pongponratn 1991; Sein & Brown 1993; Smith 1996) 
P. coatneyi has been reported as causing both natural and experimentally-induced disease in 
a variety of non-human primate species. (Kawai 1993; Kawai 1998; Lombardini 2015; Moreno 2013; 
Sein & Brown 1993; Smith 1996) The cynomolgus macaque is described as being one of the natural 
hosts of the parasite and it is theorized may have coevolved resulting in reduced clinical disease in 
comparison with experimental infections in the rhesus or Japanese macaques. (Kawai 1993; Kawai 
1995; Kawai 1998; Lombardini 2015; Moreno 2013) Tissue pathology associated with P. coatneyi 
infection in the rhesus macaque is variable and likely is dependent on the genetic heterogenicity of 
the infected population, degree of blood parasitemia, coinfection with other agents, immune status, 
age and overall health of the animals. (Lombardini 2015)  
In this part of the thesis, the ultrastructural features of P. coatneyi infected red blood cells 
and their in-situ interaction with host tissues were examined and compared to that of P. falciparum 
infections in humans. Following novel observations of the type of knob structures identified in vivo, 
further examination of the surface of the P. coatneyi infected erythrocyte were conducted using both 
scanning and atomic force microscopy. These techniques allow closer examination and quantitative 
studies on the knob and calveolar structures on the infected red cell surface. (Aikawa 1997)  
 
6.2 Results: 
6.2.1 Light microscopic findings: 
Microscopically, the earliest stage identified in tissue was the ring stage present in the 
cytoplasm of infected erythrocytes. As the parasite matured, the more spherical trophozoite stage 
could be identified comprised of a single nucleus and a food vacuole often containing hemozoin 
crystals. Trophozoite growth in P. coatneyi is associated with nuclear division followed by schizogony 
which results in the formation of 16 to 20 merozoites. The mature schizonts appeared to occur 
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primarily in the deep vasculature.  This process is termed sequestration and involves cytoadherence 
of the infected erythrocytes to both the vascular endothelium and/or to other infected and 
uninfected erythrocytes. These features are similar to those described of P. falciparum. (Aikawa 1975; 
Aikawa 1983; Aikawa 1985; Aikawa 1988; Aikawa 1988; Atkinson 1990; Bannister 2000; Barnwell 
1990; Carlson 1993; Handunnetti 1989; Kilejian 1977) 
 
6.2.2 Ultrastructural findings in Post Mortem Tissues: 
Examination of a minimum of five grids per animal from three selected tissues (brain, kidney 
and heart) from multiple experimental animals (n=15), using transmission electron microscopy, 
allowed for evaluation of the distribution of infected red blood cells (iRBC) within the deep 
microvasculature.  There was very strong synchrony of parasite stage of maturation and as such, the 
vast majority of the observed parasites were trophozoites at various stages of development.  Only a 
relatively few mature schizonts and ring forms were observed. In all three tissues, iRBCs were 
identified in both large and small blood vessels with no obvious difference in the number of iRBCs 
between tissues (Fig 1a-c). Similar appearances were recorded in the three tissues examined with 
large numbers of iRBCs observed within the blood vessels of the heart, kidney and brain in all animals 
examined (Fig 1a, b, c). 
The smaller blood vessels were typically tightly packed with a mixture of uninfected and 
infected erythrocytes (Fig 1a-c). While the majority of infected cells had a single parasite, a number 
had two or more parasites (Fig 1c). The parasites were located within a parasitophorous vacuole 
limited by a unit membrane. Trophozoites appeared to increase in size, developing from stages with a 
single nucleus (Fig 1e) to stages with multiple nuclei and finally into mature schizonts (Fig 3a). Food 
vacuoles were initially small but increased in size into large vacuoles containing a number of 
hemozoin crystals (Fig 2b, 3a). The few mature schizonts observed were comprised of multiple 
merozoites, with apical rhoptries and a posterior nucleus, centered around a body of residual 
cytoplasm containing food vacuoles filled with hemozoin crystals (Figure 3a). The erythrocytic 
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cytoplasm frequently contained numbers of circular or curved bilayered channels interpreted as 
serpentine cleft-like vesicular structures with a narrow electron lucent lumen (Figure 2b insert). 
However, the stereotypical Maurer’s clefts running parallel to the RBC plasmalemma were not 
observed.  Erythrocyte infection is associated with profound changes in the shape of the iRBCs. The 
majority of iRBCs within small blood vessels were more spherical in shape with a relatively regular 
outline (Fig 2a, b). However, others show marked deformation of shape consisting of irregular 
cytoplasmic protrusions giving the infected cells a more flattened, crenated appearance (Figure 3b, c). 
The surface of the less deformed cells appeared relatively smooth (Fig 2a, b). A feature of all iRBCs 
was the presence of a number of caveolae, small circular invaginations with an electron dense coating 
which measured approximately 90nm in diameter (Fig 2a, b, c). Additionally, in the more distorted 
cells there appeared to be a variable number of blebs or excrescences consistent with knob 
formation. These knob-like structures are approximately 70-90 nm in diameter (Fig 2c, e, h).  On 
closer inspection, while some possessed some electron dense material beneath the plasmalemma as 
previously described (Fig 2c), the majority appeared to lack the clearly defined sub-plasma membrane 
electron dense material (Fig 2e, f). However, there did appear to be plaques of electron dense 
material associated with the iRBC plasmalemma but lacking the protuberance (Fig 2d). The majority 
of iRBCs appeared to have relatively few knobs, and those that were noted were randomly 
distributed.    
In small vessels, there was often a tight association between the iRBC and the endothelial 
cells (Fig 2b), which resulted in evidence of margination of iRBCs along the luminal wall of the 
affected vessels. When examined in detail there appeared to be close apposition between the iRBC 
plasmalemma and the plasmalemma of the endothelial cells with possible areas showing connection 
via proteinaceous material (Fig 2b, g). While in the majority of cases, knob-like protuberances were 
absent from such areas, they were observed on occasion and in these cases, proteinaceous material 
connecting the knob to the surface was observed (Fig 2h) Also, there was evidence of limited 
microvillus formation by the endothelial cells with the cytoplasmic process protruding into 
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invaginations of the iRBC surface (Fig 2f). In the larger vessels, where the RBCs were more loosely 
packed, it was often possible to observe features consistent with posited auto-agglutination (Fig 3b) 
and rosette formation (Fig 3c). This was characterized by adhesion between both iRBCs and between 
RBCs and iRBCs. The iRBCs in this situation showed more severe shape changes which allowed for 
increased interdigitation between cells. Interestingly, there was less evidence of cytoadherence 
between iRBCs and the endothelium in such vessels. While both ultrastructural and light microscopic 
evaluation of the tissues noted perivascular edema, and a small degree of perivascular hemorrhage in 
cerebral samples, no examples of vessel rupture were observed by electron microscopy, although 
several endothelial cells showed some degenerative changes. There did appear to lucent and 
vacuolated areas around cerebral vessels which was interpreted to be edema. Within the vessels, a 
number of macrophages and neutrophils were observed and certain macrophages appear to have 
phagocytised packets of malarial pigment (Fig 3d).  This was consistently observed in the renal 
samples with a concentration noted in glomeruli.  However, there was no evidence of electron dense 
deposits within the basement membrane or other pathological changes observed in the glomeruli (Fig 
1c).   
Frequently, the close association between the iRBCs and either the endothelium or other 
infected erythrocytes or uninfected cells, which was interpreted as cytoadherence, resulted in the 
occlusion of microvasculature which is proposed to represent one of the most significant aspects of 
the pathogenesis of cerebral malaria.  The cytoadherance to the endothelium was often observed as 
margination of infected erythrocytes (Fig 4a), resulting in a decreased vascular lumen and suspected 
disruption of blood flood. When compounded by the distortion of the infected erythrocytes and 
either autoagglutination or rosette formation (Fig 4b), the resultant sludging of the blood and 
promotion of Virchow's triad (Factors leading to thrombosis, including hypercoagulability, 
hemodynamic changes such as stasis or increased turbulence and endothelial injury or dysfunction) 
lends to a hypothesis of decreased oxygen delivery and hypoxic and/or anoxic tissue injury.  SEM 
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images of blood from the infected animals also demonstrated binding between infected and 
uninfected erythrocytes (Fig 4c and 4d). 
 
6.2.3 Structure of iRBCs from ex vivo blood samples in both Splenectomized and Spleen-intact 
Animals: 
The observation of anomalies on the structure of the knobs described above in 
splenectomized animals was unexpected. Therefore, to see if this was a phenomenon arising from the 
use splenectomized experimental animals (eg. modulation of cytoadherence within an infection due 
to the lack of selection for splenic clearance), blood was obtained from two spleen intact animals 
infected with P. coatneyi and was examined by both TEM and SEM. These animals underwent cure 
and thus survived infection.  In these blood samples, it was observed that the iRBCs could be 
identified by a markedly irregular outline (Fig 1a, e). By TEM and SEM, the surface of the iRBCs 
showed the formation of variable numbers of caveolae and knob-like structures (Fig 5a, e). The 
structure of the caveolae with the invagination of the plasmalemma with underlying electron dense 
material could be seen by TEM (Fig 5d) and appeared as surface pores by SEM (Fig 5f). Detailed 
examination of the knob-like structures revealed circular electron dense plaques beneath the 
plasmalemma shown in longitudinal section (Fig 5b) and tangential section (Fig 5c). The knobs could 
be identified in SEM as slightly raised circular electron lucent structures (Fig 5e, f). The SEM images 
illustrated the relatively random distribution of the knob (Fig 5e, f).  
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Figure 6.2.3.1a-1c:  
Electron micrographs of P. coatneyi infected rhesus macaque tissues.  The phenotypic structure of the 
parasites (P) and the infected erythrocytes were similar in the three tissues examined (1a. Brain; 1b. 
Heart; 1c. Kidney).  Microvasculature was often tightly packed with both infected and uninfected 
erythrocytes. Infected erythrocytes typically contained a single parasite, however two or more 
parasites in a single red blood cell was not an uncommon finding (1c). Trophozoites appeared to 
increase in size, developing from stages with a single nucleus (Fig 1c) to stages with multiple nuclei 
and finally into mature schizonts (Fig 3a). Bar is 10 µm.  
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Figure 6.2.2.2a-2h: Transmission electron micrographs of P. coatneyi infected rhesus macaque 
tissues.  
a. Section through an iRBC showing a trophozoite with a centrally located nucleus (N). Note the 
surface of the iRBC exhibits caveola formation (arrowheads). Bar represents 1µm. 
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b. iRBC with a trophozoite displaying hemozoin crystals in the food vacuole (F). Note the tight 
apposition of the iRBC plasmalemma with caveola (arrowheads) with the endothelial cells (En) lining 
the vessel. Bar is 1 µm. 
Insert: Part of an iRBC cytoplasm showing the double membraned cleft-like structure. Bar is 100nm. 
c. Detail from the surface of an iRBC showing an invagination of the plasmalemma to form a caveola 
(C) with underlying electron dense material and knob (K) with underlying dense material 
(arrowheads). Bar is 100nm. 
d. Detail from the surface of an iRBC in which electron dense material (arrowheads) is associated with 
the plasmalemma of an iRBC but in the absence of any protrusion. Bar is 100nm 
e. Detail from the surface of an iRBC showing a knob that appears to lack underlying dense material. 
Bar is 100 nm. 
f. Section through the junction between an iRBC and an endothelial cell showing two microvilli from 
the endothelial cell protruding into folds in the iRBC (arrows). Bar is 1µm. 
g. Enlargement of the junction between iRBC and endothelial cell with no evidence of knob formation 
but proteinaceous material appearing to connect the plasma membranes (arrowheads). P – parasite. 
Bar is 100nm. 
h. Detail of junction between iRBC and endothelial cell where the iRBC appears to form knobs (K). 
Note the proteinaceous connecting the knob to the endothelial cell. Bar is 100nm.  
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Figure 6.2.2.3a-3d: 
Transmission electron micrographs of P. coatneyi infected rhesus macaque tissues.  
a. Cross section through a small blood vessel showing an iRBC with a mature schizont containing 
merozoites (M) with electron dense rhoptries (R) around a residual mass (RB). En -endothelial cell. 
Bar is 1µm 
b. Low power from a large vessel showing a number of iRBCs interacting with each other to form an 
auto-agglutinate- like structure. P – parasite. Bar is 1µm. 
c. Part of a vessel in which iRBCs are interacting with RBCs to form rosette-like structures. Bar is 1µm. 
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d. Section through a vessel showing macrophage that had phagocytise a packet of pigment (Pg). Bar is 
1 µm. 
 
Transmission electron micrographs of blood from P. coatneyi infected, spleen intact rhesus 
macaques. 
 
Figure 6.2.2.4a-4f 
a. Low power image showing an iRBC containing a mid-stage trophozoite (P) in which tubular or cleft-
like structures (T), caveolae (C) and knobs (K) can be identified. Bar represents 1µm. 
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b. Longitudinal section through two knobs showing the underlying dense material (arrows). Bar is 
100nm 
c. Tangential section through the surface of an iRBC showing knobs (K) with the circular appearance 
of the underlying dense material. Bar is 100nm.  
d. Longitudinal section showing the caveolae formed by the invagination of the iRBC plasmalemma 
with underlying dense material (arrows). K – knob. Bar is 100nm. 
e. Low power scanning electron micrograph of an iRBC showing the irregular (lumpy) surface 
appearance in which randomly distributed knobs (K) and caveolae (C) can be identified. Bar is 1µm. 
f. Detail of the surface of the iRBC showing the circular slightly raised electron lucent knobs (K) and 
the openings of the caveolae (C). Bar is 100nm. 
 
6.3 Host tissue changes: 
Ultrastructural tissue pathology associated with P. coatneyi infection has yet to be described.  
This study examined samples from a range of host target tissues allowing for an evaluation of the 
damage in the acute phase of the disease at high parasitemia. 
In general terms, the parasite-host interaction has been well described earlier in this chapter as well 
as by other authors (Aikawa 1992; Desowitz 1967; Desowitz 1969; Eyles 1963; Kawai 1998; Kawai 
2003; Sein 1993), however the specific changes to tissue remains to be evaluated. 
Samples collected in glutaraldehyde during the autopsy of the 15 prospective animals included a 
focus on the central nervous system (cerebrum, cerebellum, brain stem, spinal cord), heart, and 
kidney in all animals and the liver, retina, pituitary gland, and lung in a select few.  Baseline changes 
are described above and include perivascular edema, which was most pronounced in the brain, 
microvascular obstruction in all tissues with margination of infected erythrocytes, rosette formation 
and auto-agglutination.   
In all tissues, the formation of pseudopod like structures occurred on occasion between the 
endothelium and the infected erythrocytes, and the endothelial cells occasionally were noted to have 
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evidence of cytoplasmic proteolysis correlating with acute cellular swelling.  In those cases, there 
were swollen mitochondria and dilatation of the cisternae in the endoplasmic reticulum and 
fragmentation, forming vesicles.  (Figure 6.3.1-2) 
 
Figure 6.3.1-2: These ultrastructural photomicrographs highlight the endothelial degeneration 
(arrows) observed in some of the microvasculature in which there are either cytoadherent infected 
cells, rosette formation or autoagglutination. 6.3.1 TEM 4000x; 6.3.2 TEM 2500x. 
 
6.3.1 Central Nervous System (CNS): Changes in the brain were relatively consistent between the 
various sections examined, with perivascular edema being a prominent feature.  This finding 
occasionally extended into the adjacent neuropil, widely separating and displacing the matrix.  Rarely 
neurons were observed to have evidence of early neuronal chomatolysis, with preliminary stages of 
cellular swelling and proteolysis affecting the dendrites and extending into the perikaryon, 
interpreted as acute cellular injury and reversible degenerative changes (Figure 6.3.3).  
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Figure 6.3.3: Cerebrum. The neuron central to this photomicrograph displays evidence of organelle 
swelling and vacuolation.  There is loss of dendritic processes and the beginning of neuroplasmic 
angulation, suggestive of degenerative changes.  TEM 3000x. 
 
In rare instances, there was evidence of irreversible acute cellular swelling, with loss of the 
nucleolus and the chromatin and angular consolidation of the nucleus. Cytoplasmic changes 
consistent with cellular necrosis included the accumulation of residual bodies, lipid and vacuoles and 
necrotic debris.  The plasma membrane, when identifiable was undulant and fragmented (Figure 
6.3.4).  
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Figure 6.3.4: Cerebrum. In this case, the neuron is necrotic, with loss of structural architecture, 
pyknosis and fragmentation of the nucleus, rupture of the plasma membrane and loss or swelling of 
the organelles.  TEM 2500x. 
 
In one instance, assessment of a section of brain stem from an experimental animal revealed 
a focus of hemorrhage. The extravasated erythrocytes separated and surrounded myelin fibers and 
the disrupted neuropil. (Figure 6.3.5.)  
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Figure 6.3.5: Brain stem. This ultrastructural photomicrograph illustrates an example of hemorrhage 
which occurred with greater frequency in the brain stem and spinal cord in comparison with the 
cerebrum or cerebellum.  There is loss of neuropil, and replacement with extravasated erythrocytes, 
proteinaceous material and clear space. TEM 4000x. 
 
The literature concerning P. falciparum has described perivascular edema in correlation with 
sequestration and alterations of the cerebral microvascular endothelium (reviewed in Medana and 
Turner 2006).  Furthermore, cerebral disease in humans is illustrated by the typical ring hemorrhages 
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observed due to microvascular rupture. (Pongponratn 2003) While light microscopy did observe 
hemorrhaging in the CNS in the P. coatneyi experimental animals, it was predominantly noted in the 
spinal cord and the brain stem and did not assume the pattern described in deaths associated with P. 
falciparum. 
 
6.3.2 Kidney: Renal ultrastructural pathology consisted of all of those host-parasite interactions, in 
addition to significant observable injury to both the distal and the proximal tubules.  In the former, 
individual or aggregates of tubular epithelium were either degenerate or necrotic, characterized by a 
continuum of cytoplasmic swelling, with proteolysis of the cytoplasmic elements, observable 
primarily as swelling of the mitochondria, chromatolysis and condensation of the nuclei and 
fragmentation of the plasma membrane with extrusion of organelles into the tubular lumen (Figure 
6.3.6-7). 
 
Figure 6.3.6-7: This plate of ultrastructural photomicrographs demonstrates two different tubular 
epithelial cells undergoing necrotic change.  In 6.3.6, the nucleus while shrunken, still maintains 
vestiges of its architecture, in spite of complete rupture of the apical plasma membrane.  TEM 3000x. 
On the other hand, the cell represented in 6.3.7 illustrates angulation and chromatolysis of the 
nucleus with condensation of the cytoplasm (arrows).  Adjacent cells demonstrate various stages of 
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cytoplasmic vacuolization, and organelle swelling suggestive of earlier degenerative changes.  
Additionally, the tubule lumen is obscured by protein and cellular debris. TEM 4000x. 
 
Proximal tubular pathology was comprised of similar findings as those observed in the distal 
tubular epithelium with the addition of changes to the apical surface microvilli.  The condensed, 
fragmented necrotic cells demonstrated either a blunting and fusion of the microvilli or complete 
loss.  As with the distal tubules, the affected cells were noted to undergo an initial injury consisting of 
cytoplasmic and organelle swelling followed by nuclear condensation, fragmentation and extrusion of 
cellular elements into the tubular lumen. (Figure 6.3.8-9) 
 
Figure 6.3.8-9: These two figures are of proximal tubular epithelium undergoing similar necrotic 
changes to those described in the prior figures. 6.3.8 TEM 2000x; 6.3.9 TEM 5000x. 
 
Ultrastructural changes in the glomeruli were subtle, and unlike the description of a 
membranoproliferative glomerulonephritis with abnormal deposits described in early human and P. 
berghei mouse model studies (Bhamarapravati 1973; Boonpucknavig 1976), the changes in the 
glomeruli of the affected rhesus macaques were not the predominant lesions observed.  
Histologically in this study, the glomeruli were typically hypercellular, occasionally hypersegmented, 
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with glomerular capillaries often occluded by infected erythrocytes and high numbers of 
polymorphonuclear cells interpreted as neutrophils, as well as frequent macrophages containing 
phagocytosed debris. These were interpreted to be extrinsic host monocytes which are recruited due 
to the occlusion and sequestration of the glomerular tuft microvasculature.  The macrophages often 
contained cellular debris and hemozoin fragments suggestive of clearance of ghosted erythrocytes, a 
feature described in P. falciparum induced disease in humans. (Pongponratn 2003) 
Additionally, there was significant evidence under light microscopy of synechial attachment of the 
glomerular tuft to the Bowman’s membrane (Figure 6.3.10-11).  
 
Figure 6.3.10-11: 6.3.10 is an ultrastructural photomicrograph of a glomerulus with an example of the 
frequent accumulation of polymorphonuclear cells observed within the glomerular tuft 
microvasculature (arrow). TEM 1500x. The photomicrograph demonstrates the hypersegmentation, 
ectasia of the vasculature and the frequent synechiae to the parietal epithelium of Bowman’s 
capsule. HE 400x. 
 
Occasionally the foot processes of the podocytes, were mildly hypertrophic with evidence of 
fusion (Figure 6.3.12). 
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Figure 6.3.12: This ultrastructural photomicrograph of the glomerulus in an P. coatneyi infected 
rhesus, notes some of the subtle changes which were occasionally observed.  In this instance, there is 
periodic fusion of the podocyte foot processes (arrows) as well as some increased electron lucency, 
and swelling suggestive of damage to the glomerulus. TEM 4000x. 
  
In humans infected with P. falciparum, ultrastructural examination of the glomeruli suggested 
that the basement membrane was either multifocally absent or asymmetrical in thickness.  
Furthermore, depending on the study, mesangial cells have been described as being either 
proliferative and containing electron-dense deposits suggestive of an immune complex nephritis (el-
Shoura 1994) or a posited absence of immune complex glomerulonephritis as a feature of acute renal 
failure in P. falciparum malaria infection. (Nguansangiam 2007) A third study suggested that 
glomerulopathy was only observed in one fifth of autopsied victims of P. falciparum and in those 
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cases, the histopathology and ultrastructural evaluation of the tissues noted a prominent mesangial 
proliferation with only minimal basement membrane electron microscopic changes. (Barsoum 2000) 
Intensive examination of the images generated from the P. coatneyi infected macaques did not reveal 
reliably reproducible evidence of immune complex deposition in the subendothelial tissues.  Rather, 
the basement membrane underlying the podocyte foot processes was typically uniform in thickness 
and in electron density. (Figure 6.3.13). The brevity of the experimental infection (up to 
approximately 6-10days) in the rhesus may not permit adequate time for the formation of the 
subepithelial deposits, or the pathogenesis of the disease may simply not involve an immune complex 
deposition as a significant factor.  Considering there is still some debate as to the presence or 
absence of an immune-complex driven pathogenesis in the acute renal failure in P. falciparum, the 
lack of lesions in the macaques may simply be a supportive characteristic of the commonality of P. 
coatneyi and P. falciparum driven disease. 
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Figure 6.3.13: This ultrastructural photomicrograph illustrates the typical glomerulus imaged during 
this study, in which the basement membrane is of uniform thickness and the food processes are 
typically individualized.  In this instance, the capillary lumen is replete with ghost erythrocytes, 
polymorphonuclear leukocytes and both infected and uninfected erythrocytes. TEM 4000x. 
  
6.3.3 Heart: Cardiac ultrastructural pathology consists predominantly of degeneration and necrosis of 
the cardiomyocytes, accumulation of interstitial edema and debris, significant occlusion and 
sequestration of the parasitized erythrocytes within the microvasculature, without a significant 
inflammatory response. 
Under both light microscopy and electron microscopy, the degree of microvascular 
sequestration was overwhelming, with almost 100% of visible vessels being occluded. (Figure 6.3.14) 
Ultrastructurally, the parasitized erythrocytes were frequently marginated and cytoadhered to the 
endothelium (Figure 6.3.15).  The interstitium, especially in proximity to occluded vessels contained 
varying amounts of electron lucent edema.  Degenerative changes consisted of cellular hypertrophy 
with distinct loss of thick (myosin) filaments, as well as streaming and clumping of Z bands. 
Progressively with increased severity, affected cells became condensed and fragmented, with 
extensive myofibrillar lysis and loss of T tubules. Cytoplasmic organelles such as the mitochondria and 
the sarcoplasmic reticulum were swollen and electron lucent.  Occasional cardiomyocytes contained 
electron dense bodies and were separated from adjacent cells, having lost intracellular connections. 
(Figure 6.3.16-17) 
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Figure 6.3.14-17: This plate is comprised of tissue changes observed in the cardiac tissue of P. 
coatneyi infected rhesus macaques.  6.3.14 is a photomicrograph underscoring the extraordinary 
amount of parasitism and sequestration of infected erythrocytes in the myocardial microvasculature.  
HE 1000x. 6.3.15 shows the margination of the infected erythrocytes and illustrates the degree of 
cytoadherence and sequestration at an ultrastructural level. TEM 4000x. Both 6.3.16 (TEM 2000x) and 
6.3.17 (TEM 1500x) are examples of either severe degeneration or piecemeal myocardial necrosis 
with fragmentation of the myofibers, swelling of the organelles and rupture of the cells. 
 
There are only scant ultrastructural descriptions of cardiac injury in P. falciparum induced 
disease, and those reports that are in the literature typically concentrate on the microvasculature 
rather than a description of the cardiomyocytes themselves (Luse 1971; Pongponratn 1991), or are 
single case reports which describe either ischemic pathology secondary to the sequestration and 
occlusion of cardiac microvasculature (Chopra 2013), a lymphocytic myocarditis in humans or 
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determined cardiac disease based on ante-mortem clinical findings. (Costenaro 2011; Mohsen 2001) 
Additionally, this is the first study to directly focus on the cardiac tissue in P. coatneyi. Given the high 
levels of parasitized erythrocyte sequestration and clinical picture of terminal metabolic derangement 
and shock, it may be that direct parasite induced cardiomyopathy contributes to the cause of death in 
this model, similar to the mechanisms of shock postulated over a century ago in human post mortem 
studies of ‘algid’ malaria. (Dudgeon 1917) 
 
6.3.4 Lung and liver: While only a few experimental animals’ lungs and livers were evaluated, the 
ultrastructural changes observed were consistent with the histopathological findings described in 
Chapter 4.  In the pulmonary interstitium, the microvasculature was occluded by infected 
erythrocytes admixed with frequent monocytes, however there was no discernible inflammatory 
response and the alveolar space was not impaired by edema or other proteinaceous infiltrates.  
Resident alveolar macrophages were present in the alveolar space, but not in significant numbers and 
not outside of the realm of normal.  Pulmonary pathology is strongly associated with morbidity in 
severe falciparum induced malaria in humans, and the absence of significant lung pathology in the 
rhesus macaque model is an important discrepancy in the applicability of this animal model to human 
disease. (Duarte 1985) A possible consideration is that the microanatomy of the rhesus lung is more 
durable and resistant to leakage than that of the human, potentially resulting in the macaque being 
refractory to malaria induced pulmonary disease. 
The hepatic samples were frequently difficult to interpret due to a significant degree of 
dissociation, degeneration and necrosis of the hepatocytes.  Individual cells often were expanded by 
lipid and intracytoplasmic vacuoles.  As with other tissues, there was evidence of a continuum of 
degeneration to necrosis with consistent cytoplasmic and nuclear changes.  
P. falciparum infection in adults commonly causes liver function abnormalities and jaundice, although 
this is multifactorial and not necessarily due to widespread hepatic necrosis (Kochar 2003; Prommano 
2005), and is not typically associated with the degree of hepatic injury observed here in the rhesus 
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model (especially when considering the light microscopic findings of centrilobular coagulative 
necrosis, which may be secondary both to sequestration and host immune responses in the hepatic 
sinuses and the microvasculature, resulting in hypoxic insult).   
 
6.3.5 Retina: Attempts to examine retinal pathology with EM were unsuccessful. Preparation 
technique impaired the ability to adequately interpret changes in the retinal samples as the delicate 
sections frequently folded over themselves and compromised diagnostic capacity. 
 
 
6.4 Atomic Force Microscopy (AFM): 
In conjunction with an experimental anti-malarial drug trial of methylene blue in the P. 
coatneyi/Rhesus macaque model for severe malaria, blood smears were taken from multiple 
untreated animals at various degrees of parasitemia in order to conduct a more widespread 
descriptive analysis of the surface ornamentation in P. coatneyi and to compare those with 
descriptions of P. falciparum studies undertaken at the National University of Singapore (NUS), Vivax 
malaria laboratory.   
Atomic Force Microscopy was employed to further describe the structural modifications 
which occur in P. coatneyi infected erythrocytes.  The findings included confirmation and description 
of the presence of knob-like protuberances as well as the common finding of caveolae on the cell 
surface.  The diameter and overall density of knobs and caveolae observed on P. coatneyi were 
compared and contrasted with those of P. falciparum. Initially, the infected erythrocyte was staged 
using Giemsa staining to identify the parasite within the erythrocyte. (Figure 6.4.1.) 
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Figure 6.4.1: Identification of the P. coatneyi parasitophorous vacuole (arrow) within the infected cell 
to demonstrate that the selected cell is, in fact, parasitized.  The same cell examined using Giemsa 
staining was then scanned using AFM. Giemsa 1000x. 
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6.4.1 AFM Results: 
P. coatneyi infected erythrocyte surface morphology was described using TEM, SEM and AFM.   
 
Figure 6.4.2.1-6: This panel of images demonstrates the nanostructural surface ornamentation using 
each diagnostic modality at lower and higher magnification with evidence of both caveolae and 
knobs. 1,2 Transmission Electron Microscopy (TEM), 3,4 Scanning Electron Microscopy (SEM) and 5,6 
Atomic Force Microscopy. 
Knob-like excrescences which are a critical feature of P. falciparum infection, are observed 
infrequently in the prospective experimental animals in this study, which we posit is the result of the 
macaques from which the SEM and AFM samples were derived being splenectomized.  This is 
consistent with observations made in a case of fatal P. falciparum malaria in a splenectomized human 
and in P. knowlsei infected, splenectomized cynomolgus macaques. (Barnwell 1982; Barnwell 1983; 
Pongponratn 2000) In this study, in samples derived from the prospective population of 
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splenectomized experimental rhesus macaques, caveolae were observed with increased frequency 
and both knob-like structures and caveolae were measured using AFM. (Figure 6.4.3.) 
 
Figure 6.4.3: P. coatneyi infected erythrocyte atomic force microscopic scan illustrating regular and 
uniform invaginations in the cell membrane which are interpreted to be caveolae. 
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Figure 6.4.4.1: Comparative AFM images showing slight differences in the diameter of the knobs 
between P. falciparum and P. coatneyi.   
 
The knob density was measured by calculating the number of knobs per µm2. Five knobs per 
cell were randomly chosen, and the diameter of each knob was measured NanoScope Analysis 
(version 1.40).  In the former, we measured more five knobs randomly chosen from 11 trophozoite 
infected erythrocytes and five knobs on the surface of 11 cells containing schizonts.  As knobs were 
scarce in P. coatneyi infected red blood cells in the samples examined, five random knobs were 
P. falciparum  P. coatneyi 
Trophozoite Schizont Trophozoite 
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measured from two infected cells containing P. coatneyi trophozoites. The P. coatneyi-infected cell 
(bottom right), containing a trophozoite is covered with dense excrescences (mean diameter: 92 nm), 
which are morphologically distinct from the smaller knobs measured on P. falciparum trophozoite 
infected red cell (mean diameter: 64 nm) (bottom left).  P. falciparum schizont associated knobs are 
slightly larger than those on cells infected with P. falciparum trophozoites, however the diameter of 
knobs on P. coatneyi infected cells is larger than those from the human plasmodium (Figure 6.4.4.2). 
Knob density was not statistically significant due to the low numbers of P. coatneyi infected cells 
having knob-like protuberances as surface ornamentation. Examination of knob density involved 
counting the total number of excrescences over the scanned surface of the cell.  The availability of 
only a select few P. coatneyi cells displaying knob-like structures was consistent with the transmission 
electron microscopy findings, and limits the value of the comparison of knob density (Figure 6.4.4.3).   
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Figure 6.4.4.2: Graphed data of knob diameter measurements which show a slightly larger knob 
occurring on the P. coatneyi infected cells in comparison with those from P. falciparum. (* P ≤ 0.05; 
** P ≤ 0.01; *** P ≤ 0.001) 
 
Figure 6.4.4.3: Graphed data of comparative knob density measurements which unfortunately due to 
the limited number of P. coatneyi knobs, limited any significant analysis of knob density in 
comparison with those from P. falciparum.  
 
A relatively surprising finding noted during the ultrastructural analyses of the P. coatneyi infected 
erythrocytes consisted of the frequency of caveolae observed on the surface of the iRBCs.  While a 
single author has described ultrastructural evidence of caveolae in association with P. coatneyi 
(Aikawa 1975; Aikawa 1977), no elucidation of the purpose of the structure was proffered. P. vivax 
has similar surface ornamentation which has been posited to be involved in protein trafficking from 
the parasite parasitophorous vacuole to the erythrocyte surface.  (Aikawa 1988; Atkinson 1990) Using 
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AFM, we were able to conduct evaluations of the diameter of the caveolae (Figure 6.4.5.2) as well as 
of their density (Figure 6.4.5.3), however as this feature is not found on P. falciparum, no comparison 
was possible.  Future research would be of interest in comparing these nanostructural features with 
those described in P. vivax, P. ovale, P. fragile and P. cynomolgi.  
 
 
  
 
Trophozoite Schizont 
P. coatneyi 
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Figure 6.4.5.1: Caveolae were much more commonly observed using TEM, SEM and AFM, and as such, 
analysis holds greater statistical strength. The specific role of the caveolae in protein trafficking or in 
adhesion in P. coatneyi is unknown. 
 
Figure 6.4.5.2: Graph demonstrating the mean diameter of caveolae. This did not differ significantly 
between trophozoites and schizonts. As with the knobs, five caveolae per cell were randomly chosen, 
and the diameter of each was measured using NanoScope Analysis (version 1.40) 
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Figure 6.4.5.3:  The density of caveolae on the plasma membrane was measured by calculating the 
number of knobs per µm2. Again, this did not differ significantly between trophozoites and schizonts. 
6.5 Flow and binding dynamics: 
Preliminary analyses were undertaken using micropipette technology to measure the binding 
strength of the interaction between P. coatneyi-infected erythrocytes and uninfected normal RBC 
within rosette structures, as were evaluations of microfluidics in which flow dynamics of P. coatneyi 
were evaluated using flow grids designed with 2 and 4 µm channels intended on replicating the 
microvascular microstructure of the spleen (Figure 6.5.1-4).  However, this was an initial pathfinding 
study and the resultant data, generated in only single experiments, are not within the scope of this 
dissertation.  
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Figure 6.5.1-4:  The micropipette images demonstrate the binding strength between Fig 1. an 
uninfected erythrocyte and an infected RBC, Fig 2. rosette cells consisting of 2 infected erythrocytes 
and an uninfected cell binding to each other.  Fig 3. and Fig 4. are illustrations of the flow dynamics of 
P. coatneyi using flow grids to simulate the microvascular sludging resulting from the formation of 
rosettes. 
 
6.6 Discussion: 
The pathogenesis of both P. falciparum and P. coatneyi is proposed to be critically dependent 
on the capability to remodel the surface membrane of the infected erythrocyte and in doing so insert 
a range of adhesion proteins which are crucial to both the survival and pathogenicity of the parasites.  
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Mature mammalian erythrocytes lack endogenous molecules which permit a mechanism of protein 
trafficking, and as such the plasmodiae have evolved their own specialized mechanisms, which are 
extended beyond the parasitophorous vacuole of the malaria parasite into the host cell cytoplasm 
and then into the plasma membrane. (Akinyi 2012; Kats 2014) These adhesins molecules have been 
well described and are members of the protein family P. falciparum erythrocyte membrane protein 1, 
PfEMP1. (Leech 1984; Craig 2001; Quadt 2012) These molecules have been shown to be involved in 
the mediation of high-affinity interaction with an array of host vascular receptors. The library of 
parasite derived molecules expands daily however the main categories remain as 1. knob-inducing 
protein or "KAHRP"; 2. knob-associated cytoadherent proteins such as PFEMP-1; and 3. knob-
associated structural proteins. (Sharma 1991; Tilley 2011) Phenotypically these can present as the 
nanostructural modifications which are observed as knobs or knob-like excrescences in P. falciparum 
and in P. coatneyi or as caveolae which are seen in P. coatneyi and in a select few other plasmodiae 
such as P. vivax and P. ovale. 
Atomic force microscopy (AFM) is a technology which has showed extraordinary diversity in 
its application and has been used to successfully map the ultrastructural topography of malaria 
infected erythrocytes for various different plasmodial entities, to include select human parasites: P. 
falciparum (Aikawa 1996; Aikawa 1997; Akaki 2002; Garcia 1997; Li 2013; Nagao 2000; Olliaro 1997; 
Quadt 2012), P. malariae (Li 2010), P. vivax (Malleret 2015) and rodent parasites: P. yoelli (Claser 
2014). 
Knobs (or some variant thereof), caveolae, caveola-vesicle complexes, cytoplasmic clefts, and 
electron-dense material have all been described in plasmodium infected erythrocyte plasma 
membranes using various ultrastructural techniques. (Atkinson 1990) We focused on two important 
forms of surface ornamentation which are expressed on the plasma membrane of Plasmodium spp. 
infected primate erythrocytes.  These structures vary in association with the specific species of 
plasmodium causing the infection.  Knobs, or knob like protuberances, have been well described in P. 
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falciparum and P. malariae (Aikawa 1996; Aikawa 1997; Aikawa 2002; Li 2010) as well as in P. 
coatneyi (Aikawa 1992), while caveolae are seen on the surface of P. vivax, P. ovale, P. fragile, P. 
cynomolgi and rare reports of the structure observed in P. coatneyi. (Aikawa 1975; Aikawa 1977) 
There are sporadic reports which describe knobs on P. ovale (Matsumoto 1986) and portrayals of 
caveolae on the surface of P. malariae infected erythrocytes. (Atkinson 1990; Mackenstedt 1989) 
Both of these characteristic morphological alterations have been primarily described through the use 
of transmission electron microscopy and scanning electron microscopy. 
P. coatneyi infected Rhesus macaques and Japanese macaques have been employed as 
animal models for severe and cerebral malaria associated by P. falciparum. (Aikawa 1992; Davison 
1998; Kawai 1993; Lombardini 2015; Moreno 2013) P. coatneyi shares a range of pathophysiological, 
pathological and ultrastructural features with P. falciparum, as well as several distinguishing 
phenotypic characteristics.  Both species of plasmodium have 48 hour intraerythrocytic development 
cycles, subsequent to which, schizogony occurs. The newly released merozoites undergo reinvasion of 
uninfected erythrocytes and the host has a resultant febrile spike.  Both P. falciparum and P. coatneyi 
develop rosettes comprising one or multiple infected red blood cells which recruit uninfected 
erythrocytes (Doumbo 2009; Lombardini 2015; Moreno 2013), they both have well documented 
microvascular cytoadherence and both parasites appear to share some variation of knob-like 
structure on the cell surface hypothesized to be involved in the pathogenesis of cytoadhesion. The 
knobs on erythrocytes infected with mature asexual forms of P. falciparum are posited to allow the 
infected cells to cytoadhere to the vascular endothelium under shear ﬂow conditions and thus avoid 
splenic clearance. (Malleret 2015) 
Atomic Force Microscopy analysis of multiple P. coatneyi infected rhesus macaque 
erythrocytes demonstrated and confirmed the presence of both knob-like structures and caveolae on 
the modified cell wall of the infected erythrocytes.  The surface ornamentation was analyzed for 
density per millimeter as well as for the overall diameter of the structures, and in the case of the 
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knob-like structures, were compared to similar structures on P. falciparum infected human 
erythrocytes.  There appears to be a relative similarity in knob diameter, and while the data relating 
to density does not hold statistical significance, the mean data of the two P. coatneyi cells analyzed 
suggest similarity in density as well. 
The subtleties as to the specific role in pathogenesis of P. falciparum malaria as well as the 
temporal dynamics of PfEMP1 and other malaria induced adhesion molecules have been extensively 
studied (Acharya 2012; Baruch 2002; Cooke 2004; Gruenberg 1983; Horrocks 2005; Leech 1984; Li 
2006; Quadt 2012; Raventos-Suarez 1985; Su 1995), but beyond a few initial studies, the adhesion 
mechanisms of P. coatneyi infected erythrocytes remain poorly described. (Aikawa 1975; Aikawa 
1988) 
P. falciparum knob presentation appears to have maturation and temporal dependent 
mechanism as well as being linked to specific clones of PfEMP1 and chemical factors such as 
hemoglobin. (Allred 1986; Gruenberg 1983; Quadt 2012; Subramani 2015).  All of the experimental 
animals in this study, in addition to being splenectomized were closely synchronized as to parasite 
stage of development.  As such the resultant data is limited by being a single snapshot in the surface 
phenotype of the infected cells, and provides a foundation for further temporal descriptions.  
Again, taking into account the fact that the present study is temporally static, caveolae 
appear to be the predominant surface ornamentation observed with P. coatneyi. (Aikawa 1975; 
Aikawa 1988; Barnwell 1990) These, described either as caveolae or as caveola-vesicle complex 
structures, are described in P. cynomolgi, P. vivax and P. ovale (Aikawa 1975; Aikawa 1977; Akinyi 
2012; Barnwell 1990; Matsumoto 1986).  The structures in P. vivax are predominantly a pit in the 
membrane surface which ultrastructurally appear as flask-shaped indentations of the erythrocytic 
membrane.  In the case of vivax malaria, these structures are typically associated with membrane 
vesicles and as such have been termed as caveola–vesicle complexes (CVCs). In some cases, the 
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vesicles are described as being alveolar, while in other instances they are elongated and tubular 
(Aikawa 1975).  In our description of the ultrastructural appearance of P. coatneyi infected 
erythrocytes, there appears to be a network of cleft-like vesicular structures which are distinct from 
Maurer’s clefts, and which form intricate serpentine structures within the plasma membrane.  While 
we have not been able to describe a specific link between the observed caveolae and these 
structures, they likely play a role in protein trafficking between the parasite and the erythrocyte 
plasma membrane. 
It is fascinating to note that P. coatneyi, being a relatively young plasmodium in phylogenetic 
terms, shares phenotypic features which have been associated with P. falciparum and P. vivax.   This 
study confirmed the ability of P. coatneyi to cytoadhere to host vascular endothelium and other cells 
in vivo, causing microvascular obstruction similar to that seen in human studies of P. falciparum. In 
addition, P. coatneyi shares a propensity for rosette formation with vivax (Chotivanich 1998) which 
may reflect phenotypic similarities in caveolae, which have been shown in P. vivax to co-localize with 
CD71 (transferrin receptor) expression on the infected reticulocyte surface and mediates adhesion to 
CD236 (Glycophorin) on uninfected RBC during rosette formation (Lee 2014). Whether this high rate 
of rosetting observed in vitro contributes to microvascular obstruction in vivo remains unclear. 
 
6.7 Summary: 
The ultrastructural studies examining the primarily the brain, kidneys and heart asserted the fact that 
P. coatneyi is a sequestering model, with strong evidence of infected erythrocytic cytoadherence 
through direct binding to the endothelium through the surface ornamentation as well as through a 
process of interdigitation and pseudopodia formation.  Furthermore, there was abundant evidence of 
autoagglutination and rosette formation, although this proved to be excessive to that described in P. 
falciparum.  Of crucial importance was the description by transmission electron microscopy, scanning 
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electron microscopy and atomic force microscopy of the surface ornamentation which proved to 
deviate from P. falciparum in the lack of regularity of the electron dense knobs with were scattered 
on the surface of erythrocytes infected with mature trophozoites, and the fact that P. coatneyi 
infected erythrocytes are also adorned by high numbers of caveolae, a feature more in common with 
P. vivax. Finally, instead of having Maurer’s clefts, the infected RBCs contained single lamellar coiled 
vesicular structures throughout the cytoplasm.  All of these findings were confirmed in spleen intact 
samples.  The use of atomic force microscopy allowed for the actual measurement of both the knobs 
and the caveolae as well as an assessment of the density of the structures throughout the observed 
surface of the infected cells.  In addition to describing the parasite-host cell interaction and the 
changes which occur secondary to the maturation of the parasite, this study permitted the 
ultrastructural description of the tissue pathology, observations of which have not been conducted to 
date with the P. coatneyi model.   
Finally, and of substantial interest, were initial studies in micropipette measurements of 
binding strength, as well as rheology studies of adhesion which were conducted using matrices which 
mimic the splenic microvasculature.  While the data derived from these studies is only preliminary, 
there remains a wealth of information to be derived from the further development of this technology 
and its use in describing P. coatneyi infection. 
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Chapter 7: The use of the Rhesus – P. coatneyi model in a treatment 
study of Methylene Blue in severe malaria  
 
7.1 Introduction: 
The World Health Organization assessed the human malaria burden worldwide in 2012 to be 
greater than 200 million cases of infection, 90% of which were caused by Plasmodium falciparum. 
(WHO 2014) P. falciparum infections are responsible for the preponderance of the deaths due to 
complications associated with the symptomology and pathology of severe malaria.  The current crisis, 
which is becoming more and more apparent, is the escalating development of drug resistance by 
some strains of human malaria parasites, to include much of the world’s P. falciparum strains. 
(Anderson 2010; Bhumiratana 2013; Kim 2013; Noedl 2010; Verdrager 1986; WHO 2014) There is 
ongoing investigation into the use of intravenous artesunate (AS) and several different 
phenothiazines as therapeutics for severe malaria.  At present, the only United States Food and Drug 
Administration approved regimen for severe malaria is intravenous (IV) Quinidine, which has a 
narrow therapeutic index and severe potential side effects.  A complication of this drug is that, due to 
the fact that the compound is no longer used in its primary form as an anti-arrhythmic agent, due to 
safer alternatives, many hospitals in the US have stopped carrying this medicine.  
In the ongoing struggle to identify and test new potential anti-malarial drugs, there is 
significant concern relating to the very limited number of severe malaria animal models and their 
relevancy to human disease.  Primate malaria models are justifiable to the extent that they can more 
closely predict human responses to anti-malarial drugs.  It is a valid observation in malaria drug 
efficacy studies that the more phylogenetically similar the animal model, the more accurate the 
prediction of human responses.  This has been previously described in the P. coatneyi-rhesus model 
for intravenous Artesunate. (Maeno 1993)   
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7.2 Materials and Methods:  
7.2.1 Methylene Blue: 
Mefloquine, halofantrine, and doxycycline are products of the U.S. Army’s drug development 
program.  One of the ongoing efforts is to develop a parenteral drug for severe malaria to replace 
quinidine; the only FDA approved parenteral anti-malarial currently available in the United States.  
Quinidine, an antiarrhythmic drug, has significant potential side effects, and is no longer carried in 
many U.S. hospitals as it has been replaced by newer and safer antiarrhythmic drugs.  Most mortality 
from severe malaria occurs in the first 24-48 hours.  Artemisinin derivatives differ from 
quinine/quinidine, the traditional treatments of severe malaria, in that they kill parasites much more 
rapidly.  IV AS has been shown to reduce mortality in severe malaria when compared with quinine in 
two prior large Phase III trials. (Dondrop 2010, Seaquamat 2005) These agents can be given orally, 
intrarectally, intramuscularly, and intravenously. (Cao 1997) However, bioavailability and absorption 
variability are important limitations of oral agents as well as intramuscular artemether and 
artesunate (AS) suppositories. (Sabchareon 1998) Oral Artesunate-lumifantrine is available in the US 
for treatment of uncomplicated malaria, and parenteral AS is currently under evaluation by the FDA 
for use in the US for severe malaria, but it has not yet been approved.  Furthermore, the cost and 
availability of the parenteral artemesinins may limit the availability of these drugs.  Artesunate for 
injection (IV AS), is produced without internationally recommended Good Manufacturing Practices 
(GMP) by the Chinese (Guilin Pharmaceutical Factory #2, Guangxi, China), and currently is the only 
commercially available non-bulk pharmaceutical formulation.  It is packaged by Atlantic 
Pharmaceutical Co. in Bangkok and is marketed in Thailand and other parts of Southeast Asia.  The 
currently marketed AS formulation is a freeze-dried preparation which requires mixing with a sodium 
bicarbonate solution at the bedside, and then diluted with dextrose in water (Package Insert, AS for 
Injection, Atlantic Pharmaceutical Co., Bangkok).  No non-bulk GMP parenteral artemisinin product is 
available. The US Army Medical Research and Materiel Command (USAMRMC) is developing a GMP 
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formulation of IV AS for use in the USA; at present however, IV AS is available in the USA via 
Investigational New Drug (IND).  Additionally, oral artemisinin combinations for uncomplicated 
malaria are now the standard of care worldwide.  They are also widely sold over the counter as single 
agents in non-curative regimens.  The incredible drug pressure applied will ultimately result in drug 
resistance to artemisinins if patterns seen with all other anti-malarial drugs are followed.  Resistance 
has been reported on the border regions between Thailand and both Cambodia and Myanmar. 
(Noedl 2010; Rooney 1992; Sermwittayawong 2015; Wongsrichanalai 2001) Efficacious alternatives to 
AS should, therefore, be investigated for the treatment of severe malaria.  
Methylene Blue (MB) is commercially available as an IV formulation that is produced under 
GMP conditions as an U.S. Food and Drug Administration approved drug.  It is used for the treatment 
of acquired and idiopathic methemoglobinemia (Devine 1983; Ellenhorn 1988; Gennaro 1990; Krogh 
1993; Meissner 2006) and as a tissue dye in diagnostic procedures as a bacteriological stain (Devine 
1983; Gennaro 1990; Krogh 1993), as a dye in diagnostic procedures such as fistula detection, and for 
the selective staining of certain body tissues during surgery. (Devine 1983; Krogh 1993) Its most 
commonly used brand name is Urolene Blue. MB has also been used off label for cases of septic 
shock, where it has been found to stabilize blood pressure and decrease vascular permeability.  This is 
thought to largely be due to its ability to inhibit guanylate cyclase and the production of cGMP, which 
in turn decreases levels of TNF. (Harbrecht 1995; Kirov 2001) High levels of TNF have also been found 
to be an independent risk factor for severe P. falciparum cerebral malaria. (Day 1999; McCall 2010)  
MB combines with nicotinamide adenine dinucleotide phosphate reduced (NADPH), in the 
presence of NADPH-methemoglobin reductase, to produce leukoMB; leukoMB then reduces 
methemoglobin to hemoglobin. (Curry 1982; Ellenhorn 1988; Krogh 1993; Yusim 2007) In high 
concentrations, MB oxidizes the ferrous iron of hemoglobin to the ferric state, facilitating the 
conversion of hemoglobin to methemoglobin. (Curry 1982; Devine 1983; Gennaro 1990; Krogh 1993; 
Meissner 2006) It has a 70% bioavailability in oral form (Walter-Sack 2009), is rapidly reduced to 
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leukoMB (Curry 1982; Gennaro 1990), and is excreted in the urine (Curry 1982; Ellenhorn 1988; Krogh 
1993) and bile, primarily as leukoMB, although some unchanged drug is also excreted in the urine. 
MB has long been recognized as an anti-malarial, being first described as one of many 
different phenothiazine compounds by Guttman and Ehrlich in 1891. (Guttman 1891; Guttmann 
1960; Greenwood 1995) It has demonstrated activity against all malarial blood and gametocyte 
stages.  German researchers working with modifications of the basic side chains on MB eventually 
were able to synthesize the first synthetic anti-malarial, pamaquine, and later synthesized a less toxic 
analog, primaquine. (Greenwood 1995; Olliaro 1995) Primaquine is still used to eradicate refractory 
hypnozoites of P. vivax and P. ovale.  MB has recently been compared with other phenothiazine dyes 
and demonstrated a notably higher potency and selectivity in its anti-malarial activity. (Vennerstrom 
1995) More recently, MB and some of its derivatives demonstrated an ability to bind 
haem/ferriprotoporphyrin IX (FP) and appear to have anti-malarial mechanisms that are similar to 
those of chloroquine, in that their activities are partially correlated with their abilities to inhibit β-
haematin formation. (Atamna 1996) 
MB also kills Plasmodia species via an increase in Plasmodial oxidants.  Increase in oxidants 
can be due to inhibition of plasmodial glutathione reductase (so that oxidants are not removed) or by 
being a subversive substrate of the reductase (so that more oxidants are created).  MB has 
demonstrated in vitro anti-malarial activity with a mean ED50 of 0.97 ng/mL against an in vitro panel 
of seven parasites. (Ohrt ILIR 2003, unpublished) No cross-resistance with other anti-malarial drugs 
has been identified. (Ademowo 2007; Pascual 2011) Combinations of AS and MB have demonstrated 
synergism when used in vitro. (Ohrt ILIR 2002, unpublished) This synergism has been confirmed in 
both rat and mouse/P. berghei models where 3-day intravenous regimens of both compounds 
resulted in cure, whereas AS or MB alone resulted only in parasite clearance with recrudescence. (Li, 
unpublished) Additionally, MB given as combination therapy with AS appeared to increase the rate of 
reduction of malaria parasites relative to AS given as a single drug therapy. (Xie, unpublished) An 
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earlier AFRIMS study compared IV AS and IV MB in the rhesus/P. cynomolgi model and found both to 
clear parasite loads rapidly, with some synergistic effects when the agents were combined. (Barker, et 
al unpublished) Similar findings were noted when comparing IV AS and IV MB in Aotus monkeys 
infected with P. falciparum. (Ohrt, unpublished) Several human clinical studies have been conducted 
in Burkina Faso, using MB to treat mild to moderate cases of P. falciparum.  MB has demonstrated 
significant efficacy in clearing blood stage parasitemia using oral doses of 6-12 mg/kg twice daily for 
three days, regardless of chloroquine resistance. (Meissner 2006) MB has also been proven to be an 
effective addition to other anti-malarial medications including AS and Malarone, increasing rate of 
clearance. (Zoungrana 2008) By itself, MB as is true with AS, will clear blood stage parasitemia, but 
will show a high rate of recrudescence with only three days of therapy, demonstrating its need to be 
partnered with a longer acting agent to affect a cure.  
With parenteral dosage forms in humans, MB should be administered by intravenous 
injection only; either subcutaneous or intrathecal injection may result in tissue necrosis or neural 
damage (Krogh 1993), respectively.  Usual adult and adolescent parenteral dosage forms for 
methemoglobinemia are given as 1 to 2 mg per kg of body weight (Curry 1982; Ellenhorn 1988; 
Gennaro 1990; Krogh 1993; Yusim 2007), or 25 to 50 mg per square meter of body surface area 
(Ellenhorn 1988), administered over 5 minutes.  The dose may be repeated after one hour if needed.  
The usual adult prescribing limit is 7.5 mg per kg of body weight. (Ellenhorn 1988) Pharmacokinetic 
(PK) data for MB in humans, dogs and rats has been published (Aeschlimann 1996; Aeschlimann 1998; 
Disanto 1972a; Disanto 1972b; Disanto 1972c; Peter 2000; Walter-Sack 2009; White 1999), and has 
been evaluated in non-malaria infected rhesus monkeys at 2.5, 5, 10, and 20 mg/kg in a prior AFRIMS 
experiment.  Data from rhesus monkeys shows similar peak concentration properties to humans, 
however it is metabolized about 3.5 times more rapidly, resulting in a smaller AUC. (Barker, et al 
unpublished) The usual commercially available formulation is a generic at 10 mg per mL prepared and 
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packaged under GMP conditions as a 1% USP solution in water.  Sodium chloride 0.9% is compatible 
for dilution of MB.  
MB has demonstrated the ability to rapidly decrease parasitic load.  If proven non-inferior to 
IM Quinine, IV MB would make a welcome addition to the severe malaria drugs, given that it appears 
to be safer than IV quinidine, and IV AS is not readily available worldwide at this time.  It will also be 
useful to have an alternative treatment available in the event that resistance develops to IV AS.   
 
7.2.2 Dose Formulations Stability and Storage Conditions:  
1. Methylene Blue:  Methylene blue was packaged as a USP 1% solution in water for injection at 10 
mg/mL in that has already been pH adjusted with sodium hydroxide and/or hydrochloric acid.  The 
injectable solution was stored in the dark at controlled room temperature (15° - 30°C). 
 
7.2.3 Drug inoculation: 
Animals were randomly assigned to three experimental groups which were: MB 6 mg/kg IV 
twice daily (cohort 1), MB 10 mg/kg IV twice daily (cohort 2) or MB 17 mg/kg IV twice daily (cohort 3).  
Based on these groups, evaluation of the efficacy of methylene blue was achieved at low, medium 
and high doses. 
 
7.3 Donor Animals: 
P. coatneyi was inoculated from one rhesus to another through a blood challenge of infected 
erythrocytes.  Inoculation began in an infected donor by intravenous inoculation of freshly thawed 
cryopreserved P. coatneyi strain infected blood.  The stabilate stock (maintained at AFRIMS) has been 
tested and confirmed negative for Herpes B virus, SRV, SIV and STLV-1 to ensure no possibility of 
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adventitious virus transmission into the monkey colony.  One cc aliquot of a thawed stabilate of P. 
coatneyi infected RBCs was administered intravenously into a peripheral vein of the donor monkey as 
described below.  Blood smears were prepared to detect malaria parasites starting on Day 0 before 
inoculation and continued daily. 
Once the blood smear was noted to be positive, either white blood cell (WBC) and/or red 
blood cell (RBC) counts were performed daily to determine a parasite density (parasitemia).  After the 
parasitemia had reached > 50,000 parasitized RBCs per µL, 10-20 mL of blood was drawn into a 
heparinized tube, diluted with sterile PBS solution to a concentration of 5x106 infected erythrocytes 
per 1 mL suspension, and divided into equal 1 mL aliquots.  The 1 mL aliquots were subsequently 
used to infect the study animals and to prepare additional cryopreserved stabilates for future use.   
After completion of the blood draws, curative treatment was given with CQ 10 mg/kg, PO 
daily for 7 days.  The donor monkeys were considered to be off-study once blood donation had been 
completed and animals were cleared of parasites.   
 
7.4 Experimental Animals: 
A total of nine monkeys in this portion of the study were randomly assigned to each of 3 
experimental groups with three monkeys in per group.  A prior model refinement study involving 6 
untreated animals served as controls.  Experimental animals (not including donors) were euthanized 
upon treatment failure or on day six after initiation of treatment.  The ultimate goal of this study was 
to provide efficacy data for the selection of an optimal dose of MB for use in planned phase II human 
clinical trials, and to support the U.S. Army anti-malarial research program. 
The MB drug dosing schedule, euthanasia date, peak parasitemia and terminal parasitemias 
are described in Table 7.2.  Due to the intensity of blood sampling, parasitemia assessment, clinical 
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monitoring and eventual autopsy, the three MB groups were staggered by a week, and an individual 
donor macaque was randomly assigned to each group.   
The study selected nine splenectomized, chair trained, Indian origin rhesus macaques ranging 
in age from seven to 13 years old, from the AFRIMS closed colony. Both genders were represented 
and all animals were evaluated for prior experimental history to ensure that none of the animals had 
been exposed to P. coatneyi previously.  Additionally, three spleen intact donor Indian origin rhesus 
macaques were selected and randomly assigned to each dosage group. The nine experimental 
animals were splenectomized in accordance with AFRIMS surgical protocols, injected with a microchip 
temperature recording device (telemetry) in the subcutaneous tissues between the shoulder blades 
and recovered for one month prior to being infected by peripheral vein inoculation with P. coatneyi-
blood stage parasites (approximately 1 mL of 5x106 infected RBCs) drawn from the donor monkeys.  
Throughout the study, blood draws were calculated using a reference point of a 6.8kg animal 
as the least common denominator.  However, with larger animals, under the purview of the attending 
veterinarian, blood draws were increased based on their body weight and permissible blood draws 
per SOP.  All blood drawn was used in accordance with the testing described in the IACUC approved 
protocol amendments. 
 
7.4.1 Ethics: 
Research was conducted in compliance with the Animal Welfare Act and other federal 
statutes and regulations relating to animals and experiments involving animals, and adhered to 
principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 2011 
edition. The protocol was approved by AFRIMS 12-08. 
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7.5 Clinical parasitology: 
Blood smears were conducted beginning on ID-0 before the parasite inoculation and 
continued three times daily until positive parasitemias exceeding 5000 per cu mm are measured, 
typically on day five to six.  Beginning on day six, parasitemia assessments increased to eight times 
daily until the treatment criteria were reached and for several subsequent days (typically day six 
through day 10).  Once a smear was positive, WBC and/or RBC counts were performed on an 
increasing schedule both to determine parasite density and percent parasitemias (calculations per 
AFRIMS Standard Operating Procedures: Malarial Parasite Count for Quantifying Parasitemia in 
Experimental Animal’s Infected Blood), as well as for clinical chemistry evaluation and complete blood 
count (CBC). 
Blood smear samples on glass slides were fixed in methanol and stained with Giemsa.  They 
were examined for the presence or absence of parasites under the oil-immersion objective as well as 
parasite staging.  If no parasites are found in 50 microscopic oil-immersion thick fields or 
approximately per 1000 white blood cells (WBCs), the smear were considered negative.  The 
parasitemia level was reported as number of parasites per 1µl or mm3 of whole blood and converted 
to a percentage.  Parasites were counted per number of WBCs or red blood cells (RBCs), i.e., per 100 
–300 WBCs or 500 – 10,000 RBCs.  Parasitemia levels were calculated by the appropriate total blood 
cell count (white or red) per mm3. 
 
7.6 Study endpoints and Treatment Outcome Definitions: 
Response to treatment was characterized as a continuum based on parasite suppression, 
clearance and clinical symptomology.  Success was determined as a combination of a parasitemia 
decline by  75% at 48 hours with clinical improvement, combined with parasitemia clearance >99% 
at the third day after treatment initiation, and an absence of moribund behavior, stable respiratory 
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status, and stable blood pressure. Study Failure, on the other hand, included a parasitemia decline of 
less than 75% at 48 hours with clinical deterioration, failure to clear parasitemia by 99% by day 3 after 
treatment initiation, or moribund behavior, unstable respiratory status, or unstable blood pressure at 
the end of three days of therapy. 
Further treatment failure was determined by the attending veterinarian in association with 
the Principal Investigator and the infected monkeys were considered as having reached study 
endpoints if the parasitemia failed to decrease and any three predetermined clinical criteria were 
reached during the post treatment period.  These included: symptomology associated with 
persistently elevated temperatures, severely suppressed mentation, sustained anorexia, chemistry 
associated with hepatic or renal failure, coagulopathies or respiratory distress. 
It was expected, in this severe malaria model, that the animals would display signs of severe 
malaria at the initiation of therapy, and it was anticipated that they would continue to show these 
signs during the first 24 hours of therapy regardless of the medication dose used. Anticipated clinical 
signs included combinations of the above listed clinical criteria, however these were expected to be 
transient and reversible once treatment was initiated.  Additionally, clinical chemistry and 
hematological findings were expected to demonstrate organ pathology.  These included 
hypoglycemia, metabolic acidosis, severe anemia, high blood lactate and/or renal impairment 
(elevated BUN and Creatinine). 
 
7.7 Temperatures and clinical symptomology: 
Temperatures and clinical signs were monitored throughout the study with frequency 
increasing in synchrony with the rising parasitemia to a peak of every other hour over 24 hour cycles.  
Temperatures were recorded via rectum as well as by using a subcutaneous transponder that was 
injected under the skin between the shoulder blades in all animals.   
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Clinical signs were collected a minimum of 7 times daily and a maximum of 12 times daily.  These 
were in conjunction with collection of a drop of blood for parasitemia assessment and were 
noninvasive.   
Criteria evaluated and scored included the assessment of activity level as determined by 
moving around the cage and the response to the presence of a veterinarian or a technician; 
mentation which was evaluated as a response to stimuli outside the cage; menace response in which 
an animal will blink or withdraw when a sudden movement occurs close to the eyes; breathing, to 
include both the quantitative number of breaths as well as the quality: labored, shallow, gasping…etc; 
skin color to include any signs of hemorrhage, jaundice or cyanosis; presence of vomitus; skin turgor 
as a sign of hydration status; urine color and both quantitative and qualitative assessment of the 
urine captured in the pans under the cage; and appetite.  All signs were graded, with a maximum 
score of 24.  A normal animal would score 0.  
All animals had terminal blood, cerebrospinal fluid and urine collected.  Complete autopsy 
was performed in all animals with weighing of select organs (brain, lungs, heart, liver), collection of all 
tissues in 10% buffered formalin, selected tissues in Glutaraldehyde and RNA-later, as well as 
photography of all significant lesions. 
 
7.8 Histopathology: In the 15 animals enrolled in various elements of the study, widespread tissue 
sampling was performed at post mortem, and the histopathology evaluated both by a board certified 
veterinary pathologist (EDL) and medical pathologist (GDHT).  Tissue pathology was categorized in 
comparison with both AFRIMS archival tissue from normal control rhesus macaques as well as noting 
those changes that have been associated with normal aging or background variation. (Chamanza 
2012) 
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7.9 Results: 
Infected animals typically began to develop clinical symptomology around day 7 post 
inoculation, although decreased appetite or anorexia was often noted around day 4 to 5.  Initial signs 
were often found to be associated with activity level and mentation.  These were closely aligned with 
the first significant increases in temperature.  At this stage, an animal would typically have a total 
score of around 7, consisting of anorexia (3), some degree of hematuria (1-3), moderate to marked 
reduction in activity (1-2) and decreased mentation (1).  When the hematuria became more 
significant, changes in skin turgor would typically follow.  Immediately prior to death or euthanasia, 
animals had severely decreased mentation with loss of the menace response.  Animals were 
recumbent in their cages and non-responsive to external stimuli without reaching human criteria of 
true coma.  Animals would typically have been anorexic for 2 days, and at some point would have 
vomited.  Occasionally, there were episodes of dysuria, and in all animals varying degrees of 
hematuria was observed.  By day 7, most animals were showing signs of dehydration, and in a couple 
of the animals, prior to death there was evidence of dyspnea.   
Animals in cohort 1, at the point of euthanasia, while being slightly depressed, had 
normalized their clinical signs. All three animals had regained their appetites, had improved urination 
and were normothermic.  2 of the 3 animals in cohort 2 were noted to be vomiting, have decreased 
mentation, be anorexic or have dysuria at euthanasia, while the third had normalized.  In cohort 3, 2 
animals also had severe clinical signs at euthanasia, to include epistaxis, vomiting, sustained anorexia, 
decreased mentation.  The third animal had normalized. 
In normal adult animals from the AFRIMS colony, baseline temperatures measured rectally 
fluctuate between 99.5° F to 102° F (37.5° C to 38.9° C) depending on a range of physiological factors 
to include gender, feeding schedule, stress, handling time, concurrent procedures. 
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Experimentally, following the initial temperature spike at day 7, which would often be around 
104° Fahrenheit (F) or 40° Celsius (C), the temperature would remain higher than baseline, with peak 
temperatures reaching up to 107° F or 41.7° C, but fluctuating until death or euthanasia. 
Beginning on day 1 post inoculation, there was an observable parasitemia which 
subsequently decreased and by the beginning of day 3 was no longer significant.  By the 3rd sampling 
on day 3, the parasitemia had undergone an initial spike in the range of 10,000 to 30,000 
parasites/mm3 red blood cells.  The cycle continued and the parasitemia again decreased, rising again 
by the end of day 5 at which point the values ranged from 200,000 to 350,000 parasites/mm3 red 
blood cells.  A subsequent decrease over day 6 with an expected spike by the end of day 7 resulted in 
calculated parasitemia in excess of 1 million parasites/mm3 red blood cells.  In the control animals, 
the parasitemia remained sustained at that threshold until death or euthanasia which never 
exceeded day 8 without some form of medical intervention. 
Parasite life cycle stage was a crucial feature employed for a complete understanding of the 
disease progression. The parasitemia spike on day 5 represented a peak of ring stages followed by a 
predictable increase and peak in trophozoites on day 6 leading to a small spike in schizonts.  This was 
closely followed by the day 6 (evening) increase in ring forms, a smaller increase in trophozoites and 
then a schizont increase on day 7. This was followed closely by a dramatic increase in ring forms, 
which as it began to taper off, yielded to the significant increase in trophozoites at the beginning of 
day 8.  The animals in the refinement protocol (untreated controls) typically did not survive beyond 
this peak, and were euthanized or died naturally. Animals in the MB dosage groups showed similar 
initial parasitemia curves, but once the treatment window was achieved, the parasitemias were 
significantly controlled, decreased and eventually cleared in most of the drug study animals. (Figures 
7.9.1-3) 
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Figure 7.9.1: Parasitemia curves cohort 1 
 
 
Figure 7.9.2: Parasitemia curves cohort 2 
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Figure 3: Parasitemia curves cohort 3 
7.9.1 Drug-treated animals: 
The efficacy of each dose of MB is shown in Table 7.3.  MB at all doses was relatively effective 
in terms of parasite clearance. Three animals did not fully clear as the full treatment regimen could 
not be administered due to severity of clinical signs.  In those three animals (1 from cohort 2 and 2 
from cohort 3) the parasitemia was trending towards clearance at euthanasia.  6mg/kg BID MB was 
the most effective cohort, however peak parasitemias in those animals remained at 25% or below, 
while cohorts 2 and 3 reached parasitemias which peaked at between 38-45%.   Due to severe 
vomiting and dysuria in cohorts 2 and 3, furosemide and cimetidine were administered in some 
animals concurrently with MB treatment. 
For those animals who demonstrated treatment success, clearance times ranged from two to 
three days.  The increased severity of clinical signs in animals from cohorts 2 and 3 must be 
considered in the context of both the increasing drug dose and therefore a potential toxicity as well 
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as the markedly higher peak parasitemias and associated clinical signs and tissue pathology. As the 
infected control animals were also noted to have evidence of acute renal, hepatic and cardiac injury, 
we posit that the degree of parasitemia was the driving force requiring early euthanasia in 3 of the 
experimental animals rather than potential toxicity of MB. 
 
7.9.2 Gross findings: 
The primary macroscopic findings in control animals were associated with hemozoin 
deposition in tissues.  This presented as a dark brown discoloration of the parenchymal organs.  Liver, 
heart, lungs and kidneys all were severely darkened by the presence of the malaria pigment, admixed 
with the blue tinge of MB. (Figure 4) Additionally, there was enlargement of multiple organs with the 
liver being the primary organ demonstrating megaly. 
Macroscopic findings in experimental animals was primarily dependent on the duration of 
treatment and the survival period beyond peak parasitemia.  Findings ranged from lesions consistent 
with those described in the P. coatneyi infected control animals to tissues appearing only slightly 
discolored when compared with archival normal control animals.  Additionally, MB appeared to 
concentrate in specific tissues, resulting in a light blue tinge being noted in the grey matter of the 
spinal cord, brain stem, the pars intermedia of the pituitary gland (Figure 5), the prostate gland, the 
gallbladder, urinary bladder and the renal medullae. 
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Figure 7.9.2.1: Kidney. MB treated P. coatneyi Rhesus macaque. The renal parenchyma is markedly 
discolored, with concentration of the methylene blue within the cortex and the medullary pyramids. 
 
Figure 7.9.2.2: Cerebrum, cerebellum, brain stem and pituitary gland. MB treated P. coatneyi Rhesus 
macaque demonstrating the dramatic blue tinge seen in various tissues throughout the body of 
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treated animals, but which was most significant within the endocrine tissues, the kidneys and the 
central nervous system. 
 
7.9.3 Histopathology: 
In the control animals, there was significant microvascular sludging with parasitized 
erythrocytes and hemozoin pigment noted in all tissues, with increased evidence noted in the central 
nervous system, heart, hepatic sinusoids, the renal glomeruli and endocrine tissues such as the 
pancreatic islets of Langerhans, the adrenal glands and the pituitary gland.  This appeared to be 
resulting in a degree of microvascular obstruction, interpreted due to an increased congested 
appearance to many vessels and increased numbers of vessels observed per section. Due to the detail 
required for confirmation, sequestration was confirmed using transmission electron microscopy. 
Additionally, in all affected tissues, there was abundant hemozoin pigment observed. 
Tissue histopathology in the experimental cohorts ranged in severity, correlating both with 
peak parasitemia levels and survival period post treatment. (Table 7.1) The treated animals lacked 
any observable sequestration, and with the exception of the presence of free and phagocytosed 
hemozoin and hemosiderin pigments, there was no remnant evidence of the malaria infection. 
However, the lingering effect of the insult of severe malaria was evident in many of the tissues. 
(Figure 7.9.3.1-4) Occasionally, liver samples would have evidence of zonal coagulative or lytic 
necrosis while sections from the kidneys would have significant epithelial regeneration as well as 
ongoing evidence of residual damage.  Cardiac pathology was typified by piecemeal loss of 
cardiomyocytes, periodic fibrosis and single cell hypertrophic changes suggestive of reactive changes.  
The central nervous system had fewer lesions in comparison with experimental control animals and 
often there would be an absence of acute pathology, while there was a slight increase in more 
chronic evidence of injury such as degenerative changes to the neurons.  Other changes consisted of 
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expected chronic effects of the systemic erythrocyte damage, such as lymph node and (when 
available) splenunculum erythrophagocytosis and hemozoin pigment admixed with hemosiderin.  
 
Figure 7.9.3.1-4 Example photomicrographs of residual severe malaria pathology in MB treated 
macaques.  7.9.3.1 This image demonstrates an example of a focus of hepatocellular necrosis 
(arrowheads).  In this instance the lesion is near the central vein and while in this plane of section it is 
not contiguous with the centrilobular zone, there was a noted zonality hypothesized to be associated 
with hypoxic injury. HE 400x. 7.9.3.2 This photomicrograph illustrates a renal tubule with luminal 
hemoglobin pigment (asterix) and necrotic cells.  The epithelium lining the tubule demonstrates 
evidence of regeneration with mitotic activity (arrow), cellular piling and cells with a high nuclear to 
cytoplasmic ratio.  Additionally, there are scattered leukocytes infiltrating the interstitium. HE 1000x. 
7.9.3.3 This photomicrograph of the myocardium shows evidence of fibrosis and cardiomyocyte loss 
as well as reactive changes comprised of cellular hypertrophy and megakaryosis. HE 400x. 7.9.3.4 This 
image is a high magnification of the sinus of a paratracheal lymph node.  In this image, there is a sinus 
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histiocytosis with abundant phagocytosed hemosiderin pigment and abundant erythrophagocytosis. 
(arrow) HE 1000x.  
 
Table 7.1: Comparative histopathology control animals versus methylene blue treated. Scores are 
semi-quantitative based on assessment by both EDL and GDHT. The severity score was based on a 
scale of 0 to 5, and then the data was averaged by cohort to achieve a mean value per group.  The 
same was conducted for the experimental controls, thereby allowing comparison.  
Specifically, experimental animals did have pathology which was hypothesized to be 
attributed to hypoxic injury secondary to the previous sequestration.  In cohort 1, hepatic pathology 
extended from zonal glycogenosis and lipidosis to one animal having moderate, portal bridging 
coagulative necrosis of the hepatocytes.  In that particular animal, there was also evidence of 
hemorrhage within the brain stem. Cohort 2 was observed to have similar degree of hepatic severity 
as cohort 1 while cohort 3 had milder amounts of hepatic insult, and those were typically limited to a 
zonal glycogenosis, and piecemeal necrosis rather than large scale coagulative necrosis.  In all of the 
Animal # Drug dose 
Terminal 
parasitemia
Parasite 
sequestration 
severity
CNS hemorrhage 
severity and 
location
CNS edema 
severity
Cerebellum 
Purkinje 
cell degen
Axonal/neuronal injury 
severity and location
Renal 
injury 
severity
Hepatic 
injury 
severity
Cardiac 
injury 
severity
Vasculitis 
Y/N
15-264 Cohort 1 16.90% 0
3/2; brain 
stem/spinal cord 2 3 3/2; cerebrum/spinal cord 2 3 1 N
15-265 Cohort 1 24.50% 0 0 3 3
3/2; cerebrum, brain 
stem/spinal cord 4 4 3 N
15-266 Cohort 1 25.40% 0 0 1 1 1; cerebrum, brain stem 3 2 1 N
15-274 Cohort 2 42.80% 0 0 3 3 3/2; cerebrum/spinal cord 4 4 3 N
15-275 Cohort 2 45.20% 0 0 2 1 2/1; spinal cord/cerebrum 3 2 3 Y
15-272 Cohort 2 40.80% 0 1; spinal cord 2 1 1; cerebrum; brain stem 5 2 1 Y
15-271 Cohort 3 42.50% 0
3/2; spinal 
cord/brain stem 1 1 3; spinal cord 5 2 1 Y
15-273 Cohort 3 38.30% 0 0 2 0 2; cerebrum 5 2 3 N
15-276 Cohort 3 42.60% 0 1; spinal cord 2 1 1; cerebrum, brain stem 2 3 2 Y
Mean Cohort 1 22.30% 0 1 2 2.3 2.3 3 3 1.7
Mean Cohort 2 42.90% 0 0.33 2.3 1.7 2 4 3.3 2.3
Mean Cohort 3 41.10% 0 1.3 1.7 0.7 2 4 2.3 2
13-106 Control 13.60% 5 3; spinal cord 3 1 3/2; cerebrum/spinal cord 2 2 2 Y
13-107 Control 10.50% 5 3; spinal cord 3 3 3; spinal cord 2 2 2 Y
13-108 Control 7.50% 5 3; spinal cord 3 1 2; cerebrum, spinal cord 2 3 2 Y
14-198 Control 34.80% 5
2; brain 
stem/cerebrum 3 3
2/1; cerebrum/spinal cord, 
brain stem 3 3 2 N
14-199 Control 39.20% 5 1; spinal cord 3 3
2/1; cerebrum/spinal cord, 
brain stem 3 3 2 N
14-200 Control 34.20% 5 2; spinal cord 3 2
2/1; cerebrum/spinal cord, 
brain stem 2 3 2 Y
Mean Control 23.30% 5 2.3 3 2.2 2.3 2.3 2.7 2
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groups, there was a degree of acute renal damage which correlated with clinical chemistry findings.  
The methylene blue treated animals displayed slightly increased severity of renal pathology than 
control animals which appears to be a paradoxical finding. MB has been used in a range of studies as 
a reno-protective drug due to its inhibition of the Nitric Oxide (NO) pathway with the downstream 
formation of cyclic guanosine monophosphate (cGMP) through the binding of the soluble guanylate 
cyclase (sGC) heme moiety.  Combined, these results in lipopolysaccharide-associated proximal 
tubular renal toxicity. (Heemskerk 2008) As discussed previously in the chapter, MB is capable of 
binding sGC, which thereby blocks the production of cGMP.  Furthermore, MB scavenges NO as well 
as having the capability of inhibiting NO synthases. (Harbrecht 1995; Kirov 2001; Mayer 1993) We 
hypothesize that the severity of the renal pathology correlated to several interrelated factors to 
include the degree of parasitemia and the extended survival of the MB treated animals prior to 
euthanasia (average 4 days longer) in comparison with infected controls, allowing for development of 
more significant lesions in the kidneys. 
In the kidney samples, there was a histiocytic and lymphoplasmacytic interstitial nephritis 
observed in most cases, combined with a lesser neutrophilic tubulitis, as well as the presence of 
hemoglobin, cellular and protein casts.  Renal samples also had evidence of epithelial degeneration 
and necrosis, as well as a lesser degree of membranoproliferative glomerulopathy with synechiae.  
The myocardium was observed to have a moderate amount of pericyte hyperplasia, with 
cardiomyocyte degeneration, necrosis and karyomegaly suggestive of reactive changes. In rare cases 
in which the lung was affected, a histiocytic, lymphoplasmocytic and neutrophilic interstitial and 
perivascular pneumonitis was observed.  Rare fibrin thrombi were noted in certain animals, as well as 
a minimal amount of alveolar edema.   
It is important to note that while MB treatment resulted in trends towards parasite clearance, 
there was residual histopathologic and clinical chemical evidence of ongoing damage to a range of 
organ systems.  Beyond suppression of vomiting and application of diuretics to promote urination, no 
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supportive care was given to the experimental animals.  There is the potential that with fluid therapy 
and other avenues of care, that the degree of clinical symptomology which per protocol required 
euthanasia, would have been suppressed allowing for validation of complete parasite clearance at all 
drug doses. 
Animal # Cohort # Treatment Day Euthanasia day Peak parasit. % Terminal parasit. % 
R130 1 9 14 24.5 0.00 
R453 1 7 13 16.9 0.00 
R761 1 9 14 25.4 0.00 
DA977 2 7 12 45.2 0.01 
R420 2 7 11 42.8 0.06 
R711 2 7 9 40.8 4.6 
R121 3 7 8 39.6 6.8 
R338 3 7 12 42.6 0.01 
R745 3 7 9 38.3 1.7 
 
Table 7.2: Treatment schedule, peak parasitemia and terminal parasitemia.  
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 Cohort 1 Cohort 2 Cohort 3 
Dose (mg/kg/BID):   6 mg/kg 10 mg/kg 17 mg/kg 
No. animals: 3 3 3 
No. animals cleared: 3 2 1 
No. animals euthanized 
prior to clearance (*): 
0 1 2 
*Clearance defined as less than 0.1% parasitemia  
Table 7.3: Efficacy of IV MB at each dose in P. coatneyi infected Rhesus macaques. 
 
7.10 Discussion: 
This study evaluated the use of IV methylene blue as a potential therapeutic compound for 
use in the radical cure of severe malaria in splenectomized rhesus macaques infected with P. coatneyi 
as part of the strategy to combat the spread of artemisinin resistance beyond Southeast Asia.  
The rhesus macaque is one of the hardiest of the established primate malaria models and 
therefore is considered to be optimal in its ability to tolerate the required procedures for drug 
evaluation protocols.  The rhesus is superior to the New World Aotus monkey because sufficient 
blood volumes can be collected for adequate analysis without causing an adverse iatrogenic anemia 
in addition to the high predilection of background renal disease which can confound findings of 
severe malaria in these species.  (Chalifoux 1981; Gozalo 1992; Hunt 1993) The model that appears to 
mimic human severe malaria most closely is the rhesus monkey/Plasmodium coatneyi model. (Aikawa 
1992; Lombardini 2015; Maeno 1993; Moreno 2007; Moreno 2013)  
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The use of intravenous MB as an anti-malarial would be highly advantageous as the 
compound is already approved throughout the world for use in humans as a treatment for 
methemoglobinemia and therefore could be used off label rather than needing to go through the 
entire prolonged process of FDA or similar agency approval. 
Several clinical trials have now been conducted using MB either in uncomplicated malaria in 
African children, or in combination with artemesinin based therapy (Bountogo 2010; Coulibaly 2009; 
Coulibaly 2015; Fall 2015; Meissner 2006; Müller 2013; Zoungrana 2008), where in both settings, the 
compound was noted to have strong gametocidal activity, as well as transmission-blocking properties, 
both of which are potential advantages in preventing spread and which therefore in aiding in avoiding 
drug resistance to the artemesinins. (Adjalley 2011; Coulibaly 2009) The mode of action of MB in 
regards to plasmodiae, while not completely understood, is posited to act through the inhibition of 
the activity of the antioxidant glutathione reductase. (Buchholz 2008) In one study, MB therapy 
resulted in mean male gametocyte exflagellation inhibition values which were greater than 98%, in 
comparison with female gametocytes in which inhibition of activation was less than 11% suggesting 
that there are significant differences in the drug action on the different sex of gametocytes. (Delves 
2013) MB has also been evaluated in-vitro against both vivax and falciparum isolates (Ademowo 
2007; Adjalley 2011; Pascual 2011; Suwanarusk 2015; Wirjanata 2015) and as an anti-malarial in 
murine models of cerebral malaria (Atamna 1996; Dormoi 2013; Dormoi 2013b; Orht 2014; Mwangi 
2016; Nneji 2013) in which the drug has been shown to be highly effective in preventing cerebral 
malaria and in markedly decreasing mortality rates.  A single prior study of methylene blue efficacy 
has been conducted in non-human primates and was evaluated in the P. cynomolgi/rhesus macaque 
model at AFRIMS and in Aotus monkeys infected with P. falciparum at the WRAIR overseas laboratory 
in Peru as well as in P. berghei infected rats. The study noted that in the rhesus and in the rat models, 
intravenous MB was of equal efficacy as intravenous artesunate, and that combination protocols 
were superior to either compound used as a single agent treatment. (Orht 2014)  
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Based on the foundation work already conducted, the interest was in determining the 
efficacy of the compound in the P. coatneyi/rhesus macaque model of severe malaria. Our hypothesis 
was that IV MB given twice daily for 3 days at the point of development of severe malaria would have 
therapeutic efficacy and thus might represent a viable alternative to IV AS.  As such, we initiated the 
examination of IV MB in the P. coatneyi/rhesus macaque model of severe malaria.  In Rhesus 
macaques infected with P. coatneyi, IV MB was tested at varying doses dose (6 mg/kg/BID, 10 
mg/kg/BID and 17 mg/kg/BID) once the experimental animals reached a treatment threshold of 
greater than 15% parasitemia.  
MB efficacy at parasite clearance was noted at all doses, however, there was significant 
morbidity noted in the two cohorts at higher doses, which required euthanasia of the experimental 
animals.  At the lower dose, MB appeared to result in 100% clearance of parasitemia as well as 
resolution of clinical signs in animals meeting the criteria of severe malaria while having peak 
parasitemias no greater than 26%.  Clearance was observed in both the mid-range and high dose 
cohorts which coincidentally also achieved greater peak parasitemias, however those animals also 
displayed more severe symptomology. 
Macroscopic and microscopic pathologic evaluation of all tissues found that, while the 
parasites were trending towards clearance in all cases, those animals which had suffered the highest 
parasitemias (30-40%) typically demonstrated evidence of marked acute renal, hepatic and cardiac 
injury. Additionally, the histopathological evidence of P. coatneyi induced injury was consistent with 
the signs of severe malaria observed in all of three drug dose cohorts. The parasite clearance data 
was fundamentally similar to the efficacy studies conducted in murine models, and superior to those 
described in the prior WRAIR non-human primate study in which only a few of each MB treated group 
cleared. (Orht 2014) It is important to recognize that certain murine studies noted almost total 
suppression of cerebral malaria symptoms in treated cohorts with practically complete parasite 
clearance. (Dormoi 2013; Dormoi 2013b) 
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Whilst encouraged by the preliminary findings in this study, the sponsors recommend that 
subsequent trials be undertaken in which both supportive care is provided to the experimental 
animals and the post treatment period be extended, so as to determine the viability, not only in 
clearing the parasites, but also in terms of survivability of the treated animals beyond the acute 
infection and treatment period.  
7.11 Summary: 
Our study culminated with the application of methylene blue, a compound with known anti-malarial 
properties to this severe malaria model. 
The outcome was extremely encouraging, both in that MB proved to be highly parasitocidal to P. 
coatneyi, but also due to the prolonged survival of animals in comparison with untreated infected 
controls.  Of significant interest was the fact that the treated animals survived beyond day 7, 
correlating to the killing of the parasites by methylene blue, but in exchange and largely due to the 
fact that no supportive care was provided to the infected animals, this extended survival period 
allowed for the emergence of more severe clinical symptomatology. This was in evidence in increased 
levels of hepatic and renal injury which were biochemically comparable to nontreated infected 
animals.  However, we feel that the clinical symptoms of severe malaria experienced by the treated 
animals would have potentially been reversible with supportive care, and should be considered as 
part of the protocol for future studies. 
Equally importantly, the methylene blue appears to both protect against metabolic acidosis and to off 
a moderate degree of neuroprotection based on our comparable histopathologic examination of all 
of the infected animals, both treated and untreated.   
As such, this arm of the dissertation was paramount in that it both confirmed the validity, 
reproducibility and applicability of the P. coatneyi/Rhesus macaque model as a platform for anti-
malarial drug studies as well as demonstrating the potential use of methylene blue as an anti-malarial 
compound in cases of severe falciparum malaria. 
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Chapter 8: Conclusion 
8.1 Introduction:  
Our understanding and discovery of the mysteries of malaria expand daily. However, and 
crucially, the arms race for effective prophylaxis, treatment therapeutics and vaccines, looms large in 
the present, especially as plasmodiae develop drug resistance to the few effective compounds which 
remain in our armamentarium. It is sobering to remember that malaria is one of the most significant 
infectious diseases on the planet, affecting in excess of 200 million people yearly and resulting in over 
600,000 annual deaths, most of which are children under the age of five. (WHO 2015; Winzeler 2014) 
Since the 1990s, the ongoing battle against malaria has suffered significant setbacks, 
centered upon the expanding drug resistance against some of our most utilized anti-malarial 
compounds.  Chloroquine and sulfadoxine-pyrimethamine in particular were seriously compromised 
and the epicenters of this development were in regions in which malaria was endemic and where 
people were at the greatest risk.  With the advent of artemisinin derivatives as effective anti-
malarials, there was a brief reprieve in those regions hardest hit. (Ashley 2014) The widespread use of 
artemisinin based drugs and combination protocols was crucial in the significant drop in deaths 
associated in particular with falciparum malaria observed over the past 2 decades.  However, for a 
range of reasons, artemisinin resistance in P. falciparum has developed, with an epicenter in South 
East Asia. This threatens to overturn all of the recent gains in combating malaria and in decreasing 
the morbidity and mortality rates of at risk populations. (Ashley 2014; Dondorp 2009; Dondorp 2010; 
Fairhurst 2012; Price 1998; White 2016; Wongsrichanalai 2001) 
P. falciparum, responsible for most of the severe malaria syndromes and for the vast majority 
of the mortality associated with malarial infections, has developed drug resistance to practically all of 
the anti-malarial pharmacological agents at our disposal.  This has resulted in regional spikes of child 
mortality, correlated first with resistance to chloroquine and subsequently to sulfadoxine-
328 
 
pyrimethamine and mefloquine. Artemisinin-based Combination Therapies (ACT) became the 
recommended treatment for severe malaria employing artemisinin or an artemisinin derivative such 
as artesunate, artemether, or dihydroartemisinin in combination with another anti-malarial 
compound such as mefloquine, piperaquine or others. (Fairhurst 2012; Saunders 2014; Trape 2001; 
WHO 2015) 
Unfortunately, the same trends held, in spite of combination therapies, and artemisinin 
resistance began to expand its range, spreading from the forested Thai-Cambodian and Thai-
Myanmar borders, to recently include areas close to the Myanmar-Indian border. (Tun 2015; White 
2016; WHO 2015) This latest trend of resistance was first identified in Western Cambodia due to 
markedly increased ACT failure rates. (Dondorp 2009; Noedl 2008) While research continues in the 
search for novel therapeutics (White 2016), and the use of preventive measures such as insecticide-
treated bed nets have proven efficacy in the control of malaria, there is no licensed vaccine which 
provides fully-protective immunity. Thus, chemotherapy remains one of the most important 
mechanisms to ward off death and decrease morbidity.  As such, the mounting drug resistance adds 
urgency to the need for a clearer understanding of the genetic determinants of parasite resistance 
(Imwong 2010; Sidhu 2006; Winzeler 2014), for the elucidation of the pathophysiology of the disease 
in humans and, critically, for the development of reliable, replicable, applicable and fully-described 
animal model platforms in which to evaluate potential chemotherapeutics and candidate vaccines. 
Animal models of severe malaria fall primarily into one of two camps, murine and non-human 
primate models. (Craig 2012; deSouza 2010; Hunt 2010; Langhorne 2011; White 2010) Debate over 
their appropriateness and utility continues. Champions of each have launched to their defense in the 
literature and have provided abundant reasoning for each respective camp, and certainly there are 
legitimate arguments to be made for both. The debate as to the applicability and relevance of murine 
models in the study of human immunopathology has extended well beyond the domain of malaria 
and remains a topic of significant argument. (Gillespie 2014, Hagan 2013; Seok 2103; Takao and 
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Miyakawa 2015; Takao 2015; Warren 2015) To understand the current status of this dispute, it bears 
examining its foundation, especially as this particular project emerged due to a recognition of the 
debate and the need for well-considered non-human primate models of severe and cerebral malaria.   
Murine models have become the mainstay of malaria research over the past 20 years, and 
with so much work having been conducted in murine models of human disease in general, there is a 
vast wealth of crucial knowledge that is available for comparison.  Equally, with the recent advances 
in genomics and advent of knockout, transgenic animals and humanized mice, the potential for study 
appears limitless.  
 There are certain inherent benefits to using rodents in medical research.  First of all, the 
ability to use large numbers of inbred or outbred strains of laboratory rodents permits far greater 
statistical power in the analyses of such studies.  Furthermore, the cost of standard strains of 
laboratory mice is far less than that of non-human primates.  This is obviously not the case with many 
of the genetically engineered animals. However, for large scale studies using standard strains, the 
cost requirements are far reduced in comparison with the use of monkeys.  Space, which is always at 
a premium, is significantly condensed with rodents.  Standard mice are typically far easier to manage 
and present only minor physical risks to the laboratory staff. And, critically, public opinion is 
logarithmically different toward the use of laboratory rodents versus so called “higher” vertebrates 
and in particular non-human primates, although in many ways this is an arbitrary distinction based on 
a quagmire of cultural, moral and societal criteria that may have little basis in science.   
From the genetic perspective, both the mouse and the rhesus genomes have been 
sequenced. We are able to compare them with humans, and there is significant research 
demonstrating gaps in the genetic overlap of mice and of men. 75% of mouse genes have been 
shown to have an equivalent counterpart in humans, while approximately 90% of the mouse genome 
can be correlated with a region on the human genome and 99% of mouse genes appear to have a 
human analogue. However, although these percentages appear to support a relatively close genetic 
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homology between murine models and humans, it is only partially the case once one considers 
chromosomal shuffling of genes, the overall base pair difference in the mouse and human genome, 
and the effects of evolutional changes to the actual genes themselves.  In fact, from the strict point of 
view of genetic homology, there is only 5% preservation of the genome between mice and humans. 
(Church 2009; Gunter 2002; Spencer 2002)  
Sequencing of the rhesus macaque genome has demonstrated 93% shared genetic material 
with humans although the macaque and human chromosomes are mosaics of one another resulting 
from genetic rearrangement over the 21 million years of divergence between the species. (Gibbs 
2007; SoRelle 2007) Therefore the same evolutionary arguments can just as easily be lodged against 
the non-human primate modelers as against murine modelers.  Nonetheless, due to the robust 
similarities with humans, bridging genetic, developmental, physiologic, behavioral and immunologic 
domains, the rhesus macaque remains a critical platform for a diverse spectrum of biomedical 
research. (Vallender 2013)  
It would, however, be disingenuous to not mention the myriad difficulties along with the 
benefits in working with the rhesus macaque.  First and foremost, the macaque is a large non-human 
primate and is extremely strong.  The positive aspect of this is that the individual animal’s blood 
volume permits far greater sample collection than smaller primates such as the Aotus or the much 
smaller murine animals.  The negative aspect is in terms of safety.  The rhesus macaque is capable of 
inflicting significant traumatic damage to a handler and, critically, is also a reservoir for the cases of 
potentially fatal macacine herpesvirus which have occurred in laboratory workers. (Huff 2003; Sabin 
1934) Additional zoonoses of import include Mycobacterium tuberculosis, monkeypox, benign 
epidermal monkeypox, Yaba virus, molloscum contagiosum and Marburg virus to name a few. 
(Parrott 2014) This represents the double-edged sword associated with the similarity of the genome 
between humans and the rhesus which allows for this degree of zoonotic disease transmission.   
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Additional challenges in working with a macaque model are associated with the cost and 
management of housing. One mechanism through which the risk of zoonoses is mitigated is through 
the maintenance of a closed colony such as the one at AFRIMS.  There is an extremely high cost 
associated with establishing and maintaining such a population.  The animals which are available 
through vendors are typically Chinese-origin rhesus, as opposed to the Indian-origin macaques used 
in this study, and there are subtle but significant immunological differences between the populations.  
The primary distinction is associated with differences in immune responses specifically correlating to 
the MHC alleles.  An example of this is seen in patterns of T-cell activation as well as in other 
hematological and blood chemistry differences. (Champoux 1996) Chinese-origin rhesus are 
described as having greater variability in the MHC region than is seen in Indian origin macaques.  This 
can result in greater immunological variance when using the Chinese-origin animals as opposed to the 
Indian-origin monkeys. (Kanthaswamy 2004) An example of this important difference is seen in 
Simian Immunodeficiency Virus (SIV) studies in which Chinese-origin macaques are noted to be far 
more resistant to disease than rhesus of Indian-origin.  (Ling 2002; Trichel 2002)   
Specifically evaluating the validity and applicability of the P. coatneyi/rhesus macaque model of 
severe and cerebral malaria in humans, there are areas which demonstrate a strong correlation with 
human disease. These provide ample substantiation for the use of the macaque model, but there are 
other areas which do not perfectly mimic human disease.   
 The first area requiring consideration is in the use of a splenectomized model. Splenectomy 
allows for development of high circulating parasitemias, and in contrast to the spleen intact model 
used in the studies of Moreno et al, as discussed previously, this allows a shorter and more severe 
host malaria disease phenotype, mimicking the course of severe falciparum malaria in humans. Case 
report studies of splenectomized human cases of P. falciparum malaria (including pathological reports 
on fatal cases) have shown that whilst circulating parasitemia is higher, which may in analogy to this 
model cause more severe disease due to loss of control of total parasite biomass, there is an 
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accompanying modulation of cytoadherence. Parasitized erythrocytes in splenectomized patients 
show decreased knob expression and cytoadherence, probably because of the lack of immunological 
pressure to avoid splenic clearance. In this study, ultrastructural examination of P. coatneyi-infected 
RBC from spleen intact donor animals confirmed the presence of Knob proteins, and both the 
histological and ultrastructural studies provided ample evidence that cytoadhesion and resultant 
sequestration was maintained. However, the loss of the spleen in these animals may cause 
immunological modulation in response to infection which will contrast to the normal human.  
 The second area where the course of natural infection will be different to the human is the 
use of live blood stage inoculation as a mode of transmission, meaning that the initial stage of natural 
falciparum infection (the intra-hepatic stage) is bypassed. Again, this will lead to a different temporal 
challenge to the host immune system and inevitably a difference in the presentation of parasite 
antigen which guides the development of any protective, or disease ameliorating immune response. 
Disease patterns in endemic areas in humans are crucially determined by immune status, as shown by 
the eventual development of protective immunity to severe disease amongst populations in hyper 
endemic areas. The animals used in the prospective studies were selected to be naïve to any previous 
challenge with P. coatneyi. However, the use of animals in a maintained colony for multiple research 
studies may result in some animals having been involved in previous experimental protocols, 
including vaccine trials, other pathogen exposures, etc, which could significantly affect their immune 
status. This may be responsible for some elements of heterogeneity in disease response, something 
which is in reality probably more relevant to a human population than the use of genetically inbred 
strains of mice.   
A comparative review of the use of this model as described in the literature bears discussion.  
Historically, the P. coatneyi/rhesus macaque model was initially represented as a strong model of 
cerebral malaria. This view depends heavily on the fact that it is a sequestering model (Desowitz 
1969; Nakano 1996; Sein 1993; Smith 1996), based on the ultrastructural features (Aikawa 1992; 
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Kilejian 1977; Miller 1972; Rudzinska 1968), rosetting characteristics in both rhesus and Japanese 
macaques (Kawai 1995; Tegoshi 1993; Udomsangpetch 1991), and the P. falciparum-like lifecycle of 
the parasite. (Eyles 1963) In all of these studies, the study populations were small, frequently 
consisted of different species or subspecies of macaque, had markedly different criteria for 
quantitating parasitemia levels, and the evaluation of the pathophysiology was typically limited to a 
very finite range of diagnostic criteria.  While in principle, all of the studies have valid and defensible 
points, it was deemed probable that the study of a larger number of animals would reveal an inter-
animal variation more closely paralleling that found in humans infected with P. falciparum. 
A select few studies employed larger numbers of animals and have maintained stricter 
criteria for the specific use of the model.  These included the examination of P. coatneyi as a model 
for severe pregnancy malaria in humans (Davison 1998; Davison 2000), as a relapsing model for 
severe anemia and metabolic disturbance (Moreno 2007; Moreno 2013) and for use as a platform for 
a drug trial based on the prior assertions of validity as a model. (Maeno 1993) 
Unfortunately, with the exception of the studies by Davison and those by Moreno, much of 
the use of the model has been based upon the hypothesis that the P. coatneyi/rhesus macaque 
model was a strong correlate to sequestration dependent human cerebral malaria, which the clinical 
and pathological evidence from this current study suggests that it is, in fact, not perfectly parallel to 
human disease. The authors of those studies carried the hypothesis forward, derived their data and 
observations and drew conclusions based upon them.  Aspects of the model certainly do replicate 
pathology observed in CM, while others deviate from the strict definition of cerebral malaria.  
Examples include the fact that whilst sequestration does occur, the incidence of neurological 
symptoms, fitting and secondary neuropathological changes in the brain is less severe than that 
observed in humans. This in itself is a very interesting finding, because it allows for argument that 
cerebral parasitized erythrocyte sequestration is in itself not sufficient to cause coma.  
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What was lacking in the prior studies was a comprehensive description of all of the different 
aspects of the pathophysiology of the disease in a larger population of rhesus, to include the ante-
mortem clinical symptomology, hematology, blood chemistry and cytokine profile, as well as the post 
mortem histopathology, ultrastructure and immunohistochemistry.  This study has attempted to 
remedy the lack of a comprehensive description and evaluation of the model, allowing determination 
of its validity and applicability as a model of severe human malaria. 
 
8.2 Clinical synopsis: 
Focusing on the in-depth clinical data collected in the prospective studies, comprised of the 
15 animals described in Chapter 7, we have clarified both areas of confluence and divergence with 
human falciparum induced disease. It is important to note that, especially in comparison with the 
statistical strength of murine studies, an n of 15 is still quite small in order to show variance.  
However, it is an adequate number to demonstrate reproducibility of the model and is an important 
addition to the existing literature. Furthermore, the effective, reproducible and comparable 
demonstration of the use of the model in a clinical drug trial is invaluable in the ongoing arms race 
with the malarial plasmodiae and especially P. falciparum. 
It is important to reiterate and underscore that the P. coatneyi/rhesus macaque model 
employed in this series of studies was specifically geared towards an understanding, first and 
foremost, of its validity as a model of cerebral malaria which has been the primary focus of the 
literature to date.  Secondarily, and with the benefit of hindsight, we were able to examine the model 
and its applications in terms of the study of severe malaria, and the spectrum of symptomology and 
pathophysiologies associated with the wider definition of severe malaria. Fundamentally, the P. 
coatneyi/rhesus macaque model is a sequestering model of malaria, and one which does still 
demonstrate many facets of pathology and pathophysiology which mimic aspects of human disease. 
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It is also important to note that the terms “severe malaria” and “cerebral malaria” are 
themselves used variably, in the literature both in research describing P. coatneyi, and in human 
medical studies. This compounds the difficulties in attempting to specifically correlate this model with 
human disease.  The patterns of severe disease associated with P. falciparum infection differ between 
children and adults. Marked socioeconomic factors also impact the characterization of human 
diseases, as the malaria prevalence is highest in the most impoverished regions of the planet, where 
disease diagnosis and documentation is most unreliable. (WHO 2014) Add to this, the confusion and 
concealment of severe malaria created by concurrent etiologies of febrile disease such as dengue, 
chikungunya or a vast panoply of other tropical diseases. Furthermore, prior infection, immune 
status, and partial treatment can impact both diagnosis and severity of disease, and thus lead to an 
extremely heterogeneous pool of data in humans.   
The WHO uses the following broad criteria for the definition of severe malaria: “Severe 
malaria by definition is associated with a high mortality. From a clinical perspective, there is a 
continuum from asymptomatic malaria to uncomplicated illness through to severe and lethal 
malaria…In a patient with a P. falciparum asexual parasitemia and no other confirmed cause for their 
symptoms or signs, the presence of one or more of the clinical or laboratory features in Table 1 
classifies that patient as suffering from severe malaria.”  (WHO 2014) 
Table 1, referred to in the above quotation includes the following clinical indicators which are 
subdivided into prognostic value based on the age of the patient be they adult or children: impaired 
consciousness, respiratory distress, convulsions, prostration, shock, pulmonary edema (diagnosed 
radiologically), abnormal bleeding and jaundice.  These are combined with hematological and 
biochemical parameters including severe anemia, hypoglycemia, acidosis, hyperlactatemia, renal 
impairment suggestive of acute renal injury and hyperparasitemia. (WHO 2014) The specific 
laboratory criteria for inclusion have been continuously refined as taken directly from Table 4, 
Epidemiological and research definition of severe falciparum malaria. (WHO 2014):  
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1. Impaired consciousness: A Glasgow Coma Score of less than 11 of 15 in adults. 
2. Severe acidosis: Manifests clinically as respiratory distress – rapid, deep and labored 
breathing. 
3. Hypoglycemia: Blood or plasma glucose 8 meq/l or, if unavailable, a plasma bicarbonate of 5 
mM. 
4. Renal impairment (acute kidney injury): Plasma or serum creatinine >265 µM (3 mg/dl) or 
blood urea >20 mM.  
5. Jaundice: Plasma or serum bilirubin >50 lM (3 mg/dl) as well as a parasite count >100 000/ll. 
6. Pulmonary edema: Radiologically confirmed, or oxygen saturation 30/min, often with chest 
in-drawing and crepitation on auscultation.  
7. Significant bleeding: Including recurrent or prolonged bleeding from nose gums or 
venipuncture sites; hematemesis or melena.  
8. Shock: Compensated shock is defined as capillary refill ≥3 s or temperature gradient on leg 
(mid to proximal limb), but no hypotension. Decompensated shock is defined as systolic 
blood pressure <70 mm Hg in children or <80 mm Hg in adults with evidence of impaired 
perfusion (cool peripheries or prolonged capillary refill) 
9. Hyperparasitemia: P. falciparum parasitemia >10% 
Compounding the lack of clarity in the simian studies conducted over the past 50 years using the 
P. coatneyi/rhesus macaque model, these have employed a range of defining characteristics for 
“severe” and “cerebral” malaria not covered by a range of criteria similar to those in place for human 
disease. As described previously, the model has been used in focused descriptive studies consisting of 
a limited number of animals. (Aikawa 1992; Davis 1993; Desowitz 1967; Desowitz 1969; Kilejian 1977; 
Nakano 1996; Sein 1993; Smith 1996; Udomsangpetch 1991) The studies have used different 
macaque species or subspecies, (Aikawa 1992; Eyles 1962; Kawai 1993; Migot-Nabias 1999; Smith 
1996), have had differing definitions and ranges of parasitemia (Davison 1998; Moreno 2013; Smith 
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1996), and have included both spleen-intact and splenectomized animals. (Aikawa 1993; Desowitz 
1967; Desowitz 1969; Kawai 1993; Lombardini (unpublished); Maeno 1993; Moreno 2013, Smith 
1982) Further, treatment regimens were sometimes given in between legs of a study or prior to 
reaching severe and potentially irreversible symptomology. (Moreno 2013) While the wide range of 
P. coatneyi-focused studies have contributed to our understanding of the parasite and the host 
pathophysiology (and indeed the impetus for this dissertation grew from that foundation), what was 
necessary was an in-depth examination of all of the available material so as to establish parameters 
for the model and through which subsequent studies can be evaluated and compared with human 
disease.  
It should be noted that these criticisms can equally be made against the use of murine 
models, and indeed, of many human clinical studies where clinical criteria are variable. Murine 
studies tend to use specific strains of mice to represent disease syndromes, mimicking those 
observed in humans.  Examples of which include, an anemia prone mouse model or ‘cerebral’ 
combination of mouse and host parasite, or mice which have been selected for a specific end organ 
complication such as lung disease. Given that an autoimmune meningo-encephalitis can induce 
lethargy, severe systemic illness and symptoms interpreted as ‘coma’ or decreased consciousness, it 
is also tempting to wonder whether some published models are in fact just severely ill mice with 
prostration, rather than a specific cerebral syndrome.  
 
8.3 Pathology Synopsis: 
The major clinico-pathological findings derived from the prospective animals in this study, 
which concurs with the material available in the retrospective animals and the literature, includes 
multi-organ systemic disease with varying severity. Pathology was concentrated in the urinary tract, 
the central nervous system, the hepatic system and the hematopoietic system.   
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The parasitemia curves examined in this study demonstrated a cycling similar to that seen in 
falciparum malaria with a relative absence of mature stages in the peripheral circulation, implying 
deep vascular sequestration of trophozoite and schizonts stages. This, combined with the fever cycles 
and clinical symptomology in the P. coatneyi model, all of which are clearly parasite density 
dependent and very reproducible, are significant benefits in the use of this model for drug or vaccine 
trials.   
The most significant correlation of the model with human disease appears to be with the P. 
coatneyi-induced, acute kidney injury observed in the rhesus monkeys. Findings parallel those in 
humans at the levels of the symptomology (hematuria, dysuria, anuria), blood chemistry (elevated 
creatinine and blood urea nitrogen), and pathology as observed with both light and transmission 
electron microscopy. Renal disease in malaria is under-recognized in pediatric cases, but has been 
commonly reported in the adult, and is characterized by acute tubular injury. A model such as this, 
which would allow studies or adjuvant reno-protective drugs or better characterization of early 
markers of renal injury, would be of great utility. 
  The central nervous system findings are more difficult to interpret, in large part due to the 
fact that the rhesus macaque does not appear to develop coma as defined by the criteria set forth by 
the WHO. (WHO 2014) The definition of cerebral malaria is described by the WHO as “a clinical 
syndrome characterized by coma at least 1 hour after termination of a seizure or correction of 
hypoglycemia, asexual forms of Plasmodium falciparum parasites on peripheral blood smears and no 
other cause to explain the coma.” (WHO 2000; WHO 2014) The clinical hallmark of cerebral malaria is 
reported by some as impaired consciousness, with coma being the most severe manifestation. (Idro 
2011) To a certain extent, the World Health Organization’s strict definition conflicts with other 
reports in the literature which, for example, define cerebral malaria as a manifestation of CNS 
dysfunction in a victim with symptomology to include disruption of consciousness (confusion, 
delirium, obtundation, stupor, or coma), convulsions, focal neurologic deficit, and/or psychosis. 
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(Misra 2011) The definition of cerebral malaria based on coma may be open to revision, as there has 
been significant discussion into the cause of coma in humans, and the literature reports the 
hypothesis that cerebral malarial coma is the result of four distinct but associated syndromes and not 
specifically a sequela of cerebral edema.  These syndromes are comprised of a prolonged post-ictal 
state, covert status epilepticus, severe metabolic derangement and a primary neurological syndrome. 
(Idro 2011; Marsh 1996; Medana 2011) However, for the sake of clarity, this study assumed the 
WHO’s definition and, as such, the rhesus macaque does not replicate the clinical symptomology of 
human disease. Additionally, clinical symptoms of epileptic seizures or status epilepticus were absent, 
retinal abnormalities appeared mild or absent, and both neuropathological and CSF studies implied 
that the degree of secondary neurological injury in this model was limited. 
Anecdotally, discussion by the author with upwards of 20 clinical veterinarians, specializing in 
non-human primates, was not able to uncover a single instance of strict coma as defined by the 
medical literature as a prolonged or indefinite state of deep unconsciousness in which the patient 
was non-responsive to noxious stimuli. The veterinary literature contains subjective examples of 
coma in small animals (dogs and cats), however the clinical definition applied in those cases appears 
to be extremely variable.  Experimental cases of ischemic coma involving cardiac arrest have been 
reported (Ching 2013; Gurvitch 1974), and attempts to modify the Glasgow Coma score for use in 
small animals have been published. (Platt 2001) The point at which most animals would qualify for a 
strict definition of the term coma is typically peri-mortem, due primarily to severe head trauma, 
severe intracranial pressure, anesthetic death, or severe hypothermia.  Regarding rhesus macaques, 
there is even less information available relating to coma in this species.  The only report in the 
literature appears to derive from malaria researchers examining the potential use of P. knowlsei in 
rhesus macaques.  One group reported coma as occurring just prior to death (Ibimoye 1993), 
however an earlier study which examined 12 animals infected with P. knowlsei does not give 
adequate information as to the peri-mortem state of consciousness. (Spangler 1978) As such, the 
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application of the WHO clinical criterium of coma to the rhesus macaque or realistically to any animal 
model, may be forced, and not bear the degree of importance that we and other researchers in both 
camps have placed on the concept of coma.  Likely, the severely decreased mentation, decreased 
withdrawl and menace responses and severe obtundation observed in all of the P. coatneyi infected 
animals serves as an adequate correlate to the concept of coma in humans.  However, as previously 
stated, and for the sake of conformity to human disease criteria, we adopted the WHO 
symptomology for comparative purposes throughout the study. 
In the prospective study, the animals were monitored during illness on an hourly basis up 
until euthanasia or death. While the animals became markedly moribund, had severely depressed 
mentation, had a decreased menace response, and were lethargic and recumbent, at no time did 
they completely lose their ability to respond to noxious stimuli such as a pinch withdrawl test.  Thus, 
the WHO’s definition of coma was not met.  Additionally, subsequent to autopsy, additional features 
show incongruence with those described in human cerebral malaria.  The pathology in adult human 
cerebral malaria has been reported to be related to parasite sequestration in the brain (Turner 1997), 
and histopathology and electron microscopy confirmed that the same holds true in the P. coatneyi-
rhesus macaque model.  However, in spite of this, the rhesus macaque appears to be less susceptible 
to major neuropathological evidence of the types of injury described in humans such as cerebral 
hemorrhages or severe swelling of the brain. The blood brain barrier dysfunction which has been 
elucidated using immunohistochemistry in this study appears to be in line with that observed in 
leukocyte mediated immune responses described in the severe malaria of children. (Idro 2011) 
Preliminary retinal findings suggest that there may be some damage in these animals, but 
that it deviates from the pathologic findings in certain ways.  Human criteria for malarial retinopathy 
include: retinal whitening, vessel changes, retinal hemorrhages, and papilledema. (Beare 2006) While, 
several of these signs were described in the retinal imaging conducted in the few prospective animals 
examined, the very small sample size, the absence of histopathological retinal hemorrhaging and the 
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lack of control animals prohibits making any definitive statements as to significance in the macaque.  
This remains an area which warrants further controlled study to elucidate these preliminary findings 
of retinal injury. 
The severity of hepatic dysfunction observed in these animals was somewhat variable, and 
the animals that demonstrated severe evidence of coagulative necrosis typically had survived the 
initial insult.  However, there was a consistent spike in the hepatic enzymes trailing peak parasitemia 
observed in the majority of the prospective animals (in common with findings of a ‘biochemical 
malarial hepatitis’ in adult falciparum malaria, especially in South and Southeast Asia) and as such, 
the finding is clinically relevant and may be interpreted as a potential feature of the systemic multi-
organ dysfunction observed. (Kochar 2003; Shah 2009) Similar studies in children do not appear to 
show significant hepatopathy associated with falciparum malaria. (Whitten 2011) Jaundice was 
reported in P. coatneyi infected macaques as a feature in many of the retrospective pathology reports 
evaluated in this study, however the brown tinge in most organ systems associated with hemozoin 
accumulation in the prospective studies masked the presence of jaundice if present. Additionally, as 
the course of disease was so rapid in these animals, they lacked the chronicity of illness likely 
required for significant jaundice to develop. 
One interesting area of difference between humans and rhesus macaques with severe 
malaria was that cardiac pathology was noted consistently, if at low levels, in the 15 prospective 
animals, as well as in the majority of the retrospective animals examined microscopically and 
ultrastructurally.  Several of the prospective animals underwent electrocardiograms at various stages 
of infection, and while preliminary evaluation of the results does not appear to demonstrate a global 
cardiac dysfunction, the presence of reproducible single cell necrosis of cardiomyocytes combined 
with the severity of parasite sequestration in the heart is of interest. There are a few reports in the 
literature which highlight P. falciparum-induced cardiac injury in humans and recommend a 
reevaluation of the potential for damage to the heart with falciparum malaria. (Costenaro 2011) 
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While anemia was noted in several animals, the rapid onset and severity of disease in this 
model do not make it an ideal model to evaluate severe anemia of malaria. This contrasts with the 
low parasitemia, recurrent infection model which Moreno et al. have described using the spleen-
intact, P. coatneyi/rhesus macaque model. (Moreno 2013) In their report, the animals underwent 
repeated bouts of P. coatneyi infection at a lower parasitemia levels and, with the increased 
chronicity of disease, demonstrated marked changes in the bone marrow which were not found in 
this severe model.  Their study suggests a likely immunopathogenesis associated with chronicity, 
while our prospective animals succumbed too rapidly to severe malaria to elicit the same immune-
driven chronic changes.   
Hyperlactatemia was observed in the prospective animals associated with the model 
refinement portion of the study in which the animals achieved high levels of parasitemia without 
treatment.  Those animals consistently demonstrated a spike in lactate which followed after the spike 
in parasitemia. The same did not hold true for the treated animals in the methylene blue study.  The 
latter animals did not develop acidosis and the lactate levels remained stable (in normal range) 
throughout the clinical trials, suggesting the possibility that the drug had a protective effect not only 
in terms of parasite clearance but also in managing the clinical symptomology of disease.   In the 
affected animals which displayed hyperlactatemia, the specific mechanism remains unclear. However, 
hyperlactatemia has been reported in human malaria to be associated with the destruction or 
deformation of erythrocytes, as well as potentially with the degree of hemozoin accumulation and 
the resultant immune response, or as a sign of microvascular endothelial dysfunction due to 
sequestration. (Casals-Pascual 2006; Day 2000; Hanson 2015; Ishioka 2016) Additional experimental 
research would be necessary to confirm mechanisms in the rhesus macaque model.  
 Another difference from severe falciparum malaria in humans, was the absence of pulmonary 
edema in these animals, either in the retrospective or prospective groups, despite marked 
sequestration of infected erythrocytes, host leukocytes and pigmented ghosted erythrocytes in the 
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alveolar interstitial microcapillaries. The animals are often dyspneic, but based on the 
histopathological observations, this is not due to mechanical obstruction of the airways. Rather it is 
theorized to be a feature of cardiovascular shock leading to death. This finding, taken together with 
the relative integrity of the blood-brain barrier and predominant absence of cerebral hemorrhages, 
may suggest that the rhesus macaque has a greater degree of endothelial ‘resistance’ to malaria-
induced injury following direct cytoadherence of iRBC than humans.  Alternatively, it may reflect 
immune modulation of pathogenetic pathways in this model in contrast to the human. Perhaps there 
is a genetic component, suggested by the fact that the macaque is not naturally susceptible to severe 
disease from this parasite.  There is no current literature to support or negate either of these 
theories. Emerging differences in microvascular pathology between adult and pediatric CM in the 
human include the extent of platelet mediated injury and dysregulated hemostatic mechanisms in 
CNS microvessels. iRBC cytoadhesion is mediated via a number of different host receptors on cerebral 
endothelial cells, of which ICAM-1 appears to be important in the brain. (Turner 1994) More recently 
described, is the Endothelial Protein C receptor (Ho 2014), binding to which induces harmful 
hemostatic dysregulation via von WIllebrand factor and Tissue factor release, and is a receptor for 
certain parasite lines expressing specific PfEMP-1 variants. ICAM-1 and EPRC can act as co-receptors 
on brain endothelial cells (Avril 2016) so it seems likely that even if parasites sequester in a 
microvessel, it is both the type of parasite variant, the site of sequestration and the host response to 
this which may determine patterns of organ specific damage in clinical disease. 
The various microscopic modalities that were used in this study (histopathology, 
immunohistochemistry, transmission Electron Microscopy, scanning EM and Atomic Force 
Microscopy) all served to carefully and more fully examine the impact of P. coatneyi infection in a 
large number of infected rhesus macaques. It was important to examine ultrastructural host-parasite 
interactions and tissue-specific injuries in the light of the sparse existing literature examining the 
model’s relevance to human disease.  As was discussed, the animals do not mimic the clinical and 
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neuropathologic features of human disease. That is, while the macaques are obtunded and 
demonstrate severe mentation deficits in the final stages, they neither develop coma or fitting 
clinically, nor cerebral edema or ring hemorrhages with any significance and frequency histologically.  
There is subtler evidence of neuropathology in the affected monkeys, especially at the ultrastructural 
level, however the observed injuries are less extensive than the lesions that have been described in 
humans and in particular in children.  
While this may be a controversial statement, it is important to note that the human literature 
is also markedly underscored by its own heterogeneity. Few reported human autopsy studies have 
examined the brain stem (one exception being a neurotoxicity study of artemether by Hien & 
colleagues 2003) and none have described spinal cord pathology in any depth. Comparisons of 
pathology between different areas of the brain such as the cerebrum versus the cerebellum are 
limited. (Sien 1993) Additionally, while over the past century, there have been many autopsy studies 
in both adults and children (Dorovini-Zis 2011; Dudgeon 1917; Galatioto 1995; Kean 1944; Manning 
2012; Turner 1997), the histopathology studies in the human literature have significant limitations.  
Humans who are infected and succumb from P. falciparum will have undergone variable degrees of 
clinical support and treatment, will be from different geographic regions, ages and susceptibility, have 
a variable immunological response and pre-existing immunity to both infection and disease, and may 
suffer from concurrent diseases. In addition to host factors, patients may be infected by different 
strains of the plasmodium parasite, and finally, the results may have been evaluated by pathologists 
of differing experience.  These variables all influence the data that is derived from the study of these 
cases and interpretation of larger human autopsy based pathological studies. (Aikawa 1992; Clark 
1949; Dorvini-Zis 2011; Dudgeon 1917; Ewing 1902; Iano-Wossinetsky 1938; Kean 1944; MacPherson 
1985; Marchaifava 1894; Oo 1987; Ponsford 2012; Spitz 1945; Taylor 2003; Toro 1978) In a fashion, 
the human literature is just as unfocussed as those studies in animals. It is crucial to recognize that 
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one of the benefits of a controlled animal study, be it in mice or monkeys, is that it allows for a 
degree of homogeneity or standardization which is absent from human autopsy studies.   
While there is also significant heterogeneity evidenced in this study, certain factors hold.  
Firstly, the same P. coatneyi strain was used throughout.   In the prospective cohorts, we were 
therefore able to control the inoculation dose, key aspects of the genetic and immunologic 
background of the hosts, the treatment protocol, data collection, the overall signalment 
(demographics) of the animals used, and the pathologists examining the material.  One area of 
potential heterogeneity in this study related to the prior experimental history in both retrospective 
and prospective macaques.  All of the animals were exposed to P. cynomolgi and often to the dengue 
virus at various points in their history, and while we attempted to regularize the study by selecting 
experimental animals that had similar backgrounds, the lack of malaria-naïve animals raises questions 
which require further study. 
Host/parasite interaction bears many parallel features between P. coatneyi in rhesus and P. 
falciparum in humans.  Binding interactions have been illustrated ultrastructurally through the 
margination of infected erythrocytes, rosetting and autoagglutination, as well as the phenotypical 
expression of knob structures on the infected RBC cell surface, notwithstanding the structural 
differences in knobs which the EM study showed. These features of cytoadherence were 
demonstrated in the histopathology of multiple organs (heart, brain, glomeruli, hepatic sinusoids, 
endocrine tissues) in which sequestration is severe.  
There has been discussion as to the role of iRBC binding in P. falciparum infection in vivo, 
especially as cytoadherence phenotypes have been proven to be associated with increased risk of 
severe disease, such as rosetting in cerebral malaria (Rowe 1995), but have not been observed 
ultrastructurally as contributing directly to tissue pathology in human pathology studies. (Pongponrat 
2003) This potentially means that the more vivax-like rosetting behavior of P. coatneyi in the 
splenectomized rhesus model has a more significant contribution to tissue injury and microvascular 
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obstruction in this model than perhaps does P. falciparum in the human. The presence of numerous 
calveolae is also fascinating as it is a feature more typically associated with P. vivax, a parasite which 
is in fact genetically more closely related to P. coatneyi than to P. falciparum. Binding has been 
further confirmed through the preliminary micropipette and biofluidics assays, supporting a similar 
pathogenesis of disease.  The hypothesis of severe and cerebral malaria being partially modulated by 
the blood flow disruption in humans infected with P. falciparum appears equally valid for P. coatneyi 
in rhesus macaques. 
As to specific organ systems, there is room for debate as to the correlation of the CNS 
histopathology based on the prior discussion of case heterogeneity in humans.  We have confirmed 
via histopathology, TEM and immunohistochemistry that the P. coatneyi/rhesus macaque model is 
definitively associated with extensive sequestration, neuronal injury and significant Purkinje cell 
damage, along with a T-cell-driven inflammatory response which was observed early in the infection 
(at d7-10). Also observed were collections of macrophages/monocytes both within and around 
vessels, limited perivascular edema, and only rare instances of perivascular punctate and ring 
hemorrhages similar to those which have been described as characteristic in the cerebrum of both 
adult and pediatric CM in humans. Although the cerebrum was only infrequently affected in the 
monkeys, hemorrhages were observed in the brain stem and spinal cord and with greater severity 
and frequency, a finding which is important and novel. Axonal injury was limited, and platelet 
deposition almost nonexistent. These observations combined with the severe decrease in mentation 
in the end stages of disease, demonstrates relative conformity with human disease in spite of the 
absence of true coma as defined by the WHO. These similarities in CNS microscopic and 
ultrastructural pathology between the monkey and human disease, was a parallel not observed in the 
retinal histopathology of monkeys and humans. Additional work is necessary before conclusions are 
drawn in this regard, especially as retinal findings in adult humans are also not uniform. (Maude 
2009)   
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The light microscopic, ultrastructural and clinical pathological evidence of renal pathology 
described in detail in this model is significant and correlates well with human disease, rendering it a 
useful tool for better understanding of falciparum malaria-induced, acute renal injury.  This is crucial 
in that one of the important non-human primate models of falciparum malaria and one which is used 
as a platform for drug discovery and vaccine trials is the Aotus.  Owl monkeys or night monkeys have 
a significant deficit in their use in these trials, specifically relating to the kidneys. Various species of 
owl monkeys, namely Aotus nancymae, Aotus vociferans and Aotus trivirgatus, have commonly 
described chronic renal lesions, such as an immune-mediated glomerulonephritis which has been 
shown to be associated with hemolytic anemia. (Chalifoux 1981) Additionally, a large scale 
retrospective study conducted at the Peruvian Primatological Project breeding center noted chronic 
nephropathy in 10% of all necropsied A. vociferans and A. nancymae owl monkeys examined. (Gozalo 
1992) These descriptions of significant background renal disease in these species of New World 
monkey, unrelated to malaria, represents a significant confounding factor in the study of malarial 
nephropathy. This fact may unfortunately require some reevaluation of previous studies which have 
employed these species for malaria studies specific to the kidneys. (Iseki 1990; Nagatake 1992; Weller 
1992) Given the large cohort of animals examined in our study, the acute nature of the lesions 
described, and confirmed ultrastructurally and the concurrent clinical pathology, allow for a high 
degree of confidence in the veracity of this predominantly tubular, rather than glomerular pathology 
as a parallel to acute renal injury in falciparum malaria. Additional areas which would warrant 
examination would include immunohistochemistry of the immune response within the kidneys, the 
apoptotic versus necrotic nature of epithelial and endothelial damage in the kidney, and 
immunoglobulin markers specifically targeting the glomeruli to assess the presence of deposits.  
Furthermore, studies examining the chronic impact of cured or repeated P. coatneyi infections and 
the ability of the macaques to recover from nephropathy would be of interest as an adjunct to clinical 
drug studies. 
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As discussed in earlier chapters, both cardiac and hepatic injuries have been described in 
scattered cases of P. falciparum infection in adults, although these do not appear to be universal 
features of disease.  While the cardiac findings in the macaque were relatively mild in most instances, 
we theorize that the observed pathology is associated with widespread microvascular sequestration, 
occlusion and resultant hypoxia. Hepatic lesions tend to have a zonal pattern often localized around a 
central vein which further supports the concept of injury secondary to dysregulation of vascular blood 
flow.  However, to place all responsibility on the cytoadherent infected erythrocytes would be naïve.  
Systemically, the fact that animals undergo significant febrile episodes over the parasitemia cycle, 
combined with the presence of abundant hemozoin pigment in tissues and other parasite-associated 
antigens, monocytic inflammation and both direct erythrocytic and endothelial cell degeneration and 
necrosis, all combine theoretically to initiate a cytokine storm.  The likelihood is that, as with human 
disease, macaques infected with P. coatneyi, succumb to a complex combination of factors, all of 
which contribute to the progressive collapse of tissues at the cellular and eventually at the whole 
organ level.      
Patterns of injury in human falciparum malaria vary significantly as evidenced in the 
heterogeneity of case diversity as well as in the recent flood of studies comparing adults and children. 
In the large autopsy study of children in Malawi with cerebral malaria, histopathology of the brain 
was characterized first and foremost by significant iRBC sequestration in the cerebral 
microvasculature, a finding which is wholly consistent with this study in rhesus. Children in the 
Malawi study were subdivided into groups based on the presence of perivascular and intravascular 
pathology, but all cases were noted to have sequestration. (Dorovini-Zis 2011) In addition to the 
sequestration of iRBCs, the children’s brains were often described as being edematous at autopsy. 
While we did not conduct a comparative study between normal and P. coatneyi-infected brain 
weights to account for the influx of edema, histopathologic and ultrastructural examination of the 
CNS in the macaques noted perivascular edema in the sections evaluated.  This was further supported 
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by the fibrinogen immunohistochemistry which demonstrated leakage from the microvasculature. 
One other area of confluence between the Malawi study and this one was in the 
immunohistochemical identification of perivascular and intraparenchymal monocytes, which were 
observed at a mean ratio of 131:15 (infected:control) in the brain stem and 19:3 in the cerebrum, 
suggesting a significant monocytosis similar to cerebral disease in African children (although a 
significant number of the cases in the Malawi study are also HIV co-infected and this may influence 
immune responses in the brain).  Monocytosis has also been reported in morphological and 
immunohistochemical studies of adult with cerebral malaria. (Porta 1993; Patnaik 1994) The primary 
divergent feature was in the relatively few cases of thrombosis and vascular obliteration with 
subsequent hemorrhage in the macaques.  Platelet associated pathology appears to be a prominent 
feature in children with falciparum malaria while only 12 (27%) of the 45 animals in our study had 
fibrin thrombi in any tissue.  27% of the animals (combined retrospective and prospective) were 
noted to have minimal or mild hemorrhaging in the cerebrum. However, 60% had evidence of some 
degree of hemorrhage in the spinal cord.     
The immunohistochemical data in our study supports the histopathologic and ultrastructural 
descriptive evidence described in their respective chapters, but the IHC evaluation was limited to the 
central nervous system. It did provide evidence for similar changes in blood-brain barrier function, 
which are actually milder in CM than other CNS infections involving destruction of the BBB such as 
viral encephalitis or meningitis. (Brown 2000) This was mirrored by evidence of mild, perivascular 
cerebral edema and fibrinogen leakage, limited microscopic axonal injury and minimal evidence for 
widespread neuroaxonal damage in the CSF studies. However, a unique immunological response to 
CNS infection is occurring in this monkey model, as evidenced by the preliminary work describing the 
CSF cytokine signature. Many of these findings are still not fully elucidated in human studies, but the 
results in this thesis imply that the model is a potential platform for doing so, and perhaps for using 
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some of these markers as surrogate measures for neuroprotection in any studies of adjuvant 
treatments for neuro/vascular protection in the future.  
Fundamentally, the data garnered throughout the study suggest that the model has valid, 
reproducible and correlatable application as a model for severe P. falciparum-induced malaria in 
humans. The findings emphasize the importance of a thorough understanding of the basic clinical and 
pathological aspects of any animal model. Thus, while the central nervous system pathology is similar, 
but lesser in degree to that in humans, the clinical picture of coma as defined by the WHO and fitting 
in human CM are not present.  However, the model offers an opportunity to observe sequestration 
dependent end organ damage at high parasitemia, particularly in acute renal, hepatic and cardiac 
injury, and parallels severe human disease with reproducible waves of parasitemia, systemic 
metabolic disturbance and fatal outcome. 
 
8.4 Future potential uses of the model: 
This dissertation represents an in-depth evaluation of the model, which to date was lacking.  Our 
work has definitively established the model as a platform upon which to continue to elucidate the 
pathology and pathophysiology of P. coatneyi in the rhesus macaque. As such, there are certain areas 
where additional work needs to be conducted.  As shown, this is a sequestering model, and the 
present body of work, as well as satellite projects that have arisen, will allow for an accurate 
interpretation of the impact of parasite burden on the overall severity of disease and the observed 
patterns of end organ disease.   
As mentioned there has been considerable interest in using plasma HRP-2 measurement as 
an indirect measure of parasite biomass reflecting sequestered parasite burden better than a simple 
peripheral parasitemia. (Dondorp 2005; Hendriksen 2013) As part of this thesis we had hoped to use 
a similar approach to quantitate parasite burden in the Rhesus model, but faced a problem in that P. 
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coatneyi does not produce an analogue of HRP-2. One alternative to HRP-2 has recently been 
described, which is the measurement of soluble DNA released from the malaria parasite into serum. 
(Imwong 2015) At present, collaborators at the Mahidol Oxford Research Unit (led by Dr. Malika 
Imwong) are developing a quantitative real time PCR (qPCR) based on 18S rRNA in order to quantify 
the parasite biomass in P. coatneyi infections in the splenectomized rhesus macaque.  This 
explorational work has thus far succeeded in establishing a protocol with both high sensitivity and 
specificity for P. coatneyi, using cryopreserved blood samples from the prospective experimental 
animals described in this study.  It is hoped that this will eventually lead us to be able to correlate 
parasitemia data, and histopathological evidence of organ sequestration, to correlate clinical 
symptomatology with parasite burden both systemically and in an organ specific manner. In this 
manner, it may be possible to prove quantitatively whether organ specific complications such as renal 
disease correlate with sequestration is a particular organ, or overall parasitemia, as has been 
attempted in the human in the brain and kidney. (Ngaungsangiam 2007; Pongponratn 2003) 
The second major area in which samples from this study will be used in the future is 
projected to be in collaboration with the National University of Singapore’s Vivax Laboratory and Dr. 
Laurent Renia’s team at Singapore’s Agency for Science, Technology and Research (A*STAR). We are 
in the preliminary stages of conducting whole RNA sequencing (RNA-seq), also referred to as whole 
transcriptome shotgun sequencing (WTSS) on tissue samples selected from the CNS, kidney and heart 
tissues from the prospective animals in this study and will be compared with control animals. The 
intent will be to assess the activity level and specific quantity of a diverse array of RNA in the sample 
at the time of peak parasitemia in the animals.  
The tissues were selected based on the specificity of disease observed in other areas of this project, 
and with the recognition that gene expression is variable between organs and cells.  Recognizing that 
gene expression is time dependent and that the transcriptome changes throughout the course of 
disease, it would be fascinating to be able to conduct this experiment at various time-points 
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throughout infection. However, our sample collection timeline as well as the ethics governing animal 
use in this study, required minimizing the total number of animals used to focus on our study 
objectives. Bioinformatics will be conducted so as to make sense of the huge volume of data that this 
will generate.  Subsequently, the data will be compared with similar work which has been conducted 
by Dr. Turner and his collaborators at MORU on human tissues.  Finally, our preliminary assessment 
of the biofluidics and micropipette binding strength assays discussed in Chapter 6 will be expanded 
upon in collaboration with Dr. Bruce Russell and his team. 
As with all science, the act of discovery merely opens the doors to more questions, and this 
study has shed light on a range of fascinating problems that need to be addressed. Examples include 
the need to fully clarify the cardiac injury in these animals.  Evaluation of the cardiac specific marker, 
troponin, over the course of the infection may provide a great mechanism with which to substantiate 
the histopathologic and ultrastructural findings that we have described.  Combining troponin with 
examination of B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-
proBNP) as mechanisms to identify the theorized low grade cardiac ischemia would be of significant 
interest.  
Another area that still remains a mystery is the actual mechanism of death in these animals 
which appear to succumb to circulatory shock. It is theorized to be due to massive sequestration of 
parasitized RBCs, resulting in decreased blood perfusion to tissues.  The resultant hypoxia, anoxia, 
subsequent cellular injury, and multi-organ failure is posited to cause the death of these animals.  
This theory is based on the clinical symptomology of dyspnea, lethargy and decreased mentation, 
renal failure, and bleeding disorders (as noted by the ecchymoses and petechiae) that occur in some 
animals.  Furthermore, the clinical pathology finding of hyperlactatemia in the untreated macaques, 
suggestive of acidosis, abnormalities reflecting renal and hepatic injury, and the onset of anemia, all 
support the theory of circulatory insufficiency, however this remains to be confirmed.  
Histopathologic and ultrastructural evaluation of all tissues demonstrate piecemeal necrosis of cells 
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rather than wholesale death of organs. This is significant in that it supports a systemic pathology 
relating to the microvasculature.  The knowledge that this foundational work has generated would be 
further strengthened by confirming these hypotheses.  Blood pressure monitoring, real time imaging 
of tissue perfusion or tracer techniques including functional MRI imaging, throughout the course of 
an experimental infection would be difficult, but are possible with an animal model while not being 
feasible in humans. They may allow confirmation of some of these theories, which have been muted 
for years in relation to human disease without a suitable model to test them on.  
 
8.5 Final Summary:  
The successful use of the model, in conducting the methylene blue drug study, confirms the 
fact that P. coatneyi in splenectomized rhesus macaques can be effectively employed as a platform 
for the evaluation of anti-malarial compounds.  While the model has limitations in the study of 
pulmonary injury, retinal hemorrhage and chronic malarial anemia, as well as not mirroring the 
clinical picture of cerebral malaria perfectly, it has concrete and definite applicability in the study of 
malaria induced acute kidney injury, cardiac and hepatic pathology.  Practically, the model is 
extremely labor intensive, although this varies with individual study designs.  Furthermore, the model 
is expensive unless the research group has a rhesus colony or such facilities at their disposal. 
However, and crucially, we have demonstrated that the model offers significant potential in 
treatment studies, post-infection therapeutic and supportive care studies and a range of further 
pathophysiology studies.  
When considering the models currently available, and comparing the validity and applicability 
of P. coatneyi induced disease with the P. berghei ANKA or P. yoelii mouse models, the rhesus 
macaque provides a mechanism to examine the clinical course and pathology of malaria in a 
controlled manner not possible in human studies, but with direct correlation to the same. In 
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comparison with murine models, the macaque model has the advantage of a high degree of 
homology to the human immune system. Furthermore, unlike the murine models, there are 
opportunities in the macaque to engineer functional studies to evaluate metabolic and physiologic 
changes which are fundamentally difficult or impossible to perform in human malaria patients such as 
with intracranial pressure monitoring, functional MRI imaging, laser video microscopy of flow and 
EEG. In comparison with the non-sequestration dependent, immunologically mediated encephalitis of 
experimental murine cerebral malaria, the similarities of the pathophysiological tapestry of P. 
coatneyi to human falciparum malaria make its results more medically relevant.   
 Therefore, the use of this dissertation and its accompanying studies provides malaria 
investigators with a significantly more profound understanding of the animal model with direct 
relevance to the falciparum malaria of humans.  Additionally, the work accomplished herein validates 
the use of the P. coatneyi/Rhesus macaque model as an applicable, reproducible and effective animal 
model for use in anti-malarial drug trials for severe malaria. This work provides the most 
comprehensive pathologic assessment of the P. coatneyi/rhesus macaque model to date, with in-
depth description of the parasite and host-parasite interactions at all levels from the macroscopic to 
the nanostructural and molecular.  Furthermore, and fundamentally, this study has taken the model 
from the conceptual to the practical through the successful demonstration of the model’s use in 
practice with methylene blue.  With this greater understanding of the model, its proven efficacy and 
replicability translates to enormous potential for practical application as a useful platform for both 
basic science studies of malaria pathophysiology and the development of anti-malarial drugs, 
adjuvant therapies and vaccines.  
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